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Proteins are the fundamental building blocks of all living organisms. They are 
critical in the proper function of virtually all cellular processes and without them 
biological life would be impossible. Since their discovery, understanding the transition of 
DNA to functional protein has been separated into two distinct areas of research; 1) how 
are they synthesized from genetic material and 2) once formed how do they fold into their 
native tertiary and quaternary structures. Understanding how genetic material encodes the 
primary structure of amino acids was the basis of the first-half of the genetic code. This 
in part sparked a technological race to solve the sequence of whole genomes, leading to 
the human genome project and its completion in 2006. The second-half of the genetic 
code is known as the ‘protein folding problem,’ which is the primary focus of this work. 
This problem is focused on understanding the fundamental features that dictate how the 
primary structure of amino acids transition along a thermodynamic and kinetic pathway 
into a functionally folded native-state.
The protein folding problem is a multifaceted and interdisciplinary area of 
research. Two key avenues of investigation include the folding of a protein into its native 
structure and the second is misfolding into an amyloid fibril structure. In the first-half of 
this work, we investigated the folding of the B1 domain of the Streptococcal 
immunoglobulin-binding domain of protein G (GB1) as our model system. Using 
bioinformatics approaches we investigated the origin and evolution of GB1. We also
elucidated a group of conserved residues and a network of long-range interactions which 
we propose are key determinants in dictating the stability, folding and native structure of 
the protein. GB1 was initially characterized using a combination of biophysical and high- 
resolution techniques such as stopped-flow and equilibrium fluorescence, circular 
dichroism and nuclear magnetic resonance spectroscopy. A microbial system was 
developed to facilitate testing the role of conserved long-range interactions through site- 
specific l3C-labeling of tryptophan and phenylalanine. In the second-half, we investigated 
the transition of the Fas-associated death domain, an all a-helical Greek-key protein, into 
a misfolded amyloid-like state using additional techniques such as transmission electron 
and atomic force microscopy. From this work we were able to determine the extreme 
non-physiological conditions that would be required to allow for this transition. This 
result supports the ‘generic amyloid hypothesis’ that proposes that all proteins have the 
ability to form this alternative structure. In summary, this body of research has 
contributed to further advancing our understanding of the protein folding problem and 
laid the foundation for future atomic-level resolution studies.
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Protein folding is an interdisciplinary area of research that has gained significant 
attention from the scientific community [1]. The increase in interest in protein folding is 
mostly due to the growth in protein sequences and the overwhelming appeal of solving 
one of the most fundamental cellular processes. A key aspect of biological life is the 
ability to synthesize functional proteins from genetic information. Proteins play a pivotal 
role in the survival and function of all organisms by performing a myriad of biological 
processes, from cell division to apoptosis. Since the discovery of DNA and the 
subsequent solving of its structure, understanding how the primary sequence of amino 
acids is synthesized from genetic material was the basis of the first-half of the genetic 
code. In addition, the complexity and magnitude of genetic material sparked a 
technological race to solve the sequence of whole genomes, leading to the human genome 
project and its completion in 2006 [2-5]. Solving the first-half of the genetic code led to 
the advancement of biological techniques which enhanced the ability of researchers to 
investigate the second-half of the genetic code, centered on understanding how the 
primary sequence dictates the native conformation of proteins.
Currently, there are two approaches to solving the protein folding problem. The 
first is to use computational methods to predict the three-dimensional (3D) structure of a 
protein from the sequence of amino acids and the second is to understand the relationship
The Journal for this Dissertation is BM C Chemical Biology
2between the folding mechanism and the protein sequence. Since the discovery by 
Christian Anfinsen that proteins have the ability to spontaneously fold into its native-state 
structure understanding this process has been a foundational area of biochemical research 
[1]. The structure and function of a protein’s native-state is determined by the sequence 
of amino acids [1,2]. Understanding how the amino acid sequence encodes and directs 
the folding of a protein into its native-state is termed the ‘protein folding problem’. It is 
also significantly important to understand protein folding, because many protein 
misfolding diseases arise from the improper folding of proteins into their native-state.
The archetypal example of a misfolded protein is the variant Glu6Val, of hemoglobin 
which leads to sickle cell anemia. Understanding the underlying determinants of the 
protein folding problem will provide the tools for protein engineering and the design of 
protein therapies.
Proteins are polymeric in nature. They are composed of a string of amino acids 
linked together by a covalent bond between the carboxyl carbons of one amino acid to the 
amine nitrogen of the following amino acid in a condensation reaction (Figure 1). The 
sequence of amino acids in the polymer makes up the primary structure of a protein.
There are twenty naturally occurring amino acids which gives rise to a large diversity of 
possible protein sequences (Figure 2). In addition, they can be further diversified though 
amino acid modifications. The secondary structure of proteins is characterized by specific 
local structures which include a-helices, (3-sheets and p-tums stabilized by hydrogen 
bonding of the protein backbone. The tertiary structure is defined as the overall 
topological arrangement of the secondary structure in 3D space. This would also be the 
native-state structure for a globular single domain protein. There are three major
classifications of tertiary structure; all a-helical, all [3-sheet and mixed a/(3 (Figure 3). 
Forming and maintaining the tertiary structure stability is in large part due to cumulative 
hydrophobic and ionic interactions, hydrogen bonding and disulfide bonds. The 
quaternary structure refers to the packing of several individual protein chains together 
into a higher order protein structure. The formation of multimeric states (i.e. homo- or 
heterodimers) also increases functional diversity and increases the complexity of the 
protein folding problem. It’s quite amazing that despite the large number of divergent and 
functionally diverse proteins, nature evolved proteins to share common topologies, such 
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Figure 2. Common amino acids and their structure. Amino acids are chemically 
grouped by cyan borders into unsubstituted (dotted), aromatics (solid), hydroxyl (short- 
dash), carboxamide (long-dash), dicarboxylic (dash-dot-dot) and diamino (dash-dot) type. 
R-groups are highlighted and grouped by character: non-polar (blue), polar (brown), 
acidic (red) and basic (green). Proline, methionine and cysteine are grouped as 
heterocyclic, thioether and mercapto, respectively. These structures were drawn by hand 
in Microsoft Power Point (version 2010).
a- Helical [3-Sheet Mixed a/p
Figure 3. Classification of protein tertiary structure. Representations of each of the 
tertiary structure classes. The PDB codes for the structures shown are 10P1 (Left), 1TIT 
(Center) and 1TIM (Right).
Cyrus Levinthal in the late 1960’s postulated that if you had a protein whose 
primary structure contained 100 amino acids and folding occurred by attempting each 
possible conformation the length of folding time would be astronomical. Levinthal 
showed mathematically that even using a sampling rate of 10'4 nanoseconds this process 
would take 1027 years to find the native fold [6-8]. Since experimental evidence showed 
that proteins could fold on the millisecond time scale, Levinthal proposed that the process 
could not be random and the process must follow a specific pathway. Interestingly, 
directed folding was further supported by the proposal that sampling time could be 
significantly reduced if during the sampling process correct interactions were maintained 
while incorrect interactions are either not formed or not maintained and are broken to
6continue sampling conformational space [7], It was becoming clearer that protein folding 
was a directed process guided by underlying intermolecular interactions based on the 
work later done by Anfinsen. Anfinsen’s dogma indicated that the well-defined native- 
state is predetermined solely on the interactions of the amino acids, which led to him 
winning the Nobel Prize in 1972 [9, 10].
Being able to visualize what a folding protein looks like and the orientation of 
each atom with angstrom-level resolution is vital to understanding how proteins fold. To 
solve the structure of a protein we use two primary methods, X-ray crystallography and 
nuclear magnetic resonance (NMR) spectroscopy, both of which can solve the structure 
of a protein down to the atomic-level. Once protein structures are solved they are stored 
in the Protein Data Bank (PDB) for open access to the world. Being able to visualize 
these 3D forms allows us to classify proteins into groups dependent on topology. SCOP 
(Structural Classification of Proteins) and CATH (Class, Architecture, Topology and 
Homology) are the two major databases that are used to classify protein structures into 
related groups such as families and superfamilies [3,4],
Proteins fold according to a pathway or mechanism that outlines the transition 
from the unfolded state to the native-state. There are currently four dominant mechanisms 
that describe the protein folding process: framework, hydrophobic collapse, nucleation- 
condensation and folding funnel models [11, 12], It seems that in the universe of protein 
folding size is important in the folding of a protein. Small proteins generally fold rapidly 
in a two-state mechanism that involves only the denatured and native-states. The two- 
state mechanism of proteins containing less than 100 amino acids is characterized by
7rapid folding that appear to have no kinetically detectable intermediates. However, larger 
proteins increase in complexity and are often described by a multiphasic process.
In the framework model, folding begins with the formation of secondary structure 
elements prior to the formation of the tertiary structure (Figure 4). Following the 
intermediate formation is the assembly of the secondary structure into a tightly packed 
native tertiary structure either by random assembly or by the careful propagation of 
ordered tertiary interactions [12, 13]. This model was highly supported by experimental 
work on small peptides early on and it was believed that the secondary structure could 
not form without some tertiary interactions due to lack in stability [8]. A few examples of 
proteins that demonstrates the framework model is acyl-coenzyme A-binding protein 
(ACBP), engrailed homeodomain and protein A which are all a-helical proteins and 
ribonuclease A, a mixed a/p protein [8, 14-16]. In the case of ACBP twenty-six residues 
were identified as evolutionarily conserved. Mutagenesis studies on ACBP showed that 
modification of conserved hydrophobic residues in helices 1 and 4 had a significant 
depressing effect on the folding rates [15]. In their investigation they determined that the 
formation of long-range interactions was favorable based on the spatial orientation of 
helix 1 and 4. This indicated that the short-range hydrogen bonding of both helix 1 and 4 
formed prior to the formation of tertiary structure in order to bring certain hydrophobic 
residues into close proximity for initial tertiary structure formation. Once the initial 
stacking of helix 1 and 4 occurs, the final two helices form and collapse onto the structure 
forming the native topology. The formation of native interactions between two secondary 
structure elements as the rate-limiting step prior to tertiary structure formation in the 
folding of ACBP is an excellent example of a successive framework model [15]. In
addition, the framework model has been proposed as the mechanism for both T4 
lysozyme and ribonuclease T1 based on high-resolution hydrogen-deuterium exchange 
experiments coupled with two-dimensional (2D) NMR [17,18]. In both cases, the folding 
intermediates retained hydrogen bonds corresponding mostly to secondary structure 























Figure 4. Models for protein folding. Shown is a schematic of the Framework model, 
Hydrophobic collapse and Nucleation-condensation mechanism models of protein 
folding. Image redrawn and modified from information and images in references [11, 12].
9Interestingly, there is a predominance of a-helical type proteins that fold 
according to the framework model indicating that the formation of P-strands in this model 
appears to be relatively more difficult [8]. Similarly, the most commonly found 
secondary structures isolated in peptides was a-helical and turn structures and the least 
common P-hairpins [8, 19-21]. In this model the secondary structures formed from short 
peptide sequences could be considered starting points for protein folding. However, in 
practice these strong conformational preferences are not commonly seen and typically 
proteins will adopt a random coil for these peptides when included in a larger protein 
[22], So it seems that the instability of these peptides in larger proteins is stabilized by the 
formation of tertiary interactions as seen in the investigation of a series of peptides of 
chymotrypsin inhibitor 2 (CI2) in which secondary structure did not form until the 
sequence of peptides included residues involved in long-range interactions [23].
In the hydrophobic collapse model of protein folding the unfolded protein initially 
collapses in a relatively uniform fashion, followed by a formation of ordered secondary 
structure elements (Figure 4) [24-26], This process is directed by hydrophobic driving 
forces based on the expulsion of water by hydrophobic residues being attracted to each 
other in an aqueous environment [12]. It is believed that stable secondary structure can 
only form after the initial collapse of hydrophobic interactions. Folding of cytochrome c, 
an all a-helical protein containing a haem group, is one of the most well characterized 
proteins and is a relatively good model of the hydrophobic collapse [27]. The initial 
collapse of the unfolded cytochrome c involves the formation of an intermediate state 
which was shown by circular dichroism (CD) to contain about 20% of the native 
secondary structure content. In the fine-tuning phase continued compaction allows for
stabilizing contacts to form a second intermediate resembling a molten globule-like 
topology. The native conformation results from the folding of the remaining secondary 
elements and complete coordination to the haem group. In this case since most of the 
protein collapses into a hydrophobic core around the haem group prior to approximately 
80% of the secondary structure forming, it seems that the hydrophobic collapse model 
better describes the folding mechanism of cytochrome c [27]. Interestingly, it seems that 
the haem group may function as a hydrophobic nucleus in which the initial collapse is 
focused. Another more controversial example of the hydrophobic collapse model is the 
folding of the ribonuclease bamase inhibitor protein (barstar).
The folding of barstar begins with a collapse of non-specific hydrophobic acids 
into a compact core intermediate without detectable secondary structure formation [28]. 
Rapid-mixing experiments on barstar in concert with secondary and tertiary structure 
detection via CD indicated that the biphasic rate constants for the formation of tertiary 
structure is 7000 s '1 and 11 s'1 whereas for secondary structure they are 4000 s"1 and 4 s_1 
for the fast and slow phases, respectively [28]. The biphasic amplitude distributions for 
the rates of tertiary structure formation are 30 and 70 % whereas for the secondary 
structure formation they are both 50 %. The ANS binding experiment shows that 70 % of 
the hydrophobic collapse occurs in the 4 ms dead time prior to any observable folding. 
According to the data the rate of formation of the core is an order of magnitude greater 
than that for the formation of secondary or tertiary structure as calculated by CD. This 
data suggests that the folding follows the hydrophobic collapse model. However, a few 
years later it was shown experimentally using <D-value analysis, which will be discussed 
later in this chapter, that the folding of barstar also follows the nucleation-condensation
11
model of protein folding [12,29]. This was one of the first examples of a protein 
containing evidence of two folding models, which indicated that there could be a more 
unified mechanism of protein folding. In this example the phi-value analysis provided 
greater resolution into secondary and tertiary residue interactions that could not be 
discerned by CD.
The concept that folding occurs by a collapse of non-specific hydrophobic 
interactions has a few known intrinsic problems associated with it. One being that the 
excess interactions that could form in the tertiary structure during the collapse will limit 
the ability of the protein to reorganize the backbone and fine-tune amino acid orientations 
for the growth of the secondary structure elements [8]. This collapse would induce an 
energy barrier associated with dissolving and rearrangement of these interactions, which 
would be energetically unfavorable. Second, the denatured state may not be completely 
random and unstructured without any side-chain interactions. Instead, the unfolded 
protein is dynamic because there appears to be fluctuating interactions that can form 
variable secondary structures or even pockets of hydrophobic clusters [8]. Because the 
unfolded state may contain residual structure, which can be native-like or non-native, it is 
proposed that the initial hydrophobic collapse also results in the formation of some 
secondary structure elements [8]. It’s unclear if the residual structure in the unfolded state 
is simply a limiting of solvent accessibility or if the interactions are important in the 
folding process by directing folding towards the native conformation. Thus, more than 
likely there is some specificity or organization to the hydrophobic collapse.
With the advances of experimental techniques for monitoring the fine details 
involved in the structural changes during the protein folding process it has become
clearer that the vast majority of proteins fold via the nucleation-condensation model 
(Figure 4) [8, 12, 30-33]. The development of the nucleation-condensation mechanism of 
folding came from two major events in science; the first being the recognition that 
proteins could fold in a simple two-state reaction mechanism without the accumulation of 
detectable intermediates and second is the development of O-value analysis technique 
which is an indirect method to detect the presence of interactions in the transition-state. 
This model for protein folding combines both the framework and hydrophobic collapse 
models in which some discrete secondary and tertiary contacts or regions form in a 
concerted process [8, 12, 33-35], The initial collapse in the nucleation-condensation 
model is the formation of what is known as the folding nucleus made up of secondary and 
tertiary interactions that form the initial native-like topology and catalyze the folding 
process. These interactions and participating residues are now thought to be conserved in 
evolution. The folding nucleus is comprised of some native-like secondary interactions 
that are only stable in the presence of correctly formed long-range tertiary interactions 
[11, 12]. Following the collapse is the hierarchal assembly of native interactions, which 
are less conserved, as more structure condenses until the final stable native topology is 
achieved [36]. There are several well studied proteins like CI2, barstar, avian 
myeloblastosis transcription factor, tenascin, lysozyme and the 12-kDa FK506-binding 
protein that display the nucleation-condensation model of protein folding [11, 12, 29, 37- 
41].
The first example of this particular folding model is the folding of CI2 which is 
described as the archetypal protein. Investigations of scanning microcalorimetry and 
refolding kinetics showed that the folding of CI2 fits a two-state folding mechanism [34,
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42,43]. Detailed investigation of the role of specific residues on the transition-state of 
CI2 (a small protein consisting of 8 [3-strands and 2 a-helices) using O-value analysis 
showed the presence of a folding nucleus and a stabilization of the helix by interactions 
between Ala 16, Leu49 and Ile57 in the hydrophobic core. The initial nucleus had low 
stability which stabilizes as the protein forms more native-like contacts once the folding 
energy barrier has been overcome [43]. The folding of barstar, an 89-amino acid protein 
containing a three stranded parallel [3-sheet and four a-helices, was shown to be a 
reversible two-state reaction mechanism. In the O-value analysis of barstar there is a 
stabilization of helix 1 and 4 in the initial consolidation towards the transition-state. The 
folding process for barstar is triphasic as the diffuse nucleus and its growth towards the 
transitions state was mapped in three steps; 500 ps, 1 ms and 100 ms. The native-like 
topology emerges after about 100 ms as the structure is stabilized by further propagation 
of tertiary and secondary interactions [12]. Experimental investigations of CI2 and barstar 
showed that they both fit the nucleation-condensation model of protein folding because 
they both fold in a two-state reaction mechanism and form a folding nucleus comprised 
of regions of secondary structure stabilized by a discrete set of correctly formed native 
tertiary interactions [12,43]. The nucleation-condensation model may explain the rapid 
folding nature of proteins as opposed to a random sampling method. Interestingly, the 
expectations found in the folding funnel model, discussed in the next paragraph, coincide 
with data obtained from O-value analysis used to monitor the transition-state folding 
nucleus. The framework, hydrophobic and nucleation-condensation models are discussed 
in reference to small proteins with no intermediates and single transition-states. However,
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each model can be related to larger proteins that may have several intermediate states 
during their folding reaction.
The folding funnel model begins with a large ensemble of unfolded 
conformations which transition down a funnel shaped energy landscape in which there is 
a decrease in the available conformational space during the folding reaction (Figure 5)
[44,45], In this model depending on the environmental conditions the unfolding 
polypeptide can proceed towards a native-state topology or a misfolded state. If the 
environment is conducive to intramolecular contacts protein folding proceeds to the 
native-state, whereas if the environment is more favorable for intermolecular contacts 
protein misfolding can occur. The energy landscape model considers protein folding on a 
scale of free energy in which unfolded or partially folded intermediates of a higher free 
energy transition towards a global minimum free energy and entropy [46-49]. This model 
assumes that the native-state structure is considered the global free energy minimum. 
During the transition from the unfolded to the native fold, the conformational free energy 
decreases as the number of favorable native contacts increases. The protein folding 
funnel model begins with multiple folding pathways which later converge into a single 
pathway as more native contacts form. It is understood that hydrophobic residue 
sequestration away from the aqueous solvent is the underlying driving force in the 
folding funnel model to overcome the folding energy barrier. Similar to the multitude of 
unfolded conformations, the molten globule is believed to be an interrelated ensemble of 
folding intermediates that have formed from a hydrophobic collapse of fluctuating 
interactions. The molten globule intermediate is similar to the transition in the framework 
model containing most if not all of the secondary structures with very little tertiary
structure [50]. The molten globule may be present in all the previous models and some 
believe may belong to a unique class of proteins called intrinsically disorder structures 
[51]. The importance of the molten globule state is still under intense scrutiny, however 
its importance as an intermediate in the folding of several proteins, such as 
apomyoglobin, a-lactalbumin, calcium-binding lysozyme and cytochrome c is becoming 
more evident [52-59]. It is becoming increasingly more prevalent in protein research to 
isolate the molten globule state or key structural features in vitro under a specific set of 







Intramolecular contacts Intermolecular contacts
Figure 5. Energy landscape scheme of protein folding and aggregation. The blue 
surface shows the multitude of conformations ‘funneling’ to the native-state via 
intramolecular contacts and the purple area shows the conformations moving toward 
amorphous aggregates, off-pathway and potentially cell-toxic oligomers or low-energy 
amyloid fibrils via intermolecular contacts. This image is adapted from [62],
In relation to the folding funnel model the free energy of folding can be 
thermodynamically illustrated in the following equations:
AGtotal (A H total) T ( A S totai). (1)
AGtotal ( AHprotein A H S0|vent) " T (A S p rotein A S soivent). (2)
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In the equations, AGt(*ai is the change in total Gibbs free energy between the 
native and unfolded state of the folding reaction, which is related to the changes in 
enthalpy and entropy before and after the folding reaction [63]. AHtotai is the sum of total 
enthalpy of the protein (A H protein) and the solvent (A H S0|vent). A St0tai is the sum of total 
entropy of the protein (A S pro,ein) and the solvent (A S soivent) [63]. The enthalpy and entropy 
of protein folding is directly related to the intermolecular forces and chemical 
characteristics of the amino acid groups that underlie protein folding. The stability of the 
protein is largely related to the contributions of the entropy and enthalpy of the solvent as 
it relates to the character of the amino acid side chains. Hydrophobic side chains provide 
a positive solvent entropy and the polar residues contribute a negative solvent enthalpy, 
which sum to an overall negative Gibbs free energy [63]. Since the free energy is 
negative this thoroughly supports the spontaneity of the protein folding process 
discovered by Anfinsen. The folding process and rate of the reaction is regulated by the 
rate at which the unfolded polypeptide chain overcomes a free energy barrier, catalyzed 
by the formation of a transition-state structure [63].
There are a multitude of theoretical studies that show that the protein folding rate 
is influenced by size, stability and topology [13, 30,46, 64-81]. Interestingly, there is 
strong computational evidence for predicting the folding rates of proteins based on their 
relative contact order. Those proteins with greater local contacts tended to fold more 
rapidly than those with more non-local interactions [82]. The importance of local and 
non-local interactions in the native structure and there effect on the rate of the folding 
reaction was shown to significantly correlate to the relative contact order [82],
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The mechanisms of protein folding have been previously described by 
experimental work, and the process has been shown to be spontaneous process in vitro. 
However, when we look at protein folding in vivo there are other factors that we need to 
account for and the process can be quite different. Proteins in vivo are only considered 
marginally stable which makes them highly susceptible to misfolding. In addition, the 
environment of the cell is quite different due to a high crowding effect (300-400 mg/ml 
of protein and other macromolecules) that is not seen in vitro, which can result in 
disruptions in the folding process leading to non-functional aggregates [63, 83, 84]. So 
far I have for the most part only discussed the folding mechanisms as they relate to small 
(-100 amino acids) monomeric single domain proteins with a simple two-state folding 
reaction. However, the complexity of protein folding increases astronomically as many 
proteins within the cell have multiple domains and the average protein size for eukaryotes 
is approximately 450 amino acids [85]. In addition, once folded many proteins gather into 
multimeric protein assemblies to perform their function, only further increasing the 
complexity. So how does the cell rapidly fold thousands of large proteins under what 
seems to be extremely unfavorable conditions as many proteins are intolerant to high 
concentrations? In addition, the range of available conditions (i.e. buffer, pH and 
temperature) for folding inside a cell are limited and very narrow unlike the wide range 
of in vitro conditions.
To compensate, the folding process can be assisted by molecular chaperones and 
chaperonin [84, 86]. The molecular chaperone network functions in a large array of 
proteostasis but one of its key functions is to prevent protein misfolding, which is 
particularly important during cellular stress. Any protein that interacts with and aids the
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folding of another protein without being part of the final native structure defines the role 
of a chaperone. Chaperones interact with proteins either by direct interaction with the free 
nascent polypeptide chain or by interacting with the ribosome during translation and 
restricting unfavorable interactions [84]. Chaperonins and heat shock proteins (Hsps) are 
adenosine triphosphate (ATP) regulated chaperones which bind to the free nascent 
protein chain whereas, trigger factor, nascent-chain-associated complex and Hsp70Ll are 
some examples of ribosome bound chaperones that interact with the nascent protein chain 
as it exits the ribosomal tunnel [84]. In both cases, recognizing and binding hydrophobic 
segments of proteins that are typically found in the buried portion of the natively folded 
protein prevents the formation of improper intermolecular interactions [84]. Chaperones 
essentially act as kinetic partitions and redirect the polypeptide away from the pathway of 
aggregation by preventing the interaction of exposed hydrophobic residues. Binding the 
hydrophobic residues for a short time limits the available conformational space and 
allows formation of native interactions [84], The importance of protein quality control 
chaperones cannot be over emphasized as there are many disorders related to deficiencies 
in proteostasis, such as the formation of aggregated a-synuclein secluded into Lewy 
bodies in Parkinson’s disease [87, 88].
One of the major goals in computational biochemistry has been solving the 
protein folding problem using computer based prediction methods. Using computational 
algorithms to fold the primary structure of amino acids into its native structure is 
fundamentally important. It has the potential to accelerate drug discovery by replacing 
lengthy structural studies with rapid structural simulations as well as provide insight into 
the structure and function of many as yet unsolved proteins in the genome [89]. There are
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two major avenues in the approach to solving the structure of a protein using 
computational methods. The distinction in the two molecular dynamics (MD) approaches 
is that one relies on inference of structure and the other does not (ab initio). The more 
predominant approach to protein prediction uses protein databases to infer protein 
structure [89]. This originally began with databases for secondary structure prediction 
algorithms followed by the incorporation of computational physics such as atomic force 
fields and Monte Carlo simulation [90-94]. Further developments in the computational 
prediction of protein folding included homology modeling algorithms which looked at 
databases for homologous sequences to gain insight into structure [95]. Using these 
algorithms the fold of unknown sequences could be predicted based on a database of 
solved 3D structures with similar sequence and inferring similar folds [96]. In ab initio 
methods the protein structure is predicted only using known information about the 
underlying forces of protein folding.
The field of protein prediction was significantly advanced and influenced by the 
invention of the CASP (Critical Assessment of Techniques for Protein Structure 
Prediction) which was a community-wide test for the prediction of unknown structures 
[97]. Since the development of the CASP the native structure prediction of small, single- 
domain proteins using databases and advanced software have come to within 2-6 A of the 
structure verified by experiment [98-102]. In addition, the advances in rapid homology 
modelling are impressively able to compute the approximate folds for whole genome 
sequences [103, 104]. Most significant and notable advances have occurred in the ability 
to align targets with homologs, detect evolutionarily distant homologs and the 
development of reasonable models for the most difficult proteins which excitingly
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contain new folds [89,98-100]. However, with these advances in native structure 
prediction there are still many obstacles to overcome. This includes refining the 
homology models, reducing the modeling error to consistently below 3 A specifically for 
those large difficult proteins containing new folds, low homology or large P content [89, 
98-100]. In addition, significant challenges still lie in the handling of large multidomain, 
domain-swapped proteins, membrane proteins and the prediction of protein-protein 
interactions [89, 98-100].
In the field of MD simulation for protein folding, one of the greatest challenges 
not related to protein folding, is to overcome available computing power. Although MD 
has been used to study the folding process from multiple aspects, the ultimate goal of MD 
is to develop an all-atom modelling method the encompasses the full folding process. 
However, even the fastest-folding proteins overwhelm the most advanced physics-based 
simulations when it comes to all-atom approaches requiring years of simulation time for 
even 1 millisecond folding time. It is quite impractical to run simulations for years, thus 
much of conventional MD is focused on specific characteristics of the folding process 
with little work being done on the complete folding trajectories of all atoms with atomic - 
resolution [105-107]. However, with the development of ANTON, a specialized 
supercomputer for high-speed MD simulations, the ability to compute all-atom, extended 
physics-based and explicit-solvent simulations has been extended by orders of magnitude 
in comparison to what was previously possible [108-110]. Using ANTON, detailed 
mechanistic analyses of the folding process for the folding of proteins up to -100 amino 
acids which naturally fold rapidly can be examined [111, 112], With the advent of 
ANTON it is estimated that 10% of the single-chain proteins in the protein data bank are
now accessible to MD simulations [108]. With this increase in accessibility of all-atom 
full folding pathway simulations, MD is now becoming more dependent on force field 
accuracy. There are a number of force field programs currently used in protein folding 
MD. A few of those most recently updated include Amber99SB-ILDN, GROMOS and 
CHARMM force fields [113-119], These force-fields are shown to provide accurate 
representations of the structure and dynamics of small globular proteins on the 
submicrosecond scale, however they prove to be problematic on larger proteins due to 
longer folding timescales [120]. Now that MD simulation can exceed the millisecond 
timescale due to advanced computing power and the accuracy of the simulation is largely 
limited by the force field accuracy there has been a significant step in solving accurate 
fully atomistic physic-based models of fast-folding proteins [108].
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METHODS TO STUDY PROTEIN FOLDING: EQUILIBRIUM 
FLUORESCENCE
Studying protein folding, structure and stability in protein chemistry usually 
requires a spectroscopic probe that provides insight into the changing environment of the 
protein structure. Typical spectroscopic probes for protein structure and folding under 
equilibrium conditions utilize intrinsic fluorescence of the aromatic amino acids, mainly 
tryptophan (Figure 6A) [121-123]. However, tryptophan, phenylalanine and tyrosine 
typically exist in proteins naturally only at very low percentages i.e., approximately 1 
mole percentage for tryptophan alone [124]. The application of tryptophan, phenylalanine 
and tyrosine relies on the maximal absorption wavelengths of their aromatic structure and 
natural hydrophobicity which makes them sensitive to the polarity of the immediate 
environment of each probe [124]. Phenylalanine, tyrosine and tryptophan absorb 
approximately 260 nm, 280 nm and 285 nm wavelengths of light respectively.
Tryptophan is the most commonly used probe for investigating folding and unfolding due 
to its significantly larger molar extinction coefficient and fluorescence intensity in 
comparison to those of phenylalanine and tyrosine [124]. Changes in the local 
microenvironment of tryptophan typically correspond to an overall loss in native 
structure due to the cooperative nature of most unfolding transitions associated with 
many proteins [121-123]. Fluorescence probes allow for monitoring structural changes in 
a folding reaction induced by chemical denaturants, heat, pH or pressure [121]. In our 
investigation of the folding of the B 1 immunoglobulin-binding domain of protein G 
(GB1) we used 295 nm as our excitation wavelength to specifically detect the intrinsic 
fluorescence of the single tryptophan at position 43. Typically a protein with a tryptophan
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buried in its native structure will present with a shorter and higher maximum emission 
wavelength and intensity, respectively, in comparison to the denatured structure. 
Exposure of a tryptophan to a polar solvent reduces its emission potential as the 
excitation energy is dissipated by transfer into the solvent [124]. Consequently, the 














Figure 6. Aromatic amino acids and schematic of equilibrium fluorescence. (A)
Three aromatic residues used as intrinsic or synthetic spectroscopic probes of protein 
folding in equilibrium fluorescence experiments. (B) A visual schematic of equilibrium 
fluorescence data and the effect on aromatic residue emissions during the transition from 
unfolded to folded states.
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Using the equilibrium fluorescence intensity in relationship to the denaturant is 
useful in determining free energy values of folding [121]. The inherent difficulties in 
using tryptophan and tyrosine residues as fluorophores for studying protein folding lie in 
the inability to distinguish the emission contribution of each individual amino acid when 
there are multiple residues in the primary structure [121, 125]. Proteins with multiple 
fluorophores are limited in interpretation of the structural and dynamic properties of the 
side chains due to overlap of emission signals in addition tryptophan fluorescence can be 
quenched by neighboring acid or basic residues, cysteine or disulfide bridges [121, 124, 
125]. However, a potential solution to this limitation is to use site-directed mutagenesis to 
replace a specific amino acid, with non-fluorescent residue. In the case of a protein 
containing two fluorescent amino acids you can gain additional information by 
comparison of the single mutation to the wild-type (WT) protein which can reveal the 
importance of the specific amino acid in the stability and folding. An example of this has 
been shown using the tryptophan aporepressor protein from E.coli whose dimer interface 
appeared to be disrupted by the loss of either tryptophan [121]. Intrinsic tryptophan 
fluorescence has been used for many years to investigate protein folding and is 
foundational for chemical and thermal denaturation curves which provide perquisites for 
techniques such as O-value analysis and stopped-flow kinetic analysis.
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METHODS TO STUDY PROTEIN FOLDING: O-VALUE ANALYSIS
O-value analysis is a protein engineering method originally initiated by the 
Fersht laboratory [126]. This method has seen much attention and has been used in the 
past two decades to investigate well over 500 variants of more than 21 different proteins 
[127]. Some examples of proteins that have been studied by O-value analysis include 
chymotrypsin inhibitor, SH3 domains, bamase, chicken brain a-spectin, ubiquitin, E3- 
binding domain of the dihydrolipoamide succinyltransferase (BBL), Fas-associated death 
domain (Fadd-DD) and individual domains of proteins L and G [128-135]. Using O- 
value analysis we can study the role of specific amino acids on the folding kinetics and 
conformational stability of the protein folding process by determining the AG of the 
transition-state relative to the folded state [136, 137]. This method of investigating the 
folding transition-state is most amenable to small domain proteins that follow a two-state 
transition reaction. The transition-state is relatively unstructured and because it is 
transient in solution, studying the structure of the transition-state is difficult for high 
resolution techniques like protein NMR or X-ray crystallography. Using site-directed 
mutagenesis select amino acids can be modified or removed by substitution with a similar 
amino acid or alanine, respectively. In the O-value analysis the effect of an engineered 
point mutation on the AG of the protein molecule is used as a probe of the structure 
formation along the folding pathway [126, 129, 136-138]. The O-value is obtained once 
the WT protein is compared with those of the engineered protein variants. The O-value is 
an indirect measure of the mutated residues molecular interaction contribution to the 
formation of the transition-state structure, and in turn reflects what percentage of the 
native-like interaction with the mutated residue remains in the transition-state [137].
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Typically, positions that show the highest O-values are considered part of the folding 
nucleus as they are found in the most structured positions in the transition-state [137].
Due to advances in the modem laboratory techniques, mutations can be rapidly 
introduced into the plasmid construct using polymerase chain reaction (PCR) and readily 
purified using His-tagged or anion-exchange methods. In typical O-value analysis 
investigations, an impressive quantity of kinetic information can be gathered by rapidly 
mutating a large percentage of the available amino acids in a relatively short time. In this 
protein engineering method, selection of the appropriate mutations is quite important as 
non-conservative and disruptive mutations can result in a change in the native-state 
structure and alter the folding pathway completely [137]. In addition substituting a polar 
residue with a non-polar one can alter the proteins interaction with the solvent and result 
in solvation artifacts in the folding pathway [137]. O-value mutations typically are as 
conservative and mildly-disruptive as possible to prevent off-pathway folding, such as 
substituting Ile^V al which removes a single methyl group. Although this minor change 
is quite sensible, typically researchers have opted to substitute alanine in any position 
selected for mutation for three main reasons [137]. First, using a unified substitution 
method is convenient, particularly when there are a high number of mutations that are 
being performed. Second, mutations that are too conservative often have changes that are 
too small and beyond the detectable limits of the method to calculate accurate O-values. 
Lastly, substitution of alanine of all the amino acids is the least likely to form new non- 
native interactions during the folding process and results in a sufficient loss of those 
interactions [137]. Interestingly, using O-value analysis on the substitution of a variety of 
amino acids at the same position can provide a significant amount of additional
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information on the types of interactions that are important in transition-state stability 
[137]. The Of value is defined using the following equations [137]:
In the equation 3 WTAG*.U and MutAG*.u represents the change in free energy 
between the transition-state and unfolding state of the WT and mutant respectively. 
WTAGf.u and MutAGf.u represent the change in free energy between the folded and 
unfolded states of the WT and mutant respectively (Figure 7) [8, 137]. Thus, the Of value 
is a ratio of the amount of intramolecular destabilization presented by the mutated residue 
in comparison to the native interaction from the WT protein. The Of value ranges from 0 
to 1 with values near 0 suggesting that the selected amino acid has no native interactions 
and is most likely surrounded by unstructured regions in the transitions state. Values near 
1 indicate that the specific interactions of this particular residue position in the native- 
state are fully formed in the transition-state. Partial Of values indicate that only a fraction 
of the native-state interactions are formed at that position in the transition-state. In Figure 
7 A, the effect of the mutation on the energy of the transition-state is equivalent to the 
native-state transition-state energy, which calculates to a AAG*.U = 0, which results in a Of 
= 0. In opposition, in Figure 7B, the energy difference of the WT and mutant in the 
transition-states compared to the native-state results in AAGt.u = AAGf_u, which results in 
a Of = 1. AAGj-u and AAGf.u are calculated using equations 4 and 5 by substituting the 
folding rate constants (kf) for the WT and mutants into the ratio. Experimentally, the 
Gibbs free energies for the WT and mutants are determined from chemical and thermal
Of = AAG*-u/AAGf-u = (WTAG,U -  MutAG,.u)/(WTAGf.u -  MutAGf.u) 
AAGf.u = -RT ln(MuV WTjfcf) -  RT ln(Mutku/WT/fcu)





denaturation folding curves. The folding rate constants and equilibrium constants, 
determined using stopped-flow measurements and a chevron plot, are required for 
calculation of the Of [137].
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Figure 7. Energy diagram for O-value analysis of protein folding. The solid line 
shows energy levels of the unfolded, folded and transition-state for the WT protein, and 
the dotted line shows the levels for a mutant. (A) <t> = 0 and (B) 0 = 1 .  Modified and 
redrawn from references [8, 137].
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METHODS TO STUDY PROTEIN FOLDING: STOPPED-FLOW 
SPECTROSCOPY
One of the most widely used methods for determining the folding kinetics of a 
protein is a rapid-mixing stopped-flow technique. In this type of experiment the folding 
process is initiated by rapidly mixing a chemically denatured protein into an appropriate 
refolding buffer initiating spontaneous refolding by dilution of the denaturant (Figure 8). 
In a similar fashion the unfolding of a protein can be monitored by rapidly mixing a 
native protein solution with a concentrated denaturant in an appropriate buffer. Forming 
denatured protein can be accomplished using several other methods in addition to 
chemicals, such as altering temperature and pH. The process of stopped-flow folding 
kinetics can be monitored in real-time by several spectroscopic methods including 
fluorescence, near- and far-UV CD, X-ray scattering, Fourier transform infrared 
spectroscopy (FT-IR) and real time NMR spectroscopy [50, 124, 139-144]. Using 
intrinsic fluorescence probes such as tryptophan emission radiation (excitation = 295 
nm), the overall folding process can be monitored in real-time as the microenvironment 
of the tryptophan moves from a solvent exposed to a buried environment during the 
refolding process. Using CD, discussed in the next section, as the detection method 
allows for direct monitoring of structural information of a protein as it folds. These two 
detection methods are the most commonly used in the folding community [145]. Much of 
what is known about the kinetics of folding and unfolding is due to the enormous amount 
of information that has come from stopped-flow methods. There is a fundamental 
limitation to the information gathered by stopped-flow methods which is associated with 
poor time resolution. The time required to mix the solutions to initiate either unfolding or
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refolding and m ove the solution into the observation head requires in general a t least a 
few m illiseconds. This tim e delay is called the “dead tim e” o f  the instrum ent. This puts a 
limit on the observable changes associated w ith folding, as in some cases all the 
spectroscopic changes have already occurred during the dead tim e [53, 146-148]. There 
arc also studies that show that the form ation o f  secondary structures such as a-helices in a 
synthetic polym er system  is too fast to be observed by stopped-flow  techniques [149], 
However, there are som e researchers dedicated to pushing the boundaries and have built 





Figure 8. Schematic of a traditional stopped-flow instrument. Here the denatured 
protein in one syringe is rapidly m ixed with refolding buffer from another syringe in the 
follow cell and m onitored. The detector can be for exam ple, fluorescence, absorption or 
CD. This figure was redrawn and adapted from [153].
In the past 20 years there have been a significant number of advances in our 
experimental and theoretical approaches to studying the mechanism of protein folding 
[47, 154-156]. Initially it was established that it was critically important to characterize 
the kinetics and thermodynamics of simple protein systems to establish a foundation to 
studying protein folding. It makes sense that the initial studies of protein folding would 
begin with small single domain proteins such as the 83 amino acid CI2, which does not 
contain any of the complexity of disulfides, cofactors or metal associations. Investigation 
of CI2 revealed a two-state folding mechanism with no kinetically detectable 
intermediates [34], In following work on CI2, mutations were made and the relative 
effect on the folding rate and the participation of specific amino acids in the transition- 
state was monitored [31, 136]. The work with CI2 folding led to further investigations 
into the thermodynamics and kinetics of a number of other single domain proteins [1, 
157]. Kinetics data obtained from stopped-flow methods are used to calculate folding 
rates and goodness of fit with multi-parameter exponentials using a graphing and fitting 
program like SigmaPlot.
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METHODS TO STUDY PROTEIN FOLDING: FAR- & NEAR-UV CIRCULAR 
DICHROISM
In structural biology, CD is one of the fundamental spectroscopic methods for 
gathering structural information on proteins in biologically relatable environments. CD is 
a spectroscopic technique used in protein structure analysis because it can be used to 
identify the secondary and tertiary structure of proteins. This technique uses the 
differential absorption of circularly polarized UV light by chiral molecules (Figure 9A) 
[139, 158]. Unlike absorbance spectroscopy the left- and right-handed circular 
components of polarized light are absorbed differently by each of the chiral centers 
resulting in the CD spectrum (Figure 9B). In addition, non-protein cofactors like haem 
groups, pyidoxal-5’-phosphates, flavins and chlorophyll moieties can be seen in CD 
spectra [139, 159]. UV light in the far region (240 nm and below) of the spectrum are 
preferentially absorbed by the backbone amide of the peptide bond due to «—►//* and n  
—w*  electronic transitions, thus data obtained in this region correspond to the orientation 
of the polypeptide backbone or protein secondary structure (Figure 10) [139, 158, 159]. 
Far-UV CD allows for the determination of the three common types of secondary 
structures as well as disordered or irregular structure associated with denatured or 
intrinsically disordered proteins. For example, all a-helical proteins result in a strong 
negative differential of far-UV absorption with a distinctive double minimum around 208 
and 222 nm. In contrast to that, all (3-sheet proteins show a single minimum between 210 
and 225 nm with a significant decrease in the strength of the negative differential [158]. 
Disordered structures show a loss of all peaks with a near 0 differential absorption 
between 205 and 250 nm. Advances in software analysis algorithms of far-UV spectra
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allow for determination of the relative percentage each secondary structure contributes to 
the native structure of the protein molecule [139, 158]. This observation of the secondary 
structure is extremely useful in detecting changes in a protein structure due to changes in 
environmental conditions or functional changes. It is also quite valuable when predicting 
the structure of a protein, when compared to reference spectra of proteins whose structure 
has already been solved by either NMR or X-ray crystallography. There is a large 
collection of algorithms and datasets that are currently used to compare secondary 
structure. DICHROWEB is an online CD server that allows analysis of secondary 
composition directly from instrumental data, hosting the most commonly used algorithms 
including CDSSTR, SELCON, VARSLC, K2D and CONTIN [160-168], However, there 
are limitations to the database analysis when it comes to small oligopeptide structures, 





Figure 9. Origin of the CD effect. (A) The left (L) and right (R) circularly polarized 
components of plane polarized radiation: (I) the two components have the same 
amplitude and when combined generate plane polarized radiation; (II) the components 
are of different magnitude and the resultant (dashed line) is elliptically polarized. (B) The 
relationship between absorption and CD spectra. Band 1 has a positive CD spectrum with 
L absorbed more than R; band 2 has a negative CD spectrum with R absorbed more than 














Figure 10. Far-UV CD spectra associated with various types of secondary structure.
Solid line, a-helix; long dashed line, anti-parallel (3-sheet; dotted line, type I P-tum; cross 
dashed line, extended 3io-helix or poly (Pro) II helix; short dashed line, irregular 
structure. Image reprinted from [139].
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In the near-UV region (260-320 nm) the spectra obtained is related to tertiary 
structure of the protein structure due to the quantity, mobility and environment of the 
aromatic amino acids. Tryptophan, tyrosine and phenylalanine show peaks in the 290-305 
nm, 275-282 nm and 255-270 nm regions respectively (Figure 11) [139, 158]. The 
structural resolution of the specific aromatic regions is due to the differences in the 
vibrational excitation states of each aromatic amino acid [139]. Although the near-UV 
CD spectra are unique to each protein there is information that can be gained though 
coupling with techniques such as site-directed mutagenesis. Even though the theoretical 
structural analysis is limited, specific features can be assigned by selectively removing 
specific aromatic residues and monitoring the effect on the tertiary structure. A few 
examples of this can be seen in the case of human carbonic anhydrase II, bovine 
ribonuclease and the molybdate-binding transcription factor ModE form E.coli [169- 
171]. The CD data obtained in the near-UV is quite valuable as a reference fingerprint for 
the tertiary structure, which is extremely important in identifying molten globule states or 
when comparing protein variants against the WT structure. Unlike the specific structural 
elements assigned in far-UV, near-UV analysis provides very little information to the 3D 
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Figure 11. The Near-UV CD spectrum for type II dehydroquinase from
Streptomyces coelicolor. The wavelength ranges corresponding to signals from Phe, Tyr 
and Trp side chains are indicated, but it should be emphasized that there can be 
considerable overlap between the Tyr and Trp signals. Figure adapted from [172],
CD is a versatile method and is extremely important in structural biology, for 
example as a comparative reference for secondary structure content which is relatable to 
solving of protein structures using X-ray crystallography and NMR. CD can be used to 
analyze the stability and changes in protein secondary and tertiary structures as a function 
of temperature, pH, chemical denaturant and mutation [139]. The advantage to CD 
spectroscopy is that it is a quick method for gathering structural information on proteins,
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on the order of minutes to hours depending on the instrument. In addition, it involves 
very little protein and does not require extensive post-experiment data processing, 
allowing a significantly large amount data under various types of conditions to be rapidly 
obtained. The detailed analysis of structure provided by CD allow for the investigation of 
conformational changes due to solvent, ionic strength, temperature, pH and the binding of 
ligands involved in biological function. The rate of change of the secondary and tertiary 
structure in proteins can be determined in real-time when coupled with a stopped-flow 
instrument. Because high resolution structural studies like X-ray crystallography are not 
as amenable to peptides or insoluble aggregates, CD is one of the most predominate 
methods for studying structural changes associated with amyloid fibril formation [139], 
This technique is invaluable in studying the transition from a-helix to (3-sheet associated 
with amyloid fibril formation involved in the misfolding of globular proteins or peptides 
such as prions [173],
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METHODS TO STUDY PROTEIN FOLDING: NUCLEAR MAGNETIC 
RESONANCE
The NMR spectrometer is composed of a magnet, radiofrequency system, probe 
and possibly a variable temperature controller (Figure 12) [174]. The magnet stack in 
NMR of biological molecules is almost universally a helium-cooled persistent 
superconducting magnet of the highest field strength available. The radiofrequency 
system is composed of five components; the transmitter, decoupler, power amplifiers, 
receiver and field-frequency lock system [174]. The transmitter generates broadband 
excitation pulses at the select nucleus frequency to be observed and can be adjusted to 
cover all nuclei of interest [174]. The decoupler is a second source of broadband 
excitation similar to the transmitter. The power amplifiers boost the excitation pulse 
power to very high wattage levels for non-selective frequency pulses. The receiver 
detects the free induction decay of nuclear spins and operates over a wide range of 
frequencies for various nuclei detection [174]. The field-frequency lock system uses an 
internal reference, typically deuterium, as a constant reference to ensure constant 
magnetic field. Corrections to the magnetic field are made in response to drift in the 
reference signal to maintain a uniform magnetic field [174]. Probably the most important 
component in the NMR spectrometer is the probe. The primary two functions of the 
probe is to convert the radiofrequency power into oscillating magnetic fields that can be 
applied to the sample and detection of oscillating magnetic fields generated by the 
relaxing nuclei [174]. Probes can accommodate different sample sizes although typically 
5 mm probes are most common for biological NMR [174],
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Figure 12. Schematic of an NMR instrument. Shown is the general set-up for 
conducting NMR with biological samples. Here the macromolecules are placed in an 
NMR tube which is inserted into the spectrometer. The tube is positioned between two 
magnets where the atoms of interest are aligned and detected. Image was redrawn from 
Agilent technologies (http://www.agilent.com/labs/features/201 l_101_nmr.html).
NMR is a continually evolving high resolution method for studying complex 
molecules with atomic-level sensitivity. The NMR spectrum of pancreatic ribonuclease 
performed on a 40 MHz spectrometer, first reported in 1957, was the first proton NMR 
analysis of a complex macromolecule. However, the information that could be deduced
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from this early analysis was extremely limited. In the next several decades the power of 
NMR instrumentation and methodology has evolved enormously, providing the ability to 
investigate conformations and interactions of biological molecules on the atomic scale. 
The most notable developments include increased sensitivity due to much higher 
magnetic field spectrometers, development of pulse Fourier transformation methods and 
multi-dimensional NMR methods. In the most modem applications of NMR, 2D analysis 
or higher are commonly used to study biological macromolecules. Information of a 
typical one-dimensional (ID) analysis provides distinct spectral peaks for each atom of 
interest whereas 2D analysis can provide cross-peak (CRPK) information about 
connections between atomic resonances. However, the specifics of the information 
gathered depend on the type of experiment being run. CRPK’s can be observed through 
interactions of bonded atoms up to four atoms apart, interactions of atoms through-space 
that are within range of each other or through exchange interactions of the same atom in 
differing environments in the same sample. In example, the dipolar-assisted rotational 
resonance (DARR) pulse method is used to monitor l3C-13C interactions through space by 
a transfer of magnetization (Figure 13) [175, 176]. In this method CRPK’s are produced 
through an initial transfer of magnetization from ‘H to covalently bonded 13C followed by 
subsequent transfer to 13C carbons that are close in space. Short mixing times allow for 
intra-residue 13C-I3C CRPK’s while longer mixing times allow for inter-residue CRPK’s 
[175, 176],
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Figure 13. Schematic of the 2D DARR method. This schematic shows the intra-residue 
(black arrows) and inter-residue (grey arrows) magnetization transfers between 'H (blue) 
and 13C (pink). Magnetization transfers between non-covalently bonded atoms result in a 
CRPK in the 2D spectrum. This figure was redrawn by hand in Microsoft Power Point 
(V. Higman, University of Bristol).
NMR spectroscopy is possible because atoms of the same element, oriented by a 
strong magnetic field, produce distinct spectral signals depending on their atomic 
environment when irradiated with characteristic radiofrequency radiation. The resolution 
of NMR is very high because the signal is derived from individual atoms and their atomic 
interactions. The most commonly used isotopes used to study proteins in NMR are 'H, 
13C, l5N and 19F. However, because the natural abundance of the NMR active isotopes of
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carbon, nitrogen and fluorine is small in natural biological molecules, typically isotopic 
labelling can be used to make a biological molecule more NMR sensitive. When studying 
proteins the first and rate-limiting step of any NMR experiment is the assignment of all 
the resonances to specific nuclei. However, the relative complexity of the spectrum 
obtained in the single-dimension and even the second-dimension for proteins is extremely 
convoluted due to spectral overlap of signals. Moreover, in terms of applications in 
structural molecular biology, being able to combine high resolution structural date and in 
vitro experimental information makes NMR spectroscopy in valuable in protein folding.
In addition, the advance in increased magnetic field strength is continually growing. In 
the last decade, 700 and 800 MHz magnets are becoming more common and the most 
advanced spectrometers at 900 MHz and higher are gradually gaining a foothold.
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PROTEIN MISFOLDING
In the past decade there has been an increase in the identification of protein 
misfolding related diseases which include systemic amyloidosis and neurodegenerative 
diseases [8 8 , 177]. With about 20 different diseases associated with the deposition of 
amyloid fibrils, there is a need to better understand fibril etiology, pathogenesis, as well 
as the structure and mechanism of fibrillogenesis. The term amyloid has been defined by 
the Nomenclature Committee of the International Society of Amyloidosis as extracellular 
deposits of protein fibrils with the cross-P X-ray diffraction pattern, fibrillar 
characteristics under electron microscopy and an affinity for Congo red with a resulting 
apple green birefringence [178]. However, the structural biology and biochemistry 
community is looking to elucidate the molecular structure, biophysical characteristics and 
mechanism of amyloid or amyloid-like formation, and have limited the definition to 
fibrillar polypeptide aggregates with cross-P conformation [178]. Fibrillation results from 
the rearrangement of a naturally soluble protein or peptide into a stacked p-sheet rich 
insoluble ordered aggregate filaments (Figure 14), which accumulate into either 
extracellular deposits in the organs or tissues associated with the specific protein and in 
some instances leads to amyloidosis [8 8 , 177]. Conversion of proteins into amyloid fibrils 
is proposed to produce its adverse effect in specific cases by either a loss-of-function or 
gain-of-function mechanism [8 8 , 177]. It appears the process of fibrillation is not limited 
to a specific class of proteins, which indicates that the fibrillation process and resulting 
fibril morphology may be independent of the native secondary and tertiary structure and 
appears to be an intrinsic property of the primary sequence of amino acids [179, 180]. A 
fundamental molecular condition for fibrillation is the destabilization of the overall native
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structure which allows the primary structure to explore alternative conformations or 
digestion of the protein resulting in aberrant peptides [8 8 , 177]. It is not clear exactly how 
fibril aggregates form, but it has been proposed that every protein has the ability to form 
amyloid fibrils under the appropriate environmental conditions [181], Interestingly, many 
proteins not associated with diseases have been shown to form into amyloid fibrils, 
indicating that fibril formation is an alternative pathway for structural diversity [181- 
183].
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Figure 14. Mechanism of protein amyloidogenesis. Schematic was adapted from 
concepts in the following papers [184-186] and published in the present reproduced form 
in [187]. Kn and Kg are equilibrium values of nucleation and growth, respectively.
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To better understand the process of amyloid fibril formation we must also better 
understand the exact key determinants and interactions of protein folding. In normal 
protein folding the conditions for folding are relatively specific so as to prevent formation 
of disordered amorphous aggregates and yield a biologically active form [8 8 , 177]. In 
fibrillogenesis, environmental conditions are similarly specific directing an alternative 
conformation [8 8 , 177]. In contrast to normal protein folding, the mechanism underlying 
ordered protein aggregation relies on the destabilization of globular proteins reducing the 
dynamic stability of the tertiary structure, resulting in the formation of either a molten 
globule-like state or partially unfolded conformation (Figure 4) [8 8 , 177]. Intrinsically 
disordered proteins (IDP) do not have structural elements and must first adopt a partial 
fold before transitioning into amyloid fibrils [177], The molten globule-like or partially 
folded conformation allows access to the kinetically alternative folding pathways for 
conversion into the (3-sheet rich amyloid fibril structure [8 8 , 177],
Formation of disease state amyloid deposits in vivo typically result from 
instability in native protein structure or cleavage of peptides, at relevant physiological 
conditions, due to mutations, environmental changes, chemical inducers or 
overexpression of proteins which all result in the induction of conformational plasticity 
[188]. Amyloid fibrils are structurally defined as an unbranched protein polymer with a 
repeating substructure composed of cross p-sheet structure of indefinite length (Figure 
15) [8 8 , 189, 190], However, it is a multifactorial problem and other factors such as 
intercellular protein processing also play a role. Amyloid aggregation is distinguished by 
the formation of the cross-P structure substructure with a 4.7 A internal strand distance 
and 1 0  A spacing [191, 192]. Recent work revealed two unique types of core interaction
patterns, termed “dry” and “wet” interactions, found within the nucleus of the fibril 
structure, which indicate that the base unit underlying the amyloid fibril is a pair of 
stacked P-sheet structures [189]. Differences between these interactions are unique and 









Figure 15. Representative structures of amyloid fibrils and their common X-ray 
diffraction pattern. (A) Model of fiber forming segments of Ap with the cross-p 
diffraction pattern (PDB code: 30W9) [192], (B) X-ray diffraction patter of characteristic 
amyloid cross-P reflections, reproduced from reference [193] and (C) molecular structure 
of AP40 fibrils isolated from Alzheimer’s patients (PDB code: 2M4J) [190]. Areas of the 
backbone colored yellow are indicated as P-strand region. Images A and C were drawn 
with RasMol (Ver. 2.7.2.1.1).
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Fibrillation is not only related to disease states, there are many proteins that adopt 
a non-cytotoxic amyloid fibril form as a native structure to perform normal biological 
activities, called “functional amyloids,” which may indicate a fundamental alternative 
fold in protein evolution (Figure 16) [189, 194]. These functional amyloids are capable of 
accessing a higher level of protein activity in that they are capable of crossing the 
boundary of solubility, making them able to perform functions soluble proteins are 
unable to attain [195]. Functional amyloids can be distinguished from other ordered 
protein filamental structures by the unique formation of cross-]) sheet structure, whereas 
structures found in the assembly of actin filaments, microtubules, fibroins, some silk, 
collagens and keratins do not form the cross-p motif [196-199]. Transition to or from 
the functional amyloid form can regulate biological activity in which there is 
interconversion between active and in-active amyloid form. [200-202], In the case of 
HET-s prion protein the transition is accompanied by a gain of protein function, whereas 
the yeast prion protein is accompanied by a loss of function [200-202]. Functional 
amyloids have been shown to perform a variety of functions such as ligand binding, 
extracellular adhesion, biofilm formation, sorting, storage and release of hormones (Table 
1). Interestingly, of 42 peptide and protein hormones in the secretory pathway, 31 form 
amyloid fibrils in vitro under either granule-relevant pH alone or in the presence of 
heparin, a common granule glycosaminoglycan (GAG) and are biologically necessary for 
the development and survival of many organisms [195]. It is curious to find that 
fibrillation of a hormone would be a functionally relevant form as the amyloid fibril is 
considered to be a very stable low energy form [191]. Meaning that the functional 
monomeric hormones would be locked in the fibril substructure remaining non-functional
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and disassembly of the fibril structure must be a condition required for biological activity. 
This requirement is met by amyloid hormones upon dilution into the extracellular matrix 
releasing monomeric biologically active hormones [195]. The underlying mechanism of 
amyloid disassembly is still not completely understood. However, the ability of proteins 
or peptides in the secretory pathway to the form densely packed granules containing 
insoluble amyloids followed by secretion and disassembly into the extracellular space is 
significantly important in the evolution of the amyloid form. This transition appears to be 
regulated and controlled environmentally by changes in pH as well as presence of a 
cofactor GAG [195]. This reversible conversion of hormone proteins into amyloid fibrils 
as a packaging, storage and release mechanism in the secretory pathway appears to be 
uniquely evolved system that does not discriminate between proteins of differing 
secondary or tertiary structures. This function is unique and may hold key information in 
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Figure 16. Schematic that represents the possible polypeptide fates following 
translation. Each fate is tightly regulated by various control mechanisms and the 
formation of each state is dependent on the thermodynamic and kinetic accessibility 
requirements of formation. Reproduced from reference [203].
53
Table 1. Examples of small a-helieal polypeptide hormones known to be functional 
amyloids. Adapted from [195].
Protein/Peptide Organisms # o f
Residues Tissue Type
Corticotropin Releasing Factor Rat/Human 41 Hypothalamus
Urocortin II Human 38 Hypothalamus
Urocortin III Human 38 Hypothalamus
Glucagon Human 29 Pancreas
Glucagon-like Peptide 1 Human 37 Pancreas
Glucagon-like Peptide 2 Human 33 Pancreas
Gastric Inhibitory Polypeptide Human 42 Gastrointestinal tract
Exendin-4 Lizard 39 Salivary Gland
Neuromedin K Porcine 1 0 Spinal cord
Neuropeptide Y Porcine 36 Hypothalamus
The sequence of amino acids dictates the fold of a protein and a part of solving 
the protein folding problem surrounds the question; can we predict the fold of a protein 
from its primary structure? There is a very large area of research dedicated to 
understanding the sequence determinants of amyloid fibril formation and developing 
prediction methods which is the flip-side of the native protein folding problem. It is 
thought that residues important in fibrillation are different from those found in normal 
protein folding even though there appears to be cross over in residues that play critical 
roles in hydrogen bonding and forming hydrophobic surfaces [204]. There is a clear 
indication that specific sequences of amino acids tend to have a higher propensity to 
aggregate even though most of the polypeptide chain can be a part of the fibril 
substructure [188, 205]. In comparison to the nucleation or hydrophobic collapse models 
of protein folding where a specific set of amino acids form a critical folding nucleus or
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hydrophobic core respectively, short sequences of amino acids have been shown to 
induce aggregation of larger proteins that were otherwise normal, indicating the 
possibility of a similar set of critical amino acids that govern fibrillogenesis [32,206, 
207]. It was efficiently described using mutational analysis of acylphosphatase, that the 
chemical characteristics, concentration and environmental conditions of the polypeptide 
chain dictate the rate and propensity for fibril formation [208, 209].
Today, prediction programs such as TANGO and WALTZ can be used to 
determine the propensity of the entire polypeptide chain or possible patches of residues 
within a given sequence of amino acids to be susceptible to amyloid fibril formation 
respectively [210, 211]. Aggregation prediction further support the mechanistic need of 
globular proteins to form partially unfolded intermediates before fibrillation can occur 
because aggregation prone regions are not unique to a single type of secondary structure 
or location within the protein [191]. However, it should be noted that a protein that is 
misfolding can transition down either aggregation or fibrillation pathways exclusively, 
although in some instances aggregation can precede fibril formation. Despite the success 
of these programs they are still incomplete and further development of these algorithms 
to better hone their predictive capabilities is required for aggregation prediction in vivo. 
Analysis of full genomic proteins using the aforementioned prediction methodology 
revealed an important separation in protein evolution [212, 213]. Sequences of amino 
acids encoding functional proteins are significantly less amyloidogenic when compared 
to random sequences of amino acids, indicating that some external stimuli have adapted 
proteins to avoid the amyloid form [212, 213]. It is normal to assume that IDP’s would be 
more aggregation prone but in fact they are less susceptible than globular proteins to
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ordered aggregation [214]. It appears that nature has evolved internal prevention 
measures such as placing p-sheet resistant or charged residues near sequences of amino 
acids that are prone to P-sheet aggregation, using proline residues in helical membrane 
proteins to protect from improper folding, P-bulges to protect edge strands in native P~ 
sheet proteins or specifically conserved glycine, all resulting in an overall reduction of 
amyloid propensity [213,215-217]. Experimental evidence of these evolutionary designs 
can also be found in globular proteins such as p2-microglobulin (P2M), transthyretin 
(TTR), superoxide dismutase (SOD), acylphosphatase and fibronectin [217-221]. 
However, in P2M prolonged renal dialysis as well as mutations or truncations in TTR and 
mutations SOD can disrupt these designs and induce fibrillation [222-226]. It is believed 
that the protective nature of the designs mentioned above functions in increasing or 
introducing new high energy barriers that prevent the formation of intermediate unfolded 
or molten-globule like states required in the conversion to P-sheet rich aggregates [218].
It is imaginable that repetitive sequences of amino acids that alternate in polar and non­
polar character would inevitably result in rapid amyloid aggregation, but nature has 
developed proteins to avoid this sequence, further reducing aggregation propensity while 
maintaining the ability to fold into a functional protein [227]. It is truly amazing how 
proteins have evolved to avoid amyloid fibrillation while still maintaining key features 
that allow for rapid folding to the functional native state.
In this section we will discuss the fascinating fibrillation process with all proteins 
that share the all a-helical secondary structure. This will be a unique opportunity to 
investigate similarities and differences in specific conditions required for the formation of 
amyloid fibrils within a specific class of proteins. Understanding how an all a-helical
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protein transitions into (3-sheet amyloid fibrils is also of significant importance because it 
is the most extreme case of significant structural modifications required for fibrillation 
through an a-to-p conversion. Depositions of several a-helical proteins are associated 
with known disease states (Table 2). Four of these all a-helical proteins are 
apolipoprotein A-1, insulin, lung surfactant protein C (LSP-C) and prolactin (Figure 17) 
[8 8 , 180]. Deposition of these fibrils can be deleterious to the life and function of an 
organism so here we will discuss the a-helical proteins whose amyloid deposition is 
associated with a disease state (Table 2). Formation of disease state amyloid deposits in 
vivo typically result from instability in native protein structure, at relevant physiological 
conditions, due to mutations, environmental changes or overexpression of proteins which 
all result in conformational plasticity. It has been established that the in vitro formation of 
amyloid fibrils requires the destabilization of the native state of the protein by extreme 
conditions, mutations or chemical inducers. Mature fibrils found in clinical plaques are 
typically found associated with many different species such as GAG’s, metals and 
lipoproteins to name a few (61, 62). However, gross-morphologically similar amyloid 
fibrils can be formed from in vitro isolation of native protein or recombinant native 
proteins in the absence of binding species (i.e. GAG’s, metals or lipoproteins) using 
destabilizing conditions to accelerate formation (1). Five all a-helical proteins; the 
androgen receptor protein, apolipoprotein Al, insulin, LSP-C and prolactin protein have 
links to disease states [8 8 , 180]. Thus, understanding the transition of all a-helical 
proteins into amyloid fibrils has been critical to better understanding the key determinants 
of amyloid fibril formation.
Figure 17. Molecular structure of a-helical proteins related to amyloidogenic 
diseases. The a-helical proteins shown are a truncated homotetramer form of 
apolipoprotein A-I (A), monomeric apolipoprotein A-I (B), lung surfactant protein C (C), 
a monomeric insulin-like molecule (D) and human prolactin (E). The PDB codes are 
shown next to each structure. Images were made in Jmol (Ver. 13.0.4.).
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Table 2. List of all a-helical proteins known to form amyloid fibrils clinically, in
vivo or in vitro. Adapted from [180].
Disease Related all a-helical Proteins






100 mM Tris-HCl buffer 
(pH 7.4) at 37 °C 1 0
Insulin [229] Injection-siteamyloidosis
HC1 (pH 1.6) at 60 °C 






HC1 at 37 °C 14
Prolactin [231] Age-related pituitary amyloidosis
5% D-Mannitol (pH 5.5), 
0.4 mM chondroitin 
sulfate A, at 37 °C, 50 
rpm agitation
30
N o n - D i s e a s e  R e l a t e d  a l l a - h e l i c a l  P r o te i n s
Protein/Peptide Fibrillation Conditions Time(Days)
Apoptotic protease 
activating factor- 1 
caspase activating and 
recruitment domain 
[232]
Glycine-HCl buffer (pH 2.1) at 60 °C 4
Apomyoglobin [182] Na2B40 7 buffer (pH 9.0) at 65 °C 25
Bovine cytochrome c 
[233] Tris-HCl buffer (pH 9.0) at 75 °C 0.5
Bovine serum albumin 
[234, 235]
Tris-HCl buffer (pH 7.4), 75 °C; 
Glycine-HCl buffer (pH 3.0), 
50 mM NaCl, 65 °C
12.5
Cytochrome C552 
(Cys 11 Ala/Cys 14 Ala) 
[236]
Physiological Conditions (pH 7.3) 56
Fas-associated death 
domain [183]
20 mM Glycine-HCl buffer (pH 2.1), 150 mM 
NaCl, at 50 °C, 180 rpm agitation 34
a-helical hormones 
[195]
5% D-Mannitol (pH 5.5), with or without 0.4 




Since the discovery that proteins not associated with disease or formed in vivo can 
undergo the fibrillation process there have been several a-helical proteins that have been 
induced to form amyloid-like fibrils in vitro (Table 2). It is also of interest to note that 
there are a number of mainly a-helical proteins that have also been shown to convert into 
an amyloid-like form such as lysozyme [237]. Additionally, there are a select number of 
IDP and peptides, such as Afi, a-synuclein and calcitonin that form all a-helical structures 
upon exposure to additives (for example, PG vesicles, metals, fluoroalcohols or SDS 
micelles). We intend to specifically review the process for a-helical proteins to form 
aggregated species and the transition to amyloid fibrils and discuss any patterns that may 
have emerged.
Alpha-helical proteins associated with disease states
Apolipoprotein A-I
Blood contains many transport proteins that move small molecules throughout the 
body. The deposition of either WT apolipoprotein A-I (Figure 17 A) or N-terminal 
fragments (Figure 17B) has been linked to several systemic forms of amyloidosis such as 
age-related pulmonary artery amyloid found commonly in dogs or atherosclerotic plaques 
found in humans [238-241]. Apolipoprotein A-I belongs to a group of plasma 
exchangeable apolipoproteins that functions in cholesterol transport in the circulatory 
system in either high density lipoprotein bound or the less abundant lipid-poor/lipid-free 
forms [242,243]. Approximately 19 mutations of apolipoprotein A-I have been 
associated with different types of hereditary and non-hereditary forms of amyloidosis 
[240, 241, 244-249], These fibrils are found in senile plaques and have been linked to
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interactions with amyloid-(3(M2 ) indicating possible involvement in Alzheimer’s 
pathology [228]. Recent research has identified a short N-terminal sequence of residues 
46-59 of apolipoprotein A-I that may be responsible for fibrillogenesis of the full length 
protein [250]. It is worth mentioning that fibrillation of apolipoprotein A-I under 
physiological conditions may occur because of intrinsic conformational instability due to 
natural methionine oxidation and/or the ability to form higher order oligomers which 
confer structural plasticity [251-253].
Insulin
Insulin is a small 51 residue covalently linked a-helical heterodimer (Figure 17D) 
which functions in the regulation and metabolism of glucose [254, 255]. Soluble insulin 
forms higher order multimeric species under relevant physiological conditions to 
facilitate storage [256], Association of insulin monomers is regulated by a variety of 
environmental conditions (for example, pH, concentration, ionic strength and presence of 
metals) [256, 257], Dysfunction in insulin production resulting in improper regulation of 
glucose is considered one of the hallmarks of diabetes. Improper regulation of insulin in 
diabetes patients requires frequent injections of insulin as the predominant treatment. It 
seems that the deposition of insulin fibrils is possible in humans, either obtained naturally 
by aging, diabetic dysfunction or by surface deposition at insulin injection sites [256, 
258-260], The mechanism of insulin fibril formation in vivo is believed to require the 
reduction of higher ordered insulin species to the monomeric form before proceeding as 
expected with a destabilization of the native structure in favor of a partially unfolded 
intermediate [180, 256]. Fibrillation of insulin in vitro can occur under variety of 
conditions but typically require high temperatures, organic solvents, acidic pH and
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hydrophobic surfaces [261, 262]. The kinetics of insulin amyloid-like aggregation can be 
modulated by accelerants such as urea or inhibitors such as trimethylamine N-oxide 
[261]. Modulation of the hydrophobic core of insulin seems to be a critical key in 
inducing amyloid fibrillation [256]. Also differences in amino acid composition between 
differing species, such as differences between bovine and human insulin sequences, 
affect the aggregation kinetics of insulin [263].
Lung surfactant protein C
LSP-C (Figure 17C) plays a role in the very rare pulmonary alveolar proteinosis 
in which accumulation of surfactant protein amyloid-like fibrils impair respiration [230]. 
Etiology of this rare disease has been associated with improper clearance of aberrant 
surfactant proteins by macrophages [230]. LSP-C is one of the most hydrophobic 
peptides known to exist naturally and functions in concert with a complex mixture of 
proteins and phospholipids in the lungs to reduce surface tensions at the alveoli interface 
[264]. This small protein is believed to be post-translationally cleaved from a larger 
precursor protein upon insertion into a lipid-bilayer [264, 265]. Hydrogen/deuterium 
exchange experiments show that the transition of a to p occurs through short lived and 
almost completely unfolded intermediate [264]. Despite destabilizing conditions, this 
transition is relatively slow due a significant energy barrier associated with the nature of 
LSP-C’s rigid a-helical structure [265]. It is interesting to think about how nature has 
dealt with the polyvaline sequence in LSP-C which is prone to p-sheet formation [264, 
266]. Even though the structure of LSP-C is very stable it is of importance to note that the 
precursor form may be more stable when not embedded in the lipid-bilayer and may 
indicate an evolutionary adaptation to prevent the aggregation of the active protein until
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cleavage of the precursor protein occurs [264,265]. Also palmitoylation of two N- 
terminal cysteine’s may also indicate further evolutionary selection for native structure 
stability because depalmitoylation of LSP-C reduces the stability of the a-helical 
structure, decreases the energy barrier for unfolding and increases the fibrillation rate of 
LSP-C [230, 264,265]. It appears nature has evolved this highly conserved small peptide 
in many facets most likely due to its high importance in proper lung function.
Prolactin
The all a-helical 23 kDa hormone prolactin (Figure 17E) contains 199 amino 
acids in its mature form and is predominately, but not limited to secretion by the pituitary 
gland [267]. Prolactin functions in a significant number of biological processes (>300) 
making it one of the most diverse functioning peptide hormones [267]. Prolactin post- 
translational modifications such as polymerization, phosphorylation and glycosylation 
provide functional plasticity [267], Prolactin seems to be associated with group of 
functional amyloid hormones that use transient aggregation mechanisms to store high 
hormone concentrations in secretory vesicles [195,231]. Aggregation of prolactin in 
secretory granules is believed to be a more efficient method for hormone release [195, 
231]. In an investigation of spontaneous aggregation of functional amyloid hormones, 
prolactin spontaneously formed amyloid fibrils in the presence of a unique prolactin 
GAG (Table 1) [195]. Amyloid structure was verified by specific binding of Thioflavin T 
(ThT) and Congo red (CR), transmission electron microscopy (TEM) imaging and X-ray 
diffraction which will be discussed later in this chapter [195]. There are a number of 
other small a-helical hormones (Figure 18) that have been shown to form amyloid fibrils 
under similar conditions as prolactin however, with different GAG’s (Table 2) [195],
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Figure 18. Molecular structure of small hormone a-helical proteins. Hormones 
shown are corticotropin-releasing factor (L-Phel2 to D-Phe/Leul5 variant) (A), exendin- 
4 (B), glucagon (C), glucagon-like polypeptide 1 & 2 (D & E), glucose-dependent 
insulinotropic polypeptide (F), neuromedin K (G), neuropeptide Y (H), urocortin II and 
III (I & J). The PDB codes are shown next to each structure. Images were made in Jmol 
(Ver. 13.0.4.).
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Alpha-helical proteins not associated with disease
All a-helical proteins that function in apoptosis
Apoptosis can be activated by either intrinsic or extrinsic stimuli both resulting in 
programmed cell death via release of protein specific proteases [268], In the apoptotic 
cell signaling pathway, there are two all a-helical Greek-key proteins which are members 
of the death domain superfamily, apoptotic protease activating factor 1 (Apaf-1) with an 
N-terminal caspase recruitment domain (CARD) (Figure 19A) and the death domain of 
the Fas-associated death domain (Fadd-DD) (Figure 19B), that have been induced to 
form fibrils in vitro [183, 232].
The multi-domain Apaf-1 CARD protein functions as an activator of the caspase 
cascade in response to intrinsic cellular stimuli such as endoplasmic reticulum stress or 
DNA damage [269, 270]. This protein has been shown to fibrillate under a specific set of 
extreme conditions (Table 2). The transition had a lag phase of ~9 h followed by a typical 
exponential elongation phase and maturation after -80-100 h [232], This process of 
amyloid fibril formation for Apaf-1 CARD appears to be pH dependent and proceed by 
possible rearrangement of a destabilized molten globule like structure [232]. At pH 4 
there are structural changes that indicate the presence of a molten globule-like state of the 
protein that may be a possible intermediate conformation that facilitates structural 
rearrangement and formation of protofibrillar oligomers under lower acid conditions
[232]. Interestingly, the addition of NaCl for ionic strength appears to stabilize the molten 
globule state by reducing surface electrostatic repulsions, quite possibly reducing the 
ability to alter conformation. At lower pH (pH 2.1) in the absence of NaCl there is an 
indication that the molten globule-like protein rearranges in a manner that reduces
65
hydrophobic surfaces and forms precursor aggregates, which are capable of forming 
protofibrillar structures followed by mature amyloid-like fibrils [232].
lmbn
Figure 19. Molecular structure of a-helical proteins not related to disease. The a-
helical proteins shown are (A) apoptotic activating factor-1 caspase activating and 
recruitment domain, Fas-associated death domain (B), cytochrome C552 (C), bovine 
cytochrome c (D), myoglobin (E) and bovine serum albumin (F). The PDB codes are 
shown next to each structure. Images where made in Jmol (Ver. 13.0.4.)
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The Fas-associated death domain proteins are adaptor proteins that facilitate the 
formation of the death-inducing signaling complex in response to external stimuli [270], 
They appear to play a prominent role in the apoptotic pathway initiated by Ap plaques in 
Alzheimer’s disease [271,272]. Interestingly, the Fadd-DD protein also has the ability to 
form into amyloid-like fibrils in vitro [183]. The condition for amyloid-like fibrillation of 
the Fadd-DD protein is similar to that of Apaf-1 CARD requiring similar buffer and pH. 
However the conditions deviate significantly in ionic strength, temperature and 
mechanical agitation. The fibrillation of Fadd-DD seems to proceed through a 
destabilization of the native structure resulting in a partially unfolded state that still has a- 
helical composition [183]. Unlike Apaf-1 CARD, the need for ionic strength seems to be 
critical in the formation of Fadd-DD amyloid-like fibrils by possibly stabilizing 
electrostatic interactions that might cause unordered aggregation [183]. Since amyloid 
fibril formation is considered an alternative low energy conformation unique to the 
polypeptide chain, how have proteins avoided this evolutionary conformational level? It 
appears that these a-helical proteins have evolved in a manner where amyloid formation 
is avoided by requiring extreme conditions for fibrillogenesis [270].
Prosthetic all a-helical proteins
Respiration via the mitochondria is present in all eukaryotic organisms. Two 
small all a-helical c-type cytochrome proteins both functioning as electron transport 
molecules have been shown to form amyloid fibrils under unique methodologies. Both 
cytochrome C552 from Hydogenobacter themophilus (Figure 19C) and bovine heart 
cytochrome c (Figure 19D) covalently bind a haem group in their native structure and 
contain 80 amino acid and 104 amino acids, respectively. In the case of cytochrome c552
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Cysl 1 AJa/Cysl4Ala variant there is a clear structural destabilization of the native 
structure upon loss of the haem group [236], This destabilization allows this small all a- 
helical protein to form into amyloid-like fibrils under physiological conditions (Table 2) 
[236]. The presence of thioether linkages to haem may indicate why cytochrome c552 does 
not form amyloid fibrils in vivo and an evolutionary step in avoiding amyloid fibrillation. 
However, another approach using bovine cytochrome c indicate that damage, but not 
removal, of the haem group also results in the formation of amyloid aggregates as the 
protein adopts a predominant random coil to allow for conformational rearrangement
[233].
Another prosthetic protein not related to a disease that has been shown to form 
amyloid-like fibrils in vitro is myoglobin (Figure 19E). The most commonly described 
function of myoglobin is the storage of dioxygen in muscles, however it has also been 
described in nitric oxide scavenging and as a hypoxic nitrite reductase [273-275]. After 
removal of its haem group, apomyoglobin was induced to form amyloid fibrils under 
basic conditions found in Table 1 [276]. Interestingly, apomyoglobin maintains its helical 
content after removal of the haem group under mild conditions (22 °C), whereas at 65 °C 
apomyoglobin dramatically destabilized resulting in fibrillation [276]. However, 
investigation into this process revealed that at higher temperatures (i.e. 90 °C) fibrillation 
is significantly disrupted whereas at lower temperatures (i.e. 50 °C) protein folding 
appears to suppress the formation of amyloid fibril structures [182]. Mutations of WT 
myoglobin such as Trp7Phe/Trpl4Phe destroys the ability of myoglobin to bind its haem 
group and VallO significantly reduces its stability allowing this a-helical protein to form 
amyloid fibrils at physiological pH [277-279]. It appears that the evolution of protein
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function with prosthetic groups such as haem seems to also function as a stabilizing 
factor that prevents these types of protein from forming amyloid fibrils in vivo.
Serum albumins in plasma
Serum albumins are large multi-domain all a-helical plasma proteins that function 
in the transport of small molecules (i.e. metals, hormones, fatty acids and drugs) to 
specific tissues, regulate osmotic pressure, maintenance of blood pH and serve as 
predominant plasma antioxidants [280,281]. Bovine serum albumin’s (BSA) triangular 
structure (Figure 19F) is composed of three homologous domains with two subdomains 
each, stabilized by 17 disulfide bridges that provide rigidness but still allow for functional 
flexibility [234, 280, 281]. BSA was optimally formed into ordered amyloid-like fibrils 
with a cross P-sheet structure under the conditions found in Table 2 [234, 281]. The 
process of BSA fibrillation deviates from typical, lacking a defined lag phase similar to 
acylphosphatase, a small mixed a/p protein, indicating that the nucleation step may be 
highly favorable [181, 234]. Also BSA aggregates deviated from the robust resistance to 
protease typically seen in amyloid fibrils comprised of Ap peptide, lysozyme or P2- 
microglobulin [234, 282-284]. BSA aggregation under both conditions supports the 
general multistage fibrillation mechanism where under a specific set of conditions BSA 
becomes destabilized and partially or fully unfolded, forming a molten globule-like state 
under low pH and denature state under physiological pH, respectively. This results in a 
decrease in a-helical content, giving rise to an increase in P-sheet content [234, 281,285]. 
The aggregation rate of BSA can be modulated by the addition of NaCl which appears to 
prevent local monomer repulsions and accelerate aggregation [281]. The propensity of 
BSA to readily form amyloid aggregates appears to be increased by the ability of BSA to
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form dimers [234], It appears that a single unpaired cysteine at position 34 facilitates the 
aggregation process of BSA [234]. It is also interesting to discuss a temporary functional 
stability that may indicate an evolutionary advantage for BSA to avoid amyloid 
formation. Binding of BSA to a ligand inhibits the formation of amyloid-like fibrils by 
stabilizing the native state [234,286], It is clear that aggregation into ordered amyloid 
fibrils is not limited to single domain a-helical proteins and there are conditions that 
allow for rapid formation of amyloid fibrils.
Despite the significant advancements through the study of amyloid fibril 
formation and structure there is still much to be determined. One of the largest problems 
associated with furthering our understanding is obtaining the detailed atomic structure of 
amyloid fibrils. The heterogeneous size and insolubility of fibrils make them difficult to 
crystallize or study via solution-state NMR. However, advances in solid-state NMR 
methodology, spectroscopic techniques and the formation of microcrystals have paved 
the way to eventually obtaining high-resolution amyloid fibril structures. Of particular 
importance is resolving the structures of on pathway soluble oligomeric species as they 
are now believed to play a critical role in cytotoxicity in some fibril associated diseases 
such as Alzheimer’s [287]. Many fascinating and essential questions still drive current 
research and are likely to provide greater understanding of the balancing act between 
protein folding, misfolding and aggregation as the field continues to progress into the 
future.
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METHODS TO STUDY PROTEIN MISFOLDING: THIOFLAVIN T AND 
CONGO RED BINDING FLUORESCENCE
In order to diagnose amyloid related diseases and study the mechanism of 
fibrillation there is an important need for molecular probes. The P-sheet rich morphology 
of amyloid fibrils is susceptible to the binding of histological dyes for biomedical assays. 
The most commonly used dyes used for the detection of amyloid fibrils are ThT and CR 
(Figure 20). It is not clearly understood how molecular probes bind the amyloid structure 
because high-resolution techniques are not possible due to the insolubility and 
heterogeneous nature of amyloid fibrils. ThT is a fluorescent dye that shows a large 
fluorescence enhancement with excitation and emission maxima at about 450 and 480 nm 
respectively, once bound to amyloid fibrils; and is used as both a visualization and 
quantification method [288, 289]. It is still quite controversial as to how the ThT binding 
to amyloid fibril structures causes a photophysical enhancement in the fluorescence 
[289]. ThT fluorescence microscopy is used to investigate fibrillation in vitro and as an 
amyloid diagnosis in some clinical investigations of tissue sections [288,290, 291]. Other 
spectroscopic uses of ThT include direct observation of fibrillation by internal reflection 
and anisotropy fluorescence [292-294]. Amyloid fibril quantification is possible using 
ThT due to the proportionality of fluorescence intensity to the fibrillar weight 
concentration for a given protein under a specific set of conditions [288, 295]. However, 
it should be noted that several factors may affect the spectral fluorescence intensity when 
used under different conditions. These include the specific protein used, fibril 
morphology (high viscosity), ThT concentration, pH, ionic strength and the recognition 
that ThT may sometimes bind to tissues themselves [294, 296-302]. Unfortunately, it
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appears that ThT may actually promote amyloid aggregation to a small degree thus in 
vitro uses are becoming more limited [292,294, 303]. In addition, there is evidence that 
suggests that ThT is also unable to interact with the protein fibrils and potentially 





Figure 20. Chemical structure of two commonly used molecular probes for amyloid 
fibril detection. Structures shown are (A) ThT and (B) CR.
For almost a century CR has been used as a histological staining dye for to 
diagnose amyloid related diseases [307, 308]. It is the most common diagnostic test for 
detection and identification of amyloid aggregates in tissues in combination with 
polarized light microscopy [307, 308]. The binding of CR to the amyloid structure results 
in an apple-green birefringence when examined by polarization microscopy (Figure 21). 
In addition, using UV-Vis absorption spectroscopy, there is a characteristic shift in the
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absorbance maxima of CR from 490 nm to about 540 nm when bound to the amyloid 
form [292, 309-312]. CR absorption has been used as a quantification method for insulin 
and amyloid P aggregates in vitro, although the binding of CR is limited by a lack of 
sensitivity at low amyloid concentrations [313, 314]. CR absorption analysis is also 
poorly suited to in situ detection because it has been reported to interfere in fibrillation by 
either inhibiting or enhancing the process [311, 312, 315-318].
Figure 21. Congo red apple-green birefringence for the rare laryngeal amyloidosis.
Amyloid fibrils in this image involve a protein immunologically identical to the variable 
region of the light chain fragment of immunoglobulin. This image was reproduced from 
[319],
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Both ThT and CR have been proposed to bind in different molecular forms, such 
as monomeric [311, 320-328], dimeric [324, 329] or micellar [330-333].The orientation 
of ThT and CR in the binding pocket of fibrillar structures has been investigated via 
molecular dynamics simulations indicating the possibility of either parallel or 
perpendicular binding to the J3-strands in the p-sheet of the fibrillar structure [334]. 
Parallel binding would indicate intercalation between the P-strands however, X-ray fiber 
diffraction experiments show that the interstrand spacing of 4.8 A is unchanged upon 
binding [288]. A change in the internal P-strand distance would be expected due to the 
ThT binding. Binding of ThT or CR is more commonly believed to orient and bind in a 
perpendicular fashion to the p-strands intercalating between the P-sheets parallel to the 
long axis of the fibril strand [320]. X-ray fiber diffraction revealed a change in the inter­
sheet distance from 11 A to 16 A when bound to ThT [288]. It is essential to further 
understand the binding modes of these molecular probes and there derivatives for a 
number of reasons. Complete understanding of how these aromatic structures bind to the 
amyloid structure will also inform the design of nontoxic small molecule inhibitors as 
there is much evidence that derivatives of ThT and CR have been shown to inhibit fibril 
formation [315, 335-337], We can also improve interpretation of the amyloid signature 
and enhance our understanding of the amyloid structure.
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METHODS TO STUDY PROTEIN MISFOLDING: TRANSMISSION 
ELECTRON MICROSCOPY
In the study of amyloid fibril structure and morphology one of the most crucial 
techniques is the application of TEM. TEM opens the door to understanding the 
polymorphisms associated with amyloid fibrils. It is also one of the primary methods for 
investigating amyloids formation by providing snapshots of the gross fibrillation process. 
The ability to resolve and analyze structural details on the nanoscale provides significant 
insights into the area of protein misfolding. TEM has advanced tremendously in the last 
50 years in their design, preparation protocols and analysis capabilities [338]. The TEM 
is an advanced imaging system that utilizes electrons passed through a sample to produce 
contrast, similar to how objects in front of a light source produce a shadow. TEM can 
image the details of a sample with magnifications of up to 106 times and with a resolution 
of less than a tenth of a nanometer [338]. The TEM is composed of four integrated 
systems: the illumination system, the sample manipulation system, imaging system and 
the vacuum system (Figure 22). The illumination system is at the top of the microscope 
and produces the uniform electron beam of homogeneous energy that is directed onto the 
sample [338]. There are a two predominate types of electron emitters: the typical electron 
gun with a tungsten wire or lanthanum hexaboride cathode and the field emission gun 
using a tungsten crystal [338]. The sample manipulation is quite a sophisticated system in 
that the sample stage must be able to move smoothly in the x and y plane over a distance 
of 250 mm in steps as fine as 10 nm. In addition to the ultrafine movement control, it 
must also be able to maintain a stable stationary position varying no more than 0.1 nm for 
a minimum of 3 seconds for imaging purposes [338], The imaging system uses
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electromagnetic lenses to form, focus and magnify the sample image onto the viewing 
screen or imaging system. Of these electromagnetic lenses the objective lens is the single 
most important lens in the TEM as it is responsible for forming and focusing the initial 
image [338]. The viewing system at the base of the TEM uses electron phosphors to 
image the electrons that were not scattered when passing through the sample which 
shows up bright while places where electrons were scattered will show up darker [338]. 
The final integrated component is the vacuum system which is fundamental in its 
operation because the illuminating electrons would be easily deflected by collisions with 
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Figure 22. Schematic of the column design of a standard high-resolution TEM. The
TEM is generally divided into the illumination system (filament, bias shield, anode and 
gun alignment coils), the sample manipulation system (specimen exchanger rod) and 
imaging system (screen, lens and apertures). Image reproduced from [338].
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When imaging biological samples it is critically important to consider the 
appropriate sample preparation required for high resolution imaging of a sample. When 
microbiological samples are used preparation involves chemical fixation, sectioning and 
staining. Chemical fixation is a preservation method for stabilizing tissues and cells in as 
close to a “life-like” state as possible for imaging without apoptotic artifacts. 
Formaldehyde and glutaraldehyde are a few examples of chemical fixatives that are 
commonly used. In TEM the electrons must pass through the sample in order to be 
visualized. This can be problematic as most samples of interest are too thick for electrons 
to penetrate. Thus, ultramicrotomy is employed using a diamond tipped knife to cut 
cross-sections of a sample ranging from 60 to 80 nm which is thin enough to allow 
electrons to pass. In studying the amyloid fibril structure in vitro, chemical fixation and 
sectioning is not necessary to visualize them by TEM. However, where sample 
preparation plays a critical role for the study of amyloid fibrils is in the staining process. 
In the preparation of most samples TEM grids are used as a scaffold for the sample to be 
stained and imaged. Because all biological material is composed of predominantly 
carbon, nitrogen and oxygen, imaging by TEM is extremely difficult as electrons are not 
deflected or scattered by these atoms. To overcome this heavy metal stains are used to 
coat and/or stain samples which are ideal for deflecting electrons due to their heavy 
nuclei. In studying amyloid fibrils some of the common stains used, i.e. uranyl acetate 
and lead citrate, can lead to a significant contrast increase. Due to the heterogeneity and 
solubility issues of amyloid fibrils in solution, TEM serves as one of the best methods for 
investigating the structure of these polymers. In an extensive investigation of the 
polymorphic amyloid structure of the amyloid (3-peptide (1 -40), TEM was critical in
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showing the unique twists formed during fibrillation [339]. In a more recent study of hen 
egg white lysozyme fibrillation treated with functionalized gold nanoparticles TEM was 
used as the primary high-resolution imaging method to observe the resulting effect [340]. 
Interestingly, a curcumin-functionalized gold nanoparticles was shown to not only inhibit 
amyloid fibril formation but also were able to dissolve the fibril structure [340]. The 
value of TEM in the investigation of amyloid fibrils and protein misfolding is 
immeasurable.
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METHODS TO STUDY PROTEIN MISFOLDING: ATOMIC FORCE 
MICROSCOPY
Atomic force microscopy (AFM) was developed in 1986 by Gerd Binnig and is a 
surface technique for studying surface topologies with atomic-level resolution [341,342]. 
AFM was developed as an offshoot of scanning tunneling microscopy (STM) in which 
the sharp tunneling tip is replaced by a force-sensing cantilever. In STM atomic 
resolution is achieved by bringing an electrically conductive tunneling tip to within 
angstrom distance from the surface and measuring the tunneling current that is induced 
[343]. Distance of the tip and the current induced are inversely proportional allowing for 
topography imaging of a surface with atomic-level resolution. However, the drawback to 
this method is the material needs to be electrically conductive and placed in an ultra-high 
vacuum [343]. With those restrictions imaging biomolecules like proteins or amyloid 
fibrils is next to impossible. By replacing the tunneling tip with a force-sensing 
cantilever, the requirement for electrical conductive material is eliminated and a more 
diverse set of sample types can be visualized. In addition, these samples could now be 
visual under ambient conditions with high-level resolution. The AFM also retained the 
ability to visualize samples up to the atomic-level using ultra-high vacuums, previously 
achieved by STM [343]. Later, AFM was further developed by the introduction of the 
dynamic vibrating probe which provided increased versatility and resolution for material 
topometry [344-346]. Because of its versatility, dynamic AFM techniques are becoming 
the predominate method for imaging DNA, proteins and polymers in both liquid and air 
mediums [347-350]. A schematic of the fundamental design of AFM is shown in Figure 
23A. Amplitude (AM) and frequency (FM) modulation AFM are the two major modes
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used in force microscopy [344, 345, 351]. The force-sensing cantilever in dynamic AFM 
has a chemically or mechanically etched tip on a stiff microlever. AM-AFM (also known 
as tapping-mode) is a direct contact method for imaging surface dynamics [346]. The tip 
is excited at its resonance frequency and the oscillation amplitude is used to measure the 
surface dimensions [346]. Once in contact with the sample, changes in the z-axis 
increases or decreases the oscillation amplitude and are visualized as changes in surface 
topology. In addition, information about the material properties can be gained by looking 
at the phase shift between the driving force and tip oscillation [346]. An example of AM- 
AFM image on a protein structure is shown in Figure 23B. On the other hand, in FM- 
AFM (also known as non-contact mode) the cantilever oscillation amplitude is fixed and 
the image contrast comes from the forces between the sample and tip [346]. Attractive 
and/or repulsive forces of the cantilever to the surface modulated the resonance frequency 
of the free lever providing differentiation of the surface dimensions. Typically, FM-AFM 
is used in an ultra-high vacuum for atomic-level resolution whereas AM-AFM is used 







Figure 23. A fundamental schematic of the design of afm and example image 
obtained by AM-AFM. (A) Image of the cantilever tip is taken from Nanotec 
(http://www.team-nanotec.de/index.cfm). (B) AM-AFM image taken of P-synuclein 
fibrils using a Veeco DiNanoscope 3D AFM. The x-axis is in pm and the z-axis scale bar 
is from 0-50 nm.
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HIGH-RESOLUTION ANALYSIS OF a-HELICAL PROTEIN FIBRILS AND 
THEIR POLYMORPHISMS
The amyloid fibril structure is composed of regular repeating highly ordered 
macrostructures composed of a stacked array of misfolded cross P-sheet proteins along 
the fiber axis [88, 177]. The preliminary association monomeric cross p-sheet proteins 
make up the protofibrillar species, typically 2-5 nm in diameter, which further associate 
resulting in formation of single fibril strands ranging from 5-13 nm in diameter 
depending of the conditions of fibrillation [88, 352]. There is a clear indication that the 
fibrillation process can occur via multiple pathways (Figure 24) [353]. Detailed 
investigations of the fibril morphology is typically done using high-resolution electron 
microscopy and atomic force microscopy imaging, which have revealed repetitively 
twisted cross P-sheet filaments of variable morphology and length (Figure 25) [339]. 
Polymorphisms of amyloid fibrils appear to be diverse and not dependent on the amino 
acid sequence. Here we will compare the unique polymorphic structures of amyloid 
fibrils obtained from all a-helical proteins. Because transition of all a-helical proteins 
into the P-sheet rich amyloid fibril form represents the most extreme conversion this 
section will focus on the all a-helical protein fibril morphology. Understanding the subtle 
differences in morphology may hold the key to developing pharmaceuticals that 
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Figure 24. Schematic of the proposed polymorphic aggregation mechanism of 
insulin. In the nucleation and growth phase the native-state transitions to a fibril form. 
These associate through lateral aggregation into a higher-level and more complex state. 
Lastly, these lateral forms can have variable morphologies which are unique 
polymorphisms specific to mature fibril types such as insulin. Reproduced from reference 
[229].
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Figure 25. Imaging and modeling of a non-helical protein and associated amyloid 
fibril morphologies. (A) Transmission electron microscopy of types of polymorphic 
amyloid fibril structures. (B & C) Models of several organizational patterns for the 




Apolipoprotein A-I presents with what appears to be two fibril morphologies, one 
is that of a twisted ribbon with irregular twisting pattern and the other is a similarly 
twisted circular fibril loop (Figure 26) [253]. The ribbon-like structure may be due to 
lateral associations of fibril strands producing a flat ribbon of 11 nm in width [253]. The 
circular morphology indicates that the fibrils formed by apolipoprotein A-I may be 
dynamic in flexibility allowing the fibril ends to find one another. A similar morphology 
is seen in the fibrillation of apolipoprotein CII [354, 355]. Interestingly, X-ray diffraction 
indicates that the formation of amyloid fibrils from a specific Leul74Ser mutant of 
apolipoprotein A-I presented with a heterologous substructure of crossed-P and coiled- 
coil helical morphologies [356].
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Figure 26. Circular polymorphism of apolipoprotein A-I amyloid Fibrils. Electron 
microscopy imaging of (A) circular and (B) filamentous apolipoprotein A-I amyloid 
fibrils. Close up of a (C) circular and (D & E) linear form of apolipoprotein A-I. 
Reproduced from reference [253].
Insulin
The fibrillation of insulin is one of the most well studied aggregation processes 
and demonstrates a highly polymorphic nature under various conditions for fibrillation. It 
has been shown that fibril morphology of insulin is altered by differences in fibrillation 
conditions [229, 353]. In an extensive investigation of insulin fibrils using high resolution 
AFM we can clearly see the polymorphic assembly of insulin amyloid fibrils (Figure 27)
[229]. The aggregation of insulin fibrils seems to only rely on the formation of non- 
covalent interactions under destabilizing conditions mentioned previously [229]. Higher 
ordered fibril associations of insulin fibril strands occur rapidly within 30 minutes of 
incubation at 60 or 70 °C forming branched, twisted and lateral associations of amyloid 
fibril structures [229]. According to AFM height distributions of protofibrillar forms of 
insulin, the association of insulin into amyloid protofibrils produces aggregates that are 
1.1 nm in diameter [229]. Fully assembled single strands of insulin fibrils shown by TEM 
and AFM are 1-1.2 nm in diameter [229, 357]. Strands of insulin protofibrils assemble 
into intertwisted and laterally associated early fibrillation strands that are -4.4 nm in 
diameter when incubated at 60 °C and 2.9 or 6.5 nm at 70 °C with a regular repeating 
helical rotation [229]. In one case, twisting of the insulin fibrils produced braid like 
threads of 2.2 nm indicating two intertwined strands [261], Maturation of insulin fibrils 
results in an increase in polymorphic structures currently classified as parallel tubular 
fibers, twisted ribbon-like structures, rod bundles and ropelike textures with increasing 
sizes ranging from 4-9 nm in diameter (Figure 27A) [229]. Mature insulin fibrils are able 
to assemble into amyloid-like fibrils via a multiple pathway process, which include a 
hierarchy of strand intertwisting or assemble via lateral associations of twisted threads, 
producing different structural polymorphisms (Figure 24).
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Figure 27. AFM imaging of insulin fibrils and their associated polymorphisms. The
various morphologies of insulin include (A) twisted morphologies with different fibril 
diameters (arrows), (B) laterally connected double strand fibers, (C) highly-twisted with 
overlapping morphologies and (D & E) chain-like stacking of preformed amyloid 
subunits. (F) The interior canal of a single insulin fibril thread is visible by AFM. 
Reproduced from reference [229],
Lung surfactant protein C
LSP-C fibrils isolated from patients with pulmonary alveolar proteinosis and 
imaged with TEM show long amyloid fibrils of various twisted morphologies however 
higher resolution imaging is necessary for clearer determinations to be made (Figure 
28A) [230]. However, to our knowledge, high resolution polymorphisms of in vitro 
amyloid-like fibril formation of LSP-C have not been assessed.
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Prolactin
Amyloid fibrils formed from prolactin (Figure 28B) and other hormone peptides 
except for glucagon and gastric inhibitory polypeptide appear to be homogeneous in 
morphology and further higher resolution investigations into the possibility of 
polymorphisms needs to be further evaluated (Figure 28C-L). Glucagon is a unique case 
in that at equilibrium its native state appears to include both unfolded and a-helical 
species in solution, however it has been shown to form three distinct polymorphic 
structures similar to those discussed in insulin [358]. Gastric inhibitory polypeptide 
appears to have a regular twisting pattern indicating the presence of possible alternate 
morphologies. However, further investigation is also required to assess alternative 
polymorphic structures.
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Figure 28. Amyloid fibril imaging of other a-helical proteins associated with a 
disease state or functional amyloid form. Electron microscopy imaging of (A) lung 
surfactant protein C, (B) prolactin and helical hormones; (C) glucagon, (D) corticotropin 
releasing factor, (E) exendin-4, (F) gastric inhibitory polypeptide, (G & H) glucagon-like 
peptide 1 & 2, (I) neuromedin K, (J) neuropeptide Y and (K & L) urocortin II & III. 
Scale bars indicate 500 nm distances. Reproduced from references [195, 230].
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Bovine Serum Albumin
There are indications that under different conditions the aggregation process of 
BSA may follow different pathways and form morphologically distinct fibrils (Figure 
29G & F). BSA fibrils formed at 65 °C only bound ThT dye and CR, forming curly 
fibrils which were ~10 nm in diameter [234], At 60 °C ThT indicated fibrillation 
occurring whereas CR was negative, which indicates that there may be a distinction in 
fibrillar structures at these two temperatures [234]. However, more detailed investigations 
of BSA aggregation are required as the curly fibril structures indicate that the conditions 
for fibrillation may not be optimal. Interestingly, BSA fibrillation at a more basic pH 
produces aggregates that are 2-4 nm in diameter however no distinction between the 
possibility of polymorphisms were assessed [235]. Under acid pH conditions BSA 
amyloid fibrils appeared more morphologically similar to typically seen thread like 
filaments found in A(1 peptide and lysozyme indicating that these conditions may be more 
optimal and visual examination of TEM show fibrils of significantly different sizes 
indicating the presence of differing morphologies [281].
Apomyoglobin
Morphology of WT apomyoglobin mature fibrils (Figure 29E) appears to be 
indistinguishable from fibrils formed in disease state amyloids; whereas fibrils formed 
from Trp7Phe/Trpl4Phe apomyoglobin exhibited branching after long periods of 
incubation (Figure 29F) [182, 276]. Visual analysis of TEM of WT apomyoglobin fibrils 
show two types of fibril structures, curly and rod-like, having approximate diameters of 
10 and 14 nm respectively [276]. Interestingly, fibrils formed from the 
Trp7Phe/Trpl4Phe apomyoglobin mutant formed fibrils that were on average much
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larger in size, 20-50 nm in diameter. Conversely, fibrillar aggregates formed by mutants 
of residue VallO appeared twisted and smaller in size having a diameter of ~7-10 nm 
[279]. In these cases TEM data suggest that there may be polymorphisms that have yet to 
be distinguished in the current research of these proteins.
Cytochrome C522
Based on electron microscopy imaging of cytochrome c552 amyloid fibrils have a 
typical 6-13 nm diameter with variable lengths indicating the presence of possible 
polymorphic structures (Figure 29C) [236]. Electron microscopy imaging of the fibrils 
produced from the bovine homolog of cytochrome c (Figure 29D) showed similar fibrous 
thread-like fibrils. However, no indications were provided as to the morphology or the 
possible presence of polymorphic structures [233], Visual analysis of the TEM image 
indicated large fibril structures -15-30 nm in diameter [233]. Further, detailed 
investigations would be required to identify polymorphic assemblies of cytochrome c552 
and bovine cytochrome c.
Apoptotic Protease Activating Factor-1 Caspase Activation and Recruitment Domain
The process of Apaf-1 CARD fibrillation is believed to proceed from a 
destabilized molten globule-like intermediate into precursor aggregates which assemble 
into protofibrils and elongated fibrils [232]. Analysis by AFM shows that the precursor 
aggregates are -2.1 nm in diameter indicating they may not be fully formed into the 
crossed p-sheet structure indicative of amyloid fibrils [232]. Interestingly, protofibrillar 
and elongated fibrils produced by the Apaf-1 CARD protein are heterogeneous in length, 
but homogeneous in morphology with a single width distribution of -2.6 nm indicating 
that there is no intertwining of fibrillar strands (Figure 29A) [232]. This is interesting as it
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does not fit the structural variety typically seen in amyloid fibril morphology having 
larger twisted structures containing multiple strands. These sizes are much smaller than 
what is found in a classical amyloid fibril, which may indicate that the conditions for 
fibrillation in this case may not be optimal for aggregation.
Fas-associated Death Domain
Interestingly, agitation seems to be pivotal in tipping the balance between ordered 
and unordered aggregation conditions for Fadd-DD fibrillation [183]. The Fadd-DD 
fibrils that formed optimally are rod-like filaments that are uniquely shorter than fibrils 
generally seen (Figure 29B) [183]. Analysis of fibrillation using TEM indicates that 
Fadd-DD fibril length can be modulated by differences in agitation conditions [183].
High agitation (180 rpm) results in a predominance of morphologically shorter Fadd-DD 
amyloid fibrils, approximately 0.5 pm in length, whereas lower agitation (75 rpm) results 
in approximately a doubling in fibril length to 1.0 pm on average, but is accompanied by 
the formation of unordered aggregates [183]. Using AFM analysis of morphology of the 
Fadd-DD aggregation process indicates that protofibrillar species are on average 4 nm in 
diameter [183]. It appears that association of protofibrillar species results in the formation 
of single filaments, with similar size to protofibrillar structures, of mature amyloid-like 
morphology [183]. From the AFM size data analysis of mature fibril aggregates after 
about 11 days show two types of average size distributions, the second size being 8 nm 
indicating a possible twisting of two fibril strands [183]. Further investigation of the 
possible presence of polymorphic structure within Fadd-DD fibrillation needs to be 
further investigated.
Figure 29. Amyioid-like fibril imaging o f a-helical proteins not associated with a 
disease state or functional amyloid forms. Proteins shown are (A) Apaf-1 CARD, (B) 
Fadd-DD, (C) cytochrome C552, (D) bovine cytochrome c, (E) myoglobin, (F) myoglobin 
Trp->Phe variant, (G) bovine serum albumin (pH 7.4), (H) bovine serum albumin (pH 
3.0). Reproduced from references [182, 183, 232-236].
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RESEARCH GOALS
This dissertation is focused on gaining insight into the folding and misfolding 
process of the relatively small globular proteins GB1 and Fadd-DD, respectively. As 
previously discussed protein folding is a complex and dynamic process that is the 
foundation to the protein folding problem and misfolded forms are associated with a 
number of disease states. In both cases understanding both protein folding and misfolding 
are critical to not only progressing our scientific understanding of proteins but can be 
critical in guiding the design of therapeutic drugs for protein misfolding diseases and 
ultimately curative methods. This dissertation contains computational and experimental 
chapters that investigate the protein folding and misfolding problem.
In chapter II, the protein structure of GB1 was investigated from a computational 
stand point. Evolutionarily conserved features believed to be important to produce the 
a+4p fold of GB1 are revealed. The results of a bioinformatics structural alignment are 
detailed to determine both positional conservation and amino acid character conservation. 
In addition, bioinformatics investigations were done to determine a possible evolutionary 
divergence that separated GB1 from a structurally different 3-helical bundle albumin- 
binding domain of protein G (GA) shown to have an alternative fold while retaining up to 
98% similarity in sequence. Using GB1 and GA as our target, position-specific iterative 
basic local alignment search tool (PSI-BLAST) examinations are conducted to determine 
a possible common ancestral protein. Molecular modeling is used to construct a possible 
structure for the resulting sequence.
In chapter III, we use protein engineering methods such as the PCR and site-direct 
mutagenesis in order to truly understand how individual amino acids that have been
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shown to be conserved in structure and are important in the folding process. Using PCR 
and site-directed mutagenesis we remove select amino acids and investigate the resulting 
effect on the transition-state stability. This chapter discusses the work currently 
completed in collaboration with John Bedford (Graduate Student, ODU) on the site- 
directed mutagenesis of GB1. It will discuss the residues selected for mutagenesis and the 
conditions to investigate the transition state stability.
In chapter IV, we investigate the structure, thermodynamic stability and kinetic 
behavior of GB1. Uniformly and specifically 13C labeled GB1 were synthesized using 
BL21(DE3) and an E. coli auxotroph bacteria, respectively. Both uniform and 
specifically labeled GB1 are synthesized to ultimately investigate a specific set of long- 
range tertiary interactions found in the core of GB1 by solution- and solid-state-NMR 
(ssNMR). Initial ‘H and 13C NMR studies are conducted. In addition, pH-dependent 2D 
heteronuclear-single quantum coherence (HSQC) experiments were done on the 
specifically labeled GB1. We also investigated 13C-13C interactions using DARR ssNMR.
In chapter V, we use Fadd-DD as our model system to explore the hypothesis of 
Christopher Dobson (Professor, University of Cambridge), which proposes that every 
protein has the potential to form amyloid fibrils. In this chapter the specific extreme 
conditions required to transition the all a-helical Greek-key Fadd-DD protein into the 
amyloid-like fibril form is demonstrated. The fibrillar transition is further studied in 
detail by CD and high-resolution TEM and AFM. In addition, the extremely narrow 




BIOINFORMATIC ANALYSIS OF THE IMMUNOGLOBULIN- 
BINDING AND THE ALBUMIN-BINDING DOMAINS OF PROTEIN 
G: A LOOK INTO A POSSIBLE EVOLUTIONARY ANCESTOR
OVERVIEW
Since the completion of the human genome project the growth in the amount of 
sequence information available has increased significantly and has amplified the need for 
bioinformatics techniques. With over 23,000 genes in the human genome alone being 
able to quickly and accurately compare an unknown protein with respect to all the 
sequences that are uploaded to the gene bank is a great achievement. Bioinformatics is a 
multidiscipline field of biology, biochemistry, computer science and mathematics 
methods, that can complement experimental methods to investigate protein structure and 
function [36, 359, 360]. Techniques employ sophisticated computer algorithms to 
compare and analyze protein or gene sequences to a large database of known sequences 
in order to elucidate complex structural, functional and evolutionary relationships [361]. 
One of the most common bioinformatics techniques currently used is the PSI-BLAST 
[362-364], PSI-BLAST functions by constructing a multiple sequence alignment of the 
BLAST similarity search output. It then constructs a position-specific scoring matrix 
sequence and performs a BLAST database search using the matrix sequence as the query 
[363, 364]. The process may be iterated multiple times as new sequences are found from 
the search and added to the position-specific scoring matrix sequence construct [363, 
364], Generally, the matched sequences will be a part of an evolutionarly related
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superfamily. Resulting sequences and their relationship to the query can be analyzed 
using a multiple sequence alignment.
A protein superfamily is similar to a family lineage tree in that proteins originate 
from a common ancestor and will typically share similar sequence, structural and 
functional features (Figure 30). In terms of sequence similarity it has been determined 
that proteins that contain >40 % similarity are conserved in function [365]. Whereas, 
sequences conserved in fold only need to contain <25 % and a significant degree of 
functional diversity. This method of searching and developing a consensual sequence 
signature, common structure and/or function is very useful. The potential structure and 
function of an uncharacterized protein can be guided from that of its relatives whose 
native structure and function have already been determined. Even though there will be 
evolutionary drift as a protein diverges from a common ancestral sequence, there will be 
some sequence and structural features retained as they are responsible for the structural 
stability and function of the progeny protein [361, 366]. Being able to gain insight into 
the structure and function of an uncharacterized protein is particularly important as it still 
requires a significant amount of time to determine the structure and function of a protein.
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Figure 30. Representative schematic of a superfamily. Individual families of proteins 
are linked together into a superfamily structure.
We are interested in looking at the evolutionary aspects of proteins capable of 
switching folds. A protein capable of adopting more than one folded state is now more 
commonly called a metamorphic protein [367]. The most classic example of proteins 
with conformational malleability of the polypeptide chain that allow them to switch folds 
are prions. They are proteins capable of switching from a mostly a-helical fold to a toxic 
(3-rich folded state [368]. In contrast to the toxic prion there are some naturally occurring 
examples of proteins that can switch folds. These include lymphotactin, mitotic arrest 
deficient 2 protein and chloride intracellular channel protein 1 which implies that this 
ability to switch folds may be a more general phenomenon [369-372]. In these types of 
proteins there is an environmental transition which shifts the equilibrium from one fold
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topology to another. These changes can include factors like ionic strength, presence or 
absence of a ligand and redox state [373]. In other investigations of fold switching 
involving the Cro family of repressors and the RfaH protein there is a strong indication 
that evolution may have developed an evolutionary short-cut where a new fold is created 
from switching an existing structure as opposed to independently developing [374, 375]. 
The switchable folds have a few commonalities that include, flexible regions and 
diminished stability required for large conformational changes, a significant degree of 
uniqueness in the core region to retain the new fold and the development of new 
functional attributes that stabilize the new fold in order to expand function [376].
In addition to naturally occurring fold switching proteins there have been a 
number of experimental protein designs used to investigate the nature of the fold 
switching phenomenon [377-381], To trace the origins of proteins that switch folds we 
can use bioinformatics approaches which include searching for related protein sequences 
and structures and analyzing the nature of their relationship. In this chapter we endeavor 
to elucidate a possible common ancestral protein between the GB1 and the phage- 
selected domain-1 (referred to as GA in this dissertation), a construct built from 7 
albumin-binding domains (Figure 31) [382]. Both GB1 and GA are 56 residue domains 
that function in the multidomain Streptococcus cell surface protein G but have unique 
folds [383]. GB1 has the 4p+a fold and functions in binding immunoglobulin G whereas, 
GA has a conformational 3-helical bundle and functions in binding albumins found in 
human serum (Figure 32) [384-387]. GB1 and GA were mutated simultaneously using 
site-directed mutagenesis in a binary fashion in which only the amino acids of the two 
proteins are used to increase identity between them [388]. These two proteins have been
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shown experimentally to be able to switch folds with a very high (>85%) degree of 
sequence identity [388-390]. In addition, NMR structures were solved for both GB1 and 
GA at identities of 88% and 95% and both still retained different folds [389, 390]. The 
ability of these two proteins to switch topologies with unique single point mutations 
indicates a possible method by which new functions can evolve.
1 0 2
Figure 31. Images of the folds of GB1 and GA. (A) Shows the 4p+a fold of GB1 and
(B) shows the 3-helical bundle fold of GA. On the left are ribbon drawings and the right, 
the a-carbon backbone with side chains surrounded by Van der Waals radii. The 
secondary structures a-helices are colored in pink and p-strands colored in yellow. The 
loop regions, N- and C-terminal are colored grey. All images were created in RasMol 
(Ver. 2.7.2.1.1).
103
Figure 32. Structural images of ligand bound GB1 and GA. (A) Image of GB1 (red) 
bound to the Fc region of IgG (PDB code: 1FCC). (B) Image of GA (blue) bound to 




Understanding how proteins evolve is important in elucidating how function and 
fold can be conserved and will be significant in guiding the engineering of proteins in the 
future. Fold switching is an important part of protein evolution and GB1 and GA are 
potentially excellent examples of this phenomenon. In order to truly understand GB 1 and 
GA we need to determine how these two proteins evolved. Did they evolve from one 
another or are they the result of a larger protein separating into two small ones.
According to the ground breaking work by He et al. there are three critical residue 
positions that result in the populated fold switching between the a-helical bundle of GA 
and the 4p+a fold of GB1 (Figure 33). At positions 20, 25 and 45 there is a reversible 
fold switch from a-helical bundle to the 4(3+a fold by a point mutation: Leu to an Ala, lie 
to Thr or Leu to Tyr, respectively [373]. This indicates that they could have evolved from 
one another, in which the fold switch could have occurred from a point mutation in either 
GB1 or GA and resulted in a stabilization of the alternate fold over time. However, in my 
investigation, PSI-BLAST searches of both GB1 and GA did not result in hits of either 
start protein sequence. This indicates that these two proteins may have evolved from a 
common ancestral protein rather than the result of an evolutionary fold switch in which a 
new function is obtained by simply switching the conformation of an existing protein. 
Rationally, for the folds to switch so easily in vitro by a point mutation all of the 
stabilizing residues for either fold would have to be removed or changed resulting in a 
significant loss in stability.
105
A  a t  a2 a*
J L i U J U  MJL&XSJUlZJLStJLSi
1 10 30 JO 40 50
Ga98 (3a) ITYKLIUn .rW g m T lgLViaCTAIKYgTaiJaOULlVtGw A ailgT rrV T I
6.98 {4$*a) TTTKLTTj n jro im An axvna^jfcuncYiia iM B a iv iju w iB ujKiK irrv T i
Gb98*T2SI (3a) TTTKLIIjrf.yQI ITTOIKlflVDAGpULKYFXLIAMMCTVlCVirrYlOTirrrTVTI
Gb98>T25I,L20A (4f)+a) TTTXLILNlJCQ&KECAIKlf^CAGIAKirniCLIAlArrVlGVVTYlGDKirrrrVTE
Ga98 Gb98 Gb98-T25I Gb98-T25I,L20A
Figure 33. Single amino acid mutations leading to fold switching. (A) Alignment of 
amino acid sequences for the four proteins with 98 % identity, highlighting the positions 
at which changes lead to switching between 3a and 40+a folds. (B) Representative 
structures from the NMR ensembles of GA98, GB98, GB98-T25I, and GB98- 
T25I,L20A. Residues mutated are highlighted. Figure reproduced from [373].
Using a sequence alignment between GB1 and GA show that they have a 
sequence similarity of 26.9% (Figure 34). This indicates that they are both significantly 
different from each other. However, investigating further showed that there seems to still 
be some degree of similarity between GB 1 and GA. A sequence alignment of 7 randomly 
selected small proteins ranging from 50-58 residues with GB1 and GA was constructed
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using Multiple Sequence Comparison by Log-Expectation (MUSCLE). The resulting 
alignment provided an average random sequence identity of about 8 % between the 9 
aligned proteins (Figure 35). An alignment of GB1 and GA alone seems to be more 
related in some aspect as they have almost three times the sequence identity than what is 
found in a random sampling. Because this was a pairwise comparison of GB1 and GA we 
needed to see if there was a difference in comparing each sequence with GB1 or GA 
individually. The comparison resulted in a differing amount of random sequence identity. 
Thus, a pairwise comparison of GB1 with each of the 7 small proteins using MUSCLE 
resulted in an increase in average sequence identity to about 12 % (Table 3). This value is 
still less than half the sequence identity found between GB 1 and GA suggesting that there 
is some relatedness between them indicated by the significant sequence identity.
GA --------MEAVDANSLAQAKEAAIKE —  Lr\)Y
GB1 MTYKLILNGKTLKGETTTEAVDAATAF'.KVFKGY
GA GIGDYYIKLINK'AKTVEGVESLKNEILKALPTE 
GBl A----------- DNG'.'D EWTYDDATKTETV. •
Figure 34. MUSCLE sequence alignment of G Bl and GA. Positions colored in red are
positions with the exact same amino acid composition. Positions colored in blue are 
positions with high conservation in amino acid character.
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1JJS IBiD, Domain of CBP/p300 50 12.2 8.0
1YUF Type a Transforming Growth Factor 50 8.9 6.0
2L7S Adrenomedullin 53 13.5 13.0
1ZRP Rubredoxin 53 14.3 15.2
2 JOT Huwentoxin-XI 55 14.8 15.1
1KMA Domain-I of the Kazal-type Thrombin Inhibitor Dipetalin 55 12.0 12.2
2MM4
Conserved Golgi Complex- 


























2JOT TCAKFIYGGCGGNGNKFPTQEACMKRCAKA—  
1KMA PCMLTCAKHEGNPDLVQVHEGPCDEHDHDF—  
2MM4 LTALRLAAYAANIVNVSLVKPTVYVYSRVKNL
Figure 35. MUSCLE sequence alignment of G B l and GA with 7 small random 
proteins. Sequences where aligned and there were no positions of similarity of identity. 
Bolded sequences are the target sequences for comparison.
Investigations of both GBl and GA using PSI-BLAST resulted in a number of 
common protein sequences primarily in the immunoglobulin-binding cell surface proteins 
(Table 4). A MUSCLE alignment of the common sequences with both GA and GBl is 
found in Figure 36. From the sequence alignment both GBl and GA align almost fully 
onto two separate portions of the common sequences. Because the albumin-binding and 
immunoglobulin G-binding (IgG) domains are found in the protein L or G, it makes sense 
that both proteins would find their respective relatives. This could indicate that either GA 
or GBl may have evolved from a duplication event in either the IgG, albumin-binding
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family or other cell surface proteins. The duplication event would then be followed by 
sequence and functional divergence in which mutations lead to a destabilized structure 
swapping to a new structure and function. The new function is then stabilized by 
mutations favorable to the new structure and function. GA and GBl are similar in that 
they both bind proteins found in the blood and this new function would be advantageous 
to the survival of the bacteria. Recently, He et al. showed experimentally that these two 
proteins could be evolved from each other over time and what’s even more interesting is 
that during this synthetic evolution it appears that function is maintained and even at 
some point towards sequence convergence both functions persisted [373, 390]. In light of 
He et al. ’s work it seems plausible that they could have evolved from one another. 
However, based on the results of Figure 36 which reveals high sequence identity but also 
that they align on separate portions of the common sequences (Figure 37), it seems 
unlikely that any of these proteins (Table 4) are ancestral proteins from which GA or 
GBl evolved. A true ancestral protein would have overlapping sections of sequence 
alignment with GA and GBl and be accompanied with low sequence identity due to 
evolutionary modification.
1 1 0
Table 4. PSI-BLAST common sequences between G B l and GA
Accession ID Code Description
E-Value 
G Bl GA
%  Identity 
G Bl GA
A A A 26599.1 AAA4 BBM3XM [Staphylococcus xylosus] 3e-05 5e-I0 67 58
A A A 26600.1 AAA3 BBXM [Staphylococcus xylosus] 2e-05 le-10 67 58
AAA26921.1 AAAI mag [Streptococcus dysgalactiae] le-17 2e-05 87 68
A A A 86832.1 AAA2
cell surface protein precursor 
[Streptococcus equi subsp. 
zooepidem icus]
2e-I3 7e-07 73 74
B A D 00711.2 BAD1
cell surface protein precursor 
[Streptococcus equi subsp. 
zooepidemicus]
7e-14 le-10 71 68
CAA27638.1 CAA1 protein G [Streptococcus sp.] le-16 2e-09 100 58
P06654,1 POA1
Immunoglobulin G-binding protein G; 
Short=IgG-binding protein G; Flags: 
Precursor
6e-18 3e-09 100 57
PI 9909.1 PI A l
Immunoglobulin G-binding protein G; 
Short=IgG-binding protein G; Flags: 
Precursor
4e-17 8e-10 100 58
Y P_002123072.1 YPA5 IgG binding protein Zag [Streptococcus 
equi subsp. zooepidemicus]
6e-14 le-10 71 68
YP_002744821.1 YPA7
Ig, alpha2-macroglobulin and albumin 
binding protein Zag [Streptococcus 
equi subsp. zooepidemicus]
9e-14 2e-07 73 74
Y P_002746070.1 YPA8
Ig, alpha2-macroglobulin and albumin 
binding protein Eag [Streptococcus 
equi subsp. equi 4047]
le-13 2e-07 73 74
Y P_002997067.1 YPA3
Immunoglobulin G-binding protein 
[Streptococcus dysgalactiae subsp. 
equisimilis]
5e-18 6e-10 100 58
Y P_006013485.1 YPA4
IgG binding protein Zag [Streptococcus 
dysgalactiae subsp. equisimilis]
2e-17 2e-10 98 58
Y P_006042603.1 YPA6
cell surface protein precursor 
[Streptococcus equi subsp. 
zooepidemicus]
6e-14 7e-07 73 74
Y P_006859906.1 YPA1
Immunoglobulin G-binding protein 
[Streptococcus dysgalactiae subsp. 
equisimilis]
4e-18 3e-l 1 98 58
YP_006904988.1 YPA2
Immunoglobulin G-binding protein G 
[Streptococcus dysgalactiae subsp. 
equisimilis]
5e-18 6e-10 100 58
ZP_ 12571139.1 ZPA1
Immunoglobulin G-binding protein G 
[Streptococcus dysgalactiae subsp. 
equisimilis]
le-17 2e-10 100 58
I l l
G B l -------------------------- M----------------------------------------------------------------------------------------------------------
GA1 ---------------------------------------------------------------------------------------------------------------------------------------
AAA3 ---------------------------- MKKKN—  I Y S I R K L G V G I A S V T L G T L L I S G G V T  PAANAAQ----------HDEA
AAA4 ---------------------------- MKKKN—  I  YS I R K L G V G I  A S VT L G T L L I  SGGVT PAANAAQ----------HDEA
BAD1 ---------------------------- M E K N K N V SY F L R Q SA V G L A S V S-A A FL V G T S SV G A L D A A T ----------V L E P
Y P A 5 M S K F FE K SE G G K M E K N K N V SY F L R Q SA V G L A S V S-A A FL V G T S SV G A L D A A T --------- V L E P
Y P A 6 ---------------------------- M E K N K N V S Y F L R Q S A V G L A S V S -A A F L V G T S S V G A L D A T T ----------V L E P
AAA2 ---------------------------- M E K T K T V S Y F L R Q S A V G L A S V S -A A F L V G T S S V G A L D A T T ----------V L E P
Y PA 8 ---------------------------- M E K N K K V SY F L R Q SA V G L A S V S-A A FL V G T T SV G A L D A A T ----------V L E P
YPA7 ---------------------------- M E K N K K V SY F L R Q SA V G L A S V S-A A FL V G T T SV G A L D A A T ----------V L E P
AAAI. ---------------------------- M E K E K K V K Y FL R K SA FG L A S V S -A A F L V G T A V V N A E E S T V SP V T V A T D
P 0 A 1  ---------------------------- M E K E K K V K Y F L R K S A F G L A S V S -A A F L V G S T V F -A V D S P I ---------- E D T P
Y PA 1 M C W H IK IK K G E K M E K E K K V K Y F L R K S A F G L A S V S -A A F L V G S T V F -A V D S P I--------- E D T P
YPA4 ---------------------------- M E K E K K V K Y F L R K S A F G L A S V S -A A F L V G S T V F -A V D S P I---------- E D T P
Y PA 2 ---------------------------- M E K E K K V K Y F L R K S A F G L A S V S -A A F L V G S T V F -A V D S P I---------- E D T P
Y PA 3 ---------------------------- M E K E K K V K Y F L R K S A F G L A S V S -A A F L V G S T V F -A V D S P I---------- E D T P
CAA1 ---------------------------- EFNKYGVSDYYK----------------------------------------------------------------------------------------
P 1 A 1  ---------------------------- M E K E K K V K Y F L R K S A F G L A S V S -A A F L V G S T V F -A V D S P I---------- E D T P
G B l ---------------------------------------------------------------------------------------------------------------------------------------
GA1 ---------------------------------------------------------------------------------------------------------------------------------------
AAA3 V D A N FD Q FN K Y G V SD Y Y K N L IN N A K T V E G V K D L Q A Q V V E SA K K A R ISE A T D G L SD FL K SQ
AAA4 VD AN FD Q FN K Y G V SD Y Y K N L IN N A K T V E G V K D L Q A Q V V E SA K K A R ISE A T D G L SD FL K SQ
BAD1 T T A F ----------------------- I R E A V R E I N Q -------------- LSDD YAD NQE-LQAVLANAGVEALAADTVDQ
Y PA 5 T T A F ----------------------- I R E A V R E I N Q -------------- LSDD YAD NQE-LQAVLANAGVEALAADTVDQ
Y P A 6 T T A F ----------------------- IR E A V R E I N Q -------------- LSDD YAD NQE-LQAVLANAGVEALAADTVDQ
AAA2 T T A F --------------------- 1 R E A V R E IN Q ---------------LSDD YAD NQE-LQAV LAN AGV EA LA ADT VDQ
YPA8 T T A F ----------------------- I R E A V R E I N Q -------------- LSDDYADNQE-LQAVLANAGVEALAADTVDQ
YPA7 T T A F ----------------------1 REAVRE I N Q -------------- L S  DDYADNQE -LQAVLANAGVEALAADTVDQ
A A A I A V T T -----------------------S K E A L A I  I N K -------------- L S E D N L N N L D -IQ E V L A K A G R D IL A S D S A D T
POA1 U R N ----------------------- GG EL T N LL G N SE TT L A L R N E ES A T A D -L TA A A V A D T V A A A A A E N A G A
Y PA 1 U R N ----------------------- G G EL T N LL G N SE TT L A L R N E ES A T A D -L TA A A V A D T V A A A A A E N A G A
YPA4 U R N ----------------------- G G EL T N LL G N SE TT L A L R N E ES A T A D -L TA A A V A D T V A A A A A E N A G A
Y P A 2 U R N ----------------------- G G EL T N LL G N SE TT L A L R N E ES A T A D -L TV A A V A D T V A A A A A E N A G A
Y P A 3 U R N ----------------------- G G ELTN LL G N SE TT L A L R N E ESA T A D -L TA A A V A D T V A A A A A E N A G A
CAA1 ------------------------------------------- N L IN N A K T V E G V K D L Q A Q V V E SA K K A R ISE A T D G L SD FL K S Q
P 1 A 1  U R N ----------------------- G G EL T N LL G N SE TT L A L R N E ES A T A D -L TA A A V A D T V A A A A A E N A G A
Figure 36. MUSCLE alignment of common PSI-BLAST protein sequences. Sequence 
colored in red is the aligned portion for GA (3-helical bundle) and the sequence in blue is 





AAA3 T P A E D T V K SIE L A E A K V L A N R E L D K Y G V S D Y H K N L --------------------------------------------------------------
AAA4 T PA ED TV K SIE L A E A K V LA N R EL D K Y G V SD Y H K N L --------------------------------------------------------------
BAD1 AKAALDKAKAAVAGVQLDEARR-------------------E A Y R A I -----------------------------------------------------------
Y P A 5 AKAALDKAKAAVAGVQLDEARR-------------------E A Y R A I -----------------------------------------------------------
Y P A 6  AKAALDKAKAAVAGVQLDEARR-------------------E A Y R T I -----------------------------------------------------------
AAA2 AKAALDKAKAAVAGVQLDEARR-------------------E A Y R T I -----------------------------------------------------------
YPA8 AKAALDKAKAAVAGVQLDEARR-------------------E A Y R T I -----------------------------------------------------------
YPA7 AKAALDKAKAAVAGVQLDEARR-------------------E A Y R T I -----------------------------------------------------------
A A A I  IK A L L A E V T A E V T R L N E E K M A R --------------DAVDK AIAA DAA AFSELKD AQLKA YED------------
P 0 A 1  AAWEAAAAADALAKAKADALKEFNKYGVSDYYKNL------------------------------------------------------------
Y P A 1 AAWEAAAAADALAKAKADALKEFNKYGVSDYYKNL--------------------------------------------------------------
YPA4 AAWEAAAAADALAKAKADALKE FNKYGVS DYYKNL--------------------------------------------------------------
Y PA 2 AAWEAAAAADALAKAKADALKEFNKYGVSDYYKNLINNAKTVEGVKDLQAQVVESAKKAR
Y P A 3 AAWEAAAAADALAKAKADALKE FNKY GV S DYYKNLINNAKTVEGVKDLQAQVVESAKKAR
CAA1 T P A E D T V K SIE L A E A K V L A N R E L D K Y G V S D Y H K N L --------------------------------------------------------------
P 1 A 1  AAWEAAAAADALAKAKADALKEFNKYGVSDYYKNLINNAKTVEGVKDLQAQVVESAKKAR
G B l ---------------------------------------------------------------------------------------------------------------------------------------
GA1 ---------------------------------------------------------------------------------------------------------------------------------------
AAA3 -------------------------------------------------------------------------------------------------------------------------- INN A K TV EG V
AAA4 -------------------------------------------------------------------------------------------------------------------------- INN AKTVEGV
BAD1 -------------------------------------------------------------------------------------------------------------------NALSDQHESDQKV




Y PA 7 -------------------------------------------------------------------------------------------------------------------NALSDQHESDQKV
A A A I -------------------------------------------------------------------------------------------------------------------------- LAKLAADTDL
PO A1------- -------------------------------------------------------------------------------------------------------------------------- IN N A K T V E G I
Y PA 1 -------------------------------------------------------------------------------------------------------------------------- INN AKTVEGV
YPA4---------------------------------------------------------------------------------------------------------------------------------- IN N A K TV EG V
YPA2 ISE A T D G L S D F L K S Q T P A E D T V K S IE L A E A K V L A N R E L D K Y G V S D Y H K N L IN N A K T V E G V
Y P A 3 ISE A T D G L S D F L K S Q T P A E D T V K S IE L A E A K V L A N R E L D K Y G V S D Y H K N L IN N A K T V E G V
CAA1 -------------------------------------------------------------------------------------------------------------------------- IN N A K TV EG V
P 1 A 1  ISE A T D G L S D F L K S Q T P A E D T V K S IE L A E A K V L A N R E L D K Y G V S D Y H K N L IN N A K T V E G V
Figure 36. Continued.
113
6 B 1  ---------------------------------------------------------------------------------------------------------------------------------------
GA1 ------------------------------------------------------------------------------------------MEAVDANSLAQAKEAAIKEL
AAA3 K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S - - - - - - - - - - - - - QTPAA A A  ' A A A  : A :  A '  A A A '  : A A A A ;A
AAA4 K - D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S ------------- QTPAA A ,  A  A  1 A A  AA- A S " , '  A A A A  .
BAD1 QLALVAAAAKVADAVSVDQVNAAINDVREE------------- I A G i :  A A A A -  AA : A A A -  A A  A A -
Y PA 5 QLALVAAAAKVADAVSVDQVNAAINDVREE------------- I A G I I  - , A A A - . ; - A A  : A A A '  : AAA.  A  A- A
Y P A 6 QLALVAAAAKVADAASVDQVNAAIN D-----------------------AHTAAAl : AAAA A A ■ A A  -
AAA2 QLALVAAAAKVADAASVDQVNAAIND----------------------- AKTA : A A A A  . /A- A A
Y PA 8 QLALVAAAAKVADAASVDQVNAAIND----------------------- AHTA A A  A A A A  . ; AA-
Y PA 7 QLALVAAAAKVADAASVDQVNAAIND----------------------- AH TA ; - A; : ^AAA : / a - ;
A A A I D L D V A K IT NDY TTKV EN AKTAEDV KKI FF .F .SQNEVTR IKT A A , A A - A A - ' - '
P 0 A 1  K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S --------------QTPAA-' ' A " - A - A '  : A- A A -
Y PA 1 K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S ------------- Q T P A  - : '  A A  - 'A- A - ; !■
YPA4 K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S ------------- Q T P A A : A  A  A A  A A AAA-.:-: A  A A . - . - A
Y PA 2 K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S -- - - - - - - - - - - - Q T P A  • I A A  h ' A  A A : A  A  ' :  A  -- ■
Y PA 3 K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S ------------- QTPAA A  A A A A  A AA- A A, - A A-  A
CAA1 K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S ------------- QTPAA A A'  K A  A A A A A  A A ' A , AAA-
P 1 A 1  K -D L Q A Q V V E S A K K A R IS E A T D G L S D F L K S ------------- QTPAA A AAA- AA A A A  ■ A A '  Ay-A A ...
G B l --------------------------------------------------------------------------------
GA1 K QY GIGDYYIKLINNAKTVEGVESLKNEILKALPTE
AAA3 : A - A A '  A '  A A A A A A A A ' A  A A - A  A  A  A A A  ■ AAA D T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
AAA4 A- '- AAA--.A; A - "A'--A-A ' D T Y K L I L -----------------------------------------
BAD1 -A- , - - '  - A A A  A : A - A - . - A A A -  - A A A , .  A A A -  A  A A A  A ' A E V -----------------------------------------------------
Y P A 6 AA-  A ' A  ' I ! i A  A  ' ' I j ; A-A- -. J , A A A  A  A E V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Y PA8 , - A  A A  : A -  A  A  A A A  A  : - A A A  A A A  A A E V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A A A I  A A  A  ; A A  A A  - " ' : A A -  A   ----------------------------------------------------------
POA1 A ' A  A :  A ; ;  A A A - A A  A - - A ' -A A - A A- AA.  A A A D T -----------------------------------------------------
YPA4 A  A'  '■ A' A' A A A  A A A A - A A "  A- A'-. A A A  A A  AA " D T ----------------------------------------------------
Y PA 2 . A  ’ " A  ■ - - A ;  ’ A A - A- - '  ' " - A A - A - A A  A A A  - A -  ; • A 'D T -----------------------------------------------------
CAA1 1 A A  A A A  A A A  - A  ■ AA, A : A ■' A ; A  A A - A  D T Y K L IL N G K T L K G E T T T E A V D A A
P 1 A 1  - A .  A - ' A A  A A . A A  ■ ' - A - - A  A V ' D T Y K LIL N G K T L K G E T T T E A V D A A
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G B l ---------------------------------------------------------------------------------------------------------------------------------------
GA1 ---------------------------------------------------------------------------------------------------------------------------------------
AAA3 --------------------------------------------------------------------------------------------------------------------- Y K L IL N G K T L K G
AAA4 --------------------------------------------------------------------------------------------------------------------------------- NGKTLKG
BAD1 ---------------------------------------------------------------------------------------- I D A A E L T P A L T S Y K L V IK G A T F S G
Y P A 5 ---------------------------------------------------------------------------------------- I D A A E L T P A L T S Y K L V IK G A T F S G
Y P A 6  ---------------------------------------------------------------------------------------- I D A A E L T P A L T S Y K L V IK G A T F S G
AAA2 ---------------------------------------------------------------------------------------- I D A A E L T P A L T S Y K L V IK G A T F S G
Y PA 8 ---------------------------------------------------------------------------------------- I D A A E L T P A L T S Y K L V IK G A T F S G
Y PA 7 ---------------------------------------------------------------------------------------- ID A A E L T P A L T S Y K L V I K G A T F S G
A A A I --------------------------------------------------------------------------------------------------------------------------------------------------
P 0 A 1  --------------------------------------------------------------------------------------------------------------------- Y K L IL N G K T L K G
Y PA 1 --------------------------------------------------------------------------------------------------------------------- Y K L IL N G K T L K G
YPA4 --------------------------------------------------------------------------------------------------------------------- Y K L IL N G K T L K G
Y PA 2 --------------------------------------------------------------------------------------------------------------------- Y K L IL N G K T L K G
Y P A 3  --------------------------------------------------------------------------------------------------------------------- Y K L IL N G K T L K G
CAA1 TA E K V F K Q Y A N D N G V D G E W T Y D D A T K T FT V T E K PE V ID A SE L TP A V T TY K L V IN G K T LK G  
P 1 A 1  TA E K V F K Q Y A N D N G V D G E W T Y D D A T K T FT V T E K PE V ID A SE L TP A V T TY K L V IN G K T LK G
G B l ---------------------------------------------------------------------------------------------------------------------------------------
GA1 ---------------------------------------------------------------------------------------------------------------------------------------
AAA3 E TT T EA V D A A TA R S F N F P I L E N S S S V P G D ----------------------P L E S T C R H A --------------------------------
AAA4 E T T T E A V D A A T A R S F N F P IL E N S S S V P G D P L E S T C M H V E H D A E E N V E H D A E E N V E H D A E E
BAD1 ETA TK AVD AAVA EQ T-FRDYA NKN GVD GV----------------WAYDAATKTF-
Y P A 5 ETA TK AVDAAVAEQT-FRDYANKNGVDGV----------------WAYDAATKTF-
Y P A 6  ETA TK AVDAAVAEQT-FRDYANKNGVDGV----------------WAYDAATKTF-
AAA2 ETA TK AVDAAVAEQT-FRDYANKNGVDGV----------------WAYDAATKTF-
YPA8 ETA TK AVD AAVA EQ T-FRDYA NKN GVD GV----------------WAYDAATKTF-
YPA7 ETA TKAVDAAVAEQT-FRDYANKNGVDGV----------------WAYDAATKTF-
A A A I ----------------------------------------------------------------------------------------------------------------
PO A1--------ETT T EA V D A A TA EK V -FK Q Y A N D N G V D G E ----------------WTYDDATKTF-
Y P A 1 Q T T TE A V D A A TAEKV -FKQ YAN DNG VDG E ----------------WTYDDATKTF-
YPA4 Q T T TE A V D A ATAEKV -FKQ YAN DNG VDG E ----------------WTYDDATKTF-
Y P A 2 ETT T EA V D A A TA EK V -FK Q Y A N D N G V D G E ----------------WTYDDATKTF-
Y PA 3 ETT T EA V D A A TA EK V -FK Q Y A N D N G V D G E ----------------WTYDDATKTF-
CAA1 ETTTEA V D A A TA EK V -FK Q Y A N D N G V D G E ----------------WTYDDATKTF-
P 1 A 1 --------ETT T EA V D A A TA EK V -FK Q Y A N D N G V D G E ----------------WTYDDATKTF-
Figure 36. Continued.
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G B l ---------------------------------------------------------------------------------------------------------------------------------------
GA1 -----------------------------------------------------------
AAA3 ------------------------------------------------------------------------------------------------------------------------------------------------ S
AAA4 N V EH D A E E N V E H D A EE N V EE N V EE N V E E N V E E N V E E N V E EN V E EN V E EN V E EN V EE N V SS
BAD1 ------------------------------------------------------------------------------------------------------------------------------------------------ T
Y PA 5 ------------------------------------------------------------------------------------------------------------------------------------------------ T
Y P A 6 ------------------------------------------------------------------------------------------------------------------------------------------------ T
AAA2 ------------------------------------------------------------------------------------------------------------------------------------------------ T
Y PA 8 ------------------------------------------------------------------------------------------------------------------------------------------------ T
YPA7 ------------------------------------------------------------------------------------------------------------------------------------------------ T
A A A I --------------------------------------------------------------------------------------------------------------------------------------------------




Y PA 3 ------------------------------------------------------------------------------------------------------------------------------------------------ T
CAA1 ------------------------------------------------------------------------------------------------------------------------------------------------ T
P 1 A 1  ------------------------------------------------------------------------------------------------------------------------------------------------ T




BAD1 V T E Q P V A E T ------------- IE A A E L T P A L T T Y R L V IK G V T F S G E T A T K A V D A A T A E Q T F R Q Y A N D
Y PA 5 V T E Q P V A E T ------------- IE A A E L T P A L T T Y R L V IK G V T F S G E T A T K A V D A A T A E Q T F R Q Y A N D
YPA6 VTEQ PVAET------------- IEAAELTPALTTYRLVIKGATFSGETATKAVDAATAEQAFRQYAND
AAA2 V T E Q P V A E T ------------- IEAAELTPALTTYRLVIKGVTFSGETATKAVDAATAEQAFRQYAND
Y PA 8 V T E Q P V A E T ------------- IE A A E L T P A L T T Y R L V IK G V T F S G E T A T K A V D A A T A E Q T F R Q Y A N D
YPA7 V T E Q P V A E T ------------- 1E A A E L T  P A L T T Y R L V IK G V T F S G E T  S TKAVDAATAEQT FRQYAND
A A A I ---------------------------------- IDAPELTPALTTYKLVINGKTLKGETTTKAVDAETAEKAFKQYANE
POA1 V T E K P - - E V ------------- ID A SE LT PA V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A FK Q Y A N D
YPA1 V T E K P - - E V ------------- ID A PE L IP A V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A F K Q Y A N D
YPA4 V T E K P - - E V ------------- ID A SE LT PA V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A FK Q Y A N D
YPA2 V T E K P — E V ------------- ID A SE LT PA V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A FK Q Y A N D
Y PA 3 V T E K P - - E V ------------- ID A SE LT PA V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A FK Q Y A N D
CAA1 V T E K P - - E V ------------- ID A SE LT PA V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A FK Q Y A N D
P 1 A 1  V T E K P — E V ------------- ID A SE LT PA V T T Y K L V IN G K T L K G E T T T K A V D A E T A E K A FK Q Y A N D
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BAD1 N G IT G E W A Y D T A T K T F T V T E A L E E  S P A E P E K P S A S L P ------------------------- L T P L T P A T -
Y P A 5 N G IT G E W A Y D T A T K T F T V T E A L E E  S P A E P E K P S A S L P ------------------------- L T P L T P A T -
Y P A 6  NGVTGEW AY DAA TK TFTV TEALEE S P A E P E K P S A S L P ------------------------- L T P L T P A T -
AAA2 N G VTGEW AY DAA TK TFTV TEALEE S P A E P E K P S A S L P ------------------------- L T P L T P A T -
YPA8 N G VTGEW AY DAA TK TFTV TEALEE S P A D P E K P S A S L P ------------------------- L T P L T P A T -
Y PA 7 NGVTGEW AY DAA TK TFTV TEALEE S P A D P E K P S A S L P --------------------------L T P L T P A T -
AAA1 N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PK K P E A S IP ------------------------- L V P L T P A T P
P 0 A 1  N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PE K P E A SIP ------------------------- L V P L T P A T P
Y PA 1 N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PE K P E A SIP--------------------------L V P L T P A T P
YPA4 N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PE K P E A SIP ------------------------- L V P L T P A T P
Y P A 2 N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PE K P E A SIP------------------------- L V P L T P A T P
Y PA 3 N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PE K P E A SIP ------------------------- L V P L T P A T P
CAA1 NGVDGVWTYDDATKTFTVTEMVTEVPGDAPTEPEKPEASIP ------------------------- LVPLTPATP
P l A l  N G V D G V W T Y D D A T K T FT V T E M V T E V PG D A P T E PE K P E A SIP ------------------------- L V P L T P A T P
G B l
GA1
AAA3 IA K A N G T T A D K IA A D N K L A D K N M IK PG Q E L V V D K K Q P A N H A D A N K A Q A L PE T G E E -N P FI
AAA4 IA K A N G TT A D K IA A D N K L A D K N M IK PG Q E LV V D K K Q P A N H A D A N K A Q A L PE T G EE -N P FI
BAD1 ---------------- K T A PA K Q K D K Q K A K T LPTT G E K A N PFF
YPA5 ---------------- K T A PA K Q K D K Q K A K T LPTT G E K A N PFF
Y PA 6 ----------------K T A P A K Q K D K EK A K T L PT TG EK A N P FF
AAA2 ---------------- K T A P A K Q K D K EK A K T L PT TG EK A N P FF
YPA8 ---------------- K T A PA K Q K D K Q K A K T LPTT G E K A N PFF
YPA7 ---------------- K T A P A K Q K D K Q K A K T LPTT G E K A N PFF
A A A I IAKDDAKKDDTKKDDTKKED-------------- --------------A K K P E A K K E E A K K A A T L P T T G E G S N P F F
P O A I IA K D D A ----- ----- KKDDTKKED-------------- --------------A K K PE A K K D D A K K A E T L P T T G E G S N P F F
Y PA1 IA K D D A ----- ----- KKDDTKKED-------------- --------------A K K P E A K K E D A K K A E T L P T T G E G S N P F F
YPA4 IA K D D A ----- - - - K K D D T K K E D ------------- --------------A K K P E A K K E D A K K A E T L P T T G E G S N P F F
YPA2 IA K D D A ----- - - - K K D D T K K E D ------------- ------------- A K K P E A K K E D A K K A E T L P T T G E G S N P F F
YPA3 IA K D D A ----- — KKDDTKKED-------------- --------------A K K P E A K K E D A K K A E T L P T T G E G S N P F F
CAA1 IA K D D A ----- - - - K K D D T K K E D -------------- --------------A K K PE A K K E D A K K A E T L P T T G E G S N P F F





AAA3 G T T V FG G L SL A L G A A L L A G R R R E L
AAA4 G T T V FG G L SL A L G A A L L A G R R R E L
BAD1 T A AA LA IM A-GA GALAV TSKR QQ D
Y P A 5 T AAAL A IM A  -  GAG ALA V T S K RQQ D
Y P A 6 T A AA LA IM A-GA GALAV TSKR QQ D
AAA 2 TAAA LA IM A -G A G A LA V TSK R Q Q D
YPA8 T A A A L A IM A -S A G A L A V T  S KRQQD
Y PA7 T A A A L A IM A -S A G A L A V T  S KRQQD
A A A I TAAALAVMA-GAGALAVAS KRKED
POA1 TAAALAVMA-GAGALAVASKRKED
Y PA1 TAAALAVMA-GAGALAVAS KRKE D
YPA4 TAAALAVMA-GAGALAVAS KRKE D
YPA2 TAAALAVMA-GAGALAVAS KRKE D
Y PA 3 TAAALAVMA-GAGALAVASKRKE D
C A A l TAAALAVMA-GAGALAVASKRKE D
P l A l TAAALAVMA-GAGALAVAS KRKE D
Figure 36. Continued.
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Figure 37. Condensed and truncated schematic of MUSCLE alignment of common 
PSI-BLAST protein sequences. Sequences colored in red are aligned portions with GA 
(3-helical bundle) and the sequences in blue are aligned portions with GBl (4p+a fold). 
The letters are not meant to be visible. The purpose of the figure is to show the 
overlapping sections using color.
Due to their low sequence similarity it is more likely that GBl and GA evolved 
from a common ancestral type protein. To explore where this divergence may have begun 
further iterative searches were done to look at other distantly related proteins further back
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in evolution. Sequence identity and PSI-BLAST E-values less than 5e-04 are a good 
general method for identifying related sequences. Higher sequence identity indicates 
more relatedness and closer in evolution. Because the first set of PSI-BLAST common 
sequences had high sequence identity without converging onto a common sequence 
alignment, there could be other more distantly related ancestral sequences and functions 
from which they may have diverged. A protein that is still related but further back on the 
evolutionary pathway will have a lower sequence identity due to mutational variance 
indicating an indirect relationship but still linked via degrees of separation.
To explore other families a phylogenetic tree was constructed using the initial 
PSI-BLAST results of GA (Figure 38) and GBl (Figure 39) independently. The initial 
sequences of both GA and GB 1 was linked to a gram-positive signaling peptide protein 
of the YSIRK family. The YSIRK family of proteins consists of any proteins that contain 
the YSIRK cell surface targeting motif. This sequence allows for membrane bound, 
peptidoglycan anchored or transmembrane proteins to be directed and secreted to the cell 
surface [391]. Although both GBl and GA were found to be related to a YSIRK type 
protein a further BLAST search using these proteins did not result in picking up either the 
GBl related YSIRK or the GA related YSIRK proteins. We believe that this is most- 
likely due to the classification of YSIRK family proteins based on the presence of the 
motif and not necessarily by function or structural components. There are a significant 
number of proteins that function on the cell surface and this indicates that the two 
proteins may contain the signaling motif but not be directly related in evolution. It is 
interesting to note that from the phylogenetic analysis of GBl, the proteins genetically 
evolved to 88, 95 and 98 % identity of each other showed to be more closely related to
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the YSIRK protein. This indicates that the synthetically converged sequence between 
GBl and GA may be a close approximation for an evolutionary intermediate between the 
YSIRK protein and GBl. However, this is only speculative and those same sequences 
appear to be more closely related to GA in the phylogenetic analysis of GA indicating 
that the synthetic mutation may have favored the GA sequence over the GBl sequence. 
From the phylogenetic trees of GBl and GA proteins the YSIRK proteins were selected 
because they are more distant yet still related. We also believe the YSIRK signaling motif 
may be an inherited motif from the ancestral protein. The selected YSIRK proteins were 
used as the target sequence for further PSI-BLAST searches to see if there is a 
convergence between the two sequences.
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Figure 38. Phylogenetic tree of related sequences to GA from PSI-BLAST. Positions 
indicated by the diamonds are GA (red) and YSIRK family gram-positive signal peptide 
protein (blue). Evolutionary distances are shown above each link. The phylogenetic tree 
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Figure 39. Phylogenetic tree of related sequences to G B l from PSI-BLAST. Positions 
indicated by the diamonds are GBl (red) and YSIRK family gram-positive signal peptide 
proteins (blue). Panel B is connected to panel A at the Link A position. Evolutionary 
distances are shown above each link. The phylogenetic tree was constructed using the 
program, Molecular Evolutionary Genetics Analysis (MEGA Ver. 6).
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Figure 39. Continued.
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Using the YSIRK proteins as our query sequence resulted in a much more diverse 
group of related proteins with variable functions. The results of the PSI-BLAST search 
resulted in a convergence on 12 common mucus-binding proteins. From the 12 sequences 
a phylogenetic tree was constructed to determine their relationship to each other in 
evolution (Figure 40). Further analysis using MUSCLE indicated that the two YSIRK 
family proteins were more closely related to the mucus-binding protein sequence 
indicated with a red diamond in Figure 40. They are more distantly related to the oldest 
sequence of the 12 proteins (accession code: YP_005861639.1). A MUSCLE alignment 
of the YSIRK family proteins with the 12 mucus-binding proteins showed a convergence 
of sequence alignment with portions of both sequences aligned on similar regions of the 
mucus-binding proteins (Figure Al). This indicates that GA and G B l’s evolutionary 
pathways may have diverged from a common ancestral mucus-binding protein 
(WP_000287308.1) and further evolved independently. This convergence of sequence 
and the distance in evolutionary relatedness could account for the significant difference in 
sequence identity between GB1 and GA. To see how they related to each other a 
MUSCLE sequence alignment of GB1 and GA with the 12 mucus-binding proteins was 
constructed (Figure A2). From the sequence alignment of GB1 and GA with the 12 
mucus-binding proteins it is clear that these proteins are very distantly related as there are 
small regions of overlap scattered throughout the mucus-binding protein which is what is 
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Figure 40. Phylogenetic tree of 12 mucus-binding proteins. Position indicated by the 
red diamond is the sequence of highest identity between the YSIRK family gram-positive 
signal peptide proteins of GA and GB1. Evolutionary distances are shown above each 
link. The phylogenetic tree was constructed using the program, Molecular Evolutionary 
Genetics Analysis (MEGA Ver. 6).
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Both GB 1 and GA are truncated domains of the immunoglobulin G-binding 
protein G and the albumin-binding protein, respectively. We wanted to see if there was a 
relationship between the full-length immunoglobulin G-binding protein G and the 
albumin-binding protein sequences found in BLAST and the YSIRK family proteins 
found with just the individual domains. Both full length proteins were shown to be 
related to their respective YSIRK family protein after a PSI-BLAST analysis. However, 
there was a reduction in sequence identity in comparison with the individual domains 
indicating a more distant relationship. A phylogenetic analysis of all the proteins further 
supported the evolutionary relationship between each of the related proteins (Figure 41). 
From the phylogeny tree we see that the GA module is closely related to the albumin- 
binding protein. There was a speciation event that leads to separation from the YSIRK 
family protein related to GA followed by divergence from the mucus-binding protein. 
Similarly, GB 1 is closely related to the IgG-binding protein G. They both resulted from a 
speciation event leading to separation of the YSIRK family and GB1 related proteins.
The tree clearly shows that both GA and GB1 arose from a common ancestral protein 
which we postulate to be an older mucus-binding protein. In this particular analysis it 
seems that the selected ancestral protein is more closely related to the GA proteins rather 
than the GB1. This supports our previous sequence identity findings between the YSIRK 
family and the mucus-binding proteins. A schematic of the overall computational design 
was constructed and the corresponding results to show how the ancestor was determined 
(Figure 42). In the schematic we can see that the percent identity is greater with a 
significance E-value less than 0.005 indicating more relatedness.
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Figure 41. Phylogenetic analysis of all the related proteins from GB1 and GA.
Evolutionary distances are shown above each link. The phylogenetic tree was constructed 
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Figure 42. Schematic of the computational analysis and corresponding results. Solid 
lines indicate sequences related via PSI-BLAST analysis. Each solid line is labeled with 
the percent identity, regions of alignment coverage and e-values. In some cases PSI- 
BLAST was able to align the sequence multiple times with e-value less than 5e-03 
resulting in multiple significance regions. Dotted lines represent corresponding percent 
identity made using MUSCLE alignments and do not indicate direct evolutionary 
relatedness. In the last two searches multiple iterations were required in order to converge 
on the mucus-binding proteins and the number of iterations is denoted.
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To further investigate positions that may be conserved in evolution between both 
GB1 and GA a MUSCLE alignment of all the related proteins was constructed (Figure 
43). As was expected we find that there are portions of both GB1 and GA that overlap 
with the ancestral mucus-binding protein which further supports that they diverged from 
this family of proteins. Surprisingly, there is a single completely conserved Thrl 1 (GB1) 
and Thr38 (GA) through the evolutionary process which could mean that this position 
could be fundamentally critical in the function or structural stability of both proteins. An 
experimental investigation into this particular residue to determine its role would prove 
quite valuable in understanding its importance in evolutionary conservation. There are 12 
residues of the original GA and GB1 proteins that aligned completely with all related 
sequences. Interestingly, if we look at portions aligned to only the GA or GB branches 
we find large portions of overlap and, more importantly, we find a significant number of 
evolutionarily conserved positions on both sides. These conserved positions may play 
critical roles in stabilizing the fold or function functions. From the condensed sequences 
of GB 1 and GA we can see the distribution of aligned positions throughout the sequence 
(Figure 44). There are a surprising number of evolutionarily conserved positions scattered 
throughout both proteins. It is interesting that the completely aligned regions in GA 
(residues 32-40) and GB1 (residues 1-13) fall on different portions of their sequence. For 
GA we find it mainly centralized where as in GB 1 it is found at the start of the sequence. 
These particular sequences appear to have very little variation with an almost completely 
conserved LINxxKTV sequence throughout evolution. It seems that nature has cleverly 
reused the same sequence in the evolution of two separate proteins by simple
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translocation. This finding seems to indicate that, when possible, this method of reusing 
sequences is more efficient than mutating every position to achieve the required changes.
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Figure 43. MUSCLE alignment of all related proteins. Sequence Alignment of GA 
and GB1 with IgG-binding Protein G (GB1-IGG), albumin-binding (GA-AB), GA gram- 
positive signal peptide protein (GA-YSIRK), GB1 gram-positive signal peptide protein 
(GB1-YSIRK) and the possible common ancestral mucus-binding protein (AMBP). 
Residues common to all sequences are indicated in red. Residues common to only the GA 
branch are indicated in green and those common to the GB 1 branch alone are indicated in 
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Figure 43. Continued.
131
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AMBP T PK T V T Q E A K FT R EA K V N LV TG E V T Y G D W SE A K D LA EV K SP W T G F LA D K A SV P V V N V T G
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  T K V T G T G V P G A T IY V T K L P K -------------------------------------------------------------------------------------------------
G B 1 - I G G  ------------------------------------------ L P K ------------------------------------------------------------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  ------------------------------------------ V P D ------------------------------------------------------------------------------------------------
AMBP D S K D IT E V V T Y K P IG S W IP N IP G Q P T N P IK Y P N N P D D P T Q P G K P T E V L P Y V P G F T P K D K D
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  -----------------------------------------------------------------------------------NG V R D G SSSSA TV G ED G N W SV N LTEP
G B 1 - I G G  --------------------------------------------------------------------------------------------------------------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  ---------------------------------------------------------------------------------- E ----------------------------- E Q S G I E G E T S V D S
AMBP G N P L K P V D P A D P T K G Y IV P D L P T D P S Q D T P IN Y V K D T Q K A K T T F V D E K G N P IP G V D A IT E
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 ----------------------------------------------------------------------------------------------------K G E T T T E A V D A A T A E K V F -
G A -A B  A E E G D R F S I IQ V E P G K G D S K S V IK V V E N A E E K P E IQ D G F D T E E E A IA A A K K A L E N D Q IN -
G B l - I G G  --------------------------------------------------------------------T D T Y K L IL N G K T L K G E T T T E A V D A A T A E K V F -
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  E Y D F N E P E ID W SG N D E A V A E E E A A Q E E V Y T L N Y Y A Q R T Q G Q N G A T T V K A SS PR E A L E Y F- 




G B 1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  --------------------------------------------------------------------------------------------------------------------------------------------------
G B 1 - I G G  --------------------------------------------------------------------------------------------------------------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
AMBP T P D Q P K T P G T P V D P N N P D G P K Y P A G L E E K D L N K T V T R T IT Y V Y A D G T P V L N E D G T P K T V T
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --KQYANDNGVDG---------------------------------------------------------------------------------------------------------
G A -A B  — K S Y T IN Q G A D G K Y Y Y V L SP V E N D E E K PE E E K PA E Q D G Y A T Y E E A E E A A K K A L E N D PIN
G B 1 - I G G  — KQYANDNGVDG------ E W T Y D D A T K T F T V T E K P E V ID A S E L T --------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  — Q A F L N E N G L D A A D F N W S Y D S E S R A F T A S E K IE G E A S V D S E Y D F IR P D F D W S G L E E A E D  
AMBP QEAK FTREA KVN LV TG EVTYG DW SEAKD LPEV KSPVV KGYLAD KATVPATKVTAD SENTK
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  K S Y --------------------------------------------------------------------- T IS Q G A N G R Y Y Y L L S P N P A E T P E K P E E -
G B 1 - I G G  ----------------------------------------------------------------------------------------- PA V T T Y K L V IN G K T L K G E T T T K A
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  D-------------------------------------------------------------------------- E E V Q E E IY T F V Y IIQ N T K G K N G A T T V K A
AMBP E V V T Y K P I G S W I P N I P G Q P T N P I K Y P N D P T D P T K P G Q P T E T L P Y V P G F T P E D K D G N P L K P
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  -E K P E A Q D G Y A -----------------------------------------------------------------------------------------------------------------------
G B 1 - I G G  V D A E TA EK A FK -----------------------------------------------------------------------------------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  S S P E E A K A Y F E -----------------------------------------------------------------------------------------------------------------------
AMBP V D P N D P T K G Y E V PS IP T N PG E D T L IN Y V A N K A N L V V K Y V D E N G K E L L P T E T K E G K V G D D Y
GA
GB1
G A -A B
G B 1 - I G G
G A - Y S I R K
G B l - Y S I R K
AMBP
--------------------------EWTY-
- T Y EEA EAA AKEALKN- 
-QYANDNGVDG-VWTY-
-----------------------------------------E FAKENDLGELDW TY--------------------------------------------------------------------
S T S G K V IT G Y V L D R V E G E A K G K IG T D G T T V T Y V Y K P L G S W IP N IP G Q P T N P IK Y P N D P T D
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  --------------------------------------------------------------------------------------------------------------------------------------------------
G B 1 - I G G  --------------------------------------------------------------------------------------------------------------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------





G A -A B  ------------------D K IN K S  YSIR Q G A D G R Y Y Y V LS PV EA ET P S T  PE V T  PT  P -----------------------G V TPT
G B 1 - I G G  -------------------- DDATKTFTVTE-----------------M V TEVPGDA PTE P E K P E A S I --------------------------------
G A - Y S I R K  -----------------------------------------A K ----------------------------------------------------------------------------------------------------
G B l - Y S I R K  --------------------DEDTKTFTARE-----------------K V E E S Q T IE G E T S V D S V Y D F N R P E ID W S G A E E V
AMBP A N LV V K Y V D E N G K EL L PT ET K E G K V G D D Y S TS G K V ITG Y V L D R V EG EA K G K IG TD G T TV T
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  P G G Q P S T P E V P Y T P Y V P S T P G K E D K K P G E D K K P E D K K P --------------------- GEDKKPEDKKPGE
G B 1 - I G G   P L V P L T P A T  PIAKDDAKKDDTKKEDAKK-------------------- PEAKKEDAKKAET
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  Y E R E L Q A T K E A A I A E L Q G I Y I K D E E L F G R I Q D A E R I E E --------------------- V K K L R SD A ID A R Q
AMBP Y V Y K P L G S W I P N IP G Q P T T P IK Y P N D P Q D P T K P G Q P T E V L P Y V P G F T P E D K D G N P L K P V D
GA
GB1
G A -A B
G B 1 - I G G
G A - Y S I R K
G B l - Y S I R K
AMBP
DKKPGKE
L P T T G E G
ALVG KLD---------------------------------------------------------------------------------------------------------------------------------
P K D P S K G Y V V P N IP T N P G E D T P IN Y IP N V T P N G D Q D G Y T P Q P K P Q P E Q V V T Y Y V D E N G K D
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  --------------------------------------------------------------------------------------------------------------------------------------------------
G B 1 - I G G  --------------------------------------------------------------------------------------------------------------------------------------------------
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
AMBP IA P S E K G A Q A P K G IS G Y E Y V T T T K D P N G N L V H H Y K K V A T P Q P V P T T P E T P E Q P V A P V Q P E
GA --------------------------------------------------------------------------------------------------------------------------------------------------
GB1 --------------------------------------------------------------------------------------------------------------------------------------------------
G A -A B  ----------------------- EK PA N PA K PA K E E K E K T D SPN K K N K K K L P K A G SE A E IL T L A A A A L SA T A G
G B 1 - I G G  ----------------------- S N P -------------------------------------------------------------------------------- F  FT  AAAL AVMAG AG
G A - Y S I R K  --------------------------------------------------------------------------------------------------------------------------------------------------
G B l - Y S I R K  ----------------------- DQEA------------------------------------------------------------------------------ SA D SE Y D FV R PD V D
AMBP Q P T T P T Q P A V P T P A E T S V P T D S A T K P A T P K Y V D G Q K E L P N T G T E A N A S L A A F G L L G A L G G
GA
GB1
G A -A B
G B l - I G G
G A - Y S I R K
G B l - Y S I R K
AMBP
A F V S L K K R K —  
ALAVAS KRKE D
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Figure 44. Condensed GB1 and GA sequences from Figure 42. Residues common to 
all related sequences from Figure 43 are indicated in red. Residues common to only the 
GA branch are indicated in green and those common to the GB1 branch alone are 
indicated in purple. Highlighted in yellow are positions that are similar in identity or 
character within their evolutionary lineage.
The YSIRK proteins in our study are characterized by the LPxTG or YSIRK 
signal motif only. There is very little information about their structure and function. Since 
the YSIRK signal was central to determining a possible ancestor we assessed the 
presence and evolutionary conservation of motifs relevant to our study (Table 5). The 
protein families database (pfam) (27.0) contains a large collection of protein families 
already assessed and represented by sequence alignments and hidden Markov models and 
is powerful in searching for motifs and domains present in a query sequence [392, 393]. 
Analyzing the mucus-binding protein using pfam revealed the YSIRK signaling and 
LPxTG motif. The LPxTG motif is a cell wall targeting sequence that is mediated by 
transpeptidase sortase resulting in peptide bond anchoring to cell wall peptidoglycans 
[394]. This motif is significantly useful for binding cell surface proteins to the outer cell 
wall of gram-positive bacteria. Interestingly, the LPxTG motif is conserved through 
evolution to the full length proteins of GB1 and GA. However, the YSIRK signaling 
motif is only conserved in the GB1 related YSIRK protein. It is likely that the GA related
1 3 6
YSIRK protein, which is only a partial sequence, is missing the motif due to missing 
residues. Although it is missing the YSIRK signal motif, it does however contain the GA 
module domain which is not seen in the mucus-binding protein. This suggests that the 
GA module may have developed early in the evolutionary process. In comparison, the 
IgG-binding domain was only present in the IgG-binding protein indicating that this 
domain may have evolved after the GA module in evolution. Taken together, these 
results seem to indicate that the GA module may be older than IgG-binding domain in 
terms of evolution
1 3 7



























(GA) YSIRK, GA Module
105 154 7.8E-13
Partial 182 229 2.3E-10
(GB1) YSIRK













As far as we could see the GA and GB1 related YSIRK proteins are functionally 
and structurally uncharacterized. In addition, there is very little structural information on 
mucus-binding proteins. To investigate the structures of the YSIRK proteins related to 
GB1 and GA we used the SWISS-MODEL and I-TASSER modeling programs. SWISS- 
MODEL is a homology modeling program that builds a model based on a database of
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already solved structures [395]. The SWISS-MODEL of the GA-Related YSIRK protein 
revealed a 3-helical bundle topology very similar to the WT-GA structure (Figure 45 A). 
On the other hand the GB1-Related YSIRK protein model shows what appears to be two 
partially formed 4(I+a domains similar to that found in WT-GB1 (Figure 45B). These 
models further provide supporting evidence that they could indeed be distantly related to 
GA and GB1, respectively. The SWISS-MODEL of the ancestral mucus-binding protein 
has an interesting structure and appears to have a primitive form of the WT-GB1 protein 
on the C-terminal end. This could indicate that the mucus-binding proteins are more 
closely related to the IgG-binding domain structure. Interestingly, this does not support 
our phylogenetic analysis that revealed a greater relatedness to WT-GA.
1 3 9
Figure 45. SWISS-MODEL of GA and GB1 evolutionarily related proteins.
Structures were generated using SWISS-MODEL [395]. Model of the (A) GA-Related 
YSIRK protein, (B) GB1-Related YSIRK protein and (C) evolutionary mucus-binding 
protein ancestor. Structures are colored from the N-terminal in red to the C-terminal in 
blue through the sequence of colors of the visual electromagnetic spectrum. Images were 
created using RasMol (Ver. 2.7.2.1.1).
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We further assessed the structures using the I-TASSER modeling program which 
uses sequence homology threading algorithm that does not rely on any evolutionary 
information [102, 396]. The limitations in I-TASSER maximum protein length prevented 
us from modeling of the ancestral mucus-binding protein. However, structures of the GA 
and GB1 related YSIRK proteins were constructed (Figure 46). There were some 
significant differences in the structures obtained from I-TASSER in comparison to the 
SWISS-MODEL. The GA related YSIRK protein seems to still have a 3-helical bundle 
structure although now it is extended through a larger portion of the protein sequence 
(Figure 46A). The lack of secondary structure continuity throughout the whole structure 
is something that would be expected in an ancestral protein. In the GB1 related YSIRK 
protein the chain seems to have grouped into four folded domains of predominately |3- 
sheet content (Figure 46B). The N-terminal domain appears to have an early resemblance 
to the WT-GB1 structure with a partially formed a-helix and three [1-strands. These 
structures seem to have predicted structures that resemble there evolutionary progeny in 
both modeling simulations. Interestingly, an investigation to characterize the crystal 
structure of a mucus-binding protein (PDB code: 3157) and characterization of its 
function revealed a link to Ig-binding function [397]. This is strong evidence, at least in 
part that the mucus-binding proteins are related to WT-GB1.
Figure 46. I-TASSER models of GA and GB1 evolutionarily related proteins.
Structures of the (A) GA-Related YSIRK protein and (B) GBl-Related YSIRK protein 
Structures are colored from the N-terminal in red to the C-terminal in blue through the 
sequence of colors of the visual electromagnetic spectrum. Images were created using 
RasMol (Ver. 2.7.2.1.1).
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It is interesting that we were able to relate both proteins to a mucus-binding type 
protein. Mucus-binding proteins are believed to help bacteria survive inside a host 
organism by allowing it to bind to the mucus layer of epithelial cells [41]. This function 
prevents the bacteria from being expelled from the organism. It could be possible that the 
albumin-binding and IgG-binding function of GA and GB1, respectively evolved from 
mucus-binding proteins. The location of both of these types of ligands can be found in the 
blood of an organism. In the blood the most hazardous enemy to bacteria is the immune 
system response. It seems that bacteria found in the plasma of an organism may have 
evolved the mucus-binding protein to counter the immune system by binding 
immunoglobulins, essentially camouflaging itself in the blood. In addition, the 
development of the albumin-binding protein would further enhance camouflaging and 
increase survival of the bacteria in the host organism.
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MATERIAL AND METHODS 
PSI-BLAST and MUSCLE
To search for and determine a possible ancestral link between the GB1 and GA 
module, PSI-BLAST was used to search for common sequence identities [362-364]. PSI- 
BLAST is a method for determining protein sequences with distant similarity to your 
target sequence. It calculates a position-specific scoring matrix sequence which captures 
the conservation pattern in an alignment and stores it as a matrix of scores for each 
position in the alignment. In the position-specific scoring matrix sequence, highly 
conserved positions receive high scores and weakly conserved positions receive scores 
near zero. Using this profile in place of the original substitution matrix a BLAST 
database search is done to detect sequences that match the conservation pattern specified. 
By finding distantly related sequences in both GB1 (PDB code: 1PGB) and GA (PDB 
code: 2FS1), sequences found in both PSI-BLAST results suggest a possible divergence 
from an ancestral protein.
MUSCLE is a multiple sequence alignment program that use algorithms like fast 
distance estimation using kmer counting, progressive alignment using a profile function 
called log-expectation score and refinement using tree-dependent restriction partitioning 
(http://www.ebi.ac.uk/Tools/msa/muscle/) [398]. The distance estimation is performed 
using a kmer or contiguous subsequence that has length k. Sequences that are related tend 
to have high more fcmer sequences in common that could be randomly achieved.
Positions of identity or similarity is considered significant when the statistical e-value is 
<0.005.
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Determination of Random Sequence Identity
Random small globular proteins were selected by a PDB search for “small 
proteins” (Figure A3). Resulting proteins were sorted by size and selected based on 
similar sized but uniqueness of function and species. The 7 proteins were selected and 
aligned in concert and individually with GA and GB1 using MUSCLE.
Phylogenetic Analysis and Motif Analysis
Phylogenetic analysis and tree construction was done using MEGA version 6 
[399]. FAST A sequence files were constructed containing all proteins and imported into 
MEGA. An internal MUSCLE alignment was computed. The resulting alignment was 
used to construct the phylogenetic tree. Phylogenetic trees were constructed using 
statistical methods of Maximum Likelihood or Neighbor-joining with a p-distance or 
Poisson model. Phylogenetic results were tested and verified using either Bootstrap or 
Interior-branch method. Significant motifs were assessed using pfam database 
(http://pfam.xfam.org/). Each protein was assessed and resulting motifs were provided. 
Protein Modeling
The proposed evolutionary related sequence of interest that did not have a high- 
resolution NMR or crystal structure already assigned from experimental work was 
modelled using computational methods. The homology modelling programs used were 
the SWISS-MODEL and I-TASSER [101, 395,400], The SWISS-MODEL is a fully 
automated protein structure homology-modelling server, which can be accessed via the 
ExPASy web server (http://swissmodel.expasy.org/). I-TASSER employs a multiple- 
threading homology method that builds a model by collecting high-scoring target-to-
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THE PROPOSED ROLE OF CONSERVED RESIDUES IN THE 
STABILITY, STRUCTURE AND FOLDING OF THE B1 DOMAIN 
OF PROTEIN G BY SITE-DIRECTED MUTAGENESIS AND PHI-
VALUE ANALYSIS
OVERVIEW
Investigations into the protein folding problem have been significantly furthered 
by technological advances in protein engineering experiments through the advent of PCR 
and site-directed mutagenesis. Folding from the ensemble of denatured states by 
restriction of conformational space to form the initial native-like topology, prior to 
native-state secondary interaction stabilization, is believed to be due to the formation of 
an evolutionarily conserved set of amino acids for folding. Residues are typically 
conserved in a family of proteins because they make critical interactions that are more 
important in maintaining the fold which could lead to residues clustering together in a 
hydrophobic core to stabilize the initial native-like topology [401,402]. This network of 
conserved amino acids has been the target of a large amount of computational and 
experimental research which investigate the link between conserved amino acids and how 
they facilitate rapid and correct folding of a protein in to its native state [37, 137, 359, 
360,402-414]. With the application of site-directed mutagenesis the ability to distinguish 
the effects of specific amino acids on protein stability and folding kinetics, has led to 
investigations into the mechanisms of protein folding based on computational
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conservation analysis. This type of conserved amino acid view expands the folding 
nucleus concept of protein folding and there is a growing body of protein engineering 
work done that shows that these conserved amino acids are preferentially formed in the 
transition state [15, 35,415-424]. However, this area is still controversial as there are a 
few studies that seem to argue against the conservation of a folding nucleus [425,426].
To further advance our understanding, investigation into the determinants of protein 
structure and folding from an evolutionary perspective is still an evolving avenue of 
research as promising new approaches continue to emerge [427,428],
The cloning of DNA and protein engineering are the basic methodologies in 
biochemical and biological chemistry and essential in many applications. PCR is an 
extremely powerful technology, developed in the 1980s by Kary Mullis, and completely 
changed the biological field [429-431]. Its influence has enhanced the study of protein 
structure, stability and folding in speed, quantitation and specificity. It has dramatically 
changed the way we conduct molecular studies and has expanded the possibilities of 
molecular biology. PCR is used in proteins synthesis to amplify genes for insertion into 
vectors for controlled expressions and rapidly producing mutations in a process of site- 
directed primer design [432]. These tasks were much more arduous, requiring the use of 
recombinant DNA methods. PCR enhanced the identification of novel genes and 
pathogens and improved quantification of characterized nucleotide sequences [433]. The 
combination of PCR methods for rapid mutagenesis of genes in clonal DNA (cDNA) is 
of particular importance to this work. Using site-direct mutagenesis to alter conserved 
amino acids can lead to a quantifiable decrease in protein stability and cause alterations in 
secondary and tertiary structure. In addition there can be a decrease in the real-time
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folding kinetics as the formation of core native-like interactions can be impaired. Thus, 
mutagenesis is quite valuable in probing the structure of proteins to discern the 
importance of specific amino acids to the fold.
Our model system is the streptococcal immunoglobulin-binding domain of protein 
G with a Thr2Gln mutation to prevent methionine excision. Protein G is a bacterial 
membrane protein and its function is believed to be related to the survival of the 
organism. GB1 has been shown to bind the immunoglobulin constant region which 
appears to provide the bacteria with a immune system camouflage. GB1 is an ideal model 
because it is a small 56-residue protein whose general folding behavior, stability and 3D 
structure have been characterized. It can also be refolded at high concentration which is 
relevant to the studies in Chapter IV. Its structure is made up of two anti-parallel 0- 
haripins with a stacked a-helix. G B l’s comparatively simple structure makes 
investigating long-range interactions and how they relate to the formation of the tertiary 
structure visually more simplified. In this chapter we use computational methods to 
determine the conserved amino acids in GB1. We then experimentally investigate the 
effects on stability, structure and folding of a conserved residue at position 52. A 
Phe52Tyr variant was synthesized using site-directed mutagenesis. We then compared 
the WT and Phe52Tyr variant stability using equilibrium fluorescence, the structure using 
CD and folding dynamics with stopped-flow fluorescence experiments.
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RESULTS AND DISCUSSION
To determine the evolutionary conservation of amino acids in the sequence of 
GB1 we developed a structural superfamily using the Dali server [434-436]. We 
uploaded the pdb file of GB1 into the server and obtained a list of proteins whose 
structures are superimposable with GB1 within a certain degree of error dictated by the 
intrinsic algorithms. From the server, we selected 13 proteins whose fold matched GB1 
(Table 6). To ensure that the structural alignment would provide information on which 
amino acids were important in the fold and not biological function, we selected a group 
of proteins whose function varied from that of GB1. In addition we assessed the sequence 
identity to ensure that it was below 25% for all the select proteins which is considered the 
“twilight zone” (Table 7) [437]. The “twilight zone” is a percent of identity in which you 
cannot be sure or guarantee the proteins have the same 3D structure. Thus we work in 
this region to enhance sequence variability but use known 3D structures. Although the 
structural alignment provided by the Dali server is quite advanced, it is still not perfect 
and only provides a preliminary sequence alignment. To verify the sequence alignment 
provided by Dali, a manual observation of the superimposable structures is required. The 
side-chain orientation of each amino acid aligned with GB1 in each protein was verified 
in comparison to that of GB1 using the 3D structure visualization program, RasMol 
(Figure 47) [438-441], This is a significant undertaking and was done in collaboration 
with John Bedford (Graduate Student, Old Dominion University). Once each side-chain 
orientation was verified the finalized structure-based sequence alignment was completed 
(Figure 48). As expected most variability in side chain orientation is found in the loop 
regions due to high variability in the length and stability due to the absence of significant
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stabilizing interactions. Also of note is that the third [3-strand of GB1 appears to only 
have one position in which there was total side-chain orientation alignment. This could 
indicate that the formation of that strand is not evolutionarily conserved for this fold and 
could also mean that stabilization of this strand is formed post initial collapse of the 
structure during folding.





1PGB Bacteria (S tr e p to c o c c u s  sp . Group G) 56
Immunoglobulin Binding 
Protein
2PTL Bacteria (P e p to s tr e p to c o c c u s  
m a g n u s )
78 Protein Binding (Immunoglobulin L Chain)
1RLF Mouse (M u s m u scu lu s) 90 Signal Transduction Protein
3POO Halophile (H a lo fe ra x  v o lc a n ii) 89 Protein-Binding
1ENF Bacteria (S ta p h y lo c o c c u s  
a u re u s )
212 Toxin
1FMA Bacteria (E s c h e r ic h ia  c o li) 81 Transferase
2K8H
Human African
Trypanosomiasis (T ry p a n o so m a  
b ru c e i)
110 Signaling protein
1F2R Mouse (M u s m u sc u lu s) 87 DNA Binding Protein
1EUV Baker's Yeast (S a c c h a ro m y c e s  
c e r e v is ia e )
221 Hydrolase
1WM2 Human (H o m o  s a p ie n s ) 78 Protein Transport
3A4R Mouse (M u s m u scu lu s) 79 Transcription
3PT2
Crimean-Congo hemorrhagic 
fever virus (B u n y a v ir id a e  
N a iro v ir u s )
187 Hydrolase/protein Binding
1C4P P-hemolytic Bacteria 
(S tr e p to c o c c u s  e q u is im ilis )
137 Blood Clotting
2BS2 Proteobacteria (W o lin e lla  
su c c in o g e n e s )
660 Oxidoreductase
1WSP Rat (R a ttu s  n o rv e g ic u s ) 84 Signaling Protein
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Table 7. Sequence identity analysis of GB1 and 13 structurally aligned proteins.
1 K » 100%
2FTL 10.71% 100%
IftLT 7. 14% 2.56% 100%
3FOO 1.78% 6 .41% 10. 11% 100%
1ENF 5.35% 6 .41% 4 .44% 6 .74% 100%
1FMA 12.50% 6.41% 8.64% 7.40% 4 .93% 100%
2KSH 10.71% 7.69% 6.66% 7.86% 7.27% 8.64% 100%
1F2R 5.35% 6 .41% 4.59% 5.74% 4 .59% 8.64% 10.34% 100%
1EUV 1.78% 8.97% 3.48% 2 .32% 6.97% 8 .64% 8.13% 5 .81% 100%
1WM2 7 .14% 5.12% 7 .69% 8.97% 3.84% 1.28% 5.12% 12.82% 5. 12% 100%
3A4R 3 .57% 2.56% 8.86% 3 .79% 5.06% 5.06% 6 .32% 8.86% 10.12% 3 .84% 100%
1C4F 0% 3.84% 4 .44% 7 .86% 5.83% 11. 11% 6.36% 4 .59% 5.81% 2 .56% 15. 18% 100%
ZBSB 5 .35% 3.84% 11.11% 4 .49% 6 . 13% 7 .40% 6.36% 6 .89% 3.48% 3 .84% 5.06% 3.64% 100%
1WSP 3 .57% 3.84% 5.95% 5.95% 3.57% 1.23% 5.95% 5.95% 9.52% 5 .12% 7.59% 5.95% 3.57% 100%
1YG* '2PTL 1RLF :1KM tSNV 1VMA mm 1F2K i l t iv 1WM2 um 2BS2 swsr
Figure 47. Structural alignment of 1PGB and 2PTL. Image shows an example of a 
structural alignment and a pair of residues that are aligned in orientation. Residue 32 
(green) of GB1 (red) and residue 53 (yellow) of 2PTL (blue) are shown both pointing 
outward towards solvent.
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[ lwsp] -1 WAYYFcg- -epiPYRTLVravGQFKE -LL tkkg- s YRYYFkk-kil GKVEK
Figure 48. Finalized structure-based sequence alignment. All positions were verified 
visually and any position that was not conserved in side-chain orientation is shown as 
lowercase letters. Positions in red show positions of complete conservation of side-chain
orientation with no more than one gap.
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In order to know which amino acids to select for mutagenesis a conservation 
analysis is performed to determine position specific conservation over the superfamily 
(Figure 49). Using a modified Shannon’s entropy equation amino acid conservation is 
determined based on the number of amino acid types at each position. From the 
conservation analysis we found that there were 12 residue positions that where 
considered evolutionarily conserved: Tyr3, Lys4, Leu5, Thrl8, Ala20, Ala26, Phe30, 
Glu42, Asp46, Lys50, Phe52 and Val54. There are 11 positions that were considered 
moderately conserved (>0.30) and 1 position, residue Ala26, considered highly conserved 
(>0.45). It is interesting to note that there is at least one conserved amino acid found in 
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Position in alignment
Figure 49. Amino acid position conservation analysis. Positions colored in blue are 
positions considered conserved. Positions >0.45 are considered highly conserved and 
0.45> positions >0.30 are considered moderately conserved. Arrows in yellow indicate 13- 
strands, the rectangle in magenta indicates an a-helix and green rectangles indicated (3- 
turns. Backbone structure was created using RasMol (Ver. 2.7.2.1.1).
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The initial analysis determined conservation irrespective of amino acid character 
thus we also wanted to get a sense of conserved positions with respect to character. The 
conservation analysis was conducted by counting similar character types rather than the 
same specific amino acid and the results where plotted similarly (Figure 50). The data 
indicated that 11 positions were conserved in amino acid character: Tyr3, Leu5, Leu7 
Thrl8, Ala20, Ala26, Phe30, Gly41, Trp43, Phe52 and Val54. In order to discern less, 
moderately and highly conserved residues we counted any positions less than 2 standard 
deviations (StDev) from the mean as less conserved, positions greater than 2 StDev but 
less than 3 StDev as moderately conserved and any positions greater than 3 StDev as 
highly conserved. The 11 positions were separated into 4 moderately conserved (Leu7 
Thrl8, Ala20 and Gly41) and 7 highly conserved positions (Tyr3, Leu5, Ala26, Phe30, 
Trp43, Phe52 and Val54). Between the two conservation analyses there are 4 positions 
(Lys4, Glu42, Asp46 and Lys50) that were considered conserved but are not similarly 
conserved in the character analysis. This indicates that during evolution these positions 
typically maintained the same amino acid and their role may be more dependent on the 
particular amino acid structure. However, when these positions are modified it does not 
favor a particular amino acid character type and this could mean that its role in folding of 
GB1 could be secondary. Interestingly, the following 8 positions are conserved in both 
amino acid position and character: Tyr3, Leu5, Thrl8, Ala20, Ala26, Phe30, Phe52 and 
Val54. In addition, 3 positions (Leu 7, Gly41 and Trp43) that were not conserved in 
amino acid position are now considered conserved with respect to amino acid character. 
This distinctions indicates that these positions may be important in the folding of GB1 
because of the character of the amino acid. This could suggest that during evolution when
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these positions were varied they did not favor any specific amino acid in particular but 
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Figure 50. Amino acid character conservation analysis. Positions colored in blue are 
positions considered moderately conserved whereas those colored in red indicate highly 
conserved positions. Arrows in yellow indicate (3-strands, the rectangle in magenta 
indicates an a-helix and green rectangles indicated (3-tums. Backbone structure was 
created using RasMol (Ver. 2.7.2.1.1).
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To identify hydrophobic positions versus hydrophilic positions a hydropathy 
analysis was done (Figure 51). From the hydropathy analysis we see that of the 15 
positions conserved by amino acid type or character, 11 were hydrophobic while 4 were 
hydrophilic in nature. This makes sense as the 4 positions considered hydrophilic are 
either acidic or basic in character and would be expected to be found on the surface of the 
protein exposed to the solvent. Based on all the bioinformatics information gathered there 
are 15 positions that were revealed to have conservation in one way or another. A 
summary of all the data can be found in Table 8.
1 5 9
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Figure 51. Position specific hydropathy analysis. Positions colored in blue are 
positions considered conserved either by position or character conservation. Positive 
values indicate hydrophobicity and negative values indicate hydrophilicity. Arrows in 
yellow indicate 3-strands, the rectangle in magenta indicates an a-helix and green 
rectangles indicated P-tums.
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Table 8. Summary of all conserved positions from the conservation analysis










3 Tyrosine (Y) i .uni - 1 Aligned Moderately Highly Hydrophobic
4 Lysine (K) J. s ‘ r n !■ j -  i Aligned Moderately Less Hydroph i l ic
5 Leucine (L) : Aligned Moderately Highly Hydrophobic
7 Leucine (L) P - ' - ' o i n . i  ! Aligned Less Moderately Hydrophobic
18 Threonine (T) -  ‘ i 1 ! ■. i „ Aligned Moderately Moderately Hydrophobic
20 Alanine (A) Loop-2 Not Aligned Moderately Moderately Hydrophobic
26 Threonine (T) « -H e li\- l Not Aligned Highly Highly Hydrophobic
30
Phenylalanine
(F) (/-Helix-1 Aligned Moderately Highly Hydrophobic




; . V  1 j ' . i  < li j • t Not Aligned Moderately Less Hydroph i l ic




j: s : r.isul- ' Not Aligned Moderately Less Hydroph i l ic




]i  -Si r :m i!  -4 Aligned Moderately Highly Hydrophobic
54 Valine (V) |;-S( m u d  4 Aligned Moderately Highly Hydrophobic
To determine the importance and effect the 15 conserved amino acids have on the 
stability and folding kinetics we can use site-directed mutagenesis to mutate the position 
to an alanine or glycine. In this chapter, we selected the phenylalanine at position 52 as 
the first mutation to be studied. We initially selected this residue in order to selectively 
label a specific long-range interaction to be studied by NMR, which will be discussed in 
chapter IV. Thus the mutation to tyrosine is much less disruptive. However, important 
information about the effect on the structure and stability is determined experimentally. 
The WT and Phe52Tyr variant were both overexpressed in E. coli and both proteins were 
initially observed to be highly stable and non-toxic to bacterium. We were able to 
overexpress both proteins and produce anywhere from -200-300 mg of protein per 6 L of
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bacterium. This indicates that in both cases GB1 is highly soluble and stable at high 
concentrations in vivo. Any adverse effects of GB1 and its variant is not indicated as 
evidenced by the high expression levels and due to the absence of inclusion bodies in the 
post sonication milieu (which typically indicates the protein is not favorable to bacteria).
To determine the structural differences between the WT- and Phe52Tyr-GBl we 
used far- and near-UV CD (Figure 52). Far-UV CD of the Phe52Tyr variant indicated 
that the secondary structure does not change its shape in any significant way. However, 
there is a decrease in the signal indicating a possible increase in overall secondary 
structure stability. It has already been discussed that tertiary interactions can stabilize 
secondary interactions. The tyrosine could be in this case causing an increase in 
secondary content, perhaps due to an increase in helicity. Similarly, the tertiary structure 
monitored by near-UV CD shows a similar pattern between WT and Phe52Tyr variant. 
There seems to be a change in the amino acid environment of the tertiary structure in the 
core due to the additional -OH group. In both cases, at 100 °C both WT- and Phe52Tyr- 
GB1 show a random coil secondary structure and a complete loss of tertiary structure 
indicating a fully unfolding state. Figure 53 shows the thermal unfolding transition for 
WT-GB1 and the Phe52Tyr variant. It reveals that the variant is less thermostable than 
the WT protein. The WT protein has a temperature midpoint (Tm) of 80 °C while the 
Phe52Tyr variant has a Tm of 75 °C. Although we see structural changes associated with 
this mutation which is suggestive of a potentially slight increase in secondary and tertiary 
structure content in the CD, this does not correlate well with the stability data.
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Figure 52. Circular dichroism spectra of WT and Phe52Tyr-GBl. WT-GB1 at 20 °C 
(Solid-line) and 100 °C (dotted-line). Phe52Tyr-GBl at 20 °C (dashed-line) and 100 °C 
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Figure 53. Thermal denaturation of WT- and Phe52Tyr-GBl. WT-GB1 is indicated 
by the filled circles and Phe52Tyr-GBl is indicated by the unfilled circles. The data was 
plotted and visualized in SigmaPlot (Ver. 12.5)
Equilibrium experiments are useful in helping to define the native and unfolded 
state structures and their relative stability. In addition, the denaturation curves provide a 
basis for future kinetic experiments by showing how the native state changes as function 
of denaturant. To determine the stability of WT- and Phe52Tyr-GBl the folding was 
studied using intrinsic tryptophan fluorescence in 0.1 M tris base at pH 7.0. Interestingly, 
the initial baseline of the native state from the fluorescence data is not flat, which is what 
was expected (Figure 54). There is a decreasing linear change in the fluorescence native 
baseline, which indicates that the environment of the tryptophan is becoming more 
solvent exposed as the concentration of guanidine hydrochloride (Gnd-HCI) increases
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from 0 to about 1 M. At this point the unfolding transition predominates. This effect we 
believe is due to the amino acids neighboring the tryptophan. The tryptophan points into 
the hydrophobic core however, directly on the outer surface of the tryptophan there is a 
lysine at position 31 that appears to form a cation-n interaction which partially protects 
the tryptophan from solvent exposure (Figure 55). Cation-n interactions are becoming 
increasingly recognized as relevant non-covalent binding interactions in the stability of 
protein structures [442-446]. A computational study indicated that out of 593 proteins 
lysine is found to interact 30% of the time with tryptophan in a cation-n interaction [442- 
446]. Upon addition of Gnd-HCl we believe the cation-n becomes increasingly 
destabilized allowing water to come into contact with the tryptophan. There are examples 
of proteins that have similar cation-n interactions with little change to the equilibrium 
baselines such as the human serum retinol-binding protein (PDB code: ljyd) [447]. This 
change due to the addition of Gnd-HCl could be unique to GB1 due to how close Trp43 
is to the outer surface of GB1 or the angle of interaction. In addition, GBI only has one 
tryptophan providing the average fluorescence signal, whereas in other proteins the 
















Figure 54. Equilibrium folding monitored by intrinsic tryptophan fluorescence.
Fluorescence data at collected at = 330 nm for WT-GB1 unfolding is plotted against 
Gnd-HCl concentration. We can see the slanted baseline for the native state between 0-1 
M Gnd-HCl and a flat baseline for the unfolded state between 4-6 M Gnd-HCl. The data 






Figure 55. Image of the Lys31 and Trp43 proposed cation-n interaction. Secondary 
structure a-helix and (3-strand are indicated by the colors pink and yellow respectively. 
The interaction was visualized in the whole protein (A) and a close-up cross-section (B). 
The residues were visualized with RasMol (Ver. 2.7.2.1.1).
The fractional unfolding of the WT and Phe52Tyr variant was calculated and 
plotted against Gnd-HCl concentration (Figure 56). In both proteins the folding is 
reversible. The midpoint of the transition occurs at -2.57 M and -2.68 M Gnd-HCl for 
the WT unfolding and refolding curves respectively. For the Phe52Tyr variant the 
midpoint transition occurs at -1.90 M and -1.99 M Gnd-HCl for the unfolding and 
refolding curves, respectively. Visual inspection of the curves as well as the -0.68 M 
shift in the transition midpoint indicates that there is a loss in stability of the Phe52Tyr
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variant relative to the WT. The calculated AG for WT-GB1 is -4.46 kcal/mol and there is 
a 0.66 kcal/mol loss in Gibbs free energy for Phe52Tyr to -3.80 kcal/mol. However, 
although there is a small decrease in stability it appears that the introduction of the 
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Figure 56. Fraction of unfolded protein versus Gnd-HCl. The fraction of the unfolded 
population is potted against Gnd-HCl concentration for both WT (black circles) and 
Phe52Tyr (red circles) variant. Unfolding (filled circles) and refolding (unfilled circles) 
experiments were conducted to show reversibility of the folding for both proteins. Lines 
are sigmoidal regression fits for the unfolding curves. The data is plotted and fitted in 
SigmaPlot (Ver. 12.5)
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Since there is a loss in stability in the equilibrium folding studies we wanted to 
see if the real-time folding kinetics changes significantly. Rapid-mixing stopped-flow 
studies were conducted to determine the folding rates for the WT and Phe52Tyr variant. 
From the equilibrium investigation conditions were selected to ensure the protein is in a 
completely unfolded state and transitions into conditions conducive to forming the native 
state fold. We selected 4 M Gnd-HCl as the unfolded conditions and induced refolding by 
a 7:1 dilution into refolding buffer, resulting in a 0.57 M final concentration which is well 
into the native state. Refolding of 1 mg/ml was done at 10 °C into 40% glycerol refolding 
buffer for both WT and the Phe52Tyr variant (Figure 57). Proteins were refolded at a 
flow rate of 6 ml/s, with a dead time of 6.8 ms. Due to the fast rate of folding and the 
large dead time, the unfolded baselines could not be shown. However, the unfolded 
baseline for WT was at -0.57 and the Phe52Tyr variant unfolded baseline was at -0.63. 
The folding kinetics for both proteins was fit to a double exponential regression and both 
the WT and Phe52Tyr variant fold rapidly in a biphasic pathway. The WT protein’s first 
folding phase, with an amplitude of 95 % occurs at a rate of 145.39 s '1 (relaxation time 
was 6.88 ms). The second phase has an amplitude of 5 % with a folding rate of 9.94 s '1 
(relaxation time was 100.60 ms). Similarly for the Phe52Tyr variant, 95 % of the initial 
folding collapse and organization occured in the first phase with a folding rate of 153.57 
s '1 (relaxation time was 6.51 ms). The second phase is much slower with the remaining 5 
% of the folding occurring at a rate of 21.06 s '1 (relaxation time was 47.48 ms). The 
difference in folding kinetics between the WT and Phe52Tyr variant occurs in the second 
phase of folding, in which Phe52Tyr folds in about half the time required for the WT 
(Table 9). This indicates that although the initial collapse of the protein occurs similarly
and most of the native structure has formed the tyrosine mutation has an impact on the 
final stages of the “fine-tuning” phase in which the native structure is potentially 
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Figure 57. Stopped-flow kinetics of WT- and Phe52Tyr-GBl. Refolding kinetics of 
(A) WT- and (B) Phe52Tyr-GBl with the resulting residuals. Curves were plotted and fit 
with a double exponential equation in SigmaPlot (Ver. 12.5). The red line indicates the 
double exponential regression line. The residuals of the fit are shown.
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Table 9. Summary of stopped-flow kinetics data for WT- and F52Y-GB1
Protein Amplitude Rate (k) Relaxation Time
(GB1) I II I II I II
WT 95 % 5 % 145.39 ±0.951 s'1 9.94 ±0.223 s'1 6.88 ms 100.60 ms
F52Y 95% 5% 153.57 ±0.778 s'1 21.06 ±0.263 s'1 6.51ms 47.48 ms
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MATERIALS AND METHODS
All reagents were analytical grade. Tris base, NaCl, yeast extract, sodium azide 
(NaN3) were purchased from VWR. (Gibbstown, NJ). Carbenicillin disodium salt, 
sodium dodecyl sulfate (SDS) running buffer and tryptone medium were obtained from 
Teknova (Hollister, CA). G-75 Sephadex medium size and Q-Sepharose Fast Flow anion 
exchange resins were from GE Healthcare (Pittsburgh, PA). Isopropyl-p-D- 
thiogalactoside (IPTG) was purchased from IBI Scientific (Peosta, IA). NUPAGE Novex 
12% Bis-Tris Gel was obtained from Invitrogen (Grand Island, NJ). Competent 
Escherichia coli BL21(DE3) cells were purchased from Agilent Technologies Stratagene 
(Santa Clara, CA). Yeast extract was purchased from Research Organic (Cleveland, OH). 
Buffers were prepared and filtered through a 0.45 pm filter purchased from Pall Life 
Sciences (Suwannee, GA). Molecular porous membrane (1 kDa MWCO) for dialysis was 
obtained from Spectrum Laboratories (Rancho Dominguez, CA).
Structural Alignment and Percent Identity
To construct a structural alignment for GB1 the DaliLite v. 3 Sever was employed 
to determine proteins with similar structure
(http://ekhidna.biocenter.helsinki.fi/dali_server/start). The DaliLite server is a 
comprehensive search method that surveys the protein data bank and does a sum-of-pairs 
comparison of superimposable structures. This method produces a measure of similarity 
by comparing intramolecular distances and calculating a similarity measure called the 
Dali-Z score. Structures that are significantly similar have a Z-score above 2, and usually 
have similar folds [434-436,448]. The sequence identity of the structural alignment was
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obtained from DaliLite structural data. Sequence alignments of selected structures needed 
to be significantly divergent with a sequence identity less than 25% and a broad range of 
functional diversity so that similarities obtained would be related to structure. Structural 
modifications were made by hand based on the visual comparison of the side-chain 
orientation in each selected structure using RasMol (Ver. 2.7.2.1.1). This manual analysis 
is required to ensure that the obtained structural alignment is aligned properly as 
computer algorithms are imperfect.
Conservation Analysis and Hydropathy
Once a structural alignment is completed and the side chain orientation is verified 
we can calculate position specific conservation. The number of each residue type at each 
position in the superfamily sequence alignment is calculated by summation of each type 
of amino acid. A program written for us by the He group (ODU Computer Science 
Department) was used to calculate these values. With the number of amino acids of each 
type at each position, entropy can be calculated by the following equation:
m
S(0= Y ,  -{ ^ (0 ln [ />y(0]}0=l,2,3,...,14)
j  = i
In the equation Pj(i) is the fractional occurrence of each amino acid type j  at each 
residue position i and m is the number of amino acids types possible in the particular 
analysis [449]. Since our structural sequence alignment incorporated fourteen sequences, 
i ranges from 1 to 14. Positional entropy tells us about the amino acid variability at each 
position. High entropy indicates high variability and thus infers low conservation and 
vice versa. Thus, to calculate conservation the following equation from [402] is used:
From the analysis, residue positions whose conservation exceeds 0.45 are 
considered highly conserved whereas conservation between 0.45 and 0.30 are considered 
moderately conserved. Any conservation values lower than 0.30 are considered to be less 
conserved. Positions containing more than one gap are considered less conserved and are 
given a value of zero and considered non-conserved. To calculate residue specific 
hydropathy as it relates to the structural superfamily, the average hydrophobicity of all 
the amino acids at the selected position are summed according to the following equation:
ffi
Hydropathy = ^ y ( i)H /( /)
j  = i
In the equation, j(i) is the amino acid type j  at residue position i in each structural 
alignment and Hj(i) is the hydropathy of the amino acid. The summation goes from 
amino acid type j=J to m which is the maximum number of amino acid types possible. 
The hydrophobicity values used where adapted from the most commonly used amino acid 
hydrophobicity [450], The data from both conservation and hydropathy analysis were 
analyzed and plotted using SigmaPlot (Ver. 12.5, Systat Software)
Primer Design and Site-directed Mutagenesis
WT-GB1 cDNA was kindly provided by Professor Angela Gronenbom (Member 
of the National Academy of Science) from Pennsylvania State University in a pET-1 la 
vector (Figure A4). The vector contains an antibiotic resistance gene that expresses the 
carbenicillin resistant P-lactamase allowing for specific selection of bacterium containing 
the cDNA. The GB1 cDNA was amplified using NEB 5a competent E. coli (New
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England Biolabs) and expressed in 50 ml of Luria Broth (LB) with carbenicillin (200 
pg/ml). Amplified plasmid cDNA was extracted and purified using a Strataprep plasmid 
miniprep kit (Stratagene). Wild-type GB1 cDNA was mutated to Phe52Tyr GB1 using 
QuikChange II Site-Directed Mutagenesis (Agilent Technologies, Santa Clara, CA) (IBC 
biosafety protocol #12-006). The 50 pi PCR mutagenesis reactions consisted of the 
following components: 5 pi of 10X reaction buffer, 1 pi of the required 100 ng/pl cDNA 
template of WT-GB1, 1 pi of both forward and reverse primers, 1 pi dNTP mix and 1 pi 
of the provided 2.5 U/pl pfuTurbo DNA polymerase. The reaction was incubated in 16 
cycles according to the following parameters per cycle: 95 °C for 30 sec (denaturation), 
55 °C for 1 min (annealing) and 68 °C for 6 min (elongation). Primers were designed 
using the Agilent primer design program
(http://www.genomics.agilent.com/primerDesignProgram.isp) for all the selected 
conserved residues and for the control less conserved residues (Table 10). The primer for 
the mutation Phe52Tyr, sense primer 5'-
CGACGCTACCAAAACCTACACGGTAACCGAATAGG-3', and antisense primer 3- 
GCTGCGATGGTTTTGGATGTGCCATTGGCTTATCC-5' were used to mutate the 
GB1 cDNA. Stability and amplification of the resulting mutant cDNA was verified and 
performed by expression in NEB 5a competent E. coli and purified using Strataprep 
plasmid miniprep kit. The resulting purified Phe52Tyr plasmid was stored at -20 °C until 
used. The insertion of the point mutation was verified by sequencing analysis at the 
Medical College of Virginia - Virginia Commonwealth University Nucleic Acids 
Research Facilities (Richmond, VA).
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Table 10. Primers designed for mutational analysis of GB1
Codon
Mutation 5'-3' Primer 3’-5' Primer
TA AGA AGGAG AT ATAC AT ATGC A ATTCTTCCTCT AT ATGT AT ACGTC
Y3A GGCC AAGCTT ATCCTG AACGGT A CGGTTCG AAT AGG ACTTGCC ATTT
AAAC TG
L5A AGATATACATATGCAGTACAAGG CT ATCCTG AACGGT AAAACCCTG
TCTAT ATGT AT ACGTCATGTTC CG 





TCCTCT AT ATGT AT AC GTC ATGTT 








Y33A GCGGAAAAAGTTTTCAAACAGGC CGCCTTTTTC AA AAGTTTGTC CGGCGCTAACGACAACGGTGTTG CGATTGCTGTTGCCACAAC
Y45A GTTGACGGTGAATGGACCGCCGACGACGCTACCAAAAC
C AACTGCC ACTT ACCTGGCGGCT 
GCTGCGATGGT1T1G
D46A GGTGAATGGACCTACGCCGACGCTACCAAAACC
CC ACTT ACCTGG ATGC GGCTGCG 
ATGG11T1GG
F52Y CGACGCTACCAAAACCTACACGGTAACCGAATAGG
GC fGCGA'I GG'inTGGATG 1GCCA 
TTGGCTTATCC
V54A TACCAAAACCTTCACGGCAACCG AAT AGG ATCCGG
ATGGTTTTGGAAGTGCCGTTGGCT
TATCCTAGGCC
T55G CTACC A AAACCTTC ACGGT AGGC GAATAGGATCCGGC
GATGGTTTTGGAAGTGCCATCCG 
CTT ATCCT AGGCCG
*Nucleotides changed from the WT-GB1 codons are indicated as bold and underlined
Protein Expression and Purification
The expression and purification protocol was adapted from previously published 
work (IBC #12-006) [386]. The protocol for WT- and Phe52Tyr-GBl expression was 
optimized by multiple expressions with for example, increasing IPTG over variable time
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to assess conditions for maximum protein expression. The WT and Phe52Tyr cDNA 
were then transformed into BL21 (DE3) competent E. coli (New England Biolabs) and 
grown in 6 L of LB with carbenicillin (200 pg/ml) until an optical density of 0.6-0.8 
(Absgoo) was observed which indicates the mid-log phase of the bacterial growth. Protein 
expression was induced using 0.4 mM IPTG for 4 hours at 37 °C and 200 rpm agitation. 
Bacterium were harvested and sonicated for 1-3 hours one ice in 20 mM tris base (pH 
8.5). The bacterial lysate was heated at 80 °C for 10-15 minutes then centrifuged in a 
Rotanta 460R Hettich centrifuge at 11500 rpm for 30 minutes to pellet cellular debris and 
aggregated proteins. The supernatant contained predominantly GB1 protein and was 
further purified using anion-exchange column chromatography. GB1 was eluted using a 
0-500 mM NaCl sodium gradient in 20 mM tris base (pH 8.5) buffer over 480 min. Peaks 
containing GB1 were dialyzed in a 1000 MWCO membrane in double deionized H2O and 
lyophilized in a Labconco freeze dryer (Kansas City, MO) Beach, VA). Lyophilized 
protein was further purified using G-75 sephadex (medium grain) size-exclusion column 
chromatography in 50mM tris base, 200 mM NaCl and 0.005 % NaN3 (pH 7.5). GB1 
protein purity was verified by SDS-PAGE and mass spectrometry and final purified 
protein was similarly dialyzed and dried. Protein was stored at -20 °C until use.
SDS-PAGE was run on NuPAGE Novex 12% Bis-Tris mini gels at 150 V for 1 
hour. 15-20 pi of each sample and marker was loaded on to the gel. The isolated gel was 
stained with Coomassie brilliant blue stain for a minimum of 3 hours and then destained 




Protein was taken from -20 °C storage, weighed and dissolved in 0.1 M tris base 
(pH 7.0) to produce stock protein solutions. Concentration was determined by measuring 
absorbance at 280 nm and dividing by the calculated molar extinction coefficient of 1.42 
ml-mg'1 cm'1 [451]. Protein was diluted to a working concentration of 0.05 mg/ml for all 
equilibrium unfolding and refolding experiments. Protein was denatured by 0.25 M step­
wise increases in Gnd-HCl concentration per sample up to a 6 M Gnd-HCl maximum. 
Samples were analyzed in triplicate on a Cary Eclipse fluorescence spectrophotometer 
(Varian, Palo Alto, CA) by excitation at 295 nm and emissions spectra where collected 
from 315 to 415 nm. The slit widths were 5 and 10 mm for excitation and emissions, 
respectively. Each spectrum was the average of 10 scans at 20 °C. Blanks were measured 
similarly and subtracted from the initial spectra to produce final fluorescence data. 
Denaturation curves were obtained by plotting emissions at 330 or 350 nm against Gnd- 
HCl concentration. The denaturant concentration of each sample was determined by 
measuring the refractive index using a hand-held ATAGO refractometer.
To determine the stability (AG) was calculated from the equilibrium data by 
determining the equation to the curves for the native and unfolding baselines as well as 
the transition region [12]. Using the following equations the fraction unfolded (/u) is 
determined:
f  -  y ~yN
u yu-yN
In the equation, y is the observed fluorescence for each concentration of Gnd- 
HCl. The calculated equation of the line for the baselines corresponds to yn and yv for
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native and unfolded respectively. The equilibrium constant Keq at each concentration of 
Gnd-HCl is calculated according to the following equation:
The AG is dependent on the denaturant concentration and is calculated for each of 
the equilibrium constants of the transition region using the following equation:
AG[Gnd] = ' RT ln(Keq)
R is the gas constant (1.986 cal-K ' -mol"1) and T is the temperature of the 
experiment. To obtain the AG° independent of the denaturant the AGjondiat each position 
in the transition region is plotted versus Gnd-HCl concentration. A linear regression fit of 
this plot allows for the determination of the AG° according to the following equation 
where m is the slope of the line:
AG[Qnd] = AG° - m[Gnd]
Circular Dichroism Analysis
WT- and Phe52Tyr-GBl were analyzed by far- and near- UV circular dichroism 
in 0.1 M tris base (pH 7.0). A stock solution of each protein was diluted in buffer to a 
final working concentration of 0.2 mg/ml for far-UV and 0.5 mg/ml for near-UV 
spectropolarimetry. Samples were measured with a Jasco J-815 spectropolarimeter using 
continuous scan mode set to a rate of 200 nm/min. Each experiment is run in triplicate 
and is the average of 10-15 scans. The mean residue ellipticity ( G m r w )  is calculated using 
the following equation:
M R W 0obs
0 mew i o i r
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In the above equation, MRW=M/(N -1),  where M is the molecular mass of the 
polypeptide chain (in Da), and N is the number of amino acids in the chain. G^s is the 
observed ellipticity (degrees), d is the pathlength (cm), and c is the protein concentration 
(g/ml).
Stopped-Flow Folding Kinetics
Folding kinetics studies were conducted using a SFM-400 stopped-flow system 
(Bio-Logic, France). WT-GB1 and Phe52Tyr variant protein were denatured in 0.1 M 
Tris (pH 7.0) and 4 M Gnd-HCl for a minimum of 3 hours or overnight. Refolding was 
initiated by a seven-fold dilution into refolding buffer containing 0.1 M Tris-HCl and 40 
% glycerol (pH 7.0) refolding buffer at 10 °C with a flow rate of 6 ml/s. Kinetics 
experiments were run using a 1.5 mm FC-15 cuvette and a mixing dead time of 8.6 ms. 
Fluorescence changes were monitored by excitation at 295 nm and emissions detection 
>320 nm using a bandpass filter (Semrock, Rochester, NY). The slit widths were both 1 
mm for excitation and emissions for all experiments. Spectra were obtained from the 
average of 5-10 repeat experiments. Curves were analyzed and fitted to an exponential 
regression using SigmaPlot (Ver. 12.5, Systat Software).
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CHAPTER IV
DEVOLOPMENT OF A METHOD TO ELUCIDATE THE 
FORMATION OF A LONG-RANGE INTERACTION IN THE B1 
DOMAIN OF PROTEIN G USING NUCLEAR MAGNETIC 
RESONANCE SPECTROSCOPY
OVERVIEW
Protein folding is a multifaceted problem in biochemistry and has been studied 
using high-resolution for years to try and unravel the code that allows for rapid formation 
of a protein native structure in a fraction of a second. Proteins fold along an energy 
landscape by forming specific non-covalent short- and long-range interactions in an 
ordered process which results in the proper organization of structural components into a 
native conformation. These short- and long-range interactions are guided by 
intermolecular forces such as hydrogen bonding, electrostatic interactions, 
hydrophobicity and disulfide bonds. Long-range interactions are classified as interactions 
between amino acids that are greater than 7 residues from each other in the primary 
structure but within 5 A in the tertiary structure. Whereas, short-range interactions are 
less than 7 residues and are typically found in secondary structure elements [360,404, 
452], These interactions can be monitored by biophysical analysis and indirect methods. 
Understanding the underlying structural interactions of proteins is important in 
identifying key determinants that dictate the mechanism of protein folding and 
misfolding. We have previously discussed that the Trp43 is partially buried in the
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hydrophobic core and is sensitive to conformational changes in the folding of GB1 (Table 
A l) (Refer to Chapter HI). The mechanism of protein folding can be expressed as an 
increase in long-range interactions that arrange the overall topology while short-range 
interactions order the backbone structures such as a-helices, (1-hairpins and (3-tums [453], 
We must be able to understand how and why specific long-range interactions form first 
and how this process is facilitated by amino acid character and the aqueous environment. 
Using NMR spectroscopy it is possible to visualize the long-range interactions that make 
up the tertiary structure of a protein using both solution-state and magic-angle spinning 
solid-state NMR (MAS-NMR) [454-461].
Studying protein folding has typically been done with indirect biophysical 
methods such as fluorescence, absorbance and circular dichroism [462]. A high 
resolution method such as quenched-flow hydrogen-deuterium exchange coupled to 
NMR has become more specialized for protein folding but is only ideal for short-range 
interactions such as hydrogen bonds in the a-helices and [1-sheets [405]. However, atomic 
resolution studies involving the formation of specific long-range interactions in real-time 
during the folding process are virtually absent in the literature. In this chapter we intend 
to discuss a novel method of folding-freezing stopped-flow spectroscopy in combination 
with MAS-NMR to follow the interaction of three specific amino acids in the folding of 
GB1 as a ‘proof-of-concepf method. The l3C-13C CRPK’s between the selected amino 
acids are proposed to be specifically visualized using MAS-NMR. In summary, we 
propose an approach and preliminary data to monitor the formation of long-range 
interactions between Phe 30, Trp 43 and Phe 52, three amino acids found in the core of 
the protein. Changes in these three amino acids will also be investigated as a function of
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pH using HSQC NMR. Preliminary solution-state NMR studies are also conducted to 
facilitate characterizing the protein structure under different environmental conditions.
To reiterate, GB1 is a small 56-residue protein that functions as an 
immunoglobulin binding domain of the cell surface bacterial protein G. This protein was 
selected as a model system because of the ease of expression, no disulfide bond, lack of 
free cysteine, ability to fold at high concentrations, solved NMR and crystal structures in 
addition to fundamental investigations of the folding of GB1 make it an ideal candidate 
for this method. With this selected model system several advances were made to develop 
its applicability. Efforts to establish conditions to synthesize site-specifically C-labelled 
protein and monitor the formation of a conserved set of long-range interactions in the 
core of GB1 using equilibrium unfolding in concert with high-resolution NMR is an 
important first step. To the best of my knowledge the formation of specific conserved 
long-range interactions has never been shown with atomic resolution. We selected 
residues 30,43 and 52 for 13C-labeling as all three residues are conserved, found in the 
core of GB1 and play a role in several long-range interactions between them. We have 
already established reversible equilibrium unfolding conditions for WT-GB 1 (Refer to 
Chapter III). We will also show the kinetics of folding of GB1 at high concentrations 
required for NMR which is another critical step. The results from chapter III enabled the 
following work described in this chapter to be conducted. Lastly, preliminary NMR 
studies were conducted to assess appropriate conditions and parameters.
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RESULTS AND DISCUSSION
Synthesis of the 13C-Phe/l3C-Trp labelled protein was done using an engineered 
E. coli auxotroph (Aux). This strain is unable to synthesize all three aromatic amino acids 
due to a knockout in the chorismate synthase gene in the Shikimate pathway (Figure 58). 
Chorismate is a precursor molecule for phenylalanine, tryptophan and tyrosine. Carefully 
cultured Aux bacteria were A.DE3 lysogenized, incorporating the gene for T7 RNA 
polymerase into the genome of the Aux (Aux(DE3)). Incorporation of the T7 RNA 
polymerase gene allows for the overexpression of plasmid genes regulated by the lac 
operon and which selectively have a T7 promoter (Figure 59). The synthesis of the T7 
polymerase was verified using a T7 tester phage which is a phage mutant that has a T7 
deletion and is completely defective unless the host cell provides T7 RNA polymerase. 
Host cells successfully lysogenized will provide the T7 RNA polymerase and cause the 
production of plaques or halos in the presence of EPTG (Figure 60). On the other hand, 
significantly smaller plaques are observed in the absence of T7 RNA polymerase. 
Cultured Aux(DE3) was verified by a titration of tester phage in the presence of EPTG. 
We also were able to determine how tightly regulated the T7 RNA polymerase is in the 
newly synthesized Aux(DE3). The growth of Aux(DE3) without EPTG and the size of the 
resulting plaques indicated basal levels of T7 RNA polymerase expression. We needed to 
ensure that there was no leaky expression of T7 RNA polymerase to enable efficient 
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Figure 58. Schematic of the Shikimate pathway showing the synthesis of aromatic 
amino acids in E. coli. Our Aux E. coli bacteria have a knockout in the enzyme that 
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Figure 59. Schematic of the Lac Operon, T7 Promoter and its regulation of 
recombinant gene expression in E. coli. Induction by IPTG results in the dissociation of 
the repressor protein bound to the lac operon and enables the polymerase to bind to its 
corresponding promoter [464, 465]. Figure was drawn from information obtained in 
[466].
187
Figure 60. Titration of tester phage with auxotrophic lysogens. (A) Undiluted tester 
phage. (B) 20X dilution. (C) 50X dilution. (D) 2,500X dilution. (E) 125,OOOX dilution. 
(F) Undiluted tester phage control (No IPTG).
To ensure that the Aux(DE3) is a true auxotroph we tested the ability of the cells 
to grow in the absence of each aromatic amino acid (Figure 61 A). If the Aux(DE3) is a 
true auxotroph there should be little to no growth of the cells in the absence of Trp, Phe 
or Tyr independently. It is clear from Figure 61A that there is no growth of the cells in 
comparison to the control containing all three aromatics. The cultures were grown for 
-24 hours and we wanted to determine if the cells were still viable so a small amount was 
streaked onto fresh LB plates to see if they would grow (Figure 6  IB). The cells were able
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to recover and grew quite well. Now that the Aux(DE3) was verified we could now use 
them to selectively label the WT-GB1 protein.
Figure 61. Aromatic knockout verification of cultures of auxotrophic E. coli 
transfected with Phe52Tyr-GBl. (A) Minimal media cultures; Aromatics (+), Tyr(-), 
Phe(-) and Trp(-) from left to right. 100 pi of (B) Tyr(-), (C) Phe(-) and (D) Trp(-) 
cultures plated after -24 hours of incubation.
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To investigate the folding and formation of a specific set of non-covalent long- 
range interactions we synthesized a uniquely labeled protein using the previously 
discussed Aux(DE3). We initially intended to investigate only a single set of interactions 
between Phe30 and Trp43 found in the Phe52Tyr-GBl variant. However, biophysical 
analysis of the stability of Phe52Tyr-GBl, previously discussed in chapter HI, indicated 
to us that the instability of Phe52Tyr-GBl could cause problems at the high 
concentrations required for NMR (Refer to Chapter III). Thus, we selected the WT-GB1
IT •for specific and uniform C-labeling. The interactions we are interested in are between 
Phe30-Trp43 and Phe52-Trp43 (Figure 62A). Interestingly, Phe30, Trp43 and Phe52 are 
highly connected in the structure of GB 1 having a significant number of long-range
13 13interactions which indicates their importance (Figure A5). We used C-Phe/ C-Trp 
labeled BC-Phe and 13C-Trp for the specific long-range interactions investigated (Figure 
62B). For these interactions to be sensitive to NMR spectroscopy, they need to be within 
5 A distance from one another. The Phe30-pC is 4.24 and 4.30 A from the Trp while the 
Phe52-pC is 4.42 and 4.56 A from the Trp ring (Figure 63). These interactions are within 
the van der Waals radius and find each other in the core of WT-GB1 and all three amino 
acids are conserved as previously discussed (Chapter III). It is interesting to note that 
typically protein expression in minimal media result in lower yields than traditional rich 











Figure 62. Backbone structure o f GB1 with highlighted core aromatics and specific 
13C labeling of Phe and Trp. (A) Structure of the WT-GB1 backbone. Yellow and 
magenta portions indicate secondary structures p-strands and a-helix, respectively. 
Amino acids Trp (cyan) and Phe (red) are shown as ball and stick models. (B) Molecular
1Tstructure of Phe and Trp, and their respective C labeling positions in red. The residues 
are visualized with RasMol (Ver. 2.7.2.1.1).
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Figure 6 3 .13C-Labeled carbons of interest in the core structure of GB1. Yellow, 
magenta and white portions indicate regions of p-, a- and loop structures, respectively. 
Amino acids Phe30, Trp43 and Phe52 are shown as wireframe (green). The measured 
distances for the interactions between Phe30 and Trp43 (dashed cyan lines) and Phe52 
and Trp43 (solid cyan lines) are shown. This structure was visualized with RasMol (Ver. 
2.7.2.1.1).
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The purpose of using the Aux to synthesize selectively labeled protein is in 
preparation for ssNMR in which the specific labeling lends itself to our folding method 
because NMR on uniformly isotopically labeled proteins would produce an abundance of 
carbon signals. Therefore, the resonance peaks would be indistinguishable and 
identifying and monitoring specific interactions would be quite difficult (Figure A6 ). 
However, with very specific labelling of the Trp43 and two Phe-(3C’s we can 
theoretically map the interactions as they come together or separate in space (Figure 64). 
In the example schematic below, we can see that as the carbons separate in space due to 
the transition from folded to unfolded there is a loss in CRPK signal (Figure 64). In the 
end we want to be able to map all the long-range interactions (Table A2) in the folding of 
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Figure 64. Representative schematic of anticipated cross-peak formation from 
interactions of 13C-speciftcally labeled WT-GB1. Blue peaks indicated Phe30 and 
Phe52 while the red peak indicates the Trp43. Purple peaks indicate Trp-Phe CRPK’s. 
The folding transitions from (A) folded to (B) intermediate to (C) unfolded states.
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The next stage of this project was to capture a long-range interaction in the core 
of WT-GB1 using a novel folding-freezing method we are developing. An attachment to 
the stopped-flow system has been designed and engineered to potentially capture a long- 
range interaction by instantly freezing a protein sample in supercooled isopentane (-80 
°C) during the folding process (Figure 65). The design of the freezing folding stopped- 
flow experiment requires a denaturation process and a carefully characterized protein 
folding system. The method we intended to use for the unfolding and refolding transition 
is chemical denaturation by Gnd-HCl. GB 1 works well in this aspect as the folding 
transition is reversible by Gnd-HCl denaturation as previously discussed (Refer to 
Chapter III). However, this method proved to have limitations in its application and 
coupling with NMR spectroscopy. To work with this method the required amount of 
protein needed in order to be observable by MAS-NMR may be outside the range of 
possibility for protein folding. We needed to see how much protein we could conceivably 
pack into a 4 mm solid-state rotor using the chemical denaturation method. Because 
chemical denaturation requires a significant dilution in order to initiate refolding, we also 
wanted to know if it was possible to fold WT-GB1 at exceedingly high concentrations 
due to its robust structural stability. We were able to dissolve WT-GB1 at concentrations 
of up to 120 mg/ml in 4 M Gnd-HCl without any apparent precipitation. We investigated 
the folding kinetics of these high concentrations of WT-GB1 and Phe52Tyr-GB 1 at initial 
concentrations of -100 mg/ml with a 7-fold dilution down to a final concentration of -15 
mg/ml (Figure 6 6 ). The folding kinetics showed that in both WT- and Phe52Tyr-GBl 
there was still a biphasic folding transition however there was a shift in the folding 
distribution. At low concentrations the distribution was 95 % and 5 % for the first and
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second phase, respectively, however at higher concentrations a larger portion of the 
folding event occured over the second phase with a distribution of -70 and 30 % for both 
WT- and Phe52Tyr-GBl. For WT-GB1 at high concentrations the folding rate decreases 
to 100.34 s' 1 (9.97 ms relaxation time) and 17.25 s"1 (57.99 ms relaxation time) for the 
first and second phases, respectively. For Phe52Tyr-GBl the folding rate decreases to 
119.82 s' 1 (8.35 ms relaxation time) and 26.21 s' 1 (38.16 ms relaxation time) for the first 
and second phases. In comparision initial folding of the protein at high concentrations in 
both cases appeared slower followed by a more rapid second phase. This high 
concentration dependent slowing effect could be due to interactions of the unfolded 
polypeptides with one another that reduce the proteins ability to rapidly form native 
interactions or an increase in non-specific/non-native interactions within the protein. 
Interestingly, refolding the proteins at a higher dilution factor (-13-fold dilution) resulted 
in a slight change in the refolding rates particularly for Phe52Tyr-GBl (Table 11). In 
summary, the biphasic distribution between high and low concentrations with respect to 
amplitudes and to some degree the rates of the second phase differ (Refer to Chapter III). 
This finding suggests there are no serious complications to using high protein 












Figure 65. Schematic outline of a traditional versus folding-freezing stopped-flow 
instrument. In a traditional stopped-flow instrument the denatured protein in one syringe 
is rapidly mixed with refolding buffer from another syringe in the follow cell and 
monitored. The detector could be, for example, fluorescence, absorption or CD. In the 
modified folding-freezing apparatus the solutions are mixed similarly, however detection 
is removed and the protein reaction is sprayed into supercooled isopentane. The resulting 
crystals can be packed into a solid-state rotor for MAS-NMR. This Figure was redrawn 
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Figure 66. Stopped-flow fluorescence kinetics of WT- and Phe52Tyr-GBl at high 
protein concentrations. Refolding kinetics of (A) WT- and (B) Phe52Tyr-GBl with the 
resulting residuals. Curves were plotted and fit with a double exponential equation in
SigmaPlot (Ver. 12.5). The red line indicates the double exponential regression line.
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WT 7X 70% 30% 100.34 ±0.316 s '
17.25 
±0.079 s 1 9.97 ms 57.99 ms
WT 13X 6 6 % 34% 106.88 ±0.514 s' 1
17.12 
±0.113 s 1 9.36 ms 58.40 ms
F52Y 7X 72% 28% 119.82 ±0.230 s '
26.21 
±0.071 s' 1 8.35 ms 38.16 ms
F52Y 13X 73 % 27% 125.62 ±0.340 s' 1
19.27 
±0.062 s 1 7.96 ms 51.88 ms
^Initial protein concentrations were -100-110 mg/ml in all experiments
From the folding kinetics experiments we determined that we would be able to get 
-1 mg of protein into the solid-state 4 mm rotor for our experiments. However this 
amount was insufficient in acquiring ssNMR signal because the WT-GB1 only has a l3C 
mass percent of 2.5, which meant we needed much more protein. At this point we began 
to characterize the 13C-Phe/l3C-Trp labeled WT-GB1 in order to explore the possibility of 
a pH unfolding refolding jump and determine concentrations required to get significant 
signal in ssNMR. In addition we considered a high temperature rapid freezing method in 
which a heated sample is rapidly frozen in -80 °C isopentane which would allow us to 
capture a folding intermediate with the long-range interactions of interest [455].
We initially characterized the structure of the I3C-Phe/13C-Trp labeled WT-GB1 
in a ID 13C experiment using solution-state NMR (Figure 67). From the spectra we were 
able to assign peaks to specific labeled carbons using ACD/SpecManager (Ver 9.15). The 
peaks are well resolved and all the carbons that we anticipated to be labeled are visible. It
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seems that the carbons on the two Phe’s are also distinguishable and are labeled as 7a and
7b. Analysis of lyophilized 13C-Phe/13C-Trp labeled WT-GB1 protein in solid-state NMR
1 1
using cross polarization MAS (CP-MAS) for C analysis showed a similar spectrum 
(Figure 6 8 ). However, in the CP-MAS the signal is significantly broadened due to 
anisotropic interactions. In comparison to the uniformly labeled WT-GB1 spectrum 
(Figure 69) which shows a significant number of peaks corresponding to the 274 carbons 
in WT-GB1 the signal is much more resolved. The peaks in the uniformly labeled sample 
are overlapping and merged into large wide peaks corresponding to peak overlap of 
carbons in very similar environments. In the spectrum of the 13C-Phe/13C-Trp labeled 
WT-GB1 we see better resolved peaks however, because of the differences in anisotropic 
averaging the sensitivity and resolution is decreased with low separation of peaks (Figure 
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Figure 67. ID 13C solution-state NMR spectrum of 13C-Phe/13C-Trp labeled WT- 
GB1. The 13C NMR spectrum was acquired on a 400 MHz Bruker Avance III with 1024
scans. The 10 mg/ml sample was analyzed in pH 7.0. The peak numbers correlate to
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Figure 68. ID 13C ssNMR CP-MAS spectrum of 13C-Phe/13C-Trp labeled WT-GB1.
21 mg of lyophilized protein was packed into a 4 mm zirconia rotor and analyzed on a 
400 MHz Bruker Avance II with 512 scans at a spin rate of 12 kHz were collected. The 
peak numbers correlate to carbon assignments for Trp43, Phe30 and Phe52. Position 
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Figure 69. ID 13C ssNMR spectrum of uniformly labeled WT-GB1. 35 mg of
lyophilized protein was packed into a 4 mm zirconia rotor and analyzed on a Bruker 
Avance 750 MHz NMR spectrometer. The sample was spun at 12 kHz during the 
experiment.
We initially characterized the structure of the uniformly labeled WT-GB1 in a 2D 
13C-,3C DARR experiment (Figure 70). In the DARR experiment ‘H magnetization is 
transferred to 13C-carbons to enhance the NMR signal followed by subsequent transfers 
of magnetization to other 13C-carbons through space which appear as CRPK’s in the 2D 
NMR spectra. The distance in magnetization transfer is dependent on the mixing time. In 
order for there to be a l3C-l3C transfer the two carbons must be close in space. In the 
uniformly labeled WT-GB1 experiment we see many CRPK’s as all carbons are labeled.
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This particular experiment sets the foundation for the specific interactions we intend to 
monitor as the protein is denatured. The DARR NMR spectrum showed many internal 
CRPK’s between the labeled carbons of the Trp43 which was to be expected. More 
importantly, we see two CRPK’s between the Phe and Trp at positions 144 and 47 ppm 
and 129 and 47 ppm. Both of these CRPK’s are interactions of Trp43 benzene ring with 
the same Phe. However, based on the positions and interactions with the Trp43 benzene 
ring it’s difficult to determine which Phe is interacting and which is not interacting. A 
possible explanation for one Phe not interacting with the Trp could be due to the fact that 
the sample is a dry powder and the intermolecular position of the second Phe may have
o
transitioned to a position greater than 5 A from the Trp. Running the sample in ssNMR as 
a frozen solution would provide greater understanding of differences between solid- and 
solution-state structural states. However, based on these results there was evidence that 
there was structural modification on the core structure as a result of lyophilization. In any 
case this result indicated that our 13C-Phe/13C-Trp labeled sample would provide ideal 
CRPK signal for at least one Phe and could be used to monitor this long-range interaction 
during the folding process. One potential problem with respect to protein concentration 
was that it required -42 mg of solid protein analyzed for about 4 hours in order to acquire 
the clear present CRPK signal. Under solution conditions 42 mg translates into -525 
mg/ml which is extremely impractical. However, to overcome this we can reduce the 
amount of protein and increase the run time of the experiment by an order of magnitude 
(from -4  hours to -2  days). Also we could increase the rotor diameter from 4 mm to 6  
mm, which would increase the volume from 80 pi to 180 pi and change the concentration 
to -230 mg/ml. These quantities for folding maybe overestimated as the minimal amount
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of protein frozen in solution remains to be determined and will be further discussed. 
Ultimately however, it may be viable to refold with far less protein and this will also be 
discussed in future work. It is more amenable to use a combination of both to reduce the 
concentration to about 100 mg/ml. In addition, to decrease signal line broadening we can 
increase the magnetic field strength from 400 MHz to 750 MHz to increase the sensitivity 
and enhance the resulting spectrum [467]. Although it is theoretically possible it appears 
that chemical denaturation kinetics in concert with ssNMR detection seems to be on the 
edge of the detection limits of a 400 MHz ssNMR.
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Figure 70 .2D UC-°C-DARR experiment on 13C-Phe/13C-Trp labeled WT-GB1. A
lyophilized sample of 41.7 mg ,3C-Phe/l3C-Trp labeled WT-GB1 was packed into a 4 
mm rotor and analyzed on a Bruker Avance II400 MHz solid-state NMR spectrometer. 
















We looked at the behavior of the l3C-Phe/13C-Trp labeled GB1 in a pH dependent 
manner using solution state NMR for two reasons. In the first instance we wanted to 
know about the proteins behavior at physiological versus extreme pH to better understand 
its robust nature. Second, we wanted to determine if WT-GB1 formed a typical partially 
unfolded molten globule state at low pH. This would potentially enable us to dissect and 
identify any core contacts as well as use a pH jump to monitor refolding of long-range 
interactions with potentially a smaller dilution than starting with a chemically denatured 
state. We conducted ID 'H (Figure 71) and 2D HSQC NMR (Figure 72) experiments at 
pH 2.0, 7.0 and 12.1. Peaks were assigned using ACD/SpecManager (Ver 9.15) to predict 
the 2D HSQC spectra of Phe and Trp with a ’h , i3C COSY correlation. In many cases the 
protein molten globule state can be induced in vitro by placing the protein in highly acid 
conditions [58, 59]. So in addition we looked at the changes that would indicate a 
transient molten-globule form. The 2D HSQC experiments showed that the environment 
around the labeled carbons did not change very much (Figure 73). This means that even 
under high and low pH environments the core of WT-GB1 is maintained as it relates to 
the environment around Phe 30, Phe52 and Trp43. It appears that at low pH GB1 is not 
induced into a molten-globule state because there are no shifts in the overall core 
environment. It’s curious though we see an additional CRPK that I was unable to 
identify. Interestingly, prediction of a free Phe HSQC spectrum resulted in the 2 P-carbon 
hydrogens to be split by the neighboring proton identical to those peaks at the carbon 
shift of 37 ppm. Whereas if a partial backbone is included in the prediction this splitting 
pattern is no longer observed and a single peak at a carbon shift of 41 ppm is predicted. 
This could indicate that at pH 7 the two Phe residues are in orientations that are resulting
in two NMR chemical shift patterns (Figure 73). In one condition the environment is 
much more symmetrical resulting in a proton splitting pattern and in the other the 
environment the two protons are in asymmetrical conditions resulting in a single peak.
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Figure 71. ID 1H NMR spectrum of °C -Phe/u C-Trp labeled WT-GB1 versus pH.
Specifically labeled WT-GB1 was analyzed in solvent at pH 2.0 (red), pH 7.0 (blue) and 
pH 12.1 (green). Samples were examined at 128 scans on a Bruker Avance I I 400 MHz 
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Figure 72. 2D ‘H-13C HSQC spectrum of 13C-Phe/13C-Trp labeled WT-GB1 with 
proposed chemical shift assignments. The HSQC spectrum was acquired on a 400 MHz 
Bruker Avance III with 64 scans. The 10 mg/ml sample was analyzed in pH 7.0 
H2O/D2O. The peak numbers correlate to predicted lH-l3C assignments for Trp43, Phe30 
and Phe52. The sample was examined with H2O presaturation. 'H signal at 4.73 ppm is 
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Figure 73. Analysis of pH dependence on the core of GB1 using ‘H-13C HSQC NMR.
Spectrum of 13C-Phe/13C-Trp labeled WT-GB1 at pH 2.0 (red), pH 7.0 (blue) and pH
12.1 (green). The HSQC spectrum was acquired on a 400 MHz Bruker Avance III with 
64 scans. The 10 mg/ml sample was analyzed in 90 % H2O/IO % D2O solvent. The peak 
numbers correlate to ‘H-^C assignments for Trp43, Phe30 and Phe52 found in Figure 14. 
The sample was examined with H2O presaturation. 'H signal at 4.73 ppm is residual H2 O 
signal.
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To get a better understanding of what kind of structural changes were occurring at 
pH 2.0, we further characterized WT-GB1 using CD (Figure 74). A typical molten 
globule state will have native-like secondary structure while having very little to no 
tertiary structure. Interestingly, at pH 2.0 WT-GB1 seems to have a significant decrease 
in secondary structure content while maintaining almost native tertiary structure. 
Interestingly, it may be possible that the protein has a gross native-like topology with 
minimal secondary structure, and hence be an ideal equilibrium transition-state like 
structure. The near-UV CD data matches well with the ID 'H and 2D HSQC solutions 
NMR experimental data observed at pH 2.0, in that there are only minor changes to the 
tertiary structure corresponding to minor changes to the core of GB1.
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Figure 74. Molten globule analysis of WT-GB1 at pH 2.0 by CD. (A) Far-UV and (B) 
Near-UV CD of WT-GB1 at pH 7.0 (black) and pH 2.0 (green). The data was plotted and 
visualized in SigmaPlot (Ver. 12.5).
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MATERIALS AND METHODS 
Auxotrophic strain
An aromatic auxotrophic E. coli strain (K-12 derivative) with a knockout in the 
chorismate pathway to inhibit tryptophan, tyrosine and phenylalanine metabolism was 
obtained from the Coli Genetic Stock Center at Yale University and carefully cultured in 
LB media under sterile conditions. The chorismate synthase knockout was verified by 
culturing cells in minimal media supplemented with all the amino acids except for the 
selected amino acid targets: tryptophan, tyrosine and phenylalanine. Verified stock 
solutions of Aux cells were stored in 15 % glycerol at -80 °C until use.
To support the expression of genes regulated by the T7 promoter the Aux must be 
lysogenized to introduce the A.DE3 into the chromosome of the E. coli. Using a 
lysogenization kit the bacterium were grown in Luria broth supplemented with 0.2% 
maltose, 10 mM MgS04, and carbenicillin (200 pg/ml) at 37 °C to an OD6ooof 0.5. Using 
stock lysates provided XDE3 phage, helper phage, and selection phage were mixed with 
1-10 pi of the cells. Cells were incubated 37 °C for 20 min to allow phage to adsorb to 
host. The mixture was then plated onto an LB plate, covered inverted and incubate at 
37°C overnight. Surviving colonies should be Aux(DE3). Cells were verified using a 
tester phage in the presence of IPTG for the presence of the >JDE3 insertion. Verified 
stock solutions of the selected colony Aux(DE3) were stored in 15 % glycerol at -80 °C 
until use.
Transformation, expression and purification of 13C labeled WT-GB1
Specifically labeled amino acids where obtained from Cambridge isotopes 
(Tewksbury, MA). WT-GB1 plasmid was transformed into the Aux(DE3) E. coli in the
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Greene Lab (Old Dominion University), plated and cultured in minimal media containing 
the appropriate antibiotic and amino acid nutrients (IBC #12-006). Expression of 
uniformly l3C-labeled WT-GB1 follows the previously established protocol discussed in 
chapter III except that the LB media is replaced with M9 minimal media and substituted 
with l3C-glucose as the sole carbon source (1.5g/L). ,3C-Phe/l3C-Trp labeled WT-GB1 
was expressed in M9 minimal media supplemented with each of the 20 amino acids.
Table 12 outlines the quantities of each reagent in the minimal media for both
I -j
expressions. C(3-Phe was used to specifically label a single carbon at positions 30 and
1152 that interact with the uniformly labeled C-Trp at position 43. Purification of both the 
uniform and l3C-Phe/13C-Trp labeled GB1 followed the previously discussed protocol. 
Cells were lysed and purified using anion exchange and size exclusion chromatography 
to yield purified 13C labeled Phe52Tyr-GBl. Minimal media from the l3C-Phe/13C-Trp 
labeled GB1 expression was reused in a subsequent expression to exhaust the l3C-amino 
acids and maximize protein yield. The expression resulted in a significant amount of 
protein, 550 mg of the labeled !3C-Phe/13C-Trp protein and -250 mg of uniformly labeled 
protein (IBC #12-006).
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Table 12. Reagent list for 13C-Phe/13C-Trp labeled GB1 expression in Auxo(DE3)
Na2HP04 33.7
KH2P04 2 2 . 0
10X M9 Salts
NaCl 8 . 6
NH4CI 9.4
CaCl2 0.3
MgS04 1 . 0
ZnS04 • 7HzO 0.003
CuS04 • 5H20 0.006




Arg 2 . 0
Gly 7.5
His 0 . 8
lie 1 . 8
Leu 1 . 8





Thr 2 . 0




Gin* 2 . 8
Glu* 4.5
Tyr* 1 . 0
BC-Phe* 0 . 8





4-amino benzoic acid* 0 . 0 0 1
4-hydroxybenzoic acid* 0 . 0 0 1
2,3-dihdroxybenzoic acid* 0 . 0 0 1
♦Reagents sterilized via 0.2 pm syringe filter. All other reagents were sterilized by autoclave.
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Stopped-Flow Folding Kinetics
Folding kinetics studies were conducted using a SFM-400 stopped-flow system 
(Bio-Logic, France). WT-GB1 and Phe52Tyr variant protein were denatured in 0.1 M 
Tris (pH 7.0) and 4 M Gnd-HCl for a minimum of 3 hours or overnight. Refolding was 
initiated by a 7- tol4-fold dilution into refolding buffer containing 0.1 M Tris and 40 % 
glycerol (pH 7.0) refolding at 10 °C with a flow rate of 6 ml/s. Kinetics experiments were 
run using a 1.5 mm FC-15 cuvette and a mixing dead time of 8.6 ms. Fluorescence 
changes were monitored by excitation at 295 nm and emissions detection >320 nm using 
a bandpass filter (Semrock, Rochester, NY). The slit widths were both 1 mm for 
excitation and emission for all experiments. Spectra were obtained from the average of 5- 
10 repeat experiments. Curves were analyzed and fitted to a double exponential 
regression using SigmaPlot (Ver. 12.5, Systat Software).
Circular Dichroism
WT-GB1 was analyzed by far- and near-UV CD in 0.1 M tris base (pH 7.0) and 
H20  (pH 2.0) at 20 °C. A stock solution of each protein was diluted in buffer to a final 
working concentration of 0.2 mg/ml for far-UV and 0.5 mg/ml for near-UV 
spectropolarimetry. Samples were measured with a Jasco J-815 spectropolarimeter using 
continuous scan mode set to a rate of 200 nm/min. Each experiment is run in triplicate 
and is the average of 10-15 scans.
Nuclear Magnetic Resonance
Solution-state NMR samples were prepared in 90:10 H2O/D2O. Protein was 
weighed and dissolved in buffer to a final concentration of 10 mg/ml. 600 pi of sample 
was pipet into high quality NMR tubes for analysis. Samples were analyzed on an
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Avance I I400 MHz NMR spectrometer (Bruker). For solid state NMR samples were 
weighed and carefully packed into a 4 mm MAS zirconia rotor. Experiments were 
conducted on 21 and 42 mg of protein in an Avance III 400 MHz ssNMR spectrometer 
(Bruker) at room temperature. Data was obtained and analyzed using Topspin (Ver. 2.0).
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CHAPTER V 
BIOPHYSICAL ANALYSIS OF THE TRANSITION OF AN ALL a -  
HELICAL GREEK-KEY PROTEIN INTO AMYLOID-LIKE 
FIBRILS COMPOSED OF p-SHEET STRUCTURE
OVERVIEW
In an environment where specific conditions are met, many proteins and peptides 
can misfold and aggregate into variable length filaments composed of P-sheet structure 
which can further assemble into intertwined macrostructures [88]. Formation of highly 
ordered p-sheet aggregates either intracellularly or extracellularly in target tissues, has 
been associated with many devastating medical disorders such as Alzheimer's and 
Parkinson's diseases [88, 468]. It is known that the ability to form fibrils is not reliant on 
the native secondary or tertiary structure composition of the protein and that the sequence 
of amino acids appears to be fundamental in the fibrillation process and amyloid fibril 
morphology [181]. Thus there is much research into understanding the role of the amino 
acid sequence by mutational analysis [179, 208]. The specific mechanisms associated 
with the formation of P-amyloid fibrils are not yet fully understood. Currently there are 
two hypotheses describing the mechanism of fibril formation [469]. The first hypothesis 
includes a nucleation step followed by the elongation step once the nucleus has reached 
critical mass [469]. The second hypothesis includes the formation of peptide protofibrils 
of variable length which associate to form fully formed fibrils [469]. The elongation step
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is independent of initial fibril formation and has been shown to grow by the binding of 
monomeric protein to fibril extremities [469]. The process of forming amyloid fibrils in 
vitro typically involves incubating proteins or peptides under one or more extreme 
conditions such as elevated temperatures, acidic or basic pH, high ionic strength and 
mechanical agitation [232,470,471]. Thus, destabilization of the native state appears to 
be a pivotal step in the conversion process in vitro. Chemical inducers such as metal 
nanoparticles (Ti02) and destabilizers (SDS, 2,2,2-triflouroethanol and heparan sulfate) 
have also been found to promote fibril formation [237,472-474],
A key conceptual finding was the realization that proteins unrelated to disease 
states can be induced to form fibrils [181]. Several proteins not associated with diseases 
such as the SH3 domain of the p85a subunit of bovine phosphatidylinositol 3-kinase, 
acylphosphatase, P-lactoglobulin and myoglobin were induced in vitro to form amyloid 
fibrils [181, 182, 475, 476]. It has thus been hypothesized by Christopher Dobson and 
co-workers that all proteins have the intrinsic ability to form amyloid fibrils [181]. We 
are interested in testing this hypothesis with proteins that share the Greek-key topology; 
one of the most abundant forms within the protein universe [360]. Proteins with this 
topology can uniquely be composed of different secondary structures and comprise three 
distinct superfamilies: the all P-sheet immunoglobulins, the mixed a/p-plaits and the all 
a-helical death domains [360]. Representative proteins from each superfamily have been 
shown to form fibrils. p2M from the immunoglobulin superfamily forms naturally 
occurring fibrils in patients which undergo prolonged renal dialysis [222]. 
Acylphosphatase and HypF-N are in the a/p-plait superfamily and unlike P2M, only form
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fibrils in an in vitro environment [181,477]. The Apaf-1 CARD protein from the death 
domain superfamily has also been recently induced to form fibrils in vitro [232].
The death domain of the human Fadd-DD from the death domain superfamily 
contains 104 amino acids arranged into six a-helices which adopt the Greek-key topology 
(Figure 75A) [405,478]. It functions in the apoptotic pathway and induces programmed 
cell death as part of a death-inducing signalling complex [405]. In this chapter, we 
present the results of comprehensive studies focused on determining the specific 
conditions required to induce amyloid fibril formation in Fadd-DD and monitored this 
transition with different spectroscopic techniques. This is a fascinating transition which is 
most evident in the transformation of a globular, monomeric, helical protein into ordered 
P-sheet polymers. With over twenty disease states associated with amyloid fibrils there is 
a clear necessity to fully understand the physiological conditions which lead to the 
generation of amyloid fibrils and protofibrils so that we may better understand the 
pathogenesis of amyloidosis [88]. Increased understanding into this mechanism can also 
inform the design of targeted inhibitors and ultimately lead to viable treatments which do 
not exist at present. Further investigation of proteins not associated with disease will 
provide insight into the key determinants of amyloid formation. Understanding how 
proteins in general evolved to avoid amyloid fibril formation is also pivotal towards 
resolving the fundamental protein folding problem.
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Figure 75. Fadd-DD structure and thermal denaturation assay. (A) Three- 
dimensional ribbon drawing of the Fadd-DD protein drawn in RasMol (PDB ID: 1E3Y). 
The helices 1-6 are colored on a scale from blue to red gray. This domain comprises 
residues 89-192. (B) Thermal unfolding of 0.05 mg/ml Fadd-DD protein in Bis-Tris 




In order to elucidate the effect of low pH on the stability of Fadd-DD, thermal 
unfolding was performed under native conditions (pH 6.2) and in acidic conditions (pH
2.1) (Figure 75B). Analysis of the data revealed that under native conditions Fadd-DD is 
fully folded and thermo-stable up to a temperature of -60 °C. The unfolding transition 
occurs approximately between 60-80 °C with a Tm at 69 °C. At low pH the Fadd-DD 
protein only remains stable and folded up to -50 °C and the unfolding transition occurs 
between approximately 50-68 °C with a Tm of 59 °C. From this data we can see a clear 
deviation from the native state stability caused by altered solution conditions. This study 
provides information on the starting conditions to be implemented to induce fibril 
formation. We initially selected 50 °C at pH 2.1 as the optimal incubation temperature for 
fibril formation because it lies near the beginning of the transition between folded and 
unfolded states.
The successful conversion of Fadd-DD to amyloid-like fibrils occurred under the 
following conditions: 10 mg/ml Fadd-DD in 20 mM glycine-HCl (pH 2.1) and 150 mM 
NaCl was incubated with shaking at 50 °C and 180 rpm respectively for 278 hours. 
Ninety-five trials were conducted with a range of conditions which included various 
buffers such as phosphate-buffered saline, citrate, 2-[N-morpholino]ethanesulfonic acid, 
and glycine-NaOH, variable protein concentrations and a pH range of 2 to 11, high 
temperature (60-85 °C), physiological temperature (37 °C), and tests with 
triflouroethanol an agent known to induce fibril formation with the amyioid-[3 peptide and 
transforming growth factor (3 induced protein [479]. Several fibril seeding trials were 
conducted using lysozyme fibrils as a potential inducer because it has been shown that
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addition of fibrillar structures can potentially reduce or eliminate the lag phase thereby 
facilitating amyloid fibril formation [88]. However, these trials were unsuccessful. 
Increasing and decreasing concentrations of dithiothreitol (DTT) and (3-mercaptoethanol 
(pME) were used in high pH trials to prevent the three free cysteine residues from 
forming intermolecular disulfide bonds and precipitating the protein out of the solution. 
Interestingly, the conversion of an all a-helical protein into only 3-amyloid structures 
occurred in one specific condition out of ninety-five trials. This clearly indicates that the 
conversion process is not trivial and can only be achieved under very specific conditions.
We monitored the conformational changes from native a-helical structure to the 
3-amyloid structure using the chromophore ThT. This reagent becomes strongly 
fluorescent upon specific binding to amyloid fibrils and is considered a standard probe of 
the lag and growth phases associated with amyloid fibril formation [297]. In Figure 76A 
we show ThT fluorescence of Fadd-DD samples taken at several time points during the 
incubation of the protein. An overall increase in ThT intensity indicates the formation of 
Fadd-DD fibrils. The lag phase for Fadd-DD fibril formation is short and shows signs of 
a growth phase after only 24 hours of incubation. Growth rapidly continues until 
approximately 183-254 hours where growth rate of the fibrils is slowed, most likely by 
reduced availability of the monomeric form of Fadd-DD. A sample was taken at 518 
hours and the presence of amyloid fibrils was again verified using CR UV spectroscopy 
which resulted in an increase in absorbance at 540 nm suggesting amyloid fibril 
formation (data not shown) [480]. Congo red is a histological dye that has been shown to 
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Figure 76. Fibril formation studies using ThT fluorescence and far-UV CD. (A) ThT
fluorescence time course of 10 mg/ml Fadd-DD over 823 hours of incubation at pH 2.1, 
50 °C and 180 rpm shaking. The average of a triplicate incubation is shown. The data 
points were fit with a Sigmoidal Logistic, 4 Parameter regression curve in SigmaPlot 
(ver. 10) (B) Far-UV CD of 0.2 mg/ml of native Fadd-DD in glycine-HCl (pH 2.1) and 
150 mM NaCl at 20 °C (solid-line), 35 °C (long-dash line), 50 °C (short-dash line), and 
80 °C (dot-dot-dash line).
Using the biophysical technique CD we can investigate structural components of 
the protein folding process [139]. We monitored the effect of temperature on the 
secondary structure of native Fadd-DD in 20 mM glycine-HC1, 150 mM NaCl (pH 2.1) 
using temperature controlled far-UV CD. In Figure 76B we show that the secondary 
structure of the Fadd-DD protein at 50 °C still maintains a degree of a-helical structure 
however destabilized, indicated by the molar ellipticity difference. This suggests that at 
50 °C (pH 2.1) Fadd-DD has a native-like conformation but is destabilized in accordance 
with the thermal unfolding data. Using far-UV CD we were able to monitor the 
secondary structure composition of the natively folded Fadd-DD during the transition 
from a-helical to p-sheet structure (Figure 77). We monitored the far-UV CD at ~24 h 
intervals initially and the data indicates a conformational transition of the native a-helical 
structure to a stable p-sheet composition. Figure 77 A  shows the CD spectrum of the all a- 
helical fold of native Fadd-DD. The native fold of Fadd-DD is associated with two 
minimums around 207 nm and 221 nm shown in the spectrum [405]. Figure 77B-F shows 
the secondary transitioning from a-helical to P-sheet by the loss of the first minimum at 
208 nm as well as an overall increase in molar ellipticity. The transition from native 
structure to p-sheet composition seems to transition through a mixed species of a  and p 
secondary structure conformations as the p-sheet composition increases the a-helical 
content decreases. Figure 77E shows the secondary structure composition of Fadd-DD 
incubated for 80 hours in which we clearly observed a predominant conformational 
change to P-sheet structure associated with the formation of amyloid fibrils. The 
conversion to P-sheet secondary structure is indicated by a single minimum at around 219 
nm. Figure 77F-I maintain the P-sheet structure out to 823 hours as the kinetic process
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reaches equilibrium due to the lack of monomeric protein. These results demonstrate that 
the specific change from a-helical to all P-sheet structure, indicative of amyloid 
aggregates, has occurred. Interestingly, the near-UV CD spectra for Fadd-DD at pH 6.2 
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Figure 77. Amyloid fibril formation time course monitored by far-UV CD.
Secondary structure of Fadd-DD measured after (A) 0, (B) 18, (C) 36, (D) 58, (E) 80, (F) 
183, (G) 254, (H) 518 and (I) 823 hours of incubation in glycine-HCl (pH 2.1) and 150 
mM NaCl buffer at 50 °C and 180 rpm.
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Using AFM the formation of Fadd-DD amyloid fibrils was visualized in Figure 
78A-I. The formation of Fadd-DD fibrils occurred through the formation of Fadd-DD 
protofibrils with average sizes ranging from 3-6 nm. After 18 hours the protofibrils were 
present however at low concentration making it difficult to isolate multiple protofibrils in 
a single image (Figure 78B). After 36 hours there was an increase in protofibril 
concentration and elongation appears to have begun, indicated by the solid white arrow in 
Figure 78C. After 58 hours there is the presence of elongated fibrils with variable lengths 
as well as protofibrils (Figure 78D). During 80 and up to 823 hours there is an 
exponential increase of elongated fibrils (Figure 78E-I). Sectional analysis of Fadd-DD 
fibrils after 80 hours showed two distinct sizes of amyloid fibrils, one ranging from 4-6 
nm and the other ranging from 7-9 nm. This indicates the possible presence of a dimeric 
amyloid fibril containing two amyloid fibril strands wrapped into a single amyloid 
polymer. The presence of amyloid fibrils was further verified by TEM. After ~11 days, 
TEM positively established that morphologically short Fadd-DD fibrils were formed 
(Figure 79). Fadd-DD fibrils tended to have a shorter length in comparison to lysozyme, 
P-lactoglobulin, myoglobin, and p2M [182, 222, 237,476]. Visualization by AFM and 
TEM under optimized conditions indicates that Fadd-DD fibrils deviate from the 
“generic” amyloid model, having short fibrils rather than long entangled aggregates.
Figure 78. AFM images of Fadd-DD amyloid fibril formation. Topographical images 
of the formation of amyloid fibrils was done at 0 (A, J), 18 (B, K), 36 (C, L), 58 (D, M), 
80 (E, N), 183 (F, O), 254 (G, P), 518 (H, Q) and 823 (I, R) hours. Dotted white arrows 
indicate protofibrillar species, solid white arrows indicate elongated amyloid species in 
the 4-6 nm width range and double-line arrow indicate elongated species with in the 7-9 
nm width range. Color scales indicate 0-50 nm heights.
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Figure 79. TEM images of Fadd-DD fibrils. (A) Low magnification of Fadd-DD fibril 
cluster. (B) High magnification of individual Fadd-DD fibril strands. The TEM was 
conducted with a JEOL JEM-2100F.
It is interesting to note that the morphological deviation observed is related to 
deviations in environmental factors. We observed that under decreased agitation (75 rpm) 
both fibrillation and unordered aggregation occur similarly (Figure 80A), whereas under 
higher agitation (180 rpm) unordered aggregation dramatically decreases and fibrillation 
becomes more favourable (Figure 80B). Visually the fibrils occurring under decreased 
agitation appear longer and more similar to fully mature fibrils. Decreasing agitation 
appears to decrease the formation of protofibrils, increasing the length of the formed 
fibrils during the elongation. However, conversely under these decreased agitation 
conditions aggregation also occurs. It appears that there is a competitive reaction 
occurring between fibril nucleation and unordered aggregation. This suggests that 
kinetically the pathways of amyloid fibril formation and unordered aggregation under our 
conditions are close together. Additionally, when decreasing the agitation (rpm) during
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fibrillation, nucleation becomes less favourable and unordered aggregation becomes more 
favourable.
There are several all a-helical proteins reported to form amyloid-like fibrils in 
vitro. These for example include myoglobin, apomyoglobin, the CARD protein and 
Ure2p prion. Apomyoglobin and myoglobin were induced to form amyloid fibrils 
similarly in 50 mM sodium borate (pH 9.0), low protein concentrations (1 mg/ml) and 
were incubated at 65 °C over 24 hours [182,482]. The Greek-key CARD protein was 
shown to form fibrils in 50 mM glycine-HCl buffer (pH 2.0) incubated at 60 °C in a 
heating block [232]. Similarly, Fadd-DD forms fibrils under low pH conditions however 
deviations in temperature to 50 °C and the addition of NaCl for ionic strength and 
translational motion were required to overcome the stability of Fadd-DD and induce the 
fibrillar conformation (Figure 81).
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Figure 80. Effects of agitation on Fadd-DD fibril growth. TEM imaging of Fadd-DD 
fibrils grown in glycine-HCl (pH 2.1) and 150 mM NaCl buffer at 50 °C with agitation of 
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Figure 81. Representative conditions delineating pathways towards and away from  
amyloid-like fibril formation. Optimized condition for Fadd-DD amyloid formation 
pathway shown by the green arrows. Dotted red arrows indicate alterations in the 
conditions pathway and blue arrows indicate resulting effect after incubation. 
Physiological are conditions shown by the dashed black pathway.
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Conversely the all a-helical prion protein, Ure2p, is able to form amyloid fibrils in 
50 mM tris (pH 8.4), 200 mM NaCl at 8 °C with no agitation due to a fast assembly 
property induced by the 18-21 region [483], Interestingly, Fadd-DD shows no sequence 
propensity to form amyloid fibrils when analyzed with the Waltz amyloid propensity 
calculator at pH 7.0 or 2.6 using high specificity (less false positives) parameters [211]. 
Thus, the environment is the key factor.
The ability to form fibrils under the specific conditions identified in this research 
supports the “generic amyloid” hypothesis which proposes that formation of amyloid 
fibril structure is an inherent characteristic of the polypeptide chain, irrespective of the 
native secondary or tertiary structure composition [88,181, 234]. While some proteins 
tend to aggregate more readily than others, there are conditions that can be identified to 
destabilize the native structure and induce successful conformational exploration into 
alternative folding states leading to the low energy, (3-sheet rich amyloid form [88]. The 
formation of Fadd-DD fibrils shows a very short lag phase and formation of protofibrillar 
species. After formation of protofibrils, the formation of amyloid fibrils occurs 
exponentially during the growth phase. However, it appears that agitation is a critical 
factor in our model system for altering the kinetics of the nucleation step.
There appears to be no universal set of conditions favourable for amyloid fibril 
formation. As with protein folding and crystallization, optimal conditions are needed and 
vary depending on the protein. The results from studies with Fadd-DD presented in this 
paper clearly indicate that while proteins may have the intrinsic ability to form fibrils 
they can be very resistant. Previously published papers on this topic do not delineate the 
failed conditions, unless testing inhibitors or accelerators, which would actually be quite
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informative in this relatively new field of study. In our research, only one of ninety-five 
conditions generated predominantly amyloid fibrils (Figure 81). It is clear however that 
nature has evolved proteins to avoid fibril formation by optimizing the native state over a 
fibrillar structure under relevant physiological conditions. The basis for why Fadd-DD 




The chemicals used were all high quality reagents. Dithiothreitol was purchased 
from Fisher (Hanover Park, IL), Bis-Tris from Acros Organics (Geel, Belgium) and ThT 
was purchased from MP Biomedical (Irvine, CA). Protein was prepared using Ni-NTA 
His-Bind resin from Novagen (Madison, WI), Sephadex G-75 superfine resin from Sigma 
(St. Louis, MO) and concentrated with Vivaspin concentrators from Sartorius Stedim 
Biotech (Bohemia, NY). All buffers used in these studies were filtered through either a 
0.45 or 0.22 pm acrodisc sterile filter (Pall Life Sciences, Suwannee, GA). Microscopy 
materials (grids and uranyl acetate) were purchased from Electron Microscopy Sciences 
(Hatfield, PA). The clone was donated by Professor Paul Driscoll (University College 
London, U.K.). Fadd-DD was expressed and purified in accordance with previously 
published procedures (IBC biosafety protocol #14-016) [405].
Thermal Unfolding
Fadd-DD protein stock was buffer exchanged into native buffer (20 mM Bis-Tris, 
10 mM DTT, pH 6.2) and non-native buffer (20 mM glycine-HCl, 150 mM NaCl, pH
2.1) using a vivaspin 3,000 MWCO PES concentrator at 4 °C and centrifuged at 7,500 
rpm in a Rotanta 460R Hettich centrifuge until a concentration of 0.05 mg/ml was 
achieved for both conditions. Concentration was measured via analysis at 280 nm with a 
Varian Cary 50 Bio UV spectrophotometer and the calculated extinction coefficient. 
Using a Varian Cary Eclipse fluorescence spectrophotometer with a peltier thermo 
controller, fluorescence intensity was measured at 370 and 330 nm over a temperature 
range of 40-85 °C. The ratios of the two intensities (370 nm /330 nm) was plotted and 
analyzed using the SigmaPlot (version 10) scientific graphing program (San Jose, CA)
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[405]. The midpoint of the unfolding transition (where AG ~ 0) was calculated using the 
following equations [12]:
Xunfolded ~  (Aobs — Afolded) I (A Un folded — Afolded)
Keq (folded —► unfolded) — Xunfolded I (1 "Xunfolded )
AG =  -RTlnKeq
The Xunfolded is the calculated fraction unfolded based on the observed intensity (AobS). 
Afoided and Aunf0ided are the baseline values for fully folded and unfolded states. Keq is the 
equilibrium ratio between folded and unfolded, based on a normalized scale for the AobS. 
Amyloid Fibril Formation
Fadd-DD protein stock was buffer exchanged into 20 mM glycine-HCl 150 mM 
NaCl, pH 2.1 buffer using a vivaspin 20 ml concentrator and centrifuged at 7,500 rpm 
until a 10 mg/ml Fadd-DD concentration was reached. 1 ml aliquots of a 10 mg/ml stock 
of Fadd-DD in a 1.5 ml conical screw cap microcentrifuge tube with O-rings were 
incubated in a New Brunswick Scientific Innova 4000 shaker incubator at 50 °C and 180 
rpm for 278 hours. Fibril formation studies were done in triplicate.
Thioflavin T Fluorescence Assay
A stock solution of 2.5 mM ThT was made with 10 mM potassium phosphate 
buffer (pH 7.4) and 150 mM NaCl and dissolved overnight [480]. The ThT working 
solution was prepared by a fifty-fold dilution of the stock solution, filtered through a 0.22 
pm sterile filter and stored in the dark. Each time before use a ThT working solution was 
made fresh as described. Protein samples were collected and diluted forty-fold to a final 
concentration of 0.25 mg/ml. Samples were analyzed by adding 20 pi of the dilute 
protein sample to 200 pl/well of working solution in a black 96-well microtiter
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fluorescence plate. Microtiter plates were analyzed in a BioTek Synergy HT microtiter 
plate reader from BioTek Instruments Inc. (Winooski, VT). The parameters for the 
experiment are as follows: X,ex = 440 nm and Xem = 485 nm. The average of a triplicate 
study is graphed using SigmaPlot (version 10).
Circular Dichroism Analysis
Fadd-DD was diluted to a final concentration of 0.25 mg/ml for far-UV CD from 
a 10 mg/ml stock solution. Fadd-DD fibrils samples were diluted similarly for far-UV CD 
and the protein concentration was measured by UV-Vis absorption spectroscopy at 280 
nm with the calculated extinction coefficient. The WT-Fadd-DD and fibril samples were 
analyzed on a MOS 450 (Bio-logic, France). Far-UV CD was conducted with 1 mm path 
length quartz CD cuvette and slit widths of 1 mm. The temperature was maintained at 20 
°C. 15 to 30 spectra are averaged and graphed using a SigmaPlot (version 10).
Atomic Force Microscopy Imaging
Samples from far-UV CD were immediately rerun on an atomic force microscope. 
5 pi of the dilute fibrils were pipetted onto a cleaned glass sample holder and spread to an 
approximate 0.25 cm diameter and allowed to stand for 10 minute before excess solution 
was wicked from the surface. The sample was allowed to air dry and then was washed 4- 
5 times with 20 pi of distilled water and allowed to stand for 1 minute before similarly 
removing the excess solution and air drying. Samples were imaged on a Veeco 
DiNanoscope 3D AFM using AM mode microscopy.
Transmission Electron Microscopy
Fadd-DD fibril solutions where diluted 5-fold in distilled water. 10 pi of Fadd-DD 
fibrils were pipetted onto a 400 mesh formvar carbon grid and allowed to stand for 1
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minute. Excess sample was wicked off and the grid was allowed to air dry before 20 pi of 
a 2% uranyl acetate stock solution was applied to negatively stain the Fadd-DD fibrils for 
30 s. After 30 s excess urinal acetate was wicked off and samples were immediately 
rinsed with distilled water. After rinsing, the sample was heated to 75 °C overnight 
before storage in desiccators until imaging at the Applied Research Center (Newport 
News, VA) on a JEOL JEM-2100F field emission TEM at 200 kV.
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CHAPTER VI
CONCLUSIONS AND FUTURE WORK
This dissertation is an investigation into understanding and further enhancing our 
knowledge of protein folding and misfolding. Protein folding is fundamentally important 
if we hope to develop therapeutics and combat protein misfolding diseases. It is also an 
integral unanswered problem in science. Its resolution is key to advancing our knowledge 
of one of the most basic and foundational biological processes. Proteins were studied 
using a multitude of methods and techniques. In this work we investigated protein folding 
using computational and experimental methods aimed at developing our understanding of 
protein evolution and how the amino acid sequence dictates the final topology, 
respectively. In the protein folding section (Chapters II, III and IV) of this work we have 
focused on GB1 a small 56 amino acid IgG-binding protein. We investigated the 
evolutionary relationship between GB1 and the GA module, determined structurally 
conserved residues in GB1 as well as the effect of a point mutation on the structure and 
folding of GB1. We also used GB1 as our model system in developing a novel method to 
follow the formation of a conserved set of long-range interactions between Phe30, Phe52 
and Trp43 in real-time using NMR. In the protein misfolding section (Chapter V) we 
explored the concept of fibrillation being an alternative folding pathway and the idea that 
every protein has the ability to form the fibril morphology under a certain set of 
conditions. We used Fadd-DD as our model system and determine the specific conditions 
required in converting this all a-helical Greek-key protein into amyloid-like fibrils.
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Evolutionary Analysis of GB1 and GA
GB1 and GA are small domains with differing topology and functions. GB1 is a 
4|3+a fold and the IgG-binding domain of protein G, whereas GA is a 3a-helical bundle 
fold and the albumin-binding domain of protein L. He et al. showed that these two 
proteins could be mutated into a sequence of up to 98 % identity and still maintain their 
unique folds. With a point mutation these two proteins were able to switch folds and 
functions. Being able to switch folds is a unique process in evolution and could be related 
to the evolution of these two proteins. Initial evidence suggests that due to their low 
sequence identity GB 1 and GA did not evolve from each other directly, but rather from 
another group of proteins. Further research indicated that these two proteins were 
uniquely related and have evolved from a common ancestral family of proteins. In our 
work we used bioinformatics techniques to explore the evolution of the WT-GB1 and 
WT-GA. Using PSI-BLAST, an iterative process for determining distant relationships we 
discovered a relationship between WT-GB1 and WT-GA to a group of YSIRK signalling 
proteins, respectively. These two proteins, YSIRK signalling, were not interrelated but 
further analysis showed that they were both related through a group of mucus-binding 
proteins.
These proteins may have evolved from a duplication event, followed by 
subsequent mutations, sequence recombination or translocation giving rise to a new 
structure and function. The sequence alignment of our related proteins with the mucus- 
binding protein showed a unique overlap of the common sequence, LINxxKTV, similar 
to what could be considered a motif. Interestingly, instead of evolving this sequence 
independently of each other it seems that nature has simply reused it to evolve another
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protein sequence in a more efficient manner. The low variation associated with this short 
evolutionary sequence motif indicates that it is probably critical to both proteins and was 
conserved through evolution. Phylogenetic, sequence motif and MD data all seemed to 
suggest that GB1 and GA evolved from the mucus-binding protein through a YSIRK 
related evolutionary intermediate. Interestingly, a characterized mucus-binding protein 
was shown to have residual Ig-binding function which strongly supports our data.
In the future we intend to further explore the structures of the YSIRK and mucus- 
binding proteins using other modelling methods such as ab initio modelling in order to 
more confidently understand the structure and possible functions of these proteins. In 
addition it would be interesting to look at how the native 61 amino acid GA module fits 
into this evolutionary tree. We only intended to expand upon and use the two evolved 
sequences shown to swap structures with high sequence identity (GA and GB1), in this 
present dissertation research.
Conservation, Structural and Kinetic Analysis of GB1
To study the structure and folding of GB1 we needed to get a clearer 
understanding of which residues were more important for folding. To determine those 
amino acids we performed a detailed bioinformatics conservation analysis using 
structural comparison. We determined that there were 9 correctly conserved residues in 
the sequence of GB 1 with 8 being predominately hydrophobic and 1 hydrophilic in 
nature. Interestingly, there was at least one conserved residue found in each secondary 
structure component which may be important in maintaining the 4p+a fold and also may 
be critical to the thermal stability of GB1. To gain insight into the effect of a subtle
2 4 1
mutation such as Phe52Tyr, we used site-directed mutagenesis to change the sequence 
and characterized the resulting structure using biophysical techniques. It seems that this 
mutation conferred increased secondary structure content but reduced the structural 
stability of GB1. However, this change did not seem to affect the ability of GB1 to fold to 
its native conformation. This result was important as we were looking to remove the 
second Phe from the structure. For clarity, this mutation and characterization was 
conducted as preliminary experimentation focused on its applicability to future work 
done in Chapter IV. However, due to the reduced stability and structural effects observed 
we opted to proceed with the WT-GB1 form for our next research studies.
Development of a Method to Monitor Long-range Interactions in GB1 using NMR
The goal of this project was to develop preliminary methodology for a novel 
folding-freezing method in which a kinetic intermediate is captured by flash freezing 
during the folding process using supercooled isopentane. GB1 was chosen as our model 
system and we selected long-range interactions between Phe30, Phe 52 and Trp43 in the 
core of GB1. To assess the applicability of GB1 to our folding-freezing method coupled 
with MAS-NMR we needed to experimentally approach the problem from two avenues. 
First we assessed the effect on WT-GB1 folding at high concentrations which would be 
required for capturing a kinetic intermediate at concentrations visible to a NMR 
spectrometer. Thus, we characterized the folding of WT-GB1 and Phe52Tyr-GBl at high 
concentrations (-100 mg/ml), which revealed that there were no adverse effects observed 
during the folding at high concentrations. We then synthesized the selectively labelled 
protein using our Aux(DE3) system. Synthesizing a l3C-Phe/13C-Trp uniquely labelled
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WT-GB1 protein using Aux(DE3) bacterium was a significant achievement as the 
methodology needed to be refined and controlled to ensure proper growth and selective 
labelling. We were able to successfully synthesize over 500 mg of 13C-Phe/l3C-Trp 
labelled WT-GB1. This was a major accomplishment as we were able to maximize the 
use of our isotopically labelled amino acids. Additionally, we synthesized a significant 
amount of uniformly I3C-labeled WT-GB1 for control studies.
The second avenue involved experimentation with NMR. There we tested our 
l3C-13C DARR pulse program using uniformly l3C-labeled WT-GB1 and 13C-Phe/13C- 
Trp labelled WT-GB1. We performed a DARR experiment on lyophilized l3C-Phe/I3C- 
Trp labelled WT-GB1 and were able to see CRPK’s of interest. Interestingly, we were 
only able to see two of the four CRPK’s we were anticipating from the distances 
calculated from the structure. This could indicate that the lyophilized form of our protein 
may have differences in structure compared to what was found in the hydrated state. We 
further explored this using MAS-NMR with the same protein under solution-state 
conditions followed by lyophilization directly in the rotor and reassessing the structure. 
Uniformly I3C-labeled WT-GB1 resulted in a clustering of many peaks and proved to be 
less amenable to the DARR experiment. However, we needed ~41 mg of protein to 
quickly see our CRPK’s of interest and in the future we need to further assess the 
concentration dependence of l3C-Phe/13C-Trp labelled WT-GB1. We need to know what 
the minimal concentration of C-Phe/ C-Trp labelled WT-GB1 is required to see well- 
resolved CRPK’s and the minimal required acquisition time. An important control would 
involve analysing unlabelled protein for natural abundance signal in comparison to our 
enriched protein. This would be critical in evaluating whether chemical denaturation is
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the most applicable method for the folding-freezing method. Additionally, these 
foundational studies also suggest thermal unfolding and refolding may be another avenue 
to explore, since higher protein quantities can be used without dilutions.
Due to the concentration related issues we began characterizing an alternative 
folding method by solution-state NMR using pH changes to denature and fold our protein 
as this would require a significant reduction in dilution conditions for refolding. In 
addition, this was an opportunity to explore a possible molten globule structure, which 
are typically inducible at low pH’s. We analysed ,3C-Phe/13C-Trp labelled WT-GB1 at 
pH 2, 7 and 12 using 2D ' h ,13C correlation HSQC. We found that even under pH 2 and 
12 the environment of the labelled Phe and Trp remained relatively unchanged. 
Interestingly, CD indicated there was a significant loss in secondary structure content 
which was quite surprising. Our CD and HSQC data indicated that we may have found an 
intermediate-like state containing native-like tertiary structure with very little secondary 
content which could be a reverse molten globule. We propose that it may be a conserved 
expanded native topology (CENT). However, we will need to explore this potentially 
ground breaking result further in the future. It is reasonably straightforward to explore the 
hydrogen-bonding of this new state by NMR using 13C-15N labelled WT-GB1. MD can 
also be applied to assist in building a model of the proposed CENT structure.
Formation of Amyloid-like Fibrils with Fadd-DD
The propensity for proteins or peptides to misfold into amyloid deposits is 
associated with many neurodegenerative and systemic amyloid related diseases which 
include most notably Alzheimer’s and Parkinson’s. It was originally thought that
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information stored in a polypeptide chain only encodes for a single native fold. The 
transition of a protein from its soluble functional form into the P-sheet rich insoluble 
ordered filamentous polymer is a special form of misfolding and possess a great 
intellectual challenge to the scientific community which seeks to understand the 
underlying mechanism. It is now believed that amyloid fibrillation may be a separate 
alternative folding pathway. This process is not unique to any specific class of proteins 
and appears to be a unique alternative conformation of the polypeptide backbone, in 
which fibrillation conditions are dictated by the amino acid sequence.
The tendency for a protein to alternatively form highly ordered amyloid fibrils is 
dependent on many biological factors. Mutations, temperature, concentration, 
translational motion and pH play a pivotal role in inducing fibril aggregate assembly in 
vitro. The key feature appeared to be the need to destabilize the native state structure as a 
required first step. In this chapter we reported on the detailed conversion of the death 
domain of the human Fadd-DD, an all a-helical protein with a Greek-key topology, into 
an all (3-sheet amyloid-like fibril, using a comprehensive range of spectroscopic 
techniques that provide insight into this process. This transition from a-helical to p-sheet 
seems to require destabilization but not complete loss of the secondary structure to 
explore alternative conformations. This was a fascinating transition that supports the 
hypothesis that all proteins have the innate ability to form a fibril-like structure. Thus, the 
primary structure can encode two alternative 3D structures: the native, functional state 
and the P-amyloid state. We investigated the specific environment required to convert the 
Fas-associated death domain into an amyloid-like conformation. Fas-associated death 
domain does not appear to naturally form amyloid fibrils in vivo. Our results clearly
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indicate that proteins evolved to avoid amyloid fibril formation because we find that the 
conditions required for formation in our model system are very specific and far from 
physiological. There is still much that can be done using the Fadd-DD fibrillation system 
we developed. We can explore mutations in the Fadd-DD sequence to see if there are 
mutations that will allow the formation of Fadd-DD fibrils at physiological conditions. 
This would be important in understanding how amyloid related fibrils can form under 
physiological conditions. It is also important to conduct ssNMR studies of isotopically 
labelled protein to solve the 3D structure of Fadd-DD fibrils.
In summary, protein folding and misfolding are two sides of the same coin that is 
foundational to advancing not only scientific knowledge but medical research, 
therapeutics and disease prevention. Discovering new forms and folds can lead to 
revolutionary alternative avenues of research. As instrumentation and scientific methods 
rapidly advance, the importance of solving more complex protein structures with high 
resolution, folding dynamics and functions in of both folded and misfolding protein 
forms is critical to furthering our understanding of biological life. This area of science is 
hypothesis driven, experimentally proven and in some cases seems to require a bit of 
serendipity and in the words of Louis Pasteur, “Fortune favours the prepared mind.”
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APPENDIX I
BIOINFORMATICS OF GA AND GB1 EVOLUTION
W T -G B l-Y SIR K   MVGKNNYKTRTEKAAN-----------KKQRFSLKKLSVGVASVAVGTTLF-LS
W T-GA-YSIRK  MEN---------- KKMKYYLRKSAFGLAAV--SASVL-VG
YP 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------ m g m f f n k k d n d ----- -----SKQRFGIR-'LTI ACS LLSTLILGIG
WP 0 2 1 8 7 4 2 1 8 . 1 ------------------------- MVSKNNRDKKMEAVAE- - — r k p h f a i r s l t i AAS LLGTSLW-MS
K F L 9 7 0 1 6 . 1 MIYYDSKWRETGMLSKNNYQERLRKMDD----------KQERFSIR’ FSV AAS’ LVGTAIL-SM
K F L 9 5 2 3 0 . 1 MIYYDSKWRETGMLSKNNYQERLRKMDD----------KQERFSIR: FSV AAS LVGTAIL-SM
WP 0 3 3 6 8 8 7 4 0 . 1 ------------------------------------ MYKSKRRKNKSFDWYGLSQRFSIRi YHF ■AAS LLGTALI-LG
WP 0 0 3 0 9 7 6 8 8 . 1 --------------------------------------------- m e k f h g r ----- -----KAQRFSIR1 YSF AAS LLGTALF-LG
WP 0 3 3 6 8 9 1 2 7 . 1 ------------------------------------ m y s r m e k y h g r — -----RAQRFSIRi YSF ■AAS LLGTALL-LG
WP 0 2 0 9 0 3 4 6 8 . 1 ------------------------------------ MYSRMEKYHGR— -----RAQRFSIRi YSF :AAS LLGTALV-LG
WP 0 0 0 2 8 7 3 0 8 . 1 ------------------------------------ m y s r m e k y h g r - — -----RAQRFSIRiYSF AAS LLGTALL-LG
WP 0 3 3 6 8 5 3 8 0 . 1 ------------------------------------ MYSRMEKYHGR-—— RAQRFSIR’ YSF AAS LLGTALV-LG
WP 0 3 3 6 8 1 5 4 7 . 1 ------------------------------------ MYSRMEKYHGR-—— RAQRFSIRi YSF AAS LLGTALL-LG
WP 0 2 3 9 4 8 4 0 9 . 1 ------------------------------------ MYSRMDKYHGQ----- -----KVQRFSIRi’YSF AAS LLGTALL-LG
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  













AN— AVKADETST-ASAKTPEVTNSDKQKSDS---------G ST T P W ---------------------------------- E
TN— AVKADETNT-GSAKATEITNPDKQKPDS---------AITTPVV---------------------------------- E
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K E L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1 
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  













E L PE LKIDAVKADEK -  PE VKEEAKTEAKPVAEKEVADK------------- AA-------------TEKSDKE
ELPELKLDAVKADEK- SEVKE EAKPVAEKEVT DK------------- AA-------------TEKS DKE
Figure Al. MUSCLE alignment of 12 mucus-binding proteins with YSIRK family 
proteins. Positions in red indicate positions o f  com plete conservation and position in 
blue are positions conserved in am ino acid character. A ccession num bers correspond to
mucus-binding proteins found in Figure 40.
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W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
FAIAEVQAAGFTDQKYVDWINA-QE TVQDVN--------------------------GVKREILTTVPDEEQS -
-  LEKTIDNKTQLD----------------------------------------------------------------- SVKKEIQNAVDRDKIQ -
SSETTDNTKNTVNSDRAEVTNKEANTQTDSKKVTQKTSDQAVNDVNKNVAETTTDTRNTK 











W T-G B1-YSIRK  ------------------------------------------------------------------------------------- GIEEETSVDSESDFNAPDFDW
WT-GA-YSIRK -----------------------------------------------------------------------ELSNQA---------------------------
Y P _ 0 0 5 8 6 1 6 3 9 .  1 VSSYTSNLDL-------------------------------------------------------------- ENIQE S LEQQAKENNGKAL DA
W P _ 0 2 1 8 7 4 2 1 8 . 1  n i q l n e s l p s i a q a g q n g k t i v k d n d t t t q e l k i g d l s s d l s g d a l k a n l t k g n q v l l n q
K F L 9 7 0 1 6 . 1  ------------------------------------------------------------------------------------- TTSTDQ— TTSVNTTTFNTNQ
K F L 9 5 2 3 0 . 1  ------------------------------------------------------------------------------------- TTSTDQ— TTSVNTTTFNTNQ
W P _ 0 3 3 6 8 8 7 4 0  . 1  ------------------------------------------------------------------------------------- DKAGKE--AIATAVASAKVQI
W P _ 0 0 3 0 9 7 6 8 8  . 1  ------------------------------------------------------------------------------------- GVEDKQ--NLSAAITAVKLEA
W P _ 0 3 3 6 8 9 1 2 7  . 1  ------------------------------------------------------------------------------------- DDASKQ— KLSAAVAAVKLEA
W P _ 0 2 0 9 0 3 4 6 8 .  1 ------------------------------------------------------------------------------------- DVESKQ— KLSAAIAAVKLEA
W P _ 0 0 0 2 8 7 3 0 8 . 1 ------------------------------------------------------------------------------------- DEAAKK--ELAVTIEAVKLEA
W P _ 0 3 3 6 8 5 3 8 0 .  1 ------------------------------------------------------------------------------------- DVEAKQ— KLSAAIAAVKLEA
W P _ 0 3 3 6 8 1 5 4 7  . 1  ------------------------------------------------------------------------------------- DEAAKK--ELAVKIEAVKLEA
WP 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------- DVEAKQ— KLSAAIAAVKLEA
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1 
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P_033 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 .1  
WP 0 2 3 9 4 8 4 0 9 . 1
------------------------------SGNDEAVAAEA-------------------E LQAAKE S AIAE VKAAGFTDQ-----------
-------------------------------------DQIV---------------------------SAQAEKEAL--------------------------------------
KSVTSLLRSSD AANFQVLAALTENIAEADKIKANAAVTIPSTDGRYTLYISRNTWGN
SNSSEVVVGKNVDPTKQLQAMARTA------------------ MFAAVN PNAADNYTTVSD FNALQQAV
SSTAVLFSASA-----LSES KALAAT P------------------- RAS QATTNAQAKNNN YKLVT S S SE LQ
SSTAALFSASA-----LSE SKALAAT P------------------- RASSATTNAQAKNNNYKLVTSSSELQ










W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
WP 0 0 3 0 9 7 6 8 8 . 1
-KYVDW-
W P _ 0 3 3 6 8 9 1 2 7 . 
W P _ 0 2 0 9 0 3 4 6 8 .  
W P _ 0 0 0 2 8 7 3 0 8 . 
W P _ 0 3 3 6 8 5 3 8 0 . 
W P _ 0 3 3 6 8 1 5 4 7 . 





















Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  




















- I T K I E -------------------------------------VTNLAEFGA-
- I T K I E ------------------------------------- LTNLAELGA-
-VTKIE------------------------------------- LTNLAELGS-
- I T K I E ------------------------------------- LTNLAELGG-
-T T T IE -------------------------------------MKNLTGFGD-
-TTKIE------------------------------------- LKNLAGFGD-
-TTKIE------------------------------------- LKNLAGFGD-
W T-G B1-YSIRK  ----------------------------------------------------------------- EG-------------------------------------------------------------
W T-GA-YSIRK -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9  . 1  KPTPMQITQPTVKDITWTINGV-----------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  R---------------------------- NNFKNSNIAGNSVNIENGASLTINSSEINDGINLTDGGTVRVGDNA
K F L 9 7 0 1 6 . 1  SWASGSSNQNGWTVKGWNYANFSGSKVNVAADANLTINRSAIGDGIHLANNGTVNVADGG
K F L 9 5 2 3 0 . 1 S W A S G S S N Q N G W T V K G W N Y A N F S G S K V N V A A D A N L T I N R S A I G D G I H L A N N G T V N V A D G G
WP_0 3 3 6 8 8 7 4 0 . 1 --------------------------------------- NINWFDFAAASITYSNGTVVGPARKLAQPITKTITYPNGDRVEGK
W P _ 0 0 3 0 9 7  6 8 8  . 1   AFP--------- VGKEITAADGTVIGKVKSIDY------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   GLA--------- VNTEIRATDGTVVGKVKSIDF------------------------------------
W P _ 0 2 0 9 0 3 4  68  . 1   GLA--------- VNSEIRATDGTVVGKVKSIDF------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1   GLA--------- VNTEIRETDGTVVGKVKSI DY------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1   SFK--------- PGTKITAADGTVIGEVSSKET------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  AFK--------- AGTPIKAADGTTIGVVKSAAQ------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  T L -------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  Q L T I ----------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  Q L T I ----------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  ITMVRDVTYADGSKGLTTDDKFLNSGTAKYVEHLYYTGGAQNDHELYEALQEGMKFNVKT
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP_023 94 84 0 9 . 1
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
KVEGYALTATVIKLGSKAVDSDPNKTPAGPVNAVRDYGDWGSDKQLAKAQAEDKRFKANA
 ETSVDSE














W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1 
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1 
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
------------------------------HIDVNPV------------------------------------------------------ WNPKFSLS-------------








------------------------------G G E S -P F ------------------------------------------------------ WSQRKKDGK-----------
------------------------------G T T S -P Y ------------------------------------------------------ WAQRMKDGM-----------
------------------------------G T T S -P Y ------------------------------------------------------ WAQRMKDGM-----------
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  















W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
















W T -G B l-Y SIR K  AAQEEVYTL-----------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9 . 1  PGQDYQNSL-----------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  AANSNIEISKHSTTYFHSVGKTGTSGSYD---------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 AANSNINIDDHAVTYFHSVGKTTTNALGNTVGASGSFS-------------------------------------------------
K F L 9 5 2 3 0 . 1  AANSNINIDDHAVTYFHSVGKTTTNALGNTVGASGSFS-------------------------------------------------
WP_0 3 3 6 8 8 7 4 0 . 1  FGANYTSMGSKNSLPIALSQNVKTLSMYLNSAGAQAGTIGFMIYDGGDAPQSYGSAQHII
W P _ 0 0 3 0 9 7  6 8 8 . 1  FGAENLSGG-----------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  FGASNLSGN-----------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  FGASNLSGD-----------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  FGASNLSGS---------------------------------------------------------------------------- -----------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  FYAENLTAI-----------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  YSVENLTGS-----------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  YSVENLTGS-----------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P J 3 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  


















G Y Y A P Q I S K D - - - - - - - - - - - - - - - - - - - - - - - - - T E Y T A E I K V D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
-------------------------------------EYATFRVILEGRGDNP-------------------------------------------------- WDD-
---------- KFAT FRVILEGRGNNN----------------------------------------------------------------------------- YDD-
----------KFAT FRVI LEGRGNNN----------------------------------------------------------------------------- YDD-
SGKTVVTTDKGVTGKYLLLPNGNAVIEKSDNTRVLLNQGDVIEMVNPSTKLPIRGIYNHT






--------------------------------------------- GQKVLEHT----------------------------------------------------------- Y IH -
Figure AI. Continued.
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W T -G B l-Y SIR K  ---------------------------------------------------------------QGQNGATTVKASSPR-----------------------------------
W T-GA-YSIRK -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1----------------------------------------------------------------------PMPKGYVLDESATMQLNNFG------------------------
W P_021 8 7  4 2 1 8 . 1   WSLDSQNANTTAAFTSKKGAIVDIRDDN------------------------
K F L 9 7 0 1 6 . 1   WSLDSQNTNTNAAFTSKTGAIVDIRDDN------------------------
K F L 9 5 2 3 0  . 1   WSLDSQNTNTNAAFTSKTGAIVDIRDDN------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  TGALGEGTLGDEGESQLLDPAVATEYKLRQAQGNEYVLDGVRANLGVNNDKAYVRGWVDF
W P _ 0 0 3 0 9 7 6 8 8  . 1 ----------------------------------------------------------------------KGQQATFSKQGTSASLRTNN------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   KGQQPSYQKQGTSASLSENN------------------------
W P _ 0 2 0 9 0 3 4  68 . 1   KGQKANYQKQGTSASLSENN------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1   KGQQPNYQKQGTSASLSENN------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  KASKSAAQKQNT SAT IMGDN-----------
W P _ 0 3 3 6 8 1 5 4  7 . 1   KATKPSVQKQSTSVSLLTDN------------------------
WP~023 94 84 0 9 . 1   KATKPSVQKQSTSVSLLTDN------------------------
W T -G B l-Y SIR K ---------- -----------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK------------------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1------------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1--------------- -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  NNNGKFDLNESSEIVEVNQNGTYSIKFKNTPQLLDTSADSLGVRLRISLTKDEILEPTGV
W P J ) 0 3 0 9 7 6 8 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
WP__0209034 68 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 ------ -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1------------------------------------------------------------------------------------------------------------------------------------------
W P  0 2 3 9 4 8 4 0 9 . 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
W T -G B l-Y SIR K
W T - G A - Y S I R K
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _02187 4 2 1 8  . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0  . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 .1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  

















Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  NDNLPPKIVLTDKQVASEEAYTPTDSELPSNYRKGDDGKVFVERNGATVFTGEYVTVKDK
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 .  1 
W P _ 0 2 1 8 7 4 2 1 8  . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 .1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ _ 0 3 3 6 8 1 5 4 7 . 1  












- - - - - - - - - - - - - S K G S K F T I D L P N - - - - - - - - - - - - - - - - - - D E F T Y F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
WT-GBl-YSIRK ---------------------------------------------------------------------------------------EALEYFQAFL
WT-GA-YSIRK -------------------------------------------------------------------------------------- KKLVNSAKTV
Y P _ 0 0 5 8 6 1 6 3 9 . 1 -------------------------------------------------------------------------------------------------------- APITIVQKLN
W P _ 0 2 1 8 7 4 2 1 8  . 1 VVYQRIKSDGSKQIW------------------------------------------------------------------------------------LNVNDVNIPM
K F L 9 7 0 1 6  . 1 SKQIW--------------------------------------------------------------------------------------------------- LNVNGVNIPM
K F L 9 5 2 3 0  . 1  SKQIW--------------------------------------------------------------------------------------------------- LNVNGVNIPM
W P _ 0 3 3 6 8 8 7 4 0 . 1  LTFKPVDAYVGTAKGIAVRAWDDNNSSTGWEATNDTIETSKTSTTLAEKDKVLENTNNGN
W P _ 0 0 3 0 9 7 6 8 8  . 1 -------------------------------------------------------------------------------------------------------- KELEGSTNFV
W P _ 0 3 3 6 8 9 1 2 7  . 1 -------------------------------------------------------------------------------------------------------------------- KELEGSSNFV
W P _ 0 2 0 9 0 3 4  68 . 1 -------------------------------------------------------------------------------------------------------------------- KELEGSSNFV
W P _ 0 0 0 2 8 7 3 0 8  . 1 -------------------------------------------------------------------------------------------------------------------- KELEGSSNFV
W P _ 0 3 3 6 8 5 3 8 0  . 1  -------------------------------------------------------------------------------------------------------- KAIDGSKN—
W P _ 0 3 3 6 8 1 5 4 7  . 1 -------------------------------------------------------------------------------------------------------------------- RELGNGKN—





Y P _ 0 0 5 8 6 1 6 3 9 . 1 ND---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  NG---------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  SG---------------------------------------------------------------------------------------------------------------------------------
K FL952 3 0 . 1  SG---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  NGYKSMDTSYIPTVIDVRPVGEDTITEDVQGKPQSSNPTIPAYATVETVTNDKIEDTKYA
W P _ 0 0 3 0 9 7  6 8 8 . 1  NG---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  NG---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  NG---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  NG--------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  GSQTKTWTGPTVSQDFYGAN---------------
W P _ 0 2 1 8 7 4 2 1 8  . 1   FQTKDIWNNQANPDVSITGNGLT---------------
K F L 9 7 0 1 6 . 1   FQTKDIWDNQANPDVSIKGNDLT---------------
K F L 9 5 2 3 0 . 1   FQTKDIWDNQANPDVSIKGNDLT---------------
WP_033 6 8 8 7  4 0 . 1  ANFVILDKTKKPTLATQKENPGKLYTEDTKVDKETTLTLTDGTTATYKPVDKIPANTVIA
W P _ 0 0 3 0 9 7  6 8 8  . 1  ----------------------------------------------------------------- LNTASTLNPNKGDSITYRLANRW---------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   LNTASTINPNKGDSITYRPASRW---------------
W P _ 0 2 0 9 0 3 4  68 . 1   LNTASTINPNKGDSITYRPASRW---------------
W P _ 0 0 0 2 8 7 3 0 8  . 1   LNTASTINPNKGDSITYRPASRW---------------
W P _ 0 3 3 6 8 5 3 8 0  . 1  -------------------------------------------------------------------------- TVTNTNKADSISYRPAGRW---------------
W P _ 0 3 3 6 8 1 5 4 7 .  1 -------------------------------------------------------------------------- S I  KSSEVTYRPSNRW---------------
W P  0 2 3 9 4 8 4 0 9 . 1  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - S I  K S S E V T Y R P S N R W - - - - - - - - - - - - - - - - - - -
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
WP_00 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
WP_033 6 8 1 5 4 7 . 1  








— ANVRANENNVWILQD----------- GRDSGF-----------TLT PRLISPTELELTVT--------------------
— ANVKANENNVWILND----------- GRDSGF-----------TLTPRLISPTELELTVT--------------------
— ANVKANENNVWILND----------- GRDSGF-----------TLTPRLISPTELELTVT--------------------
— - NNVQANANNVWILND----------- GRDTNF-----------TLKATIKSPTELEIEVI--------------------
—  SNVQANQNNVWILQD----------- GRDTSF-----------TLKATLKSPTRLELEVI--------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1 — YGGNQLLNNGHKQIVAYFGATNESIASYSNYSSNFTFNFDESLGVTELKTPTIPGT—
W P _ 0 2 1 8 7 4 2 1 8 . 1  VDEQGNEIFPENTS-------------- SLNLKRNIILDITQDQIKKIQDYALNHTADETLEYIKNSQ
K F L 9 7 0 1 6 . 1 VYEDGTPVLDENGNQIVKTQNLNLTRKLTLDITDDKIEEIQKYALTHNADQTLEYIKNAQ
K F L 9 5 2 3 0 . 1  VYEDGTPVLDENGNQIVKTQNLNLTRKLTLDITDDKIEEIQKYALTHNADQTLEYIKNAQ
W P _ 0 3 3 6 8 8 7 4 0 . 1 PAGG TIPGGATIKT P FTN-----------------------TATNTFNNVTYNN- GQTIPAA-- SAGKIS
W P _ 0 0 3 0 9 7 6 8 8 . 1  - - E G  YIQEGSNISLSLQSLGVEKVIKDKTLTSEFSNVTYNEFGIITGG TAGN—
W P ~ 0 3 3 6 8 9 1 2 7 . 1  — EG AIQEGSTVSMPLQSLGIEKVIKDKTLTSEYSNITYEN-GLIKQG YVGN—
W P _ 0 2 0 9 0 3 4 6 8 . 1  - - E G  AIQEGSVVSMPLQSLGIEKVVKDKTLTSEYANITYEN-GLIKEG YVGN—
W P _ 0 0 0 2 8 7 3 0 8  . 1  — EG AIQEGSWSMPLQSLGIEKVIKDKTLTSEYSKITYEN-GLIKEG YVGN—
W P _ 0 3 3 6 8 5 3 8 0 . 1  — DG AIQEDSIVSIGLDKLGVEKAITNRTFSDEYSKFIYDEAGRLKDGS— VVGD—
W P _ 0 3 3 6 8 1 5 4 7 . 1  - - D G  VIQEGSTVSMALDKLGIEKVLTPRTFSDDFSKIKYDELGRVAKGS— TVGN--
WP 0 2 3 9 4 8 4 0 9 . 1  — DG VIQEGSTVSMALDKLGIEKVLTPRTFSDDFSKIKYDELGRVAKGS— TVGN—
WT-GBl-YSIRK --------------------------------------------------------------------------------WSYDSESRAF----------
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------SNYKYTITYADGTT— SEGQVNAGNTITGTGVI-----------------TNIVVSPDNF-------------
WP 0 2 1 8 7 4 2 1 8 . 1  SVAQDSGWKFTNGSGQT— VTDPYATVESPKLDG------------------- YTATIQSTNVQGLKVG
K F L 9 7 0 1 6 . 1 ---------------- GVSEDSGWVYTDAQGNT— VTDPYATWSPVEDG------------------- YTASIESSNVPGITEG
K F L 9 5 2 3 0  . 1  GVSEDSGWVYTDAQGNT— VTDPYATWSPVEDG------------------- YTASIESSNVPGITEG
W P _ 0 3 3 6 8 8 7 4 0 . 1  SLAKETSADQLVEKGKSITLDGTTYSNNDVIPKGTRTMTTYEDLRNVTLPNAVHIDPQTG
W P _ 0 0 3 0 9 7 6 8 8  . 1 ------DKTAATLTVSGGTS— INGEKEDVTTTVANG--------------------- WEINASGTPLGEPPTG
W P ~ 0 3 3 6 8 9 1 2 7  . 1  ------DKTAATLTVSGGES— VNGEKEDVITKVPNG---------------------WSIVGDGRVQGEPPTG
W P _ 0 2 0 9 0 3 4 6 8  . 1  —  DKTAATLTVSGGES— VNGEKEDVATTVPNG-------------------- WSVVGDGKVQGEPPTG
W P _ 0 0 0 2 8 7 3 0 8 . 1  ------- DKTAATLTVSGGES--VNGEKEDVATTVPNG------------------- WSVKGDGKVQGEPPTG
W P _ 0 3 3 6 8 5 3 8 0 . 1 — TDKTAATLTVSGGTP— LNGGEENVTTKVANG------------------- WKVEVGAGGNSQFETG
W P _ 0 3 3 6 8 1 5 4 7  . 1  ------DKTSATLSVTGGTP— LNGQTEEIATKVNNG---------------------WEVSVIPNGSTTVETG
WP 0 2 3 9 4 8 4 0 9 .  1 ------DKTSATLSVTGGTP— LNGQTEEIATKVNNG--------------------- WEVSVIPNGSTTVETG
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8  . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4  0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  

















Y P _ 0 0 5 8 6 1 6 3 9 . 1 -----------------------------------------------------------------------------------------------------------------------------------
WP_0 2 1 8 7 4 2 1 8 . 1  ----------------------------------------------------------------------VVYKKAVEKGSVKWYHDDTTNTEIPNT
K F L 9 7 0 1 6 . 1  WVYKKAKEVTNTLKFYDDTTKSYISTV
K F L 9 5 2 3 0 . 1   WVYKKAKEVTNTLKFYDDTTKSYISTV
W P _ 0 3 3 6 8 8 7 4 0 . 1  KVAGDPVTSKYGTDYGKAKYIPIVKPQSKASITRTIHYVYENANDNPTSQDSYKDNDPIL
W P _ 0 0 3 0 9 7 6 8 8  . 1   NEPLNEDGTKDNTNVL
W P _ 0 3 3 6 8 9 1 2 7  . 1   NIPLSEDGSKDYTNVL
W P _ 0 2 0 9 0 3 4 6 8  . 1   NIPLSEDGSKDYTNVL
W P _ 0 0 0 2 8 7 3 0 8  . 1   NIPLSEDGSKDYTNVL
W P _ 0 3 3 6 8 5 3 8 0  . 1   YAKPNEDGSYETKNIL
W P _ 0 3 3 6 8 1 5 4 7  . 1   YAPLKEDGTYETKNIL
WP 0 2 3 9 4 8 4 0 9 . 1   YAPLKEDGTYETKNIL
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 .1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P J 3 3 3 6 8 5 3 8 0 .1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P  0 2 3 9 4 8 4 0 9 . 1
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WC-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1 -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
WP_0 3 3 6 8 8 7 4 0 . 1  GSIIIGKWTAS S DQNSKFKEIIS PTVKGYTAEWTAD FT PRADGKMGHIHNGKQPVGLYT
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 .1  -----------------------------------------------------------------------------------------------------------------------------------
















Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1







----------------------------PLIKEVDGEE------------- Y IL ------------------------- ANIPTTGIEGTLSVTN
----------------------------DLVKEVNGEE------------- Y IL ------------------------- ADIPVENARGTLSVTK
----------------------------DLVKEVNGEE------------- Y IL --------------------------ADLPAENAKGTLSVTK
----------------------------DLVKEVNGEE------------- Y IL --------------------------ADIPAENTKGTLSVTK
----------------------------DLTKTIKGVE------------- YIR--------------------------VDVPSKGTTGTVNIGP
----------------------------DLVKPIAGVD------------- Y IL ------------------------- AEIPPKGPAGTINVSD
----------------------------DLVKPIAGVD------------- Y IL --------------------------AEIPPKGPAGTINVSD
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 .1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
-GTQLVANLTFTGTIQQGN---------------------
-NQNVVVTVHMK-HGVQP-----------------------






A N P A P A T G A D A K T T Y G V A T L Q G K S H T A I P Y L T A E T I K K Y E D R G Y E L V T D D Y T N N T Q G T A I
TR----------------ARDLYSTEELKENGLNASAY------------------------------------------------------------------
T R - - - - - - - - - - - - - - - - - - - - A R D L Y S E E E L K A K G I N G S A F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
TR----------------ARDLYSEEELKAKGINGSAF------------------------------------------------------------------
TR----------------ARDLYSEEELKAKGINGSAF------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  





- V V P V T P D T P N V P S N S K V S K D D L T -
-VVPVTPDTPNVPSNSKVSKDDLT-
 VVSSADLTSS-------------S
- TKKVNLTVNYVN S — D G














Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
WP_033 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
----------------------------------------------------------------- SEAT------------------------------------














Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
WP 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 .1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
-W-
Y Y V L P E - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - W - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
T --------------------------------------------------- W— TSDKTSFD-------------------------------------- K V V SP--
TWTTDNNGK FAQVT PDASIKKGDDTWT— TGVKSVDEKNAPDVLTITGKTTNEDVYVPYT 
TWTTDNNGKFAQVTPDASIKKGDDTWT— TGVKSVDEKNAPDVSTITGKTTNEDVYVPYT 
YDHITNKAIAADATDAQKAIVTFGPWTP-VGGTSNDAITLSDAEKAKDDKFNL-VNSP--
I N ------------------------------------------------- WKG-IG— DTN------------------------------- LPE-VTVP—
IN ------------------------------------------------- WKG-TDGQSTD--------------------------------LPE-LAVP—
I N ------------------------------------------------- WKG-TDGQSTD------------------------------ LP-ELAVP—
IN ------------------------------------------------- WKG-TDGQSTD------------------------------ LPE-LAVP—
I N ------------------------------------------------- WVG-NG--DTN------------------------------ LPE-VTVP—
VN------------------------------------------------- WVG-NG—  DTN------------------------------ LPE-VTVP—
V N - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - W V G - N G  —  D T N - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L P E - V T V P  —
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 .1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
---------------------------------------------------------------------------------------------------FSVYDFSTDYTKL—
-----------------------------------VEQNY-HLISISDHQDGNDVATITGLTKDSGDITVTVTYAPNGK
L S Q K T Y T G T K E T K T V T R V I N Y L D N E T K Q P V S D A V E Q T T T L S R T Q I K D E K G N V I G Y G T V S E
LSQKTYTGTKETKTVTRVINYLDNETKQPVSDAVEQTTTLSRTQIKDEKGNVIGYGTVSE
---------------------------------- EVTGYVP— D------------ NATVEATAAIDAEADDYKITVLYTPVAQ











Y P _ 0 0 5 8 6 1 6 3 9 . 
W P _ 0 2 1 8 7 4 2 1 8 .  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 
W P _ 0 0 3 0 9 7  6 8 8 .  
W P _ 0 3 3 6 8 9 1 2 7 .  
W P _ 0 2 0 9 0 3 4 6 8 . 
W P _ 0 0 0 2 8 7 3 0 8 . 
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  









------------------------- KAKTTFV--  DEKGNA—  I ---------------------------------------------------PGVA-EI
------------------------- KAKTTFV— DEKGNAI------------------------------------------------------- PGVA-EI
------------------------- KAKTIFV--  DEKGNA-- I ---------------------------------------------------PGVA-EI





Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
WP__003097 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
-EAEDD-
T N N G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - V I G T - - P K L S V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
P Y T  P E T  P A K D Q K A V V N Y V D A D E D N K L I T S S - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
VAADTPSVTDPQDVTVNVFYDHDTTPVTPDKPGHGLTHDDLNKDVTRTINYVDTTGAAVN
V A A D T P S V T D P Q D V T V N V F Y D H D T T P V T P D K P G H G L T H D D L N K D V T R T I N Y V D T T G A A V N
AVTG--------------------------------- KSEAAYPATTA----------------------------------------------------------------
S E T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - K G G D — K L T K A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
TEQG--------------------------------- GSET— PLTKE----------------------------------------------------------------
T E Q G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G S E T — P L T K E - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
T E Q G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G S E T — P L T K E - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
TEQG--------------------------------- GSEA— PLTKE----------------------------------------------------------------




Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  GAPDGKSTYTQTAHFTRTAIVDKVNDKLLGYDINGDGSVDISPDAGDFAWKSTDANLPAV
K F L 9 5 2 3 0 . 1  GAPDGKSTYTQTAHFTRTAIVDKVNDKLLGYDINGDGSVDISPDAGDFAWKSTDANLPAV
W P _ 0 3 3 6 8 8 7  4 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 TSKAPSEVGYDSVDTPWQATTVAYNSEPINVTVTYSKNAQQGSFQIHYIDEDNNNAILH
K F L 9 5 2 3 0 . 1  TSKAPSEVGYDSVDTPWQATTVAYNSEPINVTVTYSKNAQQGSFQIHYIDEDNNNAILH
W P _ 0 3 3 6 8 8 7 4 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 , 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1 ------ ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7  4 2 1 8  . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P_033 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
-EEVQEE-------------------- IYTF--------------------- V Y II--------------------------------------
--------------------------------------------------------------- GF------------------------------------------







- A D V K A K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I K E L E N K - - - - - - - - - - - - - - - - - - - - - - - - - G Y E L V S N T Y P E G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
-ADVKAK-------------------------IKELENK--------------------GYELVSNTYPEG-----------------------------
-ADVKAK-------------------------IKELENK------------------- GYELVSNTYPEG-----------------------------
- D E I  AAR-------------------------IKEAQNK--------------------GYEWSNTYPTD-----------------------------
-DEIAAR------------- IKEAQNK---------- GY E W S N T Y P T D ---------------
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  VSFKHGRKNGTTETLVPTETIHFQYADGTKAADDVHGNAGDFKFTRTPIIDTVTGQIVDP
K F L 9 5 2 3 0 . 1  VSFKHGRKNGTTETLVPTETIHFQYADGTKAADDVHGNAGDFKFTRTPIIDTVTGQIVDP
W P _ 0 3 3 6 8 8 7  4 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 ------------------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  QIHLNTLPDGTNGTYQGIIYI--------------------------------------------------------------------------------- VS
W P _ 0 2 1 8 7 4 2 1 8  . 1  ATYDND— DNTTQTYTWLRHGTQ--------------------- PVNP--------------------------------------------- TN
KFL 9 7 0 1 6 . 1  GTWNKESYTFDDGQKNVKVINGYVADKATYGNKTATPTDLNVEDTVTYRKISN11PVDEN
K F L 9 5 2 3 0 . 1  GTWNKESYTFDDGQKNVKVINGYVADKATYGNKTATPTDLNVEDTVTYRKISNIIPVDEN
W P _ 0 3 3 6 8 8 7 4 0  . 1  DKFDKD--AAVDQEYWKFKAKVVDVPS FDPTKPASN------------------------------------------------DN
W P _ 0 0 3 0 9 7  6 8 8  . 1  GAFDKD— VNTDQEFTVTLKERVV--------------------- PVTP----------------------------------------------DQ
W P _ 0 3 3 6 8 9 1 2 7  . 1  GKFDTD— KDTDQEFKVILKQKEV--------------------- TVTP----------------------------------------------DQ
W P _ 0 2 0 9 0 3 4  68 . 1  GKFDTD— KDTDQE FKVI LKQKEV--------------------- TVTP----------------------------------------------DQ
W P _ 0 0 0 2 8 7 3 0 8  . 1  GKFDTD— KDTDQE FKV I  LKQKEV--------------------- TVTP----------------------------------------------DQ
W P _ 0 3 3 6 8 5 3 8 0 . 1  GKFDKE--AGVDQE FKVTLKERVV PVT P----------------------------------------------DQ
W P _ 0 3 3 6 8 1 5 4 7  . 1  GVFDKD— VDTDQEFTVTLKERVV--------------------- PVTP----------------------------------------------DQ
WP 0 2 3 9 4 8 4 0 9 . 1  GVFDKD— VDTDQEFTVTLKERVV--------------------- PVTP----------------------------------------------DQ
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
TKGKNGATTV KASSP---------- EEAKAYFEEFAKENDLGEL-----------------------------
SQ-TPAEDTI-------------------------------------------------------------------------------------------
P T T K L T N T A Y - - - - - - - - - N  P N N T - - - - - - - - - - - - - - - - - - - - - S  N  F A P  S G I T  F N  P  D W V Q G N T  S N  L  Y - - - - - - - - - - - - - - - - - - - - - - - - - - - -













Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
KFL97 0 1 6 . 1  PTKPTNVVYTKDNAPVDKATVIVRYHDDTTNLDLPESFDSGNKEVGTDTGYTQADINKVV
K F L 9 5 2 3 0 . 1  PTKPTNVVYTKDNAPVDKATVIVRYHDDTTNLDLPESFDSGNKEVGTDTGYTQADINKVV
W P _ 0 3 3 6 8 8 7 4 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7 6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
WP__0209034 68 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  YVGANGF------------------------------------------------------------------------------------------------
W P _02187  4 2 1 8  . 1   YLDEDGN-------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  QEYEAKGYYYVTTDGTLPTTIPAGGATIVVHLAHNQIPVGPDTPDKHGVDPDQVKKAYTS
K F L 9 5 2 3 0 . 1  QEYEAKGYYYVTTDGTLPTTIPAGGATIVVHLAHNQIPVGPDTPDKHGVDPDQVKKAYTS
W P _ 0 3 3 6 8 8 7  4 0 . 1   YVYEDGT-------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1   YVYEDGT-------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   YVYADGT-------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1   YVYEDGT-------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1   YVYEDGT-------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  YVYEDGT-------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1   YVYEDGT-------------------------------------------------------------------------------------------------
W P_023 9 4 8 4 0 9 . 1   YVYEDGT-------------------------------------------------------------------------------------------------
WT-GBl-YSIRK--------- DWT-----YDEDTKTFTAR
WT-GA-YSIRK ----------------------------------------------------------------------------------------- KSLELSEAKTL
Y P _ 0 0 5 8 6 1 6 3 9  . 1 TINQVGGANTASVAQGNQNDILVDSGVSDLY----------------------------------------- GSNEMEYAVR
W P _ 0 2 1 8 7 4 2 1 8  . 1 KVSDSV---------------------EQPVNFTASGVLDKVTGEWT TPLTWS VDQTVSAVKSP
K F L 9 7 0 1 6 . 1  TLHYQDSEGKTLSPDQQQTSTWTRTVTVDTVTNQIVNGGKYDTNWTLQDANDKYSNFTVP
K F L 9 5 2 3 0 . 1  TLHYQDSEGKTLSPDQQQTSTWTRTVTVDTVTNQIVNGGKYDTNWTLQDANDKYSNFTVP
W P _ 0 3 3 6 8 8 7 4  0 . 1  PVAESDLTSVADKK— VKTLKFTRSGKINVATGEIT--------- YG-DWS----- ADQTFEAVTSP
W P _ 0 0 3 0 9 7 6 8 8 . 1  PVLNED— GTPKTV— TQEAKFTREAKVNLVTGEVT--------- YG-DWT------PAQDLSEVTSP
W P _ 0 3 3 6 8 9 1 2 7 . 1  PVLNED— GTPKTV— TQEAKFTREAKVNLVTGDVT--------- YG-DWS----- EAKDLAEVKSP
W P _ 0 2 0 9 0 3 4  6 8 . 1  PVLNED— GTPKTV— TQEAKFTREAKVNLVTGEVT--------- YG-DWS----- EAKDLAEVKSP
W P _ 0 0 0 2 8 7 3 0 8 . 1  PVLNED--GTPKTV--TQEAKFTREAKVNLVTGEVT--------- YG-DWS----- EAKDLAEVKSP
W P _ 0 3 3 6 8 5 3 8 0 . 1  PVLSED— GTPKTV— TQEAKFTREAKVNLVSGEVT--------- YG-DWS----- EAKDLPEVKSP
W P _ 0 3 3 6 8 1 5 4 7 . 1  PVLNED— GTPKTV— TQEAKFTREAKVNLVTGEVT----------YG-DWT------PAQDLAEVKSP
WP_02 3 94 8 4 0 9 . 1  PVLNED— GTPKTV— TQEAKFTREAKVNLVTGEVT--------- YG-DWT------PAQDLAEVKSP
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK AL----------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  L I ---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  VV--------------------------------------------------------------------------------------------------------------------------------
KFL97 0 1 6 . 1  VV---------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  W ---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  TLEKYTAAVAGITPAVADVPAKTVAATDKDFEETVIYSTKPTTVDPNKPTDPTNPNVTPQ
W P _ 0 0 3 0 9 7 6 8 8 . 1  VV---------------------------------------------------------------------------------------------------------------------------------
W P _ 03368  9 1 2 7 . 1  VV---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  VV---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  W ---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  KV---------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  VV---------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P J D 2 1 8 7 4 2 1 8 .1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1--------------- ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  PDDWPNDPKGRTYRELGLIEEVTHTVHYKLEDGSDAGIADNVQTLTFTRTAEVDPVTGA
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
WT-GBl-YSIRK ------------------------------------------- EKV------------------------------------------------------------
WT-GA-YSIRK ------------------------------------------- REF------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1----------------------------------------------------------- NGS------------------- GTKLTN VVAMVN LPQAS DT S FAFQ
W P _ 0 2 1 8 7 4 2 1 8  . 1  ---------------------------------------------------- S G Y H L V S V D R D Q D G N N V K D V T L T H D D N S Y I V T V R Y A
K F L 9 7 0 1 6 . 1 --------------- ---------------------------------------------------- EGYVARKTTNNGATVTTVVAGQTKVQQNLEDTVVYD
K F L 9 5 2 3 0  . 1 ---------------------------------------------------- EGYVARKTTNNGATVTTWAGQTKVQQNLEDTWYD
W P _ 0 3 3 6 8 8 7 4  0 . 1 ISNFGTWKAKGGDTTIDAVTTPNKDGY--------------------VASAKTSTERTNVAATDKDSEETIIYR
W P _ 0 0 3 0 9 7 6 8 8  . 1 -------- -------------------------------------------------- KGY------------- LAD-KATVPTVNVTADSKDTTEVVTYK
W P _ 0 3 3 6 8 9 1 2 7  . 1 -------- -------------------------------------------------- TGF------------- LAD-KASVPWNVTGDSKDITEVVTYK
W P _ 0 2 0 9 0 3 4  68 . 1 -------- -------------------------------------------------- TGF------------- LAD-KASVPVVNVTGDSKDITEVVTYK
W P _ 0 0 0 2 8 7  3 0 8  . 1  -------------------------------------------------- TGF------------- LAD-KASVPWNVTGDSKDITEWTYK
W P _ 0 3 3 6 8 5 3 8 0  . 1  -------------------------------------------------- DGY------------- LAD-KASVAVVNVTGDSEDIKEVVTYK
W P _ 0 3 3 6 8 1 5 4 7 . 1  ----------------------------------------------------KGY-------------LAD-KATVPTTKVTADSENTTEVVTYK
W P  0 2 3 9 4 8 4 0 9 . 1  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - K G F - - - - - - - - - - - - - - - - L A D - K A S V P W N V T G D S E D I K E W T Y K
WT-GBl-YSIRK 
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 .  
W P _ 0 2 1 8 7 4 2 1 8 . 
K F L 9 7 0 1 6 , 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 
W P _ 0 0 3 0 9 7 6 8 8 .  
W P _ 0 3 3 6 8 9 1 2 7  . 
W P _ 0 2 0 9 0 3 4 6 8 . 
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  

















YP_0 0 5 8 6 1 6 3 9 . 1  —  LKSNNDPDGTKPDETGYVPADQVTDW---------------------------------------------------- SK IK S11 IK
W P _ 0 2 1 8 7 4 2 1 8  . 1  — VPTVTPTDPGKDTPVPYTPVAPAKDQVAQVIYRDVNDP------------------------- NKVTQLATS
K F L 9 7 0 1 6 . 1  TPITPEDPTKDT PVPYTKDPVKAGLTVQ YI DQ----------------------------------- DNNNSVIKS
K F L 9 5 2 3 0 . 1  ------TP ITPE DPTKDT PVP YTKDPVKAGLTVQ YI DQ----------------------------------- DNNNSVIKS
W P _ 0 3 3 6 8 8 7 4 0 . 1  KPLTPKDPNDPTKGYEVPDLPTDPTENTTITYVKDGSQVAVTHFIEVNSETDKTEKGAVA
WP__003097 6 8 8 . 1  NPLKPVNPNNPEEGYIVPDLPTDPSQDTPINYVKD-TQKAKTTFVD------------EKGNPIPGV
W P _ 0 3 3 6 8 9 1 2 7 . 1  QPLKPVDPSDPTKGYIVPDLPTDPSQDTPINYVKD-TQKAKTTFVD------------ EKGNPIPGV
W P _ 0 2 0 9 0 3 4  6 8 . 1  NPLKPVDPTDPTKGYEVPNLPTDPSQDTPINYVKD-MQKAKTTFVD------------EKGNPIPGV
W P _ 0 0 0 2 8 7 3 0 8 . 1  NPLKPVDPADPTKGYIVPDLPTDPSQDTPINYVKD-TQKAKTTFVD------------EKGNPIPGV
W P _ 0 3 3 6 8 5 3 8 0 . 1  NPLKPVDPNDPKEGYEVPNLPTDPSQDTPINYVKD-TQKAKTTFVD------------EKGNPIPGV
W P _ 0 3 3 6 8 1 5 4 7 . 1  NPLKPVDPNDPTKGYEVPNVPTNPGEDTPINYVKD-TQKAKTTFVD------------ EKGNPIPGV
WP 0 2 3 9 4 8 4 0 9 . 1  QPLKPVDPNNPTKGYEVPSVPTNPGEDTPINYVKD-TQKAKTTFVD------------EKGNPIPGV
WT-GBl-YSIRK
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  













D A I T E E G D S D T P L T K E A D V K A K I K E L E N K G Y E L V S N T Y — P E G G K F D K D K D T D Q E F K V T L
WT-GBl-YSIRK  VYDFNRP
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 KVKPANITITGEA-NINFKLQYTDENGQL-QTINL------------------------- PDLSTSYNLAQNNT
W P _ 0 2 1 8 7 4 2 1 8 . 1  VHGTVPVTPTDPG-KPGEPINPNDPDGPK-WPDGT--------SEDSLKKSGTQTIHYVYSDGSK
KFL97 0 1 6 . 1  KHGTRPVTPENPA-DPNEPVDPDHPDTPTPSNPNL------- SKE DLQKTITRTIEYKYADGTQ
K F L 9 5 2 3 0 . 1  KHGTRPVTPENPA-DPNEPVDPDHPDTPTPSNPNL------- SKEDLQKTITRTIEYKYADGTQ
W P _ 0 3 3 6 8 8 7 4 0 . 1  TAKPITVNPNDPTPTKGQPIDPNNPTGPK-WTPELIKELEDGRTEEVKRTIKYVYADGSK
W P _ 0 0 3 0 9 7 6 8 8 . 1 KAKEVTVTPDQPK-TPGTPVDPNNPDGPK-YPAGL------- EEKDLNKTVTRTITYVYADGT P
W P _ 0 3 3 6 8 9 1 2 7 . 1  K A K E V T V T P D Q P K - T P G T P V D P N N P D G P K - Y P A G L - - - - - - - - - - E E K D L N K T V T R T I T Y V Y A D G T  P
W P _ 0 2 0 9 0 3 4  6 8 . 1  KAKEVTVTPDQPK-TPGTPVDPNNPDGPK-YPAGL------- EEKDLNKTVTRTITYVYEDGTP
W P _ 0 0 0 2 8 7 3 0 8 . 1  KAKEVTVTPDQPK-TPGTPVDPNNPDGPK-YPAGL------- EEKDLNKTVTRTITYVYADGTP
W P _ 0 3 3 6 8 5 3 8 0 . 1  KERVVPVTPDQPK-TPGTPVDPNNPDGPK-YPAGL------- EEKDLNKTVTRTITYLYEDGTP
W P _ 0 3 3 6 8 1 5 4 7 . 1  KERWPVTPDQPK-TPGTPVDPNNPDGPK-YPAGL------- EEKDLNKTVTRTITYVYEDGTP





Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  






------------ AHE PVKQELT FTGKGTIDLVTGNLVTVDEDGNIT SQNGKITWNHESQE FEAVPA










Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1 
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
 Y I--------------------------KDEELFGRIQDAERIEEVKKLR------------------------------
-  -VSDYY----------------------------- KKLVNSAKTVAGVKKLQAQV------------------------------
G Q V Q Y F Y - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N N A T  V L L Q A V P I Q R T  L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
P V I D G Y H - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A D K R T A G G T T I T P D D L N K E V T V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
IDHDGYYISSINQSNSTASVDGQTGAVGTETVTPNSQNGNIVI-------------------------------------
I D H D G Y Y I S S I N Q S N S T A S V D G Q T G A V G T E T V T P N S Q N G N I V I - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
P K V T N  F T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - P D K E S V P A A E V T A T A E D I N E T V I Y T T K P A N I D P S K P T D P
P V V K G F L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A D K A S V A W N V T G D S E D I K E W - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
PW TGFL----------------------------- ADKASIPVVNVTGDSKDITEVV--------------------------------------
P V V K G Y L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A D K A T V P A T K V T A D S E N T K E V V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
P V V K G Y L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A D K A T V P A T K V T A D S E N T K E V V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
PVVPGYL----------------------------- ADKASVPWNVTADSKDTTEVV--------------------------------------
P V V K G Y L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A D K A T V P T T K V T A D S E N T T E W - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
P V V K G Y L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A D K V T V P T T K V T A D S E N T T E V V - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  NTPNVTPRPDDRVPNDPKGRTYKELGLIEEVTHTVHYKLADGSDAGIPDNVQTLTFTRTA
W P_0030  97 6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7  3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  T
W P _ 0 2 1 8 7 4 2 1 8 .1   T
K F L 9 7 0 1 6 . 1  TLTRNPDVPVAAQGSINYIDDTTGQTIESANFSGNVGQKINYTT
K F L 9 5 2 3 0 . 1  TLTRNPDVPVAAQGSINYIDDTTGQTIESANFSGNVGQKINYTT
W P _ 0 3 3 6 8 8 7 4 0 . 1  DLDPVTGAISNFGTWTAKDNDTTIDAITTPNKPGYVASAAKSTERTNVQATDKDSEETII
W P _ 0 0 3 0 9 7 6 8 8 . 1   T
W P _ 0 3 3 6 8 9 1 2 7 . 1   T
W P _ 0 2 0 9 0 3 4 6 8 . 1   T
W P _ 0 0 0 2 8 7 3 0 8 . 1   T
W P _ 0 3 3 6 8 5 3 8 0 . 1   T
W P _ 0 3 3 6 8 1 5 4 7 . 1   T
W P _ 0 2 3 9 4 8 4 0 9 . 1   T
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9 . 1  YQVIDENDP----------------------------------------------------------------------------------------------------------------
W P _02187  4 2 1 8 . 1  YTPNGKIIP---------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  AGSIKNWEA-----------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  AGSIKNWEA-----------------------------------------------------------------------------------------------------------------
WP 0 3 3 6 8 8 7 4 0 . 1  YRKLGSYVPVIPEGVTPPTGTDLTPKPYENPINEDPTRPGTPTETPVVPYIPGTTPVGPN
W P ~ 0 0 3 0 9 7  6 8 8 . 1  YKPLGSWVP---------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  YKPIGSWIP---------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1 YKPIGSWIP---------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  YKPIGSWIP---------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 YKPLGSWVP----------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  YKPLGSWVP---------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  YKPLGSWIP----------------------------------------------------------------------------------------------------------------
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  GKPLTPKDPNDPTKGYEVPKVPEDPTQNTTITYVKDGSQVALVHFIKADGTAVHVSVAEA
W P _0030 97 6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1 -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  GDTGKAIKTTNIDNVKAELEAKGYEWAPTDAAYTAERVAFYAEANRTFDDKDDKGNDGI
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
WT-GBl-YSIRK -------------------------------------------------------------------------------------------------------------
WT-GA-YSIRK -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1 -------------------------------------------------------------------------- VDPN------------------------------------------------
KFL97 0 1 6 . 1 --------------- --------------------------------------------------------------------KGYNLVSNNFKDGEEVFTDGKNAFEVHLV
K F L 9 5 2 3 0  . 1 --------------- --------------------------------------------------------------------KGYNLVSNNFKDGEEVFTDGKNAFEVHLV
W P _ 0 3 3 6 8 8 7  4 0 . 1  SQVYYVIVKEGITPIDPDKPLDPNTPDVTPKPGDKVPGDPKQRTFEQLGLLDEVNRTINY
W P _ 0 0 3 0 9 7  6 8 8  . 1  -------------------------------------------------------------------------- NIPGQP--------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  -------------------------------------------------------------------------- NIPGQP--------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1  -------------------------------------------------------------------------- NIPGQP--------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  -------------------------------------------------------------------------- NIPGQP--------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1  -------------------------------------------------------------------------- NIPGQP--------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  -------------------------------------------------------------------------- NIPGQP--------------------------------------------
W P _ 0 2 3 9 4 8 4  09  . 1 -------------------------------------------------------------------------- NIPGQP--------------------------------------------
WT-GBl-YSIRK ---------------------------------------------------------------------------------------------------- SDAI-
WT-GA-YSIRK ----------------------------------------------------------------------------------------------------------V-
Y P _ 0 0 5 8 6 1 6 3 9  . 1   SNPV-
W P _ 0 2 1 8 7 4 2 1 8  . 1   G N P I-
KFL97 0 1 6  . 1 HA--------------------------------------------------------------------------------------------------------------------TTPV-
K F L 9 5 2 3 0  . 1 HA--------------------------------------------------------------------------------------------------------------------TTPV-
W P _ 0 3 3 6 8 8 7 4 0 . 1 RYANTDKVDADKRGQEARPTVEQKLRYSRKGNLNKVTGEITYTSDWTKPQILAEVTSPVI
W P _ 0 0 3 0 9 7  6 8 8 . 1   T S P I -
W P _ 0 3 3 6 8 9 1 2 7  . 1   T T P I -
W P _ 0 2 0 9 0 3 4  68  . 1   T N P I -
W P _ 0 0 0 2 8 7 3 0 8  . 1   T N P I -
W P _ 0 3 3 6 8 5 3 8 0  . 1   T N P I -
W P _ 0 3 3 6 8 1 5 4 7  . 1   T D P I -
WP 0 2 3 9 4 8 4 0 9 . 1   T T P I -
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W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1   PNVPTPQYPTDPTDP
K F L 9 7 0 1 6 . 1  ------------------------------------------------------------------------------------------------------------TPENPGKPGEP
K F L 9 5 2 3 0  . 1  ------------------------------------------------------------------------------------------------------------TPENPGKPGEP
W P _ 0 3 3 6 8 8 7  4 0 . 1  EGYVADIKAAEKVENVAHDAADSVVNVVYTPLGKYVPKVPEGFEVPKVEKPQYPNDPTDP
W P _ 0 0 3 0 9 7 6 8 8 . 1 ---------------------------------------------------------------------------------------------------------------- KYPNDPTDP
W P _ 0 3 3 6 8 9 1 2 7  . 1   KYPNDPQDP
W P _ 0 2 0 9 0 3 4 6 8  . 1   KYPNDPTDP
W P _ 0 0 0 2 8 7 3 0 8 . 1 ---------------------------------------------------------------------------------------------------------------- KYPNDPTDP
W P _ 0 3 3 6 8 5 3 8 0  . 1   KYPNDPTDP
W P _ 0 3 3 6 8 1 5 4 7  . 1   KYPNDPTDP
W P _ 0 2 3 9 4 8 4 0 9 . 1  ---------------------------------------------------------------------------------------------------------------- KYPNDPTDP
W T -G B l-Y SIR K  -----------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  — TIQPNTDLLNNGQVITGNQGSNV------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  TKV-TPDEPVPNIPGLTPSVPTVT------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  VNPTNPDDPHKYPDNYVPQELAKTVTRDVTYVYADGSQAEAPVHQEVKFTGNGYLDLVTG
K F L 9 5 2 3 0 . 1  VNPTNPDDPHKYPDNYVPQELAKTVTRDVTYVYADGSQAEAPVHQEVKFTGNGYLDLVTG
W P _ 0 3 3 6 8 8 7 4 0 . 1  TKPGTPTTVIPHVPGTTPKDPNGNPLK------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  TKPGQPTETLPYVPGFTPEDKDGNPLK------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  TKPGQPTEVLPYVPGFTPEDKDGNPLK------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  TKPGQPTETLPYVPGFTPEDKDGNPLK------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  TKPGQPTETLPYVPGFTPEDKDGNPLK------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  TKPGS DKPVLPYVPGMT PKDKDGN PLK-------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  TKPGQPTEWPYVPGYTPKDKDGNPLK------------------------------------------------------------------------
W P _02394  84 0 9 . 1  TKPGKPTDVLPYV-------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K  -----------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------ PNDATTAYDAVKNALE------------------------------------------------------------------------------------
W P_021 8 7 4 2 1 8  . 1  ------------ PTDPGKDTPVPYNPVVPAKDQAAVVNYV-------------------- DADEDNKLITSSGDLTG
K F L 9 7 0 1 6 . 1  EYVTVDNNGKITGKGQINWTPESANFDATKSIDTSKYQIVGIKENNTTANVDQTTGVVAG
K F L 9 5 2 3 0 . 1  EYVTVDNNGKITGKGQINWTPESANFDATKSIDTSKYQIVGIKENNTTANVDQTTGVVAG
W P _ 0 3 3 6 8 8 7 4  0 . 1  ------ PVDPNDPSKGY-VPPTPENPTEDTQI— TYEKDTQKAKVTYWEGTGTVLHTDNLEG
W P _ 0 0 3 0 9 7  6 8 8 . 1  — PVDPT------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------ PVDPTDPSKGYVVPNIPTDPSQDTVI--NYVANKANLWKYVDENGKDLIPSETTEG
WP_0 2 0 9 0 3 4 6 8 . 1  ------ PVDPNDPTKGYEVPSIPTNPGEDTPI— NYVANKANLWKYVDENGKELQPTETKEG
W P _ 0 0 0 2 8 7 3 0 8  . 1  ------ PVDPNDPTKGYEVPS IPTNPGEDTLI— NYVANKANLWKYVDENGKELLPTETKEG
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------ PVEPNDPTKGYEVPSVPTNPGEDTPI— NYVKDKQKAKTTFVDEKGNPIPGVDAITE
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------ PVDPNDPTKGYEVPNVPTNPGEDTPI--NYVANKANLVVKYVDEKGKDLLPAETTEG
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
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W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  










W T -G B l-Y SIR K  
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 
W P _ 0 2 1 8 7 4 2 1 8 . 
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 .  
W P _ 0 0 3 0 9 7 6 8 8 . 
W P _ 0 3 3 6 8 9 1 2 7 . 
W P _ 0 2 0 9 0 3 4 6 8 . 
W P _ 0 0 0 2 8 7 3 0 8 . 
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  









-GGKFDKDKDTDQE FKVTLKERVVPVT P DQ PK- 
-KGKIGKDGS-------------------------------------------------
-TPGAPVDPN
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _02187  4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 .1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 .1  


















Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  WDNVTGKVITDGAWNVTSHTFGNVDTPVIDGYHADKRTAGGTTITPDDLNKTVTVNYTP
K F L 9 7 0 1 6 . 1 LVDKVTGKIIDSGEWNVTSHTFGYKDT PVIDGYHADKRNAGGSWTPNDLNKKVWTYKP
K F L 9 5 2 3 0  . 1  LVDKVTGKI IDSGEWNVTSHTFGYKDTPVIDGYHADKRNAGGSWT PNDLNKKVWTYKP
W P _ 0 3 3 6 8 8 7 4 0 . 1  TGEITYGDWTAKDGDTTFDKVESPWKGYILKDAKQKEVAATTGLTADSKDENIKWYVP
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ----------------------------------------------------------------------------------------------------------------------------- YKP
W P _ 0 2 0 9 0 3 4  6 8 . 1  KYVDENGKDLIPSETTEGKVGDEYTTSGKVIPGHLLVRVDGDAKGKIGTEGSTVTYVYKP
W P _ 0 0 0 2 8 7 3 0 8 . 1  ----------------------------------------------------------------------------------------------------------------------------- YKP
W P _ 0 3 3 6 8 5 3 8 0  . 1  TGEVTYGDWTPAQD--------------- LAEVKSPWKGYLADKVTVPTTKVTADSKDTKEWTYKP
W P _ 0 3 3 6 8 1 5 4 7 . 1  ----------------------------------------------------------------------------------------------------------------------------- YKP
WP 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 58 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 023948409.1
NGKIIPVDPNG------------------ NPIPNVPTP------------- QYPTDPTDPTKVTPD— EPVPTIPG
NGKIIPTDPSG------------------ NPIPNVPTP------------- TYPTDPTDPTKWPD— EPVPDIPG







W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  AKGYVISSKSSTVPTIFGP------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  YTPS------------------------------------------------------------------TPTVTPTDPGKDTPVPYNPVVPAKD
K F L 9 7 0 1 6 .  1 MTPS------------------------------------------------------------------T PTVT PEDPGKDT PVPYN PWPAKN
K FL 9 5 2 3 0  . 1  MTPS------------------------------------------------------------------T PTVT PE DPGKDT PVPYN PWPAKN
W P _ 0 3 3 6 8 8 7 4 0 . 1  TTPVVPKDPTKPISPDNPLVPLTPVDPNDPTKGYEVPPV-PTDPSTDTPITY--------VTDK
W P _ 0 0 3 0 9 7 6 8 8  . 1 --------------------------------------------------------------DPTKGYWPNI-PTDPSQDTVINY--------VANK
W P ~03368  9 1 2 7  . 1 FT PE------------------------DKDGNPLKPVDPKDPSKGYVVPNI-PTDPSQDTVINY--------VANK
W P _ 0 2 0 9 0 3 4  68 . 1  FT PE------------------------DKDGNPLKPVDPTDPSKGYVVPNI-PTDPSQDTVINY--------VANK
W P _ 0 0 0 2 8 7 3 0 8  . 1 FT PE------------------------DKDGNPLKPVDPNDPTKGYEVPSI-PTNPGEDTPINY--------VANK
W P _ 0 3 3 6 8 5 3 8 0  . 1  HTPV------------------------DGNGQPLKPVDPKDPSKGYEVPNV-PTNPGEDTPINY--------VANK
W P _ 0 3 3 6 8 1 5 4 7  . 1  YTPK------------------------DKDGNPLKPVDPNDPTKGYEVPSV-PTNPGEDTPINY--------VANK
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
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W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1 
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
--------------------- DARQ-----------------ALVGKLDDQEASA------------------------------------------------------












W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3  9 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1   TSSTIEDLINKGYVLVNDGFPKDATYDNDDNTTQTYTW
K F L 9 7 0 1 6 . 1 --------------- ------------------------------------------------------------------------------------- TADQIKKLINQGYVLKNDGFP
K F L 9 5 2 3 0  . 1 --------------- ------------------------------------------------------------------------------------- T ADQ I  KKL INQG YVLKN DG FP
W P _ 0 3 3 6 8 8 7 4 0 . 1  SKDTDRVFDKDKSVDQIFTVTVAERIIPVTPGKPVDPNDPNLPKNPDGTPVTPSTPE-----
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  FKHGTVPVTPTNPGKPGEPINPNDPDGPKWPDGTGENSIDKTVTRTITFVDSNGKEVSSP
K F L 9 7 0 1 6 . 1  AGAVFDNDDSKNQVFYVDFIHGQAPVNPDNPHEGIDPSQYEKTVTEKVHYVGAGDKTPAD
K F L 9 5 2 3 0 . 1  AGAVFDNDDSKNQVFYVDFIHGQAPVNPDNPHEGIDPSQYEKTVTEKVHYVGAGDKTPAD
W P _ 0 3 3 6 8 8 7 4 0  . 1  ---------------------------------PGKPVFPGDPNSPVWPNTVKDLVTEKSATRTIKYVDRNGKEVSET
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
Figure Al. Continued.
3 1 9
W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P J 3 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------------ STDADKVS
W P_021 8 7 4 2 1 8 . 1  VEQSVHFTATGVIDKVTGKWVTPLSWSPDQSIDGRNVPFVDGYHWSIDK— DGNGLTNV
K F L 9 7 0 1 6 . 1  NVQNSKWTRTLTIDTVTGKVVENGQYTTDWSIAKGEKTVYDQVSTPVIDGYHADKREVPA
K F L 9 5 2 3 0 . 1  NVQNSKWTRTLTIDTVTGKWENGQYTTDWSIAKGEKTVYDQVSTPVIDGYHADKREVPA
W P _ 0 3 3 6 8 8 7 4 0 . 1  RTETIKFTREAKVNIVTGEITYGEWT-------------TDRNDDIFNGYQVPVVKGYIAKAGDLES
W P _ 0 0 3 0 9 7  6 8 8 . 1  -------------------------------------------------------------------------------GKVIPGYVLVRVDG— EAKGKIGT
W P _ 0 3 3 6 8 9 1 2 7  . 1  -------------------------------------------------------------------------------GKVIPGYLLVRVEG— EAKGKIGK
W P _ 0 2 0 9 0 3 4 6 8  . 1  ------------------------------------------------------------------------------ GKVIPGYLLVRVDG— DAKGKIGK
W P _ 0 0 0 2 8 7 3 0 8  . 1  ------------------------------------------------------------------------------ GKVITGYVLDRVEG— EAKGKIGT
W P _ 0 3 3 6 8 5 3 8 0  . 1 ------------------------------------------------------------------------------ GKVITGYVLERVEG— EAKGKIGE
WP 0 3 3 6 8 1 5 4 7  . 1 ------------------------------------------------------------------------------ GKVIKGYVLVRVDG— EAKGKIGK
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K
WT-GA-YSIRK
Y P _ 0 0 5 S 6 1 6 3 9 . 1 
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 023948409.1
-dseydfvrpdvd- -








DGTTV--------------------------- T YVYKPLGSWIPNIPGQPTT P------- IKYPNDPQDPTKPGQPTE
NGTTV--------------------------- TYVYKPLGSWVPNIPGQPTDP------- IKYPNDPTDPTKPGNDKP
DGSTV--------------------------- TYVYKPLGSWVPNIPGQPTDP------- IKYPNDPTDPTKPGKDKP
W T -G B l-Y SIR K  -----------------------------------------------------------------------------------------------------------------------------------
W T -G A -Y S IR K  --------------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 VTGKVIGYV----------------------------------------------------------------------------------------------------------------
W P _02187  4 2 1 8 . 1  V-PTIPGYT PST PTVT PT DPGKDT PVPYNPVEAKQGSVQVIFHDDTTNTTIPDVGYNSGS
K F L 9 7 0 1 6 . 1  V-PEVPGMT-----------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  V-PNIPGMTPSTPTVTPEDPGKDTPVPYNPVVPAKDQAAVVNYVDADNNNTIITSSGNLT
W P _ 0 3 3 6 8 8 7 4 0 . 1 KVPYVPGFI----------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  VLPYVPGYT----------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  VLPYVPGHT----------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 .1  VLPYVPGHT----------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  VLPYVPGFT----------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  VLPYVPGYT----------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  VLPYVPGYT---------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8  . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1 
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
W T -G B l-Y SIR K  -----------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  VDNVTGKVISTGAWNVTSHTFGNVNTPVVDGYHADKRTAGNTTITPEDLNKTVTVNYTAN
K F L 9 7 0 1 6 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  VDKVTGKVVDGGSWNVTSHTFGYKNTPVIDGYHADKRNAGGSWTPDDLNKTVTVTYKQN
W P _ 0 3 3 6 8 8 7 4 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
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KPGKPGEPINPNDPDGPKWPDTTGKDNLSKTGTQTIHYTGAGNNTPKDNVQSFTFTRTAV
NPGKPGEPINSNDPDGPKWPEGTDENSVKRTGTQTIHYVGAGDKTPSDDVQTFDFTRKMV
QKAGTKVDYTTTKS1 S DLEVKGYVYVSTDGTIPTEITADKNIT— VTVHMKHGTTTVT PD
GKAGSRIDYSTKTTIADLENKGYVLVNDGFPADATFDNDDSTTQVFTWLKHGTVPVTPE
3 2 1
W T -G B l-Y SIR K
W T-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
WP 0 3 3 6 8 8 7 4 0 . 1
W P _ 0 0 3 0 9 7  6 8 8 .  
W P _ 0 3 3 6 8 9 1 2 7 . 
W P _ 0 2 0 9 0 3 4 6 8 . 
W P _ 0 0 0 2 8 7 3 0 8 . 
W P _ 0 3 3 6 8 5 3 8 0 . 





 PVDPEGQPLK---------------- PVDPNDPTK------ GYEVPD----------------------VPGDPTQDTP
 PVDGNGQPLK---------------- PVDPNDPTQ— GYEVPN-----------------------VPNDPTKDTP
 PVDGNGQPLK---------------- PVDPNDPTK------GYEVPD----------------------IPTNPGEDTP
 PVDGNGQPLK---------------- PVDPNDPTK------ GYIS PD----------------------1PTN PGEDTP
 PEDKDGNPLK---------------- PVDPKDPSK— GYVVPN----------------------- IPTNPGEDTP
 PKDKDGNPLK---------------- PVDPNDPTK------GYEVPN----------------------VPTNPSEDTP
 PKDKDGNPLK---------------- PVDPNDPTK------ GYEVPS----------------------VPTN PGEDTP
WP 0 2 3 9 4 8 4 0 9 . 1
W T -G B l-Y SIR K  -----------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  VPY-----------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  VPYNPVKNPDKVTTVEGKQIVHFVDGDNGNTPLRDPNTQTHEFKITNGVPDESSHTFTLV
K F L 9 5 2 3 0 . 1  VPYNPVKNPDKVTTVEGKQIVHFVDGDNGNTPLRDPNTQTHEFKITNGVPDESSHTFTLV
W P _ 0 3 3 6 8 8 7 4  0 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  INY-----------------------------------------------------------------------------------------------------------------------------
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K
WT-GA-YSIRK
Y P 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  






 IP N -------------------- SPKPNPTPYP-------------------- GPTPAPTPKPEPKPE-------------------
 IPNVTPNGDQNGYTPQPKPQPEQWTYYVDENGKDIAPSEKGAQAPK-------- GISGY
 IPNVTPNGDQDGYTPQPKPQPEQVVTYYVDENGKDIAPSEKGAQAPK-------- GISGY
 IP N -------------------- SPKPNPTPYP-------------------- GPTPAPTPKPEPKPE-------------------
 VPN--------------------------------------------------------------------------------------------------------------------
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W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _02187  4 2 1 8  . 1   PAPHGEKPEEPDRPA---PAPHAPKAP--
K F L 9 7 0 1 6 . 1  PTDPTKWPNEPVPAITGKTPDKTSVTPVDPTKDT PWYKNNEVPATPNSQKAWNFIDV
K F L 9 5 2 3 0  . 1  PTDPTKWPNEPVPAITGKTPDKTSVTPVDPTKDTPWYKNNEVPATPNSQKAWNFIDV
W P _ 0 3 3 6 8 8 7 4 0 . 1  PKPEPKPEPETPQPVT PADDGDNN------GNNNGTPSTPAQP-------------------
W P__0030976 8 8  . 1  --------------------------------------------- TPQPVTPADNGDNN GNNNETPTTPAQP-------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   PAPVPSTPETPEQPVAPVQPEQPTTPTQP-------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  EYVTTTKDPNGNLVHHYKKVATPQPVPSTPETPEQPVAPVQPEQQTNPNQP--------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  EYVTTTKDPNGNLVHHYKKVATPQPVPTTPETPEQPVAPVQPEQPTTPTQP--------------------
WP_0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------PAPVPST PET PEQPVAPMQPEQPTNPNQP--------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1   PREVEKPAKPAQP-------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W T -G B l-Y SIR K  ------------------------------------------------------------------------------------------------------------------------------------
W T-GA-YSIRK ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _02187  4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 NTGKLIKTSGILSGRPGEDINKLYSSAEVIKQLEEAGYEWYNAFDGDGVTKYFDDDDNT
K F L 9 5 2 3 0 . 1  NTGKLIKTSGILSGRPGEDINKLYSSAEVIKQLEEAGYEWYNAFDGDGVTKYFDDDDNT
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 .1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
W T -G B l-Y SIR K
WT-GA-YSIRK
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 .1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
WP 0 2 3 9 4 8 4 0 9 . 1
------------------------------------------------------------------------------ TAKGNNT PVKENKTVPTAA- PW K













Y P _ 0 0 5 8 6 1 6 3 9 . 1   TITDGDNAWTSVNNTWSAFTP------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  NEQTPEAELPQTGEKNDSAAAILGATAGMIGLIGLLGVKKKHSEN- 
K F L 9 7 0 1 6 . 1 KTNNKKEVLPQTGADNNEAASILGAVATAIGMTSLIGAKRRKKDDK
K F L 9 5 2 3 0 . 1  KTNNKKEVLPQTGADNNEAASILGAVATAIGMTS LIGAKRRKKDDK
W P _ 0 3 3 6 8 8 7 4 0 . 1  QYMDGQRELPNTGTEDHASLAALG-LLGALSGFGLI-ARKKREDEE 
W P _ 0 0 3 0 9 7  6 8 8 . 1  QYMDGQRELPNTGTEDNASLAALG-LLGVLSGFGLV-ARKKKED—  
W P _ 0 3 3 6 8 9 1 2 7 . 1  KYVDGQKELPNTGTEANAS LAALG- LLGALGG FGLL-T RKKKE D—
W P _ 0 2 0 9 0 3 4  6 8 . 1  KYVDGQKELPNTGTEANASLAALG-LLGALGGFGLL-ARKKKED—  
W P _ 0 0 0 2 8 7 3 0 8 . 1  KYVDGQKELPNTGTEANASLAAFG-LLGALGGFGLL-ARKKKED—  
W P _ 0 3 3 6 8 5 3 8 0 . 1  KYVDGQKELPNTGTEANASLAALG-LLGALGGFGLL-SRKKKED—
W P _ 0 3 3 6 8 1 5 4 7 . 1  KYVEGQKELPNTGTEANASLASLG-LLGALGGIGLL-TRKKKED—
WP 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------




Y P _ 0 0 5 8 6 1 6 3 9  . 1   MGMFFNKKDNDSKQRFGIRKLTIGACSVLLSTLIL------------- GI
W P _ 0 3 3 6 8 8 7 4 0 . 1  ------------------------MYKSKRRKNKSFDWYG-LSQRFSIRKYHFGAASVLLGTALILGAAQTTA
W P _ 0 0 3 0 9 7 6 8 8  . 1  --------------------------------------------- MEKFHGRKAQRFSIRKYSFGAASVLLGTALFLGAN— GV
W P _ 0 3 3 6 8 9 1 2 7  . 1  -------------------------------------MYSRMEKYHGRRAQRFSIRKYSFGAASVLLGTALLLGAN- -AV
W P _ 0 2 0 9 0 3 4 6 8  . 1  -------------------------------------MYSRMEKYHGRRAQRFSIRKYSFGAASVLLGTALVLGAN--GV
W P _ 0 0 0 2 8 7 3 0 8  . 1  ------------------------------------ MY S RMEKYHGRRAQR F S I  RKY S FGAASVLLGTALLLGAN— AV
W P _ 0 3 3 6 8 5 3 8 0  . 1  -------------------------------------MYSRMEKYHGRRAQRFS I  RKY S FGAASVLLGTALVLGAN— GV
W P _ 0 3 3 6 8 1 5 4 7  . 1  -------------------------------------MYSRMEKYHGRRAQRFSIRKYSFGAASVLLGTALLLGAN--AV
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------- MYSRMDKYHGQKVQRFSIRKYSFGAASVLLGTALLLGTN— AV
W P _ 0 2 1 8 7 4 2 1 8 . 1  -------------------------- MVSKNNRDKKMEAVAERKPHFAIRKLTIGAASVLLGTSLWMSTSTSTV
K F L 9 7 0 1 6 . 1 MIYYDSKWRETGMLSKNNYQERLRKMDDKQERFSIRKFSVGAASVLVGTAILSMQNVQTV
K F L 9 5 2 3 0 . 1  MIYYDSKWRETGMLSKNNYQERLRKMDDKQERFSIRKFSVGAASVLVGTAILSMQNVQTV
WT-GA ------------------------------------------------------------------------------------------------------------------------------------
WT-GB1 ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9  . 1  GTQEQNSKAQAATTETSNTASS------------------------------------T DLVDNHRNKNTYLSS SEVNET
W P _ 0 3 3 6 8 8 7 4 0 . 1  KAEETVT— ENKTEAVASAPKDDKASENVTNVTTPALSATTEAAVVEKPTLSDEEVAKLA
W P _ 0 0 3 0 9 7  6 8 8 . 1  RADEATPSVNPATSGLSNSDKNVSGSTLSTPWEKLPELKIDAVKADENAEVKEESKNEV
W P _ 0 3 3 6 8 9 1 2 7 . 1  KADETLP-VNPTASDLAATNKKDADSALTTPWEELPELKIDAVKADEKAKAKEDAKTEA
W P _ 0 2 0 9 0 3 4  6 8 . 1  QAEETVA-VNPATSELSNSDKNLSGSTLSTPVVEELPELKIDDVKAEEKTEAKEDAKTAA
W P _ 0 0 0 2 8 7 3 0 8 . 1  KADETST-ASTKTSEVTNSDKQKPDSAITTPWEELPELKIDAVKADEKPEVKEEAK-------
W P _ 0 3 3 6 8 5 3 8 0 . 1  QADETLP-VNPATSDLAATNKKDADSALTTPVVEELPELKIDAVKADEKAEPKEDVKTEA
W P _ 0 3 3 6 8 1 5 4 7 . 1  KADETST-ASAKTPEVTNSDKQKSDSGSTTPWEELPELKIDAVKADEKPEVKEEAKTEA
W P _ 0 2 3 9 4 8 4 0 9 . 1  KADETNT-GSAKATEITNPDKQKPDSAITTPWEELPELKLDAVKADEKSEVKEEAK-------
W P _ 0 2 1 8 7 4 2 1 8  . 1  HADETDNNDSDAKTNLESNQSASTGH---------------------------VEKVWEQNQTANENTDDSTKT
KFL97 0 1 6  . 1  HADATTDTEKGTTDVTSKNDEQNKQK---------------------------AYNQWSEDQNKASKTTDTTMV
K F L 9 5 2 3 0  . 1 RADATTDTEKGTTDVTSKNDEQNKQK---------------------------AYNQWSEDQNKASKTTDTTMV
WT-GA
WT-GB1
YP 0 0 5 8 6 1 6 3 9 . 1
W P _ 0 3 3 6 8 8 7 4 0 , 
WP 0 0 3 0 9 7 6 8 8 ,
WP 0 3 3 6 8 9 1 2 7 . 1
W P _ 0 2 0 9 0 3 4 6 8 , 
WP 0 0 0 2 8 7 3 0 8 .
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1
ATKVNEKETSAGNEQQDSQSAVAQDKQSGEKAADVVTNNRSTVED-KSSNNAESSETTDN
AEASKKDDKASETATTEKTEAADKEKATLTAPLTDKKADKAVDEKADKKDEKKAENPITA
TTVAEKEVTEATT DKTDKKTET DVKEKS DKEHADKTEADKEKT-------------EKVETEKAQDD
T PVVEKEITEATAEKT DKKLET DVKEKS DKEQADKKEATKEKTDK-KTSEKVETEKVQDD 
TPVAEKEVTEATADKTDKKLETDVKEKSDKEQSDKKEADKEKTNK-ETSEKVETEKAQDD
-  PVAEKEVT DKAA----------------------- TEKSDKEQADKKEVAKEKTDK-E S PKKAATEKAQDE
T PWEKEV S DKS DKEAS---------------KEKSDKEQADKKEATKEKTDK-ETSEKVETEKAQDD
KPVAEKEVADKAA------------------------TEKSDKEQADKKEADKEKTNK-ETSEKATTEKAQDE




Figure A2. MUSCLE alignment of 12 mucus-binding proteins with WT-GB1 and
GA. Accession numbers correspond to mucus-binding proteins found in Figure 40.
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WT-GA  MEAVDANS LAQAKEAA
W T-GBI ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 TKNTVN--------------------- SDRAEVTNKEANTQTDSKKVTQKTSDQAVNDVNKNVAETTTDTR
W P _ 0 3 3 6 8 8 7 4 0 . 1  TKTVLEQLTSEAEVLNTTASNFADKKAEDKAGKEAIATAVASAKVQIEASKKALAAGEIT 
W P _ 0 0 3 0 9 7 6 8 8 . 1  VKTVLTQLTSEADVMATVASNFSDKEVTGVEDKQNLSAAITAVKLEATASKELL-LSDAS 
W P _ 0 3 3 6 8 9 1 2 7 . 1  VKTVLTQLTSEADVMASVASNFSDKEVKDDASKQKLSAAVAAVKLEAVASKGLL-SSDAS 
W P _ 0 2 0 9 0 3 4 6 8 . 1  VKTVLTQLTSEADVMATVASNFSDKEVKDVESKQKLSAAIAAVKLEAVASKGLL-SSDAS 
W P _ 0 0 0 2 8 7 3 0 8 . 1  VKTVLTQLTSEAEVMASVASNFSDKEVKDEAAKKELAVTIEAVKLEAAKSNDLL-SSDAS 
W P _ 0 3 3 6 8 5 3 8 0 . 1  VKTVLTQLTSEAEVMATVASNF5DKEAKDVEAKQKLSAAIAAVKLEAVAAKGLLYSNDST 
W P _ 0 3 3 6 8 1 5 4 7 . 1  VKTVLTQLTSEAEVMAKVASNFSDKEVKDEAAKKELAVKIEAVKLEAAKSNDLL-SSDAS 
W P _ 0 2 3 9 4 8 4 0 9 . 1 VKTVLTQLTSEAEVMATVASN FS DKEAKDVEAKQKLSAAIAAVKLEAVASKGLL-SS DAS
WP 0 2 1 8 7 4 2 1 8  . 1  DKTTKTKQDDNKSSQTIDNKKSSEKAATDTSNKNNVEQSANSVENNANIDNSIAANTQTD 
K F L 9 7 0 1 6 . 1  DAVADKSTEDKTNTATTQESSDNKSTENKTTDAQKVESKVATAKATTDTANSVKTASTTS
K F L 9 5 2 3 0 . 1  DAVADKSTEDKTNTATTQESSDNKSTENKTTDAQKVESKVATAKATTDTANSVKTASTTS
WT-GA IK EL---------------------------------------------------------------------------------------------------------------------------
W T-GBI -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9  . 1 NTKVSSYTSNL— DLENIQESLEQ---------------------------------------------------------- QAKENNGKA-
W P ~ 0 3 3 6 8 8 7 4 0 . 1 KQELDAQLQRISSAIEAVYDEMKR---------------------------------------------------------- AGHLGKVEAV
W P _ 0 0 3 0 9 7 6 8 8  . 1 KDQMVAQVNRLSDAIEAVYAEMKR---------------------------------------------------------- AGHAGKVEAV
W P _ 0 3 3 6 8 9 1 2 7  . 1  KDQMVAQVNRLSAAIEAVYAEMKR---------------------------------------------------------- AGHAGKVESV
W P _ 0 2 0 9 0 3 4  68  . 1  KDQMVAQVNRLSAAIEAVYAEMKR---------------------------------------------------------- AGHAGKVEAV
W P _ 0 0 0 2 8 7 3 0 8  . 1  KDQMVAQVNRLSAAIEAVYTEMKR---------------------------------------------------------- AGHAGKVESV
W P _ 0 3 3 6 8 5 3 8 0  . 1  EEQLTSQVNRISSAIEAVYAEMKR---------------------------------------------------------- AGHAGKVEAV
W P _ 0 3 3 6 8 1 5 4 7  . 1  KDQMVAQVNRLSAAIEAVYAEMKR---------------------------------------------------------- AGHAGKVEAR
WP 0 2 3 9 4 8 4 0 9 . 1  KDQMVAQVNRLSAAIEAVYAEMKR---------------------------------------------------------- AGHAGKVEAV
W P _ 0 2 1 8 7 4 2 1 8 . 1  ITKSNIQLNESLPSIAQAGQNGKTIVKDNDTTTQELKIGDLSSDLSGDALKANLTKGNQV
K F L 9 7 0 1 6 . 1  TDQTTSVNTTTFNT------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  TDQTTSVNTTTFN--------------------------------------------------------------------------------------------------------
WT-GA
WT-GBI
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
WP 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 








LAETHT----------- GKALIKEGKAWN VQNAYITMNADN SAP--------------------------------------------








Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  AG GATVTINGVKTNIPSGDTWGTAGTKNLEQLKNNINWFDFAAASITYSNGTVVGP
W P _ 0 0 3 0 9 7 6 8 8  . 1   KAWGFDSTFDTSDLQAG--------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   TGWGFDTTISTSTLNAG--------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  68  . 1   TGWGFDTTISTSTLKAG--------------------------------------------------------------------------
WP_0 0 0 2 8 7 3 0 8 . 1  -------------------VGWGFDTTI ST STLKAG--------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1   KAWGIDVVFDTSQAQNG--------------------------------------------------------------------------
W P J ) 3 3 6 8 1 5 4 7  . 1   TAWGIEISFDTSRTQKG--------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1   TAWGIEISFDTSRTQKG--------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  SGVNISGNITAYG-DLNINRT FTIKGADNNATLS LGQNKIN-------------------------------------------
K F L 9 7 0 1 6 . 1 AGINIDRSIDASNVNLAITNTFAIVGINDAAVLNLGQKSLN------------------------------------------
K F L 9 5 2 3 0 . 1  AGINIDRSIDASNVNLAITNTFAIVGINDAAVLNLGQKSLN------------------------------------------
WT-GA ------------------------------------------------------------------------------------------------------------------------------------
WT-GBI -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  ARKLAQPITKTITYPNGDRVEGKITMVRDVTYADGSKGLTTDDKFLNSGTAKYVEHLYYT
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
WT-GA ------------------------------------------------------------------------------------------------------------------------------------
WT-GBi -------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9  . 1  ADKIKANAAV------------------------------
W P J ) 3 3 6 8 8 7 4 0 . 1  GGAQNDHELYEALQEGMKFNVKTKVEGYALTATVIKLGSKAVDSDPNKTPAGPVNAVRDY
W P _ 0 0 3 0 9 7 6 8 8 . 1 ---------------------------------------DITKIEVTNLAEFGAAFPVGK----------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  ---------------------------------------SITKIELTNLAELGAGLAVNT----------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1  ---------------------------------------DVTKIELTNLAELGSGLAVNS----------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  ---------------------------------------SITKIELTNLAELGGGLAVNT----------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1  ---------------------------------------DTTTIEMKNLTGFGDSFKPGT----------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  ---------------------------------------DTTKIELKNLAGFGDAFKAGT----------------------------------------------
WP_02 3 9 4 8 4 0 9 . 1  ---------------------------------------DTTKIELKNLAGFGDAFKVGT----------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  ---------------------------------------NNGQLTLDDITVNGSILGNGTVNIKGTVTSNVNSVNSSV------
K F L 9 7 0 1 6 . 1  ---------------------------------------NSGNLTLQDITINGAVSGNGTVNIKGNVTSNVNENNSLIKGA





Y P _ 0 0 5 8 6 1 6 3 9 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7  4 0 . 1  GDWGSDKQLAKAQAED---------------KRFKANATKNKTTLANNPTVSVNGVALTLPEYPTETF
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ _ 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1   PTQDQFKAQNYTG------------------------------ NRN-----------N FKN SN IAGN SVNIENGASLTI
K F L 9 7 0 1 6 . 1 TADAANAALKDQTSTGTIGTQGTSWASGSSNQNGWTVKGWNYANFSGSKVNVAADANLTI
K F L 9 5 2 3 0 . 1  TADAANAALKDQTSTGTIGTQGTSWASGSSNQNGWTVKGWNYANFSGSKVNVAADANLTI
WT-GA ------------------------------------------------------------------------------------------------------------------------------------
W T-GBI -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  TIPSTDGRY-------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7  4 0 . 1  ANTDAYYSKAAAYNGAVKAYNQAIDAQQLSATKLSETGFTYVNVNGKAVPNGSANLYKKI
W P _ 0 0 3 0 9 7  6 8 8  . 1   EITAADGT---------------------------------------------------------------------V I -------
W P _ 0 3 3 6 8 9 1 2 7  . 1   EIRATDGT---------------------------------------------------------------------VV-------
W P _ 0 2 0 9 0 3 4 6 8  . 1   EIRATDGT---------------------------------------------------------------------VV-------
W P _ 0 0 0 2 8 7 3 0 8 . 1  EIRETDGT---------------------------------------------------------------------VV-------
W P _ 0 3 3 6 8 5 3 8 0  . 1   KITAADGT---------------------------------------------------------------------V I -------
W P _ 0 3 3 6 8 1 5 4 7  . 1   PIKAADGT---------------------------------------------------------------------T I -------
W P _ 0 2 3 9 4 8 4 0 9 . 1   PIKAADGT---------------------------------------------------------------------T I -------
W P _ 0 2 1 8 7 4 2 1 8 . 1  NSSEINDGINLTDGGTVRVGDNA— TLNVNLTNASTTATRYHVAGVFAKNGGNFIS-------
K F L 9 7 0 1 6 . 1 ----------------NRSAIGDGIHLANNGTVNVADGGQLTINMNTNNDLNTTARYHNAGIFAVGNGNFTT-------
K F L 9 5 2 3 0 . 1 ----------------NRSAIGDGIHLANNGTVNVADGGQLTINMNTNNDLNTTARYHNAGIFAVGNGNFTT-------
WT-GA -----------------------------------------------------------------------------------------------------------------------------------
WT-GBI -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  GNERKADVLITAQDTQWSYLRKAGLPTINPDGSEMLTAFTSSRDESNVGVTFALSATYNG
W P _ 0 0 3 0 9 7  6 8 8 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
W P _ 0 3 3 6 8 9 1 2 7 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
W P _ 0 2 0 9 0 3 4 6 8  . 1 ----------------------------------------------------------------------------------------------------------------------------------G
W P _ 0 0 0 2 8 7  3 0 8 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
W P _ 0 3 3 6 8 5 3 8 0 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
W P _ 0 3 3 6 8 1 5 4 7 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
W P _ 0 2 3 9 4 8 4 0 9 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
W P _02187  4 2 I 8 . 1  ----------------------------------------------------------------------------------------------------------------------------------G
K F L 9 7 0 1 6 . 1  ----------------------------------------------------------------------------------------------------------------------------------G





Y P _ 0 0 5 8 6 1 6 3 9 . 1 --------------------------------------------- TLYISRNTWGNTTD GNQPTKVLLSGNVLS---------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  RIVDVNVIAADAEEAGRTEIVQFETDGTKWEQFMALNLQKDIDEKTAQGVYPSRQSDVNA
W P _ 0 0 3 0 9 7 6 8 8 . 1  KVKSIDYKTSTGNNNNKSV— PYWAQRTQRGMTYDERVAEQPAIANETGTYTY--------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  KVKSIDFKTTTGNNNNKSV—  PYWAQRTQRGMTYDQRVAEQPAVANETGTYTY----------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  KVKSIDFKTTTGNNNNKSV— PYWAQRTQRGMTYDQRVAEQPAVANETGTYTY----------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  KVKSIDYKTTTGNNNNKST— PYWGQRTQRGMTYDQRVAEQPAVANETGTYTY--------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  EVSSKETTNSVGSRGGES-------- PFWSQRKKDGKTYEERLAEQPAIPNEVGTTTY--------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  VVKSAAQSNSTGNKGTTS-------- PYWAQRMKDGMTYEERLAEQPAIPNEVGTITY--------------
WP_02 3 94 8 4 0 9 . 1  VVKSAAQSNSTGNKGTTS-------- PYWAQRMKDGMTYEERLAEQPAIPNEVGTITY--------------
W P _02187  4 2 1 8 . 1  YKSNVNFNTGLGQAIAIGATRPTGTDSDRFGGYGARSRNDGPTLVQLGDSSTFNFTGRDG 
K F L 9 7 0 1 6 . 1  YKSWTLNTSIGQGIAMTGMRPYVTDTDVFGGYSARDRGDGSGQINLGQYSTLNFTGRDG
K F L 9 5 2 3 0 . 1  YKSWTLNTSIGQGIAMTGMRPYVTDTDVFGGYSARDRGDGSGQINLGQYSTLNFTGRDG
WT-GA ------------------------------------------------------------------------------------------------------------------------------------
WT-GBI ------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 --------------------------------- GDTVTISIPSYGIVGVNSPTI---------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  DGRLAEAGYNPKDWVNVDENGNPSAYGTNTFGANYTSMGSKNSLPIALSQNVKTLSMYLN
W P _ 0 0 3 0 9 7 6 8 8  . 1  -------------------------------- NIEWNEKAKDYPNISFGAENL-----------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1   NIEWNDKVKDYPNVSFGASNL----------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1  NIEWNDKVKDYPNVSFGASNL----------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1   NIEWNDKVKDYPNVSFGASNL----------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1   TIRWNDKAKNYAVTTFYAENL----------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  -------------------------------- TIEWNEKASNYPVTTYSVENL----------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1   T IEWNEKASNYPVTT YSVENL-----------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  IILGNNAN F IS  GEN SNVHFENKGRGVALDLAAN S N I ----------------------------------------------------
K F L 9 7 0 1 6 . 1  VILGNNSNFNVGDSANVHFENKGRGVALDLAANSNI----------------------------------------------------
K F L 9 5 2 3 0 . 1  VILGNNSNFNVGDSANVHFENKGRGVALDLAANSNI----------------------------------------------------
WT-GA -----------------------------------------------------------------------------------------------------------------------------------
W T-GBI -----------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------- D--------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  SAGAQAGTIGFMIYDGGDAPQSYGSAQHIIGDFNKEWKDGVKTQVTATQPYLGNVKGDP
W P _ 0 0 3 0 9 7  6 8 8 . 1  -------------------------------------------------------------------------------------SG------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -------------------------------------------------------------------------------------SG------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -------------------------------------------------------------------------------------SG------------------------------------------
W P _ 0 0 0 2 8 7  3 0 8 . 1  -------------------------------------------------------------------------------------SG------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -------------------------------------------------------------------------------------TG------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  -------------------------------------------------------------------------------------TG------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  -------------------------------------------------------------------------------------EISKHSTTYFHSVGKT----------
K F L 9 7 0 1 6  . 1  -------------------------------------------------------------------------------------NIDDHAVTYFHSVGKTTTNAL





YP_0 0 5 8 6 1 6 3 9 . 1   ANYGSASLKDMGNDKWIY---------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  DFRSTKTDPSGGWVLDDLITSEKYKETPLESGKTVVTTDKGVTGKYLLLPNGNAVIEKSD
W P _ 0 0 3 0 9 7 6 8 8  . 1  --------------------- GGYLAPQISKDTDYKATIKIDGRTW----------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  --------------------- NGYLAPQISKDTPYTATIKIDGRTVL----------------------------------------------------
WP_0 2 0 9 0 3 4 6 8 . 1  --------------------- DGYLAPEI SKDT PYTAT IK I  DGRTVL-----------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1 ------  SGYYAPEISKDTPYTATIKIDGRTVL----------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------TAIDYYAPNISKDT EYTAAISVNGQPIL----------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  ---------------------- SGYYAPQISKDTEYTAEIKVDGQKVL---------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 ---------------------- SGYYAPQISKDTEYTAEIKVDGQKVL---------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1   GTSGSYDGYNYIGVNEGGNITVDEYATFRVIL------------------------------------------------
K F L 9 7 0 1 6 . 1 GNTVGASGSFSGYNYIGVNEGGNITVGKFATFRVIL---------------------------------------------------
K F L 9 5 2 3 0 . 1  GNTVGASGSFSGYNYIGVNEGGNITVGKFATFRVIL---------------------------------------------------
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBi -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1 NTRVLLNQGDVIEMVNPSTKLPIRGIYNHTTGALGEGTLGDEGESQLLDPAVATEYKLRQ
W P _ 0 0 3 0 9 7 6 8 8 . 1 ----------------------EHT--------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1 ----------------------EHT--------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  -------------- EHT--------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -------------- EHT--------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 --------------------- EHK--------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 --------------------- EHT--------------------------------------------------------------------------------------------------------------
W P _02394 8 4 0 9 . 1 ------ ---------------EHT--------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ---------------EGRGDNPWDDVVSLDSQNANTTAAFTSKKGAIVDIRDDNTNFYAELISFPLGG
K F L 9 7 0 1 6 . 1--------------- --------------- EGRGNNNYDDVVSLDSQNTNTNAAFTSKTGAIVDIRDDNTNFYAELISFPLGA
K F L 9 5 2 3 0 . 1 --------------- --------------- EGRGNNNYDDWSLDSQNTNTNAAFTSKTGAIVDIRDDNTNFYAELISFPLGA
WT-GA -------------------------------------------------------------------------------------------------------------
W T -G B I --------------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  AQGNEYVLDGVRANLGVNNDKAYVRGWVDFNNNGKFDLNESSEIVEVNQNGTYSIKFKNT
W P _ 0 0 3 0 9 7 6 8 8  . 1   YTRKGQ--------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1   YTRKGQ--------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1   YTRKGQ--------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  YTRKGQ--------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1  YTHKAS--------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1   YTHKAT--------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9  . 1   YIHKAT--------------------------------------------------------------
W P _02187  4 2 1 8 . 1  SNSRIDIQDPLMLNLQRYSKGGATTGWMPTGGDMINTTSAEYTSNLIYMSGNKGVFSVSG
K F L 9 7 0 1 6 . 1  SNTRIDIHDPLMLNLQRYSSGGPTTGWMPIGGDMINTTSNQYTANLIYMSGSKGVFSVDG





Y P _ 0 0 5 8 6 1 6 3 9  . 1   NFTTS
W P _ 0 3 3 6 8 8 7 4 0 . 1  PQLLDTSADSLGVRLRISLTKDEILEPTGVASSGEVEDFETHVIHMPRGTKHETKDFQGR
W P _ 0 0 3 0 9 7 6 8 8  . 1   QATFSKQ
W P _ 0 3 3 6 8 9 1 2 7  . 1   QPSYQKQ
W P _ 0 2 0 9 0 3 4 6 8  . 1   KANYQKQ
W P _ 0 0 0 2 8 7 3 0 8  . 1   QPNYQKQ
W P _ 0 3 3 6 8 5 3 8 0  . 1   KSAAQKQ
W P _ 0 3 3 6 8 1 5 4 7  . 1   KPSVQKQ
W P _ 0 2 3 9 4 8 4 0 9  . 1   KPSVQKQ
W P _ 0 2 1 8 7 4 2 1 8 . 1  GDYDPSNPNSSGFVVYQRIKSDGSKQIWLNVNDVNIPMNGFQTKDIWNNQANPDVSITGN
K F L 9 7 0 1 6 . 1 TNY---------------------WYQKIKSDGSKQIWLNVNGVNIPMSGFQTKDIWDNQANPDVSIKGN




W P ~ 0 3 3 6 8 8 7 4 0 . 1  EQTVKLPTNAMFTASGKNKDSNYKQWAQIENDNLPPKIVLTDKQVASEEAYTPTDSELPS
W P _ 0 0 3 0 9 7  6 8 8 . 1  GTSASLRTNNGLGYVSNELKSK------------------------------------------------------ SDTLEINTDSDIR-
W P _ 0 3 3 6 8 9 1 2 7  . 1  GTSASLSENNGLTYLNNEQTGR------------------------------------------------------ SDSIVLKTDSDIR-
W P __020903468 . 1  GTSASLSENNGLKYLNNEQISR------------------------------------------------------ SDSIVLKTDSDVR-
W P _ 0 0 0 2 8 7  3 0 8  . 1  GTSASLSENNGLTYLNNEQTGR------------------------------------------------------ SDSIVLKTDSDVR-
W P ~ 0 3 3 6 8 5 3 8 0 . 1  NTSATIMGDNILGYKGSERVRK------------------------------------------------------ SDAVVINTDSDVR-
W P _ 0 3 3 6 8 1 5 4 7  . 1  STSVSLLTDNGVNYNGSSLVKK------------------------------------------------------ NDAWINTDTDVR-
WP_ 0 2 3 9 4 8 4 0 9 . 1  STSVSLLT DNGVNYNGSSLVKK------------------------------------------------------ NDSWINTDTDVR-
W P _ 0 2 1 8 7 4 2 1 8 . 1  GLTGGIRANQVHNYNGSPLTGKDAPYYGISTQRASQQIWIPHR— TPLEITGNHTNTIK- 
K F L 9 7 0 1 6 . 1  DLTSGIRANQVHNYDGTPLTGKDAPYYGISTQRASQQIWFPHK— TQMEVVGSHTNTIK-
K F L 9 5 2 3 0 . 1  D L T S G I R A N Q V H N Y D G T P L T G K D A P Y Y G I S T Q R A S Q Q I W F P H K — T Q M E V V G S H T N T I K -
WT-GA
WT-GBI
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _02394  84 0 9 . 1  
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1
----------------------------------------------------------------------------------------------------------- k q y --------
------------------------------------------------------------------------------------------------ MTYKLIL
















Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1
NG----------------------------------------------------------------------------------------------------------











NADQTLEYIKNAQGVSEDSGWVYTDAQGNTVT D PYATVVS PVE DGYTASI---------------------
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9  . 1 ----------------------------------------------------------- NETN— GVAPGQDYQNSLPYPSSKIN---------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  EATNDTIETSKTSTTLAEKDKVLENTNNGNNGYKSMDTSYIPTVIDVRPVGEDTITEDVQ
W P _ 0 0 3 0 9 7 6 8 8 . 1  ---------------------------------------------------- NENNVWILQDGREGGFTLTPKLISPTELEVTVTE—
W P _ 0 3 3 6 8 9 1 2 7  . 1  ---------------------------------------------------- NENNVWILQDGRDSGFTLTPRLISPTELELTVTE—
W P _ 0 2 0 9 0 3 4  68  . 1  ---------------------------------------------------- NENNVWILNDGRDSGFTLTPRLISPTELELTVTE—
W P _ 0 0 0 2 8 7 3 0 8  . 1 ----------------------------------------------------NENNVWILNDGRDSGFTLTPRLISPTELELTVTE—
W P ~ 0 3 3 6 8 5 3 8 0 . 1 ----------------------------------------------------NANNVWILNDGRDTNFTLKATIKSPTELEIEVID—
W P _ 0 3 3 6 8 1 5 4 7  . 1 ----------------------------------------------------NQNNVWILQDGRDTSFTLKATLKSPTRLELEVID--
W P _ 0 2 3 9 4 8 4  0 9  . 1 ----------------------------------------------------------- NQNNVWILQDGRDTSFTLKATLKSPTRLELEVID—
W P _ 0 2 1 8 7 4 2 1 8  . 1  ---------------------------------------------------- QSTNVQGLKVGEDASSVTAKFAVNPSEDIVQNGELT
K F L 9 7 0 1 6 . 1--------------- ---------------------------------------------------- ESSNVPGITEGADGTSVTAKLQYK--EELVQNGELS
K F L 9 5 2 3 0  . 1 ---------------------------------------------------- E S S N V P G I T E G A D G T S V T A K L Q Y K — E E L V Q N G E L S
W T -G A
W T -G B l
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P_0030 97 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _02187  4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 

















Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 .1  
W P _ 0 3 3 6 8 9 1 2 7 .1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 , 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  















Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  










 GNQNWVTVHMKHGVQPVT PDTPT------------------------------------------------------------------ P
DFGKFGKDGKT FVVHLTHKVVPVT PDT---------------------------------------------------------------------- P
D F G K F G K D G K T F V V H L T H K V V P V T P D T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - P
WT-GA -------------------------------------------------------------------------------------------------------------
W T -G B l --------------------------------------------------------------------------------------------------------------------------------------------
YP_0 0 5 8 6 1 6 3 9 . 1  YQLVGSYNIPMPN-------------------------------- TATT YTAD— AP------------------------------------------
W P _ 0 3 3 6 8 8 7  4 0 . 1  AASAGKISSLAKETSADQLVEKGKSITLDGTTYSNNDVIPKGTRTMTTYEDLRNVTLPNA
W P _ 0 0 3 0 9 7  6 8 8 . 1  EPPTGAVVIGLKDLETGKI---------------IGHATTKYDGN--RPLNEDGTKDNTNVLGKKY-----
W P _ 0 3 3 6 8 9 1 2 7 . 1  EPPTGAVVRTFKDLVTGEV--------------- IGFEPTRYTGN— IPLSEDGSKDYTNVLGNKY-----
W P _ 0 2 0 9 0 3 4  6 8 . 1  EPPTGAVVRTFKDLVTGEV--------------IGFEPTRYTGN— IPLSEDGSKDYTNVLGNKY—
W P _ 0 0 0 2 8 7 3 0 8 . 1  EPPTGAVVRTFKDLVTGEV--------------- IGFEPTRYTGN— IPLSEDGSKDYTNVLGNKY-----
W P _ 0 3 3 6 8 5 3 8 0 . 1  QFETGAVTITLVNIETGEE---------------FAYEPTSYDGY— AKPNEDGSYETKNILGKKY-----
W P _ 0 3 3 6 8 1 5 4 7 . 1  TVETGAVTLTLKDLETGKI--------------- IGYIPTEYNGY— APLKEDGTYETKNILGKKY-----
W P _ 0 2 3 9 4 8 4 0 9 . 1  TVETGAVTLTLKDLETGKI--------------- IGYIPTEYNGY— APLKEDGTYETKNILGKKY-----
W P _02187  4 2 1 8 . 1  DVPKNTPAEAQPDQLTKKVNLTVNYVNSDGSTFTAT--VPANAKQTVTFTGTAYVDKVTG
K F L 9 7 0 1 6 . 1  NVPSNS— KVSKDDLTKTATRTIHYVENDQNGAE LKESTVQTVNYTGTAYVDWTG





YP 0 0 5 8 6 1 6 3 9 . 1
W P _ 0 3 3 6 8 8 7 4 0 . 
W P _ 0 0 3 0 9 7  6 8 8 .  
W P _ 0 3 3 6 8 9 1 2 7 .  
W P _ 0 2 0 9 0 3 4  6 8 .  
W P _ 0 0 0 2 8 7 3 0 8 . 
W P _ 0 3 3 6 8 5 3 8 0 . 
W P _ 0 3 3 6 8 1 5 4 7 . 
W P _ 0 2 3 9 4 8 4 0 9 .  
W P _ 0 2 1 8 7 4 2 1 8 . 
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1
VHIDPQTGEVTSVPRRYTKVTETEIVIENEGTYTLNQDTGEITFIPDPKFVGTGTGVTKQ
QLVNA-------------TQQNGQWVIDEN-
QMVNAKADGKDAQGNT TYVVDT D- 
QMVNAKADGKDAQGNTTYVVDTD-





Y P _ 0 0 5 8 6 1 63 9 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 .1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _02394  84 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 















W T -G B l
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 .1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
















Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1 
W P _ 0 0 0 2 8 7 3 0 8 . 1 
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1  







Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 .1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7  . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 .1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1




W T -G B l
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 03368  9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P_033 6 8 5 3 8 0  . 1  
W P _ 0 3 3 6 8 1 5 4 7  . 1  
W P _02394  84 0 9 . 1  
W P _02187  4 2 1 8  . 1  
K F L 9 7 0 1 6 . 1 









Y P _ 0 0 5 8 6 1 6 3 9 . 1  NNDGSQTKTWTGPTVSQDFYGANDQIPLAQVPLY
W P _ 0 3 3 6 8 8 7 4 0 . 1 IDLDATGDARILEVQNANPAPATGADAKTTYGVATLQGKSHTAIPYLTAETIKKYEDRGY
W P _ 0 0 3 0 9 7 6 8 8 . 1  — IPTTGIEGTLSVTNTR----------------- ARDLYSTEELKENGLNASAYVT PVDYNYVKKTRV
W P _ 0 3 3 6 8 9 1 2 7 . 1  - - IPVENARGTLSVTKTR------------------ ARDLYSEEELKAKGINGSAFVNPVNYDYVKKTKV
W P _ 0 2 0 9 0 3 4  6 8 . 1  —  LPAENAKGTLSVTKTR-------------------ARDLYSEEELKAKGINGSAFVTPAEYDYVKKTKV
W P _ 0 0 0 2 8 7 3 0 8 . 1  --IPAENTKGTLSVTKTR------------------ ARDLYSEEELKAKGINGSAFVTPAEYDYVKKTKV
WP_03 3 6 8 5 3 8 0 . 1  - -VPSKGTTGTVNIGPKR------------------ ASAIYSSEELQANGVNPNAFVNNWYYYVKKTKV
W P _ 0 3 3 6 8 1 5 4 7 . 1  — IPPKGPAGTINVSDKR----------------- IRDIYTADEITAAGLN PNAYVNNVIYSYVKKTKV
W P _ 0 2 3 9 4 8 4 0 9 . 1  — IPPKGPAGTINVSDKR----------------- 1RDIYTADEITAAGLN PNAYVNNVIYSYVKKTKV
W P _ 0 2 1 8 7 4 2 1 8 . 1  — TPAKDQKAWNYVDAD-------------- EDNKLITSSGDLTGKAGTKIDYSTNSTIEDLTNKGY
K F L 9 7 0 1 6 . 1 YSKNAQQGSFQIHYIDED------------- NNNAILHQDTVSDKIGDSVTYSTADQIQLWE SKGY
K F L 9 5 2 3 0 . 1  YSKNAQQGSFQIHYIDED--------------N-NNAILHQDTVSDKIGDSVTYSTADQIQLWESKGY
WT-GA
WT-GBl
Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
WP 0 0 0 2 8 7 3 0 8 . 1
W P _ 0 3 3 6 8 5 3 8 0 .  
W P _ 0 3 3 6 8 1 5 4 7 . 
W P _ 0 2 3 9 4 8 4 0 9 .  
W P _ 0 2 1 8 7 4 2 1 8 . 
K F L 9 7 0 1 6 . 1  






















- V N E D - N N G K T Y I V S F K H G R K N G T T E T L V P T E T I H F Q Y A D
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1------ ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------
WP_00 0 2 8 7 3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  GTKAADDVHGNAGDFKFTRTPIIDTVTGQIVDPGTWNKESYTFDDGQKNVKVINGYVADK





Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P J D 3 3 6 8 8 7 4 0 .1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 , 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1 
W P _ 0 0 0 2 8 7 3 0 8 . 1 
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4  7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 .1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  







Y P _ 0 0 5 8  6 1 6 3 9 . 1   AY----------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  VTRTIEYKYASTDDVPA----------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8  . 1   DDAQG----------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1   DNVEG----------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  68 . 1   DNVAG----------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  DNVAG----------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1   DDVKD----------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1   DDVKN----------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9  . 1   DDVKN-----------------------------------------------------------------------------------------------
W P _0218 7 4 2 1 8 . 1   PGEPINPNDPDG-----------------------------------PKYPTG----------------------------------------------
KFL9 7 0 1 6 . 1  S PKVPSGWTIS PNQPEGVTPNTTTNTAKVTPVDPTKPTNVVYTKDNAPVDKATVIVRYHD
K F L 9 5 2 3 0 . 1  SPKVPSGWTISPNQPEGVTPNTTTNTAKVTPVDPTKPTNVVYTKDNAPVDKATVIVRYHD
WT-GA -------------------------------------------------------------------------------------------------------------
W T -G B l --------------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  68  . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7  3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  DTTNLDLPESFDSGNKEVGTDTGYTQADINKVVQEYEAKGYYYVTTDGTLPTTIPAGGAT





Y P _ 0 0 5 8 6 1 6 3 9 . 1 -------------------------------------------------------------------------------------------- GGNQLLNNGHKQIVAYFGA- -
W P _ 0 3 3 6 8 8 7 4 0  . 1 ----------------------------------------------------------------------------------- DKRGTTAAPTVTETLHFERDRT
W P _ 0 0 3 0 9 7 6 8 8  . 1  ------------------------------------------------------------------------------------- LAGQQVFDPTTQTVSYKGT—
W P _ 0 3 3 6 8  9 1 2 7  . 1  ------------------------------------------------------------------------------------- LAGTEVFPSQKQTVSYTGS—
WP_0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------- LAGTEVFPSQKQTVSYTGS -  -
W P _ 0 0 0 2 8 7 3 0 8  . 1  ------------------------------------------------------------------------------------- LAGTEVFPSQKQTVSYTGS —
W P _ 0 3 3 6 8 5 3 8 0  . 1  ------------------------------------------------------------------------------------- LAGQEVFEPTKQTVSYTGT—
W P _ 0 3 3 6 8 1 5 4 7  . 1  ------------------------------------------------------------------------------------- LAGQQVFE PTKQTVS YTGT—
W P _ 0 2 3 9 4 8 4 0 9 , 1 ------------------------------------------------------------------------------------- LAGQQVFE PTKQTVS YTGT—
W P _ 0 2 1 8 7 4 2 1 8  . 1  -------------------------------------------------- SNEVTKTVTRTIQYLDEDGNKVSDSVEQPVNFTASGV
KFL9 7 0 1 6 . 1  IVVHLAHNQIPVGPDT PDKHGVDPDQVKKAYTST LHYQDSEGKTLS PDQQQT STWTRTVT
K F L 9 5 2 3 0 . 1  IVVHLAHNQIPVGPDTPDKHGVDPDQVKKAYTSTLHYQDSEGKTLSPDQQQTSTWTRTVT
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 -------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  IDYTLAAKEYPTEYAAYKAVLDASGYDSPEEYKARVVYYDHITNKAIAADATDAQKAIV-
W P _ 0 0 3 0 9 7  6 8 8 . 1  --------------------------------------------------------------------------------------------------------------------------- VKT-
W P _ 0 3 3 6 8 9 1 2 7 . 1  ----------------------------------------------------------------------------------------------------------------------------IK L -
W P _ 0 2 0 9 0 3 4  6 8 . 1  ----------------------------------------------------------------------------------------------------------------------------IK L -
W P _ 0 0 0 2 8 7 3 0 8 . 1  --------------------------------------------------------------------------------------------------------------------------- IK L -
W P _ 0 3 3 6 8 5 3 8 0 . 1  ----------------------------------------------------------------------------------------------------------------------------IQ V-
W P _ 0 3 3 6 8 1 5 4 7 . 1  --------------------------------------------------------------------------------------------------------------------------- VKL-
W P J D 2 3 9 4 8 4 0 9 . 1 --------------------------------------------------------------------------------------------------------------------------- VKL-
W P _ 0 2 1 8 7 4 2 1 8 . 1  LDKVT------------ GEWTTPLTWSV------DQTVSAVKSPVVSGYHLVSVDRDQDGNNVKDVTL-
K F L 9 7 0 1 6 . 1  VDTVTNQIVNGGKYDT— NWTLQDANDKYSNFTVPVVEGY— VARKTTNNGATVTTVVAG
K F L 9 5 2 3 0 . 1  VDTVTNQIVNGGKYDT— NWTLQDANDKYSNFTVPVVEGY— VARKTTNNGATVTTVVAG
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9  . 1 ---------------------------------------------------------TNESIASYSNYSSNFTFNFDESLG VTELKTPTI
W P _ 0 3 3 6 8 8 7 4 0 . 1 -------------------------------------------------- TFGPWTPVGGTSNDAITLSDAEKAKDDKFNLVNSPEV
W P _ 0 0 3 0 9 7 6 8 8  . 1  NAEGKAEIGSNDKPIYINWKGIGDTN--LPEVTVPQK
W P _ 0 3 3 6 8  9 1 2 7  . 1   TAEGKAVINSNDRPVYINWKGTDGQSTDLPELAVPQK
W P _ 0 2 0 9 0 3 4  68 . 1   TAEGKAVINSNDRPVYINWKGTDGQSTDLPELAVPQK
W P _ 0 0 0 2 8 7 3 0 8  . 1  -------------------------------------------------- TAEGKAVINSNDRPVYINWKGTDGQSTDLPELAVPQK
W P _ 0 3 3 6 8 5 3 8 0  . 1  NDKNEAQVDANRKPIYINWVGNGDTN--LPEVTVPQK
W P _ 0 3 3 6 8 1 5 4 7  . 1---------------------------------------------------------NSDGKAAVDSNDKPIYVNWVGNGDTN— LPEVTVPQK
W P _ _ 0 2 3 9 4 8 4 0 9 .1 -------------------------------------------------- NSDGKAAVDSNDKPIYVNWVGNGDTN— LPEVTVPQK
W P _ 0 2 1 8 7 4 2 1 8 . 1  -THDDNSYIVTVRYAKNGKIIPVDPNGH-PIPNVPQPQYPTDPNNPAKV— TPDEPVPNI
K F L 9 7 0 1 6 . 1  QTKVQQNLEDTVVYDKVGKLVPVGPDGKTPIPDAPTPSYPNDPTDPTKV--IPNEPVPDV





Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1
PGT--------------------------------------- SNYKYT IT  YA--------------------------- DGTTSEGQV-------- NAG
TGYVPDNAT-VEATAAIDAEADDYKITVLYTPVAQKAVVKFVEVDPTNTDKVITPGLADP
EGYIASVEK-V-PVQPTTATDEDYEYWTYSPI-QKAKTTFVYQDKDGNVKQV-------- EGN
EGYIASVEK-V-PVQATTATDEDYEYWKYTAI-QKAKTTFV— DEKGNA— I -------- PGV
EGYIASVEK-V-PVQATTATDEDYEYWKYTAI-QKAKTTFV— DEKGNA— I -------- PGV
EGYIASVEK- -  VPVQATTATDEDYEYWKYTAI -QKAKTIFV- -  DEKGNAI-------------PGV
EGYIASVEK— VPVQPTTATDEDYEYWTYTAI-QKAKTTFV— DEKGNPI-------------PGV
EGYIASVEK— VPVQPTTATDEDYEYWTYSPI-QKAKTTFVYQDKDGNVKQV-------- EGN






Y P _ 0 0 5 8 6 1 6 3 9 . 1 NTITGTGVITNIV VSPDNFERDQSTAVDLPTNKF-----------------------ANQTTQSVNAFE
W P _ 0 3 3 6 8 8 7 4 0 . 1  IAVTGKSEAAYPATTATSVTDKIAELVKKGYELVDNGF— VSADKFDKDAAVDQEYWKF
W P _ 0 0 3 0 9 7 6 8 8 . 1  TPISETGKGGDKLTKADEIAAKIKEAQNKGYELVSNTY— PTDGAFDKDVNTDQEFTVTL
W P _ 0 3 3 6 8 9 1 2 7 . 1  AEITEQGGSETPLTKEADVKAKIAELENKGYELVSNTY— PEGGKFDTDKDTDQEFKVIL
W P _ 0 2 0 9 0 3 4  6 8 . 1  AEITEQGGSETPLTKEADVKAKIKELENKGYELVSNTY--PEGGKFDTDKDTDQEFKVIL
W P _ 0 0 0 2 8 7 3 0 8 . 1  AEITEQGGSETPLTKEADVKAKIKELENKGYELVSNTY— PEGGKFDTDKDTDQEFKVIL
W P _ 0 3 3 6 8 5 3 8 0 . 1  DEITEQGGSEAPLTKEADVKAKIKELENKGYELVSNTY— PEGGKFDKEAGVDQEFKVTL
W P _ 0 3 3 6 8 1 5 4 7  . 1  TPISETGKGGDKLTKADEIAARIKEAQNKGYEWSNTY— PTDGVFDKDVDTDQEFTVTL
WP_0 2 3 9 4 8 4 0 9 . 1  TPISETGKGGDKLTKADEIAARIKEAQNKGYEWSNTY— PTDGVFDKDVDTDQEFTVTL
W P _ 0 2 1 8 7 4 2 1 8 . 1 GDLTGKAGSEIDY NAQSEIDNLINKGYVLKNNGF— PAGAVFDNDDNKTQTFYIDF
K F L 9 7 0 1 6 . 1  DAVDGNIGDKIDY STASSITDFENKGYILVTDGFTGQAGDEFTTENN-GQVYKVVF
K F L 9 5 2  3 0 .  1  D A V D G N I G D K I D Y  S T A S S I T D F E N K G Y I L V T D G F T G Q A G D E F T T E N N - G Q V Y K V V F
WT-GA
W T -G B l
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1 
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  




























Y P _ 0 0 5 8  6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  




























Y P _ 0 0 5 8 6 1 6 3 9 . 1  SNTATGQSN VGYL------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4  0 . 1  DQTFEAVTSPTLEKYTAAVAGITPAVADVPAKTVAATDKDFEETVIYSTKPTTVDPNKPT
W P _ 0 0 3 0 9 7 6 8 8 . 1 AQDLSEVTS PWKGYL-------------------------------AD------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1 AKDLAEVKSPVVTGFL-------------------------------- AD------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1  AKDLAEVKSPVVTGFL-------------------------------- AD---------------------- -------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  AKDLAEVKSPVVTGFL-------------------------------- AD------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0  . 1  AKDLPEVKSPKVDGYL-------------------------------- AD------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  AQDLAEVKSPWKGYL-------------------------------- AD------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9  . 1  AQDLAEVKSPWKGFL-------------------------------- AD------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  SHTFGNVDTPVIDGYH-------------------------------- AD------------------------------------------------------------
K F L 9 7 0 1 6 . 1 ---------------- SQEFEAVPAIDHDGYYIS SINQSN STASVDGQ------------------------------------------------------------
K F L 9 5 2 3 0 . 1 ---------------- SQEFEAVPAIDHDGYYISSINQSNSTASVDGQ------------------------------------------------------------
WT-GA -------------------------------------------------------------------------------------------------------------
W T -G B l --------------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . I  DPTNPNVTPQPDDWPNDPKGRTYRELGLIEEVTHTVHYKLEDGSDAGIADNVQTLTFTR
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7  3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
KFL97 0 1 6 . 1  ------------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------SVYAGG GQTNNIYEP
W P _ 0 3 3 6 8 8 7 4 0 . 1  TAEVDPVTGAISNFGTWKAKGGDTTIDAVTTPNKDGYVASAKTSTERTNVAATDKDSEET
W P _ 0 0 3 0 9 7 6 8 8  . 1   KATVPTVNVTADSKDTTEV
W P_033 68 9 1 2 7 . 1   KASVPWNVTGDSKDITEV
W P _ 0 2 0 9 0 3 4  68 . 1  KASVPWNVTGDSKDITEV
W P _ 0 0 0 2 8 7 3 0 8  . 1   KASVPWNVTGDSKDITEV
WP_0 3 3 6 8 5 3 8 0 . 1  ----------------------------------------------------------------------------------------- KASVAWNVTGDSEDIKEV
W P _ 0 3 3 6 8 1 5 4 7  . 1   KATVPTTKVTADSENTTEV
W P _ 0 2 3 9 4 8 4 0 9  . 1   KASVPWNVTGDSEDIKEV
W P _02187  4 2 1 8  . 1  ------------------------------------------------------------------------------------------KRTAGGTTITPDDLNKEVT
K F L 9 7 0 1 6 . 1  ----------------------------------------------------------------------------------------- TGAVGTETVT PNSQNGNIV
K F L 9 5 2 3 0  . 1  ----------------------------------------------------------------------------------------- TGAVGTETVTPNSQNGNIV
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  IFYYVLPEWFSVY---------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  IIYRKLGSYVPVVPEGITP-------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  VTYKPLGSWVPNIPGQPTN-------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  VTYKPLGSWIPNIPGKTPT-------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  VTYKPIGSWIPNIPGQPTN-------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  VTYKPIGSWIPNIPGQPTN-------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  VTYKPLGSWVPNIPGQPTD-------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 VTYKPLGSWIPNIPGQPTD-------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  VTYKPLGSWVPNIPGQPTN-------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  VTYTPNGKIIPVDPNGN-----------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 ITLTRNPD-VPVAAQGSINYIDDTTGQTIESANFSGNVGQKINYTTAGSIKNWEAKGYNL
K F L 9 5 2 3 0 . 1  ITLTRNPD-VPVAAQGSINYIDDTTGQTIESANFSGNVGQKINYTTAGSIKNWEAKGYNL
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ----------------------------------------------------------------------------------------- DFSTDYTK------------------------
W P _ 0 3 3 6 8 8 7 4 0  . 1  -------------------------------------------------------------PADADLNPKPYPNATPADPTKPGTP-TETPVV
W P _ 0 0 3 0 9 7 6 8 8  . 1  -------------------------------------------------------------P I ------------------------ KYPNDPQDPTKPGQPTETL
W P _ 0 3 3 6 8 9 1 2 7  . 1  -------------------------------------------------------------P I ------------------------ KYPNNPNDPTKPG-DKPIL
W P _ 0 2 0 9 0 3 4 6 8  . 1  -------------------------------------------------------------P I ------------------------ KYPNNPDDPTQPGKPTEVL
W P _ 0 0 0 2 8 7 3 0 8  . 1  -------------------------------------------------------------P I ------------------------ KYPNNPDDPTQPGKPTEVL
W P _ 0 3 3 6 8 5 3 8 0  . 1  -------------------------------------------------------------P I ------------------------ KYPNDPTDPTTPGTDKPKV
W P _ 0 3 3 6 8 1 5 4 7  . 1  -------------------------------------------------------------P I ------------------------ KYPNDPTDPTKPGKDKPVL
W P _ 0 2 3 9 4 8 4 0 9 . 1 -------------------------------------------------------------P I ------------------------ KYPNDPTDPTKPGQPTEW
W P _ 0 2 1 8 7 4 2 1 8  . 1  -------------------------------------------------------------P I -P N V P ---------TPQYPTDPTDPTKV-TPDEPV
K F L 9 7 0 1 6 . 1  VSNNFKDGEEVFTDGKNAFEVHLVHATTPVTPENPGKPGEPVNPTNPDDPHKY— PDNYV





Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 .1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P J 3 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1
















Y P _ 0 0 5 8 6 1 6 3 9 . 1  
WP_033 6 8 8 7 4  0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 

























W T -G B l --------------------------------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9 . 1   RQWKIDYSG
W P _ 0 3 3 6 8 8 7 4 0  . 1 -------------------------------------------------------------------------- AESWDTGDTGKAFTKAADVTATIEALKA
W P _ 0 0 3 0 9 7 6 8 8  . 1  AITEEGDSDTPLTKEAEVKAKIKELEN
W P _ 0 3 3 6 8 9 1 2 7  . 1  EITEQGDSDTPLTKEAEVKAKIKELEN
W P _ 0 2 0 9 0 3 4  68 . 1   AITEQGDSDTPLTKEADVKAKIKELEN
W P _ 0 0 0 2 8 7  3 0 8  . 1   AITEEGDSDTPLTKEADVKAKIKELEN
W P _ 0 3 3 6 8 5 3 8 0  . 1   AITEEGDSDTPLTKEAEVKAKIKELEN
W P _ 0 3 3 6 8 1 5 4 7  . 1   AITEEGDSDTPLTKEAEVKAKIKELEN
W P _ 0 2 3 9 4 8 4 0 9  . 1   AITEEGDSDTPLTKEADVKAKIKELEN
W P _ 0 2 1 8 7 4 2 1 8  . 1   GETINYSTADTIKDLEN
K F L 9 7 0 1 6 . 1  WITLANKPAPWEKGSITVKVHDLTDNVDLPQYGKESGEQEVGTSFTYDKNAVITELIN





Y P J 3 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7  . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  















Y P _ 0 0 5 8 6 1 6 3 9 . 1  PSGITFNPDWVQG— NTSNLYYVGANGFTINQ-------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 .1  TPELIKELEDGRTEEVKRTIKYVYADGSKAADSVQETKEFKRSATINPVTGKVTFGDWSP
W P _ 0 0 3 0 9 7  6 8 8 . 1  PAGL-EEKDLNKT— VTRTITYVYADGTPVLN--------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  PAGL-EEKDLNKT--VTRTITYVYADGTPVM---------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  PAGL-EEKDLNKT— VTRTITYVYEDGTPVLN-------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  PAGL-EEKDLNKT— VTRTITYVYADGTPVLN---------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  PAGL-EEKDLNKT— VTRTITYLYEDGTPVLN-------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  PAGL-EEKDLNKT— VTRTITYVYEDGTPVLN--------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  PAGL-EEKDLNKT--VTRTITYVYEDGTPVLN-------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  PDNS-GENNLSKT— GTQTIHYTGA-----------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  PEGT-DENSVKRT— GTQTIHYEGA-----------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  PEGT-DENSVKRT— GTQTIHYEGA-----------------------------------------------------------------------------
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  AQTFEAVTSPKVTNFTPDKESVPAAEVTATAEDINETVIYTTKPANIDPSKPTDPNTPNV
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 .1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1  -----------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  VGGANT------------------------------------------------------------------------ASVAQGNQNDILV---------
W P _ 0 3 3 6 8 8 7 4 0 . 1  TPRPDDRVPNDPKGRTYKELGLIEEVTHTVHYKLADGSDAGIPDNVQTLTFTRTADLDPV
WP_0 0 3 0 9 7 6 8 8 . 1 ---------------EDGT PK------------------------------------------------------------------------TVTQEAKFTREAKVNLV
W P _ 0 3 3 6 8 9 1 2 7  . 1   ENGAPK------------------------------------------------------------------------WTQEAKFTREAKVNLV
W P _ 0 2 0 9 0 3 4 6 8  . 1   EDGTPK------------------------------------------------------------------------TVTQEAKFTREAKVNLV
W P _ 0 0 0 2 8 7 3 0 8  . 1   EDGTPK------------------------------------------------------------------------TVTQEAKFTREAKVNLV
W P _ 0 3 3 6 8 5 3 8 0  . 1   EDGTPK------------------------------------------------------------------------WTQEAKFTREAKVNLV
W P _ 0 3 3 6 8 1 5 4 7  . 1   EDGTPK------------------------------------------------------------------------VVTQEAKFTREAKINLV
WP_02 3 94 8 4 0 9 . 1   EDGTPK------------------------------------------------------------------------TVTQEAKFTREAKVNLV
W P _ 0 2 1 8 7 4 2 1 8 . 1  GDKTPE------------------------------------------------------------------------DNKQEFTFTKTMWDNV
K F L 9 7 0 1 6 . 1   GDKTPS------------------------------------------------------------------------DDVQTFDFTKKMLVDKV
K F L 9 5 2 3 0  . 1   GDKTPS------------------------------------------------------------------------DDVQAFDFTKKMLVDKV
WT-GA -------------------------------------------------------------------------------------------------------------
WP 0 3 3 6 8 8 7 4 0 . 1  TGAISNFGTWTAKDNDTTIDAITTPNKPGYVASAAKSTERTNVQATDKDSEETIIYRKLG
WP 0 3 3 6 8 8 7 4 0 . 1  SYVPVIPEGVTPPTGTDLTPKPYENPINEDPTRPGTPTETPWPYIPGTTPVGPNGKPLT
Y P _ 0 0 5 8 6 1 6 3 9 . 1 -----------DSGVSDLYGSN
P _ 0 3 3 6 8 8 7 4 0 . 1 FGTWTAKDND'
W P _ 0 0 3 0 9 7  6 8 8 . 1  TGDV-TYGDWT-PAQD'
W P _ 0 3 3 6 8 9 1 2 7 . 1  TGEV-TYGDWS-EAKD
W P _ 0 2 0 9 0 3 4 6 8 . 1 TGEV-TYGDWS-EAKD'
W P _ 0 0 0 2 8 7 3 0 8 . 1  TGEV-TYGDWS-EAKD
W P _ 0 3 3 6 8 5 3 8 0 . 1  TGEV-TYGDWT-PAQD
W P _ 0 3 3 6 8 1 5 4 7 . 1  TGEV-TYGDWT-PAQD
W P _ 0 2 3 9 4 8 4 0 9 . 1 TGEV-TYGDWT-PAQD
W P _ 0 2 1 8 7 4 2 1 8 . 1  TGKVITDGAWNVTSHT
K F L 9 7 0 1 6 . 1  TGKIIDSGEWNVTSHT
K F L 9 5 2 3 0 . 1  TGKIIDSGEWNVTSHT
WT-GA -----------------------------
WT-GBl -----------------------------
Y P _ 0 0 5 8  6 1 6 3 9 . 1 ------------------------------------------
P _ 0 3 3 6 8 8 7 4 TPPTGT:
W P _ 0 0 3 0 9 7 6 8 8 . 1  -----------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 -----------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------
KFL97 0 1 6 . 1  -----------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  PKDPNDPTKGYEVPKVPEDPTQNTTITYVKDGSQVALVHFIKADGTAVHVSVAEAGDTGK
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P 0 0 0 2 8 7 3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 --------------- ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1-------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  AIKTTNIDNVKAELEAKGYEWAPTDAAYTAERVAFYAEANRTFDDKDDKGNDGISQVYY
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1 -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1 --------------- ------------------------------------------------------------------------------------------------------------------------------------
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBi -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8 6 1 6 3 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 S 7 4 0 . 1  VIVKEGITPIDPDKPLDPNTPDVTPKPGDKVPGDPKQRTFEQLGLLDEVNRTINYRYANT
W P _ 0 0 3 0 9 7  6 8 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  6 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P_033 6 8 5 3 8 0 , 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1 -----------------------------------------------------------------------------------------------------------------------------------
W P _02187  4 2 1 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1 --------------- -----------------------------------------------------------------------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1 -----------------------------------------------------------------------------------------------------EMEYAVRLINGSGT
W P _ 0 3 3 6 8 8 7 4 0 . 1  DKVDADKRGQEARPTVEQKLRYSRKGNLNKVTGEITYTSDWTKPQILAEVTSPVIEGYVA
W P _ 0 0 3 0 9 7 6 8 8  . 1  -----------------------------------------------------------------------------------------------------LAEVKSPWKGFLA
W P _ 0 3 3 6 8 9 1 2 7  . 1  -----------------------------------------------------------------------------------------------------LAEVKSPWTGFLA
W P _ 0 2 0 9 0 3 4  68 . 1   LPEVKSPWKGYLA
W P _ 0 0 0 2 8 7 3 0 8  . 1   LPEVKSPWKGYLA
W P _ 0 3 3 6 8 5 3 8 0  . 1  -----------------------------------------------------------------------------------------------------LAEVKSPWPGYLA
W P _ 0 3 3 6 8 1 5 4 7  . 1  -----------------------------------------------------------------------------------------------------LAEVKSPWKGYLA
W P _ 0 2 3 9 4 8 4 0 9 . 1 -----------------------------------------------------------------------------------------------------LAEVKS PWKGYLA
W P _ 0 2 1 8 7 4 2 1 8  . 1   FGNVDTPVIDGYHA
K F L 9 7 0 1 6  . 1 --------------- -----------------------------------------------------------------------------------------------------FGYKDTPVIDGYHA
K F L 9 5 2 3 0 . 1 --------------- -----------------------------------------------------------------------------------------------------FGYKDT PVIDGYHA
WT-GA
WT-GBl
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1
E------------------------------------------------------------------------------------------------
---------------------YDDATKTFTVTE-----------------------------------------------------------------











D - K R N A G G S V V T P N D L N K K V V V T Y K P N G K I I P T D P S G N P I P N V P T P T Y P T D P T D P T K V - V
WT-GA
WT-GBl
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7 6 8 8 .1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
WP_03 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _02394  8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
















W T-G B l
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7  4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1 
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1
 DRS DRLIFTGID PN-------------------------------------LVN DAGKTGYI---------------------STG
YV-----VEGTGTVLHTDNLEGKSGE P IE Y S -------- TVTKLAE LKALGY DLVT DG FTTAT DKN
YV-----DENGKDLIPSETTEGKVGD— EYT-------- TTG--------- KVIPGHLLVRVEG— ESKGK
YV-----DENGKELQPTETKEGKVGD— DYS---------TSG--------- KVITGYVLDRVEG— EAKGK








Y P _ 0 0 5 8 6 1 6 3 9 .  
W P _ 0 3 3 6 8 8 7 4 0 . 
W P _ 0 0 3 0 9 7  6 8 8 .  
WP 0 3 3 6 8 9 1 2 7 .
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7  3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1 
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _02394  8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 .1  
K F L 9 7 0 1 6 . 1  
















Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7 6 8 8  . 1  
W P _ 0 3 3 6 8 9 1 2 7  . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8  . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7  . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1 
KFL97 0 1 6 . 1  














Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7  . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1








Y P _ 0 0 5 8 6 1 6 3 9 . 1 -KPF-ISSLAV-YNSSTVANKVKPANITITGEANINFK------------------------------------ LQYTDE
W P _ 0 3 3 6 8 8 7 4 0 . 1  VGKVTITVPPGVTPPTPVTDTPYENVPGEPGKWPPSPTKPQDPQDPNSPKVPVIPHIPG
W P _ 0 0 3 0 9 7 6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  -GSW-IPNIPG-QPTTPIKYPNDPQDPTKPGQ—  PTEV------------------------------------ LPYVPG
W P _ 0 2 0 9 0 3 4 6 8  . 1  -GSW-IPNIPG-QPTNPIKYPNDPQDPTKPGQ— PTEV------------------------------------ LPYVPG
W P _ 0 0 0 2 8 7 3 0 8  . 1 -GSW-IPNIPG-QPTNPIKYPNDPTDPTKPGQ--PTET------------------------------------ LPYVPG
W P _ 0 3 3 6 8 5 3 8 0  . 1  LGSW-IPNIPG-QPTNPIKYPNDPADPTKPGSDKPV-----------------------------------------LPYVPG
W P _ 0 3 3 6 8 1 5 4 7  . 1  -GSW-VPNIPG-QPTNPIKYPNDPTDPTKPGQ— PTEV------------------------------------ VPYVPG
W P _ 0 2 3 9 4 8 4 0 9 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  NGKI-IPVDPNGKPIPNVPTPQYPTDPTDPSKWPNEP------------------------------------ VPTIPG
K F L 9 7 0 1 6  . 1 NGKI-IPTDPSSNPIPNVPNPTYPTDPTDPTKVVPDQP------------------------------------ VPEVPG
K F L 9 5 2 3 0  . 1 NGKI-IPTDPSSNPIPNVPNPTYPTDPTDPTKWPDEP------------------------------------ VPNIPG
WT-GA
WT-GBl
Y P _ 0 0 5 8 6 1 6 3 9 , 
WP 0 3 3 6 8 8 7 4 0 .
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8 . 1  
KFL97 0 1 6 . 1  
K F L 9 5 2 3 0 . 1















Y P _0  0 5 8 6 1 6 3 9 . 1  PAN YE IKSAT LQSGGKT---------------------------------------------------------------------- WQT DAPEGT PV
W P _ 0 3 3 6 8 8 7 4 0 . 1  TNFVDEKGKWSTPWDEGDSGANFTKSKVDEVTKTIEKLEKAGYRWKNE FPSKDTDRV
W P _ 0 0 3 0 9 7 6 8 8 . 1  VKYVDENGKDLIPAETTEGKVGDEYTTSGK-----------------------VIPGYVLVRVDGEAKGKIGT
W P _ 0 3 3 6 8 9 1 2 7 . 1  VKYVDENGKDLIPSETTEGKVGDEYTTTGK-----------------------VIPGYLLVRVEGEAKGKIGK
W P _ 0 2 0 9 0 3 4 6 8 . 1  VKYVDENGKDLIPAETTEGKVGDEYTTTGK-----------------------VIPGYLLVRVDGDAKGKIGK
W P _ 0 0 0 2 8 7 3 0 8 . 1  VKYVDENGKELLPTETKEGKVGDDYSTSGK-----------------------VIT GYVLDRVEGEAKGKIGT
W P _ 0 3 3 6 8 5 3 8 0 . 1  VKYVDENGKELLPSETTEGKVGDEYATSGK-----------------------VITGYVLERVEGEAKGKIGE
W P _ 0 3 3 6 8 1 5 4 7 . 1  VKYVDEKGKDLLPAETTEGKVGDEYATSGK-----------------------VIKGYVLVRVDGEAKGKIGK
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  IPDVGYNSGSQKAGTKVDYTTTKSISDL----------------------------E VKG YVYVST DGTI PTE ITA
K F L 9 7 0 1 6 . 1  VHFVDGDNGNT----------------------------------------------------------------- PLRDPNTQTHEFKITNGVPD
K F L 9 5 2 3 0  . 1  TIITSSGNLTGKAGSRIDYSTKTTIADL--------------------------- ENKGYVLVNDGFPADATFDN
WT-GA
WT-GBl
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4  0 . 1  
W P _ 0 0 3 0 9 7 6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4  6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1 
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _02187  4 2 1 8 . 1  
KFL97 0 1 6 . 1  














Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 .1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7  . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1 
W P _ 0 2 1 8 7 4 2 1 8  . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1
NSPVWPNTVKDLVTEKSATRTIKYVDRNGKEVSETRTETIKFTREAKVNIVTGEITYGEW
YTGAGNNTPKDNVQSFTFTRTAVVDNVTGKVISTGAWNVTSHTFGNVNTPVVDGYHADKR





Y P _ 0 0 5 8 6 1 6 3 9 . 1  DLLNNG-------------------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  TTDRNDDIFNGYQVPWKGYIAKAGDLESSTKDVQVTPDTIKDINETVIYDKLGSWIPNI
W P _ 0 0 3 0 9 7 6 8 8 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4 6 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  TAGNTTIT PE DLNKTVTVNYTANG--------------------------------------------------------------------------------
K F L 9 7 0 1 6 . 1   TWYHKVG-------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  NAGGSWTPDDLNKTVTVTYKQNG-------------------------------------------------------------------------------
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
YP_0 0 5 8  6 1 6 3 9 . 1  ----------------------------------------------------QVITGNQGSNVPNDATTAYDAVKNALEAK---------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  PGTPTNPITYPNDPKDPTKPGTDKPKVPYVPGFIPVDPEGQPLKPVDPNDPTK---------------
W P _ 0 0 3 0 9 7 6 8 8  . 1  ----------------------------------------------------PVLPYVPGYTPVDGNGQPLKPVDPNDPTQ---------------
WP_0 3 3 68 9 1 2  7 . 1  ---------------------------------------------------- PVLPYVPGHTPVDGNGQPLKPVDPNDPTK---------------
WP_02 0 9 0 3 4 6 8 . 1  ----------------------------------------------------PVLPYVPGHTPVDGNGQPLKPVDPNDPTK---------------
W P _ 0 0 0 2 8 7 3 0 8  . 1  ----------------------------------------------------EVLPYVPGFTPEDKDGNPLKPVDPKDPSK---------------
W P _ 0 3 3 6 8 5 3 8 0  . 1  ----------------------------------------------------PVLPYVPGYTPKDKDGNPLKPVDPNDPTK---------------
W P _ 0 3 3 6 8 1 5 4 7  . 1  ---------------------------------------------------- PVLPYVPGYTPKDKDGNPLKPVDPNDPTK---------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  ----------------------------------------------------KIIPVDPNGKPIPNVPTPTYPTDPNDPTKWPNEPV
K F L 9 7 0 1 6 .  1 ----------------------------------------------------KIVPVDPNGNPIPNVPTPSYTNDPTDPTKVVPNEPV
K F L 9 5 2 3 0  . 1 ----------------------------------------------------KIVPVDPSGNPIPNVPNPTYPTDPTDPTKWPDQPV
WT-GA -------------------------------------------------------------------------------------------------------------
WT-GBl -------------------------------------------------------------------------------------------------------------
Y P _ 0 0 5 8  6 1 6 3 9 . 1  --------GY-------V I S S  KSSTVPTIFGP---------------------------------------------------------------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  --------GY------- EVPDVPGDPTQDTPINYIP---------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  --------GY------- EVPNVPNDPTKDTPINYVP---------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7 . 1  --------GY-------EVPDIPTNPGEDTPINYIP---------------------------------------------------------------------
W P _ 0 2 0 9 0 3 4  68 . 1  --------GY— ISPDIPTNPGEDTPINYIP----------------------------------------------------------------------
W P _ 0 0 0 2 8 7 3 0 8 . 1  --------GY-------VVPNIPTNPGEDTPINYIP---------------------------------------------------------------------
W P _ 0 3 3 6 8 5 3 8 0 . 1  --------GY-------EVPNVPTNPSEDTPINYIP---------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  --------GY------- EVPSVPTNPGEDTPINYVP---------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8 . 1  PTIPGYKPSVPTVTPSDPGKDTPVPYAP----------------------------------------------------------------------
KFL97 0 1 6 . 1  PAITGKT PDKTSVT PVDPTKDT PVVYKN----------------------------------------------------------------------





Y P _ 0 0 5 8 6 1 6 3 9 . 1  ------------------------------------------------------------------------------------------------------------- DNT---------------
W P _ 0 3 3 6 8 8 7 4 0 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 0 3 0 9 7  6 8 8 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  --------------------------------------------------------------------------------------------------------------N-------------------
W P _ 0 2 0 9 0 3 4 6 8  . 1  --------------------------------------------------------------------------------------------------------------NVTP------- NG
W P _ 0 0 0 2 8 7 3 0 8  . 1  ------------------------------------------------------------------------------------------------------------- NVTP--------NG
W P _ 0 3 3 6 8 5 3 8 0 . 1 ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 3 9 4 8 4 0 9 . 1  ------------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1  ------------------------------------------------------------------------------------------------------------- QTTPVTPN—
K F L 9 7 0 1 6 . 1--------------- ------------------------------------------------------------------------------------------------------------------------------------
K F L 9 5 2 3 0 . 1  TQTHEFKITNGVPDESSHTFTLVDVPVIPGYVAEVKSAGGKTVTPDTPLAEVTVVYHKVG
WT-GA
WT-GBl
Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1 
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7  . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  













Y P _ 0 0 5 8 6 1 6 3 9  . 1 ------------------------------------------------------------------------------------------KTINV-------------------------------------
W P _ 0 3 3 6 8 8 7 4 0  . 1  -----------------------------------------------------------------------------------K P E P K P E P K P E P K P E P E - - - - - - - - - - - - -
W P _ 0 0 3 0 9 7  6 8 8 . 1 ------------------------------------------------------------------------------------------KPEPKPE---------------------------------
W P _ 0 3 3 6 8 9 1 2 7  . 1  -----------------------------------------------------------------------------------KPEPKP-----------------------------------
WP_0 2 0 9 0 3 4 6 8 . 1  -----------------------------------------------------------------------------------KGAQAPKGISGYEYVTTTKDPN
W P _ 0 0 0 2 8 7 3 0 8 .  1 -----------------------------------------------------------------------------------K G A Q A P K G I S G Y E Y V T T T K D P N
W P _ 0 3 3 6 8 5 3 8 0  . 1 -----------------------------------------------------------------------------------KPEPKP-----------------------------------
W P _ 0 3 3 6 8 1 5 4 7 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _02394  84 0 9 . 1  -----------------------------------------------------------------------------------------------------------------------------------
W P _ 0 2 1 8 7 4 2 1 8  . 1 -----------------------------------------------------------------------------------HGEDVPVTPNEP----------------------
K F L 9 7 0 1 6  . 1  -------------------------------------------------------------------------------GRPGEDINKLYSSAEVIKQLEEAG
K F L 9 5 2 3 0 . 1  VYKNNEVPATPNSQKAVVNFIDVNTGKLIKTSGILSGRPGEDINKLYSSAEVIKQLEEAG
Figure A2. Continued.
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W T - G A
WT-GBl
Y P _ 0 0 5 8 6 1 6 3 9 . 1 
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  
K F L 9 5 2 3 0 . 1
----------------------- STPDQWPSTSTDADKV--------



















Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7 . 1 
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 . 1  
W P _02187 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1  




T --------- PAETSVATDSATQTATPKYVDGQ--------------- KELPNTGTEANAS LAALGLL-GAL
A --------- PAET S VAT D S ATQ PAT PKYVDGQ--------------- KELPNTGTEANAS LAALGLL-GAL
T --------- PAETSVPTDSATKPAT PKYVDGQ--------------- KELPNTGTEANASLAAFGLL-GAL










Y P _ 0 0 5 8 6 1 6 3 9 . 1  
W P _ 0 3 3 6 8 8 7 4 0 . 1  
W P _ 0 0 3 0 9 7  6 8 8 . 1  
W P _ 0 3 3 6 8 9 1 2 7  . 1  
W P _ 0 2 0 9 0 3 4 6 8 . 1  
W P _ 0 0 0 2 8 7 3 0 8 . 1  
W P _ 0 3 3 6 8 5 3 8 0 . 1  
W P _ 0 3 3 6 8 1 5 4 7 . 1  
W P _ 0 2 3 9 4 8 4 0 9 .1  
W P _ 0 2 1 8 7 4 2 1 8 . 1  
K F L 9 7 0 1 6 . 1 
K F L 9 5 2 3 0 . 1
FTP----------------------------
SGFGLIARKKREDEE-
















Figure A3. Structure of 7 small globular proteins. PDB codes are presented with each 
structure. The a-helices are colored in pink and P-strands colored in yellow. The loop 




METHODS FOR CLONING, EXPRESSION AND PURIFICATION 

















Figure A4. Diagram of the pET-1 la  vector map. Schematic shows the ampicillin and 
cloning region with the T7 promoter and terminator. Image was redrawn from 
http:// www. genomics. agilent.com/en/home .j sp.
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APPENDIX III
NMR METHOD TO STUDY LONG-RANGE INTERACTION IN GB1






1 Met 65.2 29 Val 66.4
2 Thr 56.2 30 Phe 3.2
3 Tyr 4.5 31 Lys 48.8
4 Lys 36.1 32 Gin 87.8
5 Leu 0 33 Tyr 41.8
6 lie 48.7 34 Ala 2.6
7 Leu 2.4 35 Asn 94.9
8 Asn 54 36 Asp 83.9
9 Gly 0 37 Asn 50.4
10 Lys 84.7 38 Gly 100
11 Thr 98.9 39 Val 3.2
12 Leu 33.3 40 Asp 100
13 Lys 63.6 41 Gly 22.4
14 Gly 95.8 42 Glu 99.1
15 Glu 55.5 43 Trp 20.6
16 Thr 50.9 44 Thr 80.9
17 Thr 52.9 45 Tyr 25.5
18 Thr 31.9 46 Asp 66.8
19 Glu 79.7 47 Asp 74.9
20 Ala 14.4 48 Ala 90
21 Val 94.2 49 Thr 70
22 Asp 59.9 50 Lys 36.5
23 Ala 37.7 51 Thr 17.9
24 Ala 82.3 52 Phe 3.4
25 Thr 41.5 53 Thr 36.8
26 Ala 0.5 54 Val 0.1
27 Glu 47.2 55 Thr 56.2
28 Lys 72.1 56 Glu 13.4
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22
Figure A5. Network schematic of long-range interactions in GB1. Red circles indicate 
residues and blue lines represent contact between residues that are within 5 A and greater 
than 7 residues apart from each other in the sequence. Orange lines indicate interactions 
of interest between Phe30, Phe 52 and Trp 43.
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200 150 100 50 0 F2 [ppmj
l3C Chemical Shift
Figure A6. 2D 13C-13C-DARR experiment on uniformly labeled WT-GB1. A dry
sample of -36 mg uniformly labeled WT-GB1 was packed into a 4 mm rotor and 
analyzed on a Bruker Avance 750 MHz MAS-NMR spectrometer located at the College 
of William and Mary. The sample was spun at 10 kHz. Outlined in a dashed red circle are 
representative CRPK.
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1 18 3 5 43 6 20 26 3
1 19 15 5 52 19 23 45 6
1 20 16 5 53 3 23 52 6
1 21 1 5 54 5 26 52 9
1 50 5 6 14 9 27 52 16
2 17 3 6 15 7 30 43 9
2 18 11 6 51 4 30 52 11
2 19 16 6 52 9 31 43 30
2 50 4 6 53 22 34 43 3
3 16 3 6 54 9 34 54 1
3 17 11 7 13 13 38 56 4
3 18 19 7 14 23 39 54 3
3 20 12 7 15 5 39 56 20
3 21 3 7 16 1 40 54 1
3 22 17 7 33 6 40 55 2
3 23 12 7 39 2 40 56 19
3 26 8 7 54 11 41 54 4
3 30 9 8 54 13 41 55 10
3 45 8 8 55 25 41 56 7
3 50 25 8 56 9 42 53 3
3 52 6 9 39 2 42 54 10
4 15 19 9 54 1 42 55 17
4 16 13 9 56 15 43 52 6
4 17 11 10 56 24 43 53 16
4 30 11 11 56 1 43 54 32
4 50 7 12 33 3 44 51 3
4 51 24 12 37 6 44 52 11
4 52 14 12 39 3 44 53 32
5 14 3 16 30 8 45 51 18
5 15 9 16 33 9 45 52 36
5 16 24 17 30 8
5 17 2 18 26 3
5 30 31 18 29 1
5 33 2 18 30 15
Degree long-range contacts between residues A and B with a contact distance cutoff of 5 A and
residue sequence spacing of 6 residues. Comprehensive list of 1025 long-range interactions found 
in the structure of GB1. List represents potential interactions to be monitored by folding-freezing 
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